,compound_id,standard_inchi_key,compound_name,synonym,target_id,target_pref_name,gene_names,wildtype_or_mutant,mutation_info,pubmed_id,standard_type,standard_relation,standard_value,standard_units,activity_comment,ep_action_mode,assay_format,assaytype,assay_subtype,inhibitor_type,detection_tech,assay_cell_line,compound_concentration_value,compound_concentration_value_unit,substrate_type,substrate_relation,substrate_value,substrate_units,assay_description,title,journal,doc_type,annotation_comments,pDTC_Value,SMILES,base_rdkit_smiles
0,CHEMBL12,AAOVKJBEBIDNHE-UHFFFAOYSA-N,DIAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
1,CHEMBL12,AAOVKJBEBIDNHE-UHFFFAOYSA-N,DIAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21
2,CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21
3,CHEMBL1090526,ABDWUBPDHWDFCV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,0.7,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CN=C3OC,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(F)ccc21
4,CHEMBL60435,ABEZUHIZVKNNOT-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,95499.26,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.019999993643078,C1C[C@@H](NC1)CC(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CCN(C(=O)C[C@H]3CCCN3)CC2)cc1)C1CC1
5,CHEMBL990,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,BUTENAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32,CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
6,CHEMBL990,ABJKWBDEJIDSJZ-UHFFFAOYSA-N,BUTENAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)CN(C)CC2=CC=CC3=CC=CC=C32,CN(Cc1ccc(C(C)(C)C)cc1)Cc1cccc2ccccc12
10,CHEMBL270853,ABOWDNIHZHLENL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C,Cc1ccc2c(-c3nnc(SCCCCN4CCc5cc6c(cc5CC4)C(=O)N(C)C6)n3C)cccc2n1
11,CHEMBL256659,ABWRXTVIPWIMTE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)N=C(O5)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3ccc4nc(C(F)(F)F)oc4c3CC2)n1C
12,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,11000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.9586073148417755,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
13,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,17000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.769551078621727,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
14,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,23000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.638272163982408,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
15,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,20.6,NM,,,cell_based,binding,,,,,,,,,,,,,,,,7.6861327796308485,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
16,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,58.8,NM,,,cell_based,binding,,,,,,,,,,,,,,,,7.230622673923862,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
17,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,140.0,NM,,,,binding,,,,,,,,,,,,,,,,6.853871964321763,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
18,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,16.6,NM,,,,,,,,,,,,,,,,,,,,7.779891911959945,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
19,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,115.0,NM,,,,,,,,,,,,,,,,,,,,6.939302159646387,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
20,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,186.0,NM,,,,,,,,,,,,,,,,,,,,6.730487055782085,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
21,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,1998.0,NM,,,,,,,,,,,,,,,,,,,,5.699404516110038,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
22,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,24.0,NM,,,,,,,,,,,,,,,,,,,,7.619788758288393,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
23,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,247.0,NM,,,,,,,,,,,,,,,,,,,,6.607303046740334,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
24,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,268.0,NM,,,,,,,,,,,,,,,,,,,,6.571865205971212,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
25,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,290.0,NM,,,,,,,,,,,,,,,,,,,,6.5376020021010435,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
26,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,293.0,NM,,,,,,,,,,,,,,,,,,,,6.533132379645891,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
27,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,327.0,NM,,,,,,,,,,,,,,,,,,,,6.485452247339714,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
28,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,553.0,NM,,,,,,,,,,,,,,,,,,,,6.257274868695301,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
29,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,560.0,NM,,,,,,,,,,,,,,,,,,,,6.251811972993798,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
30,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,822.0,NM,,,,,,,,,,,,,,,,,,,,6.0851281824599495,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
31,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,998.0,NM,,,,,,,,,,,,,,,,,,,,6.0008694587126294,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
32,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,1087.0,NM,,,,,,,,,,,,,,,,,,,,5.963770455913704,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
33,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,1437.0,NM,,,,,,,,,,,,,,,,,,,,5.8425432318657755,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
34,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,3224.0,NM,,,,,,,,,,,,,,,,,,,,5.491604966866947,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
35,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27717652.0,Ki,=,3867.0,NM,,,,,,,,,,,,,,,,,,,,5.4126258279269335,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
36,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27839919.0,Ki,>,10000.0,NM,,,cell_based,binding,,,,,,,,,,,,,,,,5.0,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
37,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,5.8,NM,,,,,,,,,,,,,,,,,,,,8.236572006437061,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
38,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,,,,,,8.300162274132754,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
39,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,,,,,,7.199970640755867,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
40,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,6.31,NM,,,,,,,,,,,,,,,,,,,,8.199970640755867,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
41,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,8.91,NM,,,,,,,,,,,,,,,,,,,,8.050122295963126,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
42,,ABZSPJVXTTUFAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(=O)NC1=CC=C(C=C1)C(=O)NC2=C(C=CC(=C2)C3=CC=CS3)N,CC(=O)Nc1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cc1
43,CHEMBL765,ACGDKVXYNVEAGU-UHFFFAOYSA-N,GUANETHIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCCN(CCC1)CCN=C(N)N,NC(N)=NCCN1CCCCCCC1
44,CHEMBL765,ACGDKVXYNVEAGU-UHFFFAOYSA-N,GUANETHIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCCN(CCC1)CCN=C(N)N,NC(N)=NCCN1CCCCCCC1
45,CHEMBL496,ACGUYXCXAPNIKK-UHFFFAOYSA-N,HEXACHLOROPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
46,CHEMBL496,ACGUYXCXAPNIKK-UHFFFAOYSA-N,HEXACHLOROPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=C(C(=C1Cl)Cl)CC2=C(C(=CC(=C2Cl)Cl)Cl)O)O)Cl,Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl
47,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3,O=C(c1ccc(OCCCc2cnc[nH]2)cc1)C1CC1
48,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3,O=C(c1ccc(OCCCc2cnc[nH]2)cc1)C1CC1
49,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15608078.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3,O=C(c1ccc(OCCCc2cnc[nH]2)cc1)C1CC1
50,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3,O=C(c1ccc(OCCCc2cnc[nH]2)cc1)C1CC1
51,CHEMBL14638,ACQBHJXEAYTHCY-UHFFFAOYSA-N,CIPROXIFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,2511.89,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,C1CC1C(=O)C2=CC=C(C=C2)OCCCC3=CN=CN3,O=C(c1ccc(OCCCc2cnc[nH]2)cc1)C1CC1
52,CHEMBL272694,ACRMNEFOWLXFLY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C)oc6c(C)c5CC4)n3C)cccc2n1
53,CHEMBL96732,ACTVOFFLDWZANE-KHMGXFTDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,27.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.568636235841013,CN(C)CC1C[C@@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CN(C)CC1C[C@H]2c3ccccc3Cc3ccccc3[C@H]2O1
54,CHEMBL329566,ACTVOFFLDWZANE-NSISKUIASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.54,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.267606240177033,CN(C)C[C@H]1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CN(C)C[C@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1
55,CHEMBL329566,ACTVOFFLDWZANE-NSISKUIASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,0.43,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,9.366531544420411,CN(C)C[C@H]1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CN(C)C[C@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1
56,CHEMBL92667,ACTVOFFLDWZANE-ODFWGIBRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.7,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.154901959985743,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CN(C)CC1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1
57,CHEMBL329268,ACTVOFFLDWZANE-PWIZWCRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.63,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.200659450546418,CN(C)C[C@@H]1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CN(C)C[C@@H]1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1
58,CHEMBL327651,ACTVOFFLDWZANE-VDGAXYAQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.74,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.42712839779952,CN(C)C[C@@H]1C[C@@H]2[C@@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CN(C)C[C@@H]1C[C@H]2c3ccccc3Cc3ccccc3[C@@H]2O1
59,CHEMBL1069,ACWBQPMHZXGDFX-QFIPXVFZSA-N,VALSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
60,CHEMBL1069,ACWBQPMHZXGDFX-QFIPXVFZSA-N,VALSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NNN=N3)[C@@H](C(C)C)C(=O)O,CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C
63,CHEMBL1669412,ADLLYWYUHVDQBH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4.3,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.366531544420411,C1CN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,c1ccc2c(c1)CC(CCN1CCC1)=C2Cc1cnccn1
64,CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N,COc1cc(N)nc2[nH]c(-c3ccc(F)cc3)c(-c3ccncc3)c12
65,CHEMBL115769,ADQZGIYHFQQPRB-UHFFFAOYSA-N,RWJ-68354,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=NC2=C1C(=C(N2)C3=CC=C(C=C3)F)C4=CC=NC=C4)N,COc1cc(N)nc2[nH]c(-c3ccc(F)cc3)c(-c3ccncc3)c12
67,CHEMBL1702607,ADVPTQAUNPRNPO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S(=O)O,NC(CS(=O)O)C(=O)O
68,CHEMBL322194,ADZSGFZICHOKOJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.42,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.192464971931146,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC=CC=C6,CCOCCn1c(C(=O)C2CCN(CCC3(c4ccccc4)CCN(C(=O)c4cc(OC)c(OC)c(OC)c4)C3)CC2)nc2ccccc21
69,CHEMBL322194,ADZSGFZICHOKOJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,381.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.419075024324381,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC=CC=C6,CCOCCn1c(C(=O)C2CCN(CCC3(c4ccccc4)CCN(C(=O)c4cc(OC)c(OC)c(OC)c4)C3)CC2)nc2ccccc21
72,CHEMBL470564,AECNWVFAWBLCAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,3500.0,NM,,,,,,,,,,,,,,,,,,,,5.455931955649724,CC(C1=CC=CC=C1)C(=O)NC(=NCCCC2=CN=CN2)N,CC(C(=O)NC(N)=NCCCc1cnc[nH]1)c1ccccc1
74,CHEMBL252557,AEMRFAOFKBGASW-UHFFFAOYSA-N,GLYCOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)O,O=C(O)CO
75,CHEMBL252557,AEMRFAOFKBGASW-UHFFFAOYSA-N,GLYCOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)O,O=C(O)CO
79,CHEMBL44884,AEUTYOVWOVBAKS-UWVGGRQHSA-N,ETHAMBUTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NCCN[C@@H](CC)CO,CC[C@@H](CO)NCCN[C@@H](CC)CO
80,CHEMBL44884,AEUTYOVWOVBAKS-UWVGGRQHSA-N,ETHAMBUTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NCCN[C@@H](CC)CO,CC[C@@H](CO)NCCN[C@@H](CC)CO
81,CHEMBL513893,AEWLECDUIOHVBW-QBNMFFNISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18768318.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CCN1CCCCC1)C(=O)C2CCC3(CC2)C4=C(C=C(C=C4)OC)C(=O)O3,COc1ccc2c(c1)C(=O)OC21CCC(C(=O)N(C)CCN2CCCCC2)CC1
82,CHEMBL2171022,AEWQIKDEAWAPPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC(=CC=C4)OCC(=O)O,O=C(O)COc1cccc(C(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
83,CHEMBL398996,AFNIUHMJOXEVTF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5.C(=O)O,CS(=O)(=O)c1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1
84,CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
85,CHEMBL1221,AFNXATANNDIXLG-UHFFFAOYSA-N,SULCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(CSC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
86,CHEMBL486964,AFTLSANLJDCKNX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,,,,,,5.638272163982407,CC(C1CCCCC1)C(=O)NC(=NCCCC2=CN=CN2)N,CC(C(=O)NC(N)=NCCCc1cnc[nH]1)C1CCCCC1
87,CHEMBL486964,AFTLSANLJDCKNX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,6000.0,NM,,,,,,,,,,,,,,,,,,,,5.221848749616356,CC(C1CCCCC1)C(=O)NC(=NCCCC2=CN=CN2)N,CC(C(=O)NC(N)=NCCCc1cnc[nH]1)C1CCCCC1
89,CHEMBL508112,AFZSMODLJJCVPP-UHFFFAOYSA-N,BENZOTHIAZYL DISULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
90,CHEMBL508112,AFZSMODLJJCVPP-UHFFFAOYSA-N,BENZOTHIAZYL DISULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=C(S2)SSC3=NC4=CC=CC=C4S3,c1ccc2sc(SSc3nc4ccccc4s3)nc2c1
91,CHEMBL134342,AGBQKNBQESQNJD-SSDOTTSWSA-N,LIPOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSS[C@@H]1CCCCC(=O)O,O=C(O)CCCC[C@@H]1CCSS1
92,CHEMBL134342,AGBQKNBQESQNJD-SSDOTTSWSA-N,LIPOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSS[C@@H]1CCCCC(=O)O,O=C(O)CCCC[C@@H]1CCSS1
93,CHEMBL267744,AGHANLSBXUWXTB-UHFFFAOYSA-N,TICRYNAFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
94,CHEMBL267744,AGHANLSBXUWXTB-UHFFFAOYSA-N,TICRYNAFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl
95,CHEMBL270376,AGHXSXMZVMLSGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=C(SC(=N1)C)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F,Cc1nc(C)c(-c2nnc(SCCCN3CCc4ccc5oc(C(F)(F)F)nc5c4CC3)n2C)s1
97,CHEMBL1741,AGOYDEPGAOXOCK-KCBOHYOISA-N,CLARITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
98,CHEMBL1741,AGOYDEPGAOXOCK-KCBOHYOISA-N,CLARITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
99,CHEMBL330172,AHIOIWMCDDMDRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.38,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.195179321278838,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CN=CC=C6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4cccnc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
100,CHEMBL330172,AHIOIWMCDDMDRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,416.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.380906669373259,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CN=CC=C6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4cccnc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
101,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
102,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
103,CHEMBL490,AHOUBRCZNHFOSL-YOEHRIQHSA-N,PAROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4,Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
104,CHEMBL402422,AHTVKTAOAOXKMG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C,Cc1nc2c3c(ccc2o1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
105,CHEMBL1090186,AIGMIQVSRPRWAQ-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,C[C@H](C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CN=C3OC,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccnc1OC
106,CHEMBL583,AIJTTZAVMXIJGM-UHFFFAOYSA-N,GREPAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
107,CHEMBL583,AIJTTZAVMXIJGM-UHFFFAOYSA-N,GREPAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C(=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)C)F,Cc1c(F)c(N2CCNC(C)C2)cc2c1c(=O)c(C(=O)O)cn2C1CC1
108,CHEMBL567993,AIMNRLCNWYRUPJ-HDICACEKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,1600.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.795880017344076,CC1=CC(=CC=C1)C(=O)NC2CCC(CC2)NC3=NC=C(C(=N3)N(C)C)C,Cc1cccc(C(=O)NC2CCC(Nc3ncc(C)c(N(C)C)n3)CC2)c1
109,CHEMBL1767144,AIQKTJZHRRQKTE-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,>,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,5.800000874803202,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)C(=O)O,CN1CCC[C@@H]1Cn1nc(Cc2ccc(C(=O)O)cc2)c2ccccc2c1=O
110,CHEMBL180233,AITHPZKEMCVCDZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,9.55,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.019996628416253,CC(C)OC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O,CC(C)OC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
111,CHEMBL14,AIXAANGOTKPUOY-UHFFFAOYSA-N,CARBACHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)N.[Cl-],C[N+](C)(C)CCOC(N)=O
112,CHEMBL14,AIXAANGOTKPUOY-UHFFFAOYSA-N,CARBACHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)N.[Cl-],C[N+](C)(C)CCOC(N)=O
115,CHEMBL54440,AJLFOPYRIVGYMJ-INTXDZFKSA-N,MEVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
116,CHEMBL54440,AJLFOPYRIVGYMJ-INTXDZFKSA-N,MEVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1CCC=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O,CC[C@H](C)C(=O)O[C@H]1CCC=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
117,CHEMBL1618305,AJPSBXJNFJCCBI-YOHUGVJRSA-N,NALOXONAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
118,CHEMBL1618305,AJPSBXJNFJCCBI-YOHUGVJRSA-N,NALOXONAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1[C@H]2[C@]3([C@]4(C5=C(C2)C=CC(=C5O[C@H]4/C(=N/N=C\6/[C@@H]7OC8=C(C=CC9=C8[C@]72[C@]([C@@H](C9)N(CC2)CC=C)(CC6)O)O)/CC3)O)CC1)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2/C(=N/N=C2\CC[C@@]4(O)[C@H]6Cc7ccc(O)c8c7[C@@]4(CCN6CC=C)[C@H]2O8)CC[C@@]3(O)[C@H]1C5
121,CHEMBL2208426,AJUWTQZJBKWQNV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CS(=O)(=O)C1=CC=C(S1)C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O,CS(=O)(=O)c1ccc(C(=O)NC[C@@H](O)CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)s1
123,CHEMBL593494,AKEGHAUFMKCWGX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,64.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.1938200260161125,CNCCC(C1=CC=CC=C1)C2=CC=CC=C2,CNCCC(c1ccccc1)c1ccccc1
124,CHEMBL364713,AKNNEGZIBPJZJG-MSOLQXFVSA-N,NOSCAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C
125,CHEMBL364713,AKNNEGZIBPJZJG-MSOLQXFVSA-N,NOSCAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC3=C(C(=C2[C@@H]1[C@@H]4C5=C(C(=C(C=C5)OC)OC)C(=O)O4)OC)OCO3,COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C
127,CHEMBL158352,AKTMNFPHGGUJFY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,251.19,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.599997654072044,C1=C(NC=N1)CCCCCCCCCCCN,NCCCCCCCCCCCc1cnc[nH]1
128,CHEMBL158352,AKTMNFPHGGUJFY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,398107170553497.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.6,C1=C(NC=N1)CCCCCCCCCCCN,NCCCCCCCCCCCc1cnc[nH]1
130,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8730737.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12
131,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12
132,CHEMBL1255834,ALFGDCNSEBJYSP-UHFFFAOYSA-N,BW-723C86,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CC1=CNC2=C1C=C(C=C2)OCC3=CC=CS3)N,CC(N)Cc1c[nH]c2ccc(OCc3cccs3)cc12
133,CHEMBL1783963,ALOWJQCLRWGVOV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,110.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9586073148417755,CC1=NC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)F,Cc1ccc(CCn2c3c(c4cc(F)ccc42)CN(C)CC3)cn1
134,CHEMBL1783963,ALOWJQCLRWGVOV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,730.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.136677139879544,CC1=NC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)F,Cc1ccc(CCn2c3c(c4cc(F)ccc42)CN(C)CC3)cn1
135,CHEMBL60143,ALQYYBXQKWSMNS-HHHXNRCGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,5495.41,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2599999003114535,CC(C)(C)OC(=O)N[C@H](CC1=CC=CC=C1)C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,CC(C)(C)OC(=O)N[C@H](Cc1ccccc1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
136,CHEMBL240567,ALWGROOEKGXBRR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC(=CC(=C5)F)F.C(=O)O,O=C(c1cc(F)cc(F)c1)N1CCN(c2ccc(OC3CCN(C4CCCC4)CC3)cc2)C(=O)C1
137,CHEMBL3357035,AMBATUWSQRROKC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,1274.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.894830572000668,CC(C)COC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CC(C)COC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
138,CHEMBL2207284,AMEQLQYPRVOFMB-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CNS(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O,CNS(=O)(=O)c1ccc2c(C(=O)NC[C@@H](O)CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)c[nH]c(=O)c2c1
139,CHEMBL1909080,AMGRXJSJSONEEG-UHFFFAOYSA-L,STRONTIUM CHLORIDE HEXAHYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,O.O.O.O.O.O.[Cl-].[Cl-].[Sr+2],O
140,CHEMBL1909080,AMGRXJSJSONEEG-UHFFFAOYSA-L,STRONTIUM CHLORIDE HEXAHYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,O.O.O.O.O.O.[Cl-].[Cl-].[Sr+2],O
142,CHEMBL2208420,AMQPWRCXJRAWTN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)CCCOC3=CC=CC(=C3)C#N,N#Cc1cccc(OCCCN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)c1
143,CHEMBL1946256,ANQFIBHZMVNJLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CC3=NC4=CC=CC=C4S3,Clc1ccc(N2CCCN(Cc3nc4ccccc4s3)CC2)cc1
144,CHEMBL1242950,ANTKBACNWQHQJE-UHFFFAOYSA-N,AC-42,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20684563.0,Ki,=,610.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,"Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.",J. Med. Chem.,PUBLICATION,,6.214670164989233,CCCCC1CCN(CC1)CCCC(=O)C2=CC=CC=C2C,CCCCC1CCN(CCCC(=O)c2ccccc2C)CC1
145,CHEMBL451,ANTSCNMPPGJYLG-UHFFFAOYSA-N,CHLORDIAZEPOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1795.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.7459355470856615,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O,CN=C1CN(O)C(c2ccccc2)=c2cc(Cl)ccc2=N1
146,CHEMBL451,ANTSCNMPPGJYLG-UHFFFAOYSA-N,CHLORDIAZEPOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,208.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.681936665037237,CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O,CN=C1CN(O)C(c2ccccc2)=c2cc(Cl)ccc2=N1
148,CHEMBL521589,ANZXOIAKUNOVQU-UHFFFAOYSA-N,BAMBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1
149,CHEMBL521589,ANZXOIAKUNOVQU-UHFFFAOYSA-N,BAMBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)OC(=O)N(C)C)OC(=O)N(C)C)O,CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1
150,CHEMBL460499,AOCCBINRVIKJHY-UHFFFAOYSA-N,CARMOFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O
151,CHEMBL460499,AOCCBINRVIKJHY-UHFFFAOYSA-N,CARMOFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCNC(=O)N1C=C(C(=O)NC1=O)F,CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O
152,CHEMBL194206,AOENLUNXEDMDRT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)F)OC,COc1ccc(NC(=O)N2CCN(c3ccc(F)cc3)CC2)cc1N1CCN(C)CC1
153,CHEMBL53463,AOJJSUZBOXZQNB-TZSSRYMLSA-N,DOXORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
154,CHEMBL53463,AOJJSUZBOXZQNB-TZSSRYMLSA-N,DOXORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
155,CHEMBL417,AOJJSUZBOXZQNB-VTZDEGQISA-N,EPIRUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
156,CHEMBL417,AOJJSUZBOXZQNB-VTZDEGQISA-N,EPIRUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1
157,CHEMBL96442,AOMZRTTZRBZOAC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.44,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.191114132640188,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccccn4)CC3)(c3ccccc3)C2)cc(OC)c1OC
158,CHEMBL96442,AOMZRTTZRBZOAC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,366.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.436518914605589,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccccn4)CC3)(c3ccccc3)C2)cc(OC)c1OC
159,CHEMBL1277492,AOSLQNBDHSOLAE-HAQQTFLXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.699991797446188,C1C[C@H](CN(C1)C2CCC3(C2)C4=CC=CC=C4OC5=C(C3=O)C=C(C=C5)Cl)C(=O)O,O=C(O)[C@@H]1CCCN(C2CCC3(C2)C(=O)c2cc(Cl)ccc2Oc2ccccc23)C1
160,CHEMBL1200623,AOXRBFRFYPMWLR-XGXHKTLJSA-N,ETHYLESTRENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
161,CHEMBL1200623,AOXRBFRFYPMWLR-XGXHKTLJSA-N,ETHYLESTRENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CCCC[C@H]34)C)O,CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CCCC[C@@H]4[C@H]3CC[C@@]21C
164,CHEMBL267345,APKFDSVGJQXUKY-INPOYWNPSA-N,AMPHOTERICIN B,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2
165,CHEMBL267345,APKFDSVGJQXUKY-INPOYWNPSA-N,AMPHOTERICIN B,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2
168,CHEMBL878,AQCHWTWZEMGIFD-UHFFFAOYSA-N,METOLAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
169,CHEMBL878,AQCHWTWZEMGIFD-UHFFFAOYSA-N,METOLAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl,Cc1ccccc1N1C(=O)c2cc(S(N)(=O)=O)c(Cl)cc2NC1C
170,CHEMBL452861,AQHHHDLHHXJYJD-AWEZNQCLSA-N,(-)-PROPANOLOL ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@H](O)COc1cccc2ccccc12
171,CHEMBL452861,AQHHHDLHHXJYJD-AWEZNQCLSA-N,(-)-PROPANOLOL ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@H](O)COc1cccc2ccccc12
172,CHEMBL275742,AQHHHDLHHXJYJD-CQSZACIVSA-N,DEXPROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@@H](O)COc1cccc2ccccc12
173,CHEMBL275742,AQHHHDLHHXJYJD-CQSZACIVSA-N,DEXPROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@H](COC1=CC=CC2=CC=CC=C21)O,CC(C)NC[C@@H](O)COc1cccc2ccccc12
174,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
175,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
176,CHEMBL27,AQHHHDLHHXJYJD-UHFFFAOYSA-N,PROPRANOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O,CC(C)NCC(O)COc1cccc2ccccc12
177,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
178,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
179,CHEMBL30,AQIXAKUUQRKLND-UHFFFAOYSA-N,CIMETIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CSCCNC(=NC)NC#N,CN=C(NC#N)NCCSCc1nc[nH]c1C
181,CHEMBL2171045,AQIZHUDMGJRAMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC(=C4)C(F)(F)F,O=C(NS(=O)(=O)c1cccc(C(F)(F)F)c1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
182,CHEMBL768,AQNDDEOPVVGCPG-UHFFFAOYSA-N,ESMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
183,CHEMBL768,AQNDDEOPVVGCPG-UHFFFAOYSA-N,ESMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1
184,CHEMBL517244,AQQFXOLTZFTABW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,40.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.397940008672037,CN(CCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24)CC5=CC=C(C=C5)OCCCN6CCCCC6,CN(CCCC12CCC(c3ccccc31)c1ccccc12)Cc1ccc(OCCCN2CCCCC2)cc1
185,CHEMBL3094114,AQRDKFVOYVDLCT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CC1CN2CCC3=C(CC2)C=C(C=C3)OCC4=CC=CC=C4,c1ccc(COc2ccc3c(c2)CCN(CC2CC2)CC3)cc1
186,CHEMBL2158791,AQVKRBFXFFKXJV-NDEPHWFRSA-N,AZ-12436092,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O,Cc1cc(Cl)ccc1OC1CCN(CC2CCN([C@@](C)(Cc3ccc(F)cc3)C(=O)O)CC2)CC1
187,CHEMBL571819,ARFONFXLNJVMPP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=C(C=C1)CCCC(=O)N2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,Cc1ccc(CCCC(=O)N2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
188,CHEMBL1614641,ARPYQKTVRGFPIS-VIFPVBQESA-N,FLUNOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1
189,CHEMBL1614641,ARPYQKTVRGFPIS-VIFPVBQESA-N,FLUNOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)F)C(=O)O,C[C@H](C(=O)O)c1ccc2oc(-c3ccc(F)cc3)nc2c1
190,CHEMBL1276860,ASARBMLXIRIMCK-SABQLHICSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415903,C1CC2(CC1N3C[C@@H]4[C@H](C3)C4C(=O)O)CC5=CC=CC=C5CC6=CC=CC=C26,O=C(O)C1[C@H]2CN(C3CCC4(Cc5ccccc5Cc5ccccc54)C3)C[C@@H]12
193,CHEMBL659,ASUTZQLVASHGKV-JDFRZJQESA-N,GALANTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2
194,CHEMBL659,ASUTZQLVASHGKV-JDFRZJQESA-N,GALANTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O,COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2
195,CHEMBL446,ASWVTGNCAZCNNR-UHFFFAOYSA-N,SULFAMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1
196,CHEMBL446,ASWVTGNCAZCNNR-UHFFFAOYSA-N,SULFAMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NC(=N1)NS(=O)(=O)C2=CC=C(C=C2)N)C,Cc1cc(C)nc(NS(=O)(=O)c2ccc(N)cc2)n1
197,CHEMBL444633,ATEBXHFBFRCZMA-VXTBVIBXSA-N,RIFABUTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(c4c3C2=O)=NC2(CCN(CC(C)C)CC2)N=5)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
198,CHEMBL444633,ATEBXHFBFRCZMA-VXTBVIBXSA-N,RIFABUTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=NC6(CCN(CC6)CC(C)C)N=C25)O)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(c4c3C2=O)=NC2(CCN(CC(C)C)CC2)N=5)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
199,CHEMBL2171021,ATPAZLJUTRYFNR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C3CCN(CC3)C(=O)C4=CC(=CC=C4)S(=O)(=O)C)Cl,Cc1c(Cl)ccc(OC2CCN(C3CCN(C(=O)c4cccc(S(C)(=O)=O)c4)CC3)CC2)c1Cl
201,CHEMBL158780,AUTKMGMMFJXIDV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,175.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.7569619513137065,C1C2=CC=CC=C2C(C3=CC=CC=C31)CCCN,NCCCC1c2ccccc2Cc2ccccc21
202,CHEMBL50588,AUVVAXYIELKVAI-CKBKHPSWSA-N,EMETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21
203,CHEMBL50588,AUVVAXYIELKVAI-CKBKHPSWSA-N,EMETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1CN2CCC3=CC(=C(C=C3[C@@H]2C[C@@H]1C[C@@H]4C5=CC(=C(C=C5CCN4)OC)OC)OC)OC,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21
204,CHEMBL1544,AUYYCJSJGJYCDS-LBPRGKRZSA-N,LIOTHYRONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
205,CHEMBL1544,AUYYCJSJGJYCDS-LBPRGKRZSA-N,LIOTHYRONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O,N[C@@H](Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)O
206,CHEMBL964,AUZONCFQVSMFAP-UHFFFAOYSA-N,DISULFIRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCN(CC)C(=S)SSC(=S)N(CC)CC
207,CHEMBL964,AUZONCFQVSMFAP-UHFFFAOYSA-N,DISULFIRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)C(=S)SSC(=S)N(CC)CC,CCN(CC)C(=S)SSC(=S)N(CC)CC
208,CHEMBL66388,AVBATPOOKQCBKS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,4085.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.388807939131565,C1CCC2=C(C3=CC=CC=C3N=C2CC1)NCCCN4CCCC4,c1ccc2c(NCCCN3CCCC3)c3c(nc2c1)CCCCC3
209,CHEMBL563451,AVFYUSOOXDDQAW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,1.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)N(C)C,Cc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1
210,CHEMBL174,AVKUERGKIZMTKX-NJBDSQKTSA-N,AMPICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O
211,CHEMBL174,AVKUERGKIZMTKX-NJBDSQKTSA-N,AMPICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O
214,CHEMBL456,AVOLMBLBETYQHX-UHFFFAOYSA-N,ETHACRYNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl
215,CHEMBL456,AVOLMBLBETYQHX-UHFFFAOYSA-N,ETHACRYNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl,C=C(CC)C(=O)c1ccc(OCC(=O)O)c(Cl)c1Cl
216,CHEMBL3094128,AVVIXBQVVAAVHK-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,2511.89,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3CC[C@@H](C3)NC(=O)C4=CC5=C(C=C4)OCO5,O=C(N[C@H]1CCN(Cc2ccc(OCCCN3CCCCC3)cc2)C1)c1ccc2c(c1)OCO2
217,CHEMBL603049,AVZFSLTZULXZCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,31.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.508638306165728,CC1=CC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)F,Cc1ccc(CCn2c3c(c4cc(F)ccc42)CN(C)CC3)cc1
218,CHEMBL1946122,AWIYLVWAILOVMX-RLAPIPATSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,4149.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,5.382056565171027,C1C[C@H]2CC(C[C@@H]1N2CCCOC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2CCCOc1ccc(F)cc1
219,CHEMBL3321789,AWIYLVWAILOVMX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,4149.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.382056565171027,C1CC2CC(CC1N2CCCOC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCOc1ccc(F)cc1
222,CHEMBL1767165,AWKFJGDSZGEFRY-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.100179497572904,COC1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4CCCCC5=CC=C(C=C5)OCCCN6CCCCCC6,COc1ccc(Cc2nn(C[C@H]3CCCN3CCCCc3ccc(OCCCN4CCCCCC4)cc3)c(=O)c3ccccc23)cc1
223,CHEMBL64479,AWRHPMGJQNISSW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,870.96,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0600017900878385,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CCC,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)CCC)CC2)cc1
224,CHEMBL540982,AWYSEPZPTVMKBT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,11.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,CN(C)CCC1=C(C2=CC=CC=C2S1)CC3=CC=C(C=C3)F,CN(C)CCc1sc2ccccc2c1Cc1ccc(F)cc1
225,CHEMBL60559,AXEYQIQVIRZLKE-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9772.37,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.010000098195094,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CSC=C4)N,N[C@H](Cc1ccsc1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
226,CHEMBL1095819,AXIFLPLKZRNVDP-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.045757490560677,CN1CCC[C@H](C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN1CCC[C@@H](c2nc3ccccc3n2Cc2ccc(F)cc2)C1
227,CHEMBL1087089,AXIFLPLKZRNVDP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.5,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.30102999566398,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
228,CHEMBL440294,AXKPFOAXAHJUAG-UHFFFAOYSA-N,PIPAMPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,2400.0,NM,,,,,,,,,,,,,,,,,,,,5.619788758288393,C1CCN(CC1)C2(CCN(CC2)CCCC(=O)C3=CC=C(C=C3)F)C(=O)N,NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1
229,CHEMBL18972,AXNGJCOYCMDPQG-UHFFFAOYSA-N,GLEMANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15999145.0,Ki,=,1604.0,NM,,,,,,,,,,,,,,,,,,,,5.794795636051855,C1CN(CCC1C(C2=CC=CC=C2)O)CCC3=CC=CC=C3,OC(c1ccccc1)C1CCN(CCc2ccccc2)CC1
232,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,1.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,8.886056647693161,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
233,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
234,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,1.5,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
235,CHEMBL556506,AYEYSXMZCARQKR-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)C,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1cnccn1
237,CHEMBL2158790,AYPGYVOWMUSFPT-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O,Cc1c(OC2CCN(CC3CCN([C@@](C)(Cc4ccc(F)cc4)C(=O)O)CC3)CC2)ccc(Cl)c1Cl
238,CHEMBL1278113,AYWYOYAKLYFQAR-JVPYDEADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.0,C1C[C@@]2(CC1N3CCNC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CCN1
241,CHEMBL3238444,BAAHTFHSCKWFDS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,29512.09,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,4.530000033355806,CC1=NN=C(N1C2=CC=C(C=C2)OCCCN3CCCCC3)C,Cc1nnc(C)n1-c1ccc(OCCCN2CCCCC2)cc1
242,CHEMBL559664,BACLISNXCXJOMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,40.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.397940008672037,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCN(CCCN3c4ccccc4Sc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
243,CHEMBL559664,BACLISNXCXJOMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,40.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.397940008672037,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCN(CCCN3c4ccccc4Sc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
244,CHEMBL2158778,BATQCPTUBUKUDO-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,398.11,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,C1CN(CCC1CN2CCC(CC2)OC3=CC=C(C=C3)Cl)[C@@H](CC4=CC=C(C=C4)F)C(=O)O,O=C(O)[C@H](Cc1ccc(F)cc1)N1CCC(CN2CCC(Oc3ccc(Cl)cc3)CC2)CC1
245,CHEMBL565551,BAZQBEOFVYAFHT-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,810.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.091514981121351,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)NC(=O)C3=CC=C(C=C3)F,Cc1cnc(NC2CCC(NC(=O)c3ccc(F)cc3)CC2)nc1N(C)C
246,CHEMBL1669420,BBPIYFSEHZGVJE-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,48.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3187587626244115,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CS4,C[C@H](C1=C(CCN(C)Cc2nccs2)Cc2ccccc21)c1cnccn1
247,CHEMBL1222695,BBQVIKFUQPNVLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC(=C4)Cl)C(=O)O,CC(C)(CN1CCN(C2=Cc3ccccc3Cn3cc(Cl)nc32)CC1)C(=O)O
249,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,16.0,NM,,,,,,,,,,,,,,,,,,,,7.795880017344076,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
250,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,37.0,NM,,,,,,,,,,,,,,,,,,,,7.431798275933005,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
251,CHEMBL11,BCGWQEUPMDMJNV-UHFFFAOYSA-N,IMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23919353.0,IC50,=,27.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Polypharmacology - foe or friend?,J. Med. Chem.,PUBLICATION,,7.568636235841013,CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCCN1c2ccccc2CCc2ccccc21
259,CHEMBL1783974,BDDPDGBPFDDYBY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,2790.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5543957967264035,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CN=CC=C5,Cc1ccc2c(c1)c1c(n2CCc2cccnc2)CCN(C2CCN(C)CC2)C1
260,CHEMBL1783974,BDDPDGBPFDDYBY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CN=CC=C5,Cc1ccc2c(c1)c1c(n2CCc2cccnc2)CCN(C2CCN(C)CC2)C1
262,CHEMBL157273,BDMUROBIUYESLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,398.11,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.399996913372259,C1=CN=CC=C1CCCCCCCCCCCCN,NCCCCCCCCCCCCc1ccncc1
263,CHEMBL157273,BDMUROBIUYESLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1=CN=CC=C1CCCCCCCCCCCCN,NCCCCCCCCCCCCc1ccncc1
264,CHEMBL1774498,BDOFZYNAHBHVET-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,54.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.267606240177032,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4CCC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4CCc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
265,CHEMBL271073,BDRCTGAXOWRNQU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=C(OC=N1)C2=NN=C(N2C)SCCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C,Cc1nc2cc3c(cc2o1)CCN(CCCCSc1nnc(-c2ocnc2C)n1C)CC3
266,CHEMBL608689,BDSUMBDGCUOHGR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,70.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.154901959985742,CN(C)CCCC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCCC(c1ccccc1)c1ccccc1
267,CHEMBL1276859,BEAHZBHBRZMAIL-OSHJFMDRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.500038134403809,C1C[C@@]2(CC1N3CCC(C3)CC(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)CC1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
270,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16621538.0,Ki,=,259.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor by radioligand binding assay,"Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.585695311871668,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1
271,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16621538.0,Ki,=,1467.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor by radioligand binding assay,"Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.833569886156718,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1
272,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,259.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.585695311871668,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1
273,CHEMBL150161,BETHXCLHMRGYBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,1467.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,5.833569886156718,C1CN(CC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)C1)c1ccc(F)cc1
274,CHEMBL94834,BEYBSSSCFNIKNG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.33,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.198596289982643,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=C(C=C7)C(F)(F)F,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(C(F)(F)F)cc3)C2)cc(OC)c1OC
275,CHEMBL94834,BEYBSSSCFNIKNG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,473.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3251388592621876,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=C(C=C7)C(F)(F)F,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(C(F)(F)F)cc3)C2)cc(OC)c1OC
276,CHEMBL42442,BEZZFPOZAYTVHN-UHFFFAOYSA-N,OXFENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc([S+]([O-])c3ccccc3)cc2[nH]1
277,CHEMBL42442,BEZZFPOZAYTVHN-UHFFFAOYSA-N,OXFENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)S(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc([S+]([O-])c3ccccc3)cc2[nH]1
278,CHEMBL588119,BFCDFTHTSVTWOG-YLJYHZDGSA-N,SULOCTIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5176.8,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.285938613185849,CCCCCCCCN[C@H](C)[C@H](C1=CC=C(C=C1)SC(C)C)O,CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1
279,CHEMBL588119,BFCDFTHTSVTWOG-YLJYHZDGSA-N,SULOCTIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2475.9,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.606266900170993,CCCCCCCCN[C@H](C)[C@H](C1=CC=C(C=C1)SC(C)C)O,CCCCCCCCN[C@H](C)[C@@H](O)c1ccc(SC(C)C)cc1
280,CHEMBL256481,BFIAPIAYPVHYPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCCCN4CCc5cc6nc(C)oc6c(C)c5CC4)n3C)cccc2n1
282,CHEMBL691,BFPYWIDHMRZLRN-SLHNCBLASA-N,ETHINYL ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
283,CHEMBL691,BFPYWIDHMRZLRN-SLHNCBLASA-N,ETHINYL ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)O,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C
284,CHEMBL283036,BFQIOOYNLCWKIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)C(F)(F)F,FC(F)(F)c1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
286,CHEMBL1200604,BGDKAVGWHJFAGW-UHFFFAOYSA-N,TROPICAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1
287,CHEMBL1200604,BGDKAVGWHJFAGW-UHFFFAOYSA-N,TROPICAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC1=CC=NC=C1)C(=O)C(CO)C2=CC=CC=C2,CCN(Cc1ccncc1)C(=O)C(CO)c1ccccc1
289,CHEMBL267044,BGRJTUBHPOOWDU-NSHDSACASA-N,LEVOSULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
290,CHEMBL267044,BGRJTUBHPOOWDU-NSHDSACASA-N,LEVOSULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
291,CHEMBL26,BGRJTUBHPOOWDU-UHFFFAOYSA-N,SULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
292,CHEMBL26,BGRJTUBHPOOWDU-UHFFFAOYSA-N,SULPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCCC1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC,CCN1CCCC1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC
293,CHEMBL1092812,BHMPPLVSPUZBNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,120.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CC(C1=CN=C(C=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,COc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1
294,CHEMBL205596,BHQCQFFYRZLCQQ-OELDTZBJSA-N,CHOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O
295,CHEMBL205596,BHQCQFFYRZLCQQ-OELDTZBJSA-N,CHOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](C[C@H](O)[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O
296,CHEMBL64667,BHZVLTKKVOPLTE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1047.13,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.979999397807418,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)N3CCCC3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)N3CCCC3)CC2)cc1
298,CHEMBL3084803,BIDUPMYXGFNAEJ-APGVDKLISA-N,ASTROMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N,CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN
299,CHEMBL3084803,BIDUPMYXGFNAEJ-APGVDKLISA-N,ASTROMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H]([C@@H]([C@@H]([C@H]([C@H]2O)N(C)C(=O)CN)OC)O)N)N)N,CO[C@H]1[C@@H](O)[C@H](N)[C@@H](O[C@H]2O[C@H]([C@H](C)N)CC[C@H]2N)[C@H](O)[C@@H]1N(C)C(=O)CN
300,CHEMBL1629810,BIIFEDMBGOQTDO-USCPGHQQSA-N,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(COC[C@H]1[C@H]2[C@H]([C@@H](CO1)O[C@H]3[C@@H](O[C@H]([C@H]([C@@H]3O)O)O[C@H]4[C@@H](O[C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H](O[C@H]([C@H]([C@@H]5O)O)O[C@H]6[C@@H](O[C@H]([C@H]([C@@H]6O)O)O[C@H]7[C@@H](O[C@H]([C@H]([C@@H]7O)O)O[C@H]8[C@@H](O[C@H]([C@H]([C@@H]8O)O)O[C@H]9[C@@H](O[C@@H](O2)[C@H]([C@@H]9O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O,CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)OC[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@H]9[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O
301,CHEMBL1629810,BIIFEDMBGOQTDO-USCPGHQQSA-N,2-HYDROXYPROPYL-BETA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(COC[C@H]1[C@H]2[C@H]([C@@H](CO1)O[C@H]3[C@@H](O[C@H]([C@H]([C@@H]3O)O)O[C@H]4[C@@H](O[C@H]([C@H]([C@@H]4O)O)O[C@H]5[C@@H](O[C@H]([C@H]([C@@H]5O)O)O[C@H]6[C@@H](O[C@H]([C@H]([C@@H]6O)O)O[C@H]7[C@@H](O[C@H]([C@H]([C@@H]7O)O)O[C@H]8[C@@H](O[C@H]([C@H]([C@@H]8O)O)O[C@H]9[C@@H](O[C@@H](O2)[C@H]([C@@H]9O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O,CC(O)COC[C@@H]1O[C@H]2O[C@H]3[C@H](COCC(C)O)O[C@@H](O[C@H]4[C@H](COCC(C)O)O[C@@H](O[C@H]5[C@H](COCC(C)O)O[C@@H](O[C@H]6[C@H](COCC(C)O)OC[C@@H](O[C@H]7[C@H](COCC(C)O)O[C@@H](O[C@H]8[C@H](COCC(C)O)O[C@@H](O[C@H]9[C@H](COCC(C)O)O[C@@H](O[C@@H]1[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]9O)[C@@H](O)[C@@H]8O)[C@@H](O)[C@@H]7O)[C@@H]6O)[C@@H](O)[C@@H]5O)[C@@H](O)[C@@H]4O)[C@@H](O)[C@@H]3O
302,CHEMBL1935426,BITWXVYTBYRISR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153342.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OCC5CCS(=O)(=O)CC5)CC2,O=S1(=O)CCC(COc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
305,CHEMBL445206,BJIOGJUNALELMI-ARJAWSKDSA-N,ISOEUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C\C1=CC(=C(C=C1)O)OC,C/C=C\c1ccc(O)c(OC)c1
306,CHEMBL445206,BJIOGJUNALELMI-ARJAWSKDSA-N,ISOEUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C\C1=CC(=C(C=C1)O)OC,C/C=C\c1ccc(O)c(OC)c1
307,CHEMBL402794,BJQHLKABXJIVAM-BGYRXZFFSA-N,BIS(2-ETHYLHEXYL)PHTHALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC,CCCC[C@H](CC)COC(=O)c1ccccc1C(=O)OC[C@H](CC)CCCC
308,CHEMBL402794,BJQHLKABXJIVAM-BGYRXZFFSA-N,BIS(2-ETHYLHEXYL)PHTHALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC,CCCC[C@H](CC)COC(=O)c1ccccc1C(=O)OC[C@H](CC)CCCC
309,CHEMBL430368,BKLPUYQJSHHECO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O,CC(C)N1CCC(Oc2ccc(N3CCN(C(=O)c4cc(F)cc(F)c4)CC3=O)cc2)CC1
310,CHEMBL157138,BKRGVLQUQGGVSM-KBXCAEBGSA-N,LISURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,160.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.795880017344076,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
311,CHEMBL157138,BKRGVLQUQGGVSM-KBXCAEBGSA-N,LISURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,19.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.721246399047171,CCN(CC)C(=O)N[C@@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCN(CC)C(=O)N[C@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
313,CHEMBL278172,BLFLLBZGZJTVJG-UHFFFAOYSA-N,BENZOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=CC=C(C=C1)N,CCOC(=O)c1ccc(N)cc1
314,CHEMBL278172,BLFLLBZGZJTVJG-UHFFFAOYSA-N,BENZOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=CC=C(C=C1)N,CCOC(=O)c1ccc(N)cc1
315,CHEMBL15245,BLGXFZZNTVWLAY-SCYLSFHTSA-N,YOHIMBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21
316,CHEMBL15245,BLGXFZZNTVWLAY-SCYLSFHTSA-N,YOHIMBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21
317,CHEMBL499,BLJRIMJGRPQVNF-JTQLQIEISA-N,TIMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1
318,CHEMBL499,BLJRIMJGRPQVNF-JTQLQIEISA-N,TIMOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=NSN=C1N2CCOCC2)O,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1
319,CHEMBL1306,BLSQLHNBWJLIBQ-OZXSUGGESA-N,TERCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
320,CHEMBL1306,BLSQLHNBWJLIBQ-OZXSUGGESA-N,TERCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1CCN(CC1)C2=CC=C(C=C2)OC[C@H]3CO[C@](O3)(CN4C=NC=N4)C5=C(C=C(C=C5)Cl)Cl,CC(C)N1CCN(c2ccc(OC[C@H]3CO[C@](Cn4cncn4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
321,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4
322,CHEMBL567597,BLUAFEHZUWYNDE-DKGJTOOQSA-N,ARTEMISININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H](C(=O)O[C@H]3[C@@]24[C@H]1CC[C@@](O3)(OO4)C)C,C[C@@H]1CC[C@H]2[C@@H](C)C(=O)O[C@@H]3O[C@]4(C)CC[C@@H]1[C@]32OO4
323,CHEMBL1070,BLXXJMDCKKHMKV-UHFFFAOYSA-N,NABUMETONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,COc1ccc2cc(CCC(C)=O)ccc2c1
324,CHEMBL1070,BLXXJMDCKKHMKV-UHFFFAOYSA-N,NABUMETONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC,COc1ccc2cc(CCC(C)=O)ccc2c1
326,CHEMBL1381010,BMBIEKJDTGAZCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-mepyramine from human histamine H1 receptor expressed in HEK293T cells after 1 to 1.5 hrs by liquid scintillation counting analysis,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,MedChemComm,PUBLICATION,,5.0,CC1=CC(=NC(=N1)N2CCOCC2)N3CCN(CC3)C,Cc1cc(N2CCN(C)CC2)nc(N2CCOCC2)n1
330,CHEMBL302005,BMMSDSQQAGDCHS-RQZCQDPDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,11.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,CN(C)C/C=C/1\C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,CN(C)C/C=C1\c2ccccc2COc2ccc(CC(=O)O)cc21
331,CHEMBL302005,BMMSDSQQAGDCHS-RQZCQDPDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,Ki,=,11.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.9586073148417755,CN(C)C/C=C/1\C2=CC=CC=C2COC3=C1C=C(C=C3)CC(=O)O,CN(C)C/C=C1\c2ccccc2COc2ccc(CC(=O)O)cc21
333,CHEMBL192,BNRNXUUZRGQAQC-UHFFFAOYSA-N,SILDENAFIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
334,CHEMBL192,BNRNXUUZRGQAQC-UHFFFAOYSA-N,SILDENAFIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=NN(C2=C1N=C(NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C,CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
336,CHEMBL197796,BNXUKTBRYQQOIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)SC)OC,COc1ccc(NC(=O)N2CCN(c3ccc(SC)cc3)CC2)cc1N1CCN(C)CC1
337,CHEMBL1200545,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,DIFLORASONE DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
338,CHEMBL1200545,BOBLHFUVNSFZPJ-JOYXJVLSSA-N,DIFLORASONE DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C)OC(=O)C)C)O)F)C)F,CC(=O)OCC(=O)[C@@]1(OC(C)=O)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
339,CHEMBL214311,BOQXUEKBVIXPKQ-JSGCOSHPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1[C@@H]([C@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl,Clc1ccc(CNCC[C@H]2C[C@@H]2c2cnc[nH]2)cc1
340,CHEMBL214311,BOQXUEKBVIXPKQ-JSGCOSHPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,IC50,=,8500.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human H1 receptor expressed in 293-EBNA cells assessed as inhibition of histamine agonist activity by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.070581074285707,C1[C@@H]([C@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl,Clc1ccc(CNCC[C@H]2C[C@@H]2c2cnc[nH]2)cc1
341,CHEMBL213886,BOQXUEKBVIXPKQ-TZMCWYRMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1[C@H]([C@@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl,Clc1ccc(CNCC[C@@H]2C[C@H]2c2cnc[nH]2)cc1
342,CHEMBL213886,BOQXUEKBVIXPKQ-TZMCWYRMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,IC50,=,6800.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human H1 receptor expressed in 293-EBNA cells assessed as inhibition of histamine agonist activity by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.1674910872937625,C1[C@H]([C@@H]1C2=CN=CN2)CCNCC3=CC=C(C=C3)Cl,Clc1ccc(CNCC[C@@H]2C[C@H]2c2cnc[nH]2)cc1
343,CHEMBL427216,BOVGTQGAOIONJV-UHFFFAOYSA-N,GLICLAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1
344,CHEMBL427216,BOVGTQGAOIONJV-UHFFFAOYSA-N,GLICLAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2,Cc1ccc(S(=O)(=O)NC(=O)NN2CC3CCCC3C2)cc1
345,CHEMBL539843,BOYLPLUVCXUHDJ-UHFFFAOYSA-N,VAPITADINE DIHYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,19.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.721246399047171,C1CN2C(=CN=C2C3(CCNCC3)C4=CC=CC=C41)C(=O)N.Cl.Cl,NC(=O)c1cnc2n1CCc1ccccc1C21CCNCC1
346,CHEMBL1940420,BPDDCCYSOYRMEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,262.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.581698708680254,C1CN(CCN1CCCOC2=CC=C(C=C2)F)C3=CC=CC=N3,Fc1ccc(OCCCN2CCN(c3ccccn3)CC2)cc1
347,CHEMBL1774504,BPDWWCSMAZGENY-AQHIEDMUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,63.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.200659450546419,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCCN(CC/C=C3/c4ccccc4COc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
348,CHEMBL240178,BPDXEOHDRPKAKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCCC5.C(=O)O,CS(=O)(=O)c1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCCC5)CC4)cc3)C(=O)C2)cc1
349,CHEMBL400224,BPXYTXXFLQUXFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C(=O)N6CCC6.C(=O)O,O=C(c1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1)N1CCC1
351,CHEMBL275507,BPZGZNLONLANFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,794.33,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.0999990348465305,C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3,NCCc1cnc(CCC(c2ccccc2)c2ccccc2)[nH]1
352,CHEMBL275507,BPZGZNLONLANFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,501187233627271.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.699999999999998,C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3,NCCc1cnc(CCC(c2ccccc2)c2ccccc2)[nH]1
353,CHEMBL398615,BQDBKDMTIJBJLA-UHFFFAOYSA-N,METOPIMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,Ki,=,8.4,NM,,,,binding,,,,,,,,,,,,,,,,8.075720713938116,CS(=O)(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCC(CC4)C(=O)N,CS(=O)(=O)c1ccc2c(c1)N(CCCN1CCC(C(N)=O)CC1)c1ccccc1S2
360,CHEMBL1783964,BRMMBDRDSQRBHU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,120.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=NC=C4,CN1CCc2c(c3ccccc3n2CCc2ccncc2)C1
361,CHEMBL1783964,BRMMBDRDSQRBHU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,500.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=NC=C4,CN1CCc2c(c3ccccc3n2CCc2ccncc2)C1
365,CHEMBL193639,BSOLCASXROXPRZ-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,0.52,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,9.283996656365199,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24,CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1
366,CHEMBL193639,BSOLCASXROXPRZ-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,0.6,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,9.221848749616356,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24,CN(C)C[C@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1
367,CHEMBL366164,BSOLCASXROXPRZ-MUKKUYKPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.853871964321762,CN(C)C[C@H]1C[C@H]2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24,CN(C)C[C@H]1C[C@@H]2c3ccccc3Sc3ccc(F)cc3[C@H]2O1
368,CHEMBL363581,BSOLCASXROXPRZ-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.920818753952375,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)SC4=CC=CC=C24,CN(C)C[C@@H]1CC2c3ccccc3Sc3ccc(F)cc3[C@H]2O1
370,CHEMBL320003,BSVGNAQMDXJFNE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.39,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.1944991418416,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4)C6=CC(=C(C=C6)Cl)Cl,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5[nH]4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
371,CHEMBL25,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,ASPIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)Oc1ccccc1C(=O)O
372,CHEMBL25,BSYNRYMUTXBXSQ-UHFFFAOYSA-N,ASPIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=CC=C1C(=O)O,CC(=O)Oc1ccccc1C(=O)O
373,CHEMBL104344,BTCOIJOGNYPDOY-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,2500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6020599913279625,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)Cl)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3ccc(Cl)cc3)C2)cc1)C1CC1
374,CHEMBL239964,BTGWCFVBMYAJIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O,N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCCC5)CC4)cc3)C(=O)C2)cc1
376,CHEMBL106596,BTQCFHMSBTVCNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,7762.47,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.110000065251387,C1CC(CN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)O,N#Cc1ccc(-c2ccc(OCCCN3CCCC(O)C3)cc2)cc1
377,CHEMBL328573,BTSCZNWXJQSJIE-QFBILLFUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,0.64,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.193820026016114,CN(C)C[C@@H]1C[C@@H]2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)C[C@@H]1C[C@@H]2c3ccccc3Cc3ccccc3N2O1
378,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,6.76,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.170053304058364,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
379,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
380,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,6.76,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.170053304058364,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
381,CHEMBL83658,BTSCZNWXJQSJIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,=,6.76,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.170053304058364,CN(C)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CC1CC2c3ccccc3Cc3ccccc3N2O1
382,CHEMBL105071,BTXYSVCTMDAUJN-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,CC(C)(C)c1ccc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)cc1
383,CHEMBL1762,BUJAGSGYPOAWEI-UHFFFAOYSA-N,TOCAINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,Cc1cccc(C)c1NC(=O)C(C)N
384,CHEMBL1762,BUJAGSGYPOAWEI-UHFFFAOYSA-N,TOCAINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C(C)N,Cc1cccc(C)c1NC(=O)C(C)N
392,CHEMBL257901,BVMLPMCCWDUGDH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCN4CCc5cc6nc(C)oc6c(C)c5CC4)n3C)cccc2n1
393,CHEMBL1092496,BVRYNXDISKCAFZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,69.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.161150909262744,CC1=NC=C(C=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1ccc(C(C)c2c(CCN(C)C)sc3ccccc23)cn1
394,CHEMBL1910379,BWBDWEIXBARWJD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,776.25,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.109998386815363,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)Cl)C5=CC=CC=N5,COc1ccc(CN(CCN2CCN(C(=O)c3cc4cc(Cl)ccc4[nH]3)CC2)c2ccccn2)cc1
397,CHEMBL63003,BWVYMOZIPOAYMY-MUUNZHRXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=CC5=CC=CC=C54)N,N[C@H](Cc1cccc2ccccc12)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
398,CHEMBL294502,BXDDBQXEMSRCFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1905.46,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CC,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)CC)CC2)cc1
399,CHEMBL1765111,BXUKKRHEMKVWOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.799970733446231,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C1CCCN(CCc2ccc(OCCCN3CCCCCC3)cc2)CC1
400,CHEMBL1460,BXZVVICBKDXVGW-NKWVEPMBSA-N,DIDANOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1
401,CHEMBL1460,BXZVVICBKDXVGW-NKWVEPMBSA-N,DIDANOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O,O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1
402,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
403,CHEMBL91,BYBLEWFAAKGYCD-UHFFFAOYSA-N,MICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
404,CHEMBL292275,BYKHDCPMWIUHPJ-VGOFMYFVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,616.6,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.209996479609512,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)/C=C/C3=CC=C(C=C3)OC,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)/C=C/c3ccc(OC)cc3)cc2)CC1
405,CHEMBL256650,BYMRLNXYRMIIKD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCN4CCc5cc6nc(C)oc6cc5CC4)n3C)cccc2n1
406,CHEMBL628,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,PENTOXIFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
407,CHEMBL628,BYPFEZZEUUWMEJ-UHFFFAOYSA-N,PENTOXIFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C1=O)C,CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
409,CHEMBL20,BZKPWHYZMXOIDC-UHFFFAOYSA-N,ACETAZOLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CC(=O)Nc1nnc(S(N)(=O)=O)s1
410,CHEMBL20,BZKPWHYZMXOIDC-UHFFFAOYSA-N,ACETAZOLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=NN=C(S1)S(=O)(=O)N,CC(=O)Nc1nnc(S(N)(=O)=O)s1
412,CHEMBL1630579,BZRYYBWNOUALTQ-UHFFFAOYSA-N,MYRTECAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOCCC1=CCC2CC1C2(C)C,CCN(CC)CCOCCC1=CCC2CC1C2(C)C
413,CHEMBL1630579,BZRYYBWNOUALTQ-UHFFFAOYSA-N,MYRTECAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOCCC1=CCC2CC1C2(C)C,CCN(CC)CCOCCC1=CCC2CC1C2(C)C
416,CHEMBL147077,CAAOWRJNPRFDJE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,9857099.0,Ki,=,491.0,NM,,,,,,,,,,,,,,,Binding affinity for recombinant human Histamine H1 receptor using [3H]pyrilamine as radioligand.,Design and synthesis of novel alpha1a adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia.,J. Med. Chem.,PUBLICATION,,6.308918507877031,CC1=C(C(C(=C(N1)C)C(=O)NCCCN2CCC(CC2)(C3=CC=CC=C3)C(=O)OC)C4=CC=C(C=C4)[N+](=O)[O-])C(=O)NC,CNC(=O)C1=C(C)NC(C)=C(C(=O)NCCCN2CCC(C(=O)OC)(c3ccccc3)CC2)C1c1ccc([N+](=O)[O-])cc1
418,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,,,,,,9.0,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
420,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8496700.0,Ki,=,1.6,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from histamine H1 receptor,The role of receptor binding in drug discovery.,J. Nat. Prod.,PUBLICATION,,8.795880017344075,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
421,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,,,,,,9.0,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
422,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.11,NM,,,,,,,,,,,,,,,,,,,,8.954677021213342,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
423,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.53,NM,,,,,,,,,,,,,,,,,,,,8.8153085691824,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
424,CHEMBL855,CBEQULMOCCWAQT-WOJGMQOQSA-N,TRIPROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,3.01,NM,,,,,,,,,,,,,,,,,,,,8.521433504406156,CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3,Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1
425,CHEMBL1159650,CBGUOGMQLZIXBE-XGQKBEPLSA-N,CLOBETASOL PROPIONATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
426,CHEMBL1159650,CBGUOGMQLZIXBE-XGQKBEPLSA-N,CLOBETASOL PROPIONATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl,CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
427,CHEMBL395110,CBHCDHNUZWWAPP-UHFFFAOYSA-N,MEPAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,27.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.568636235841013,CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1
428,CHEMBL395110,CBHCDHNUZWWAPP-UHFFFAOYSA-N,MEPAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3.13,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.504455662453552,CN1CCCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42,CN1CCCC(CN2c3ccccc3Sc3ccccc32)C1
429,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
430,CHEMBL115,CBVCZFGXHXORBI-PXQQMZJSSA-N,INDINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5,CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O
432,CHEMBL2171020,CCJZAFYMSHLKFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CNC(=O)C5=CC=CC=C54,O=C(c1c[nH]c(=O)c2ccccc12)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
435,CHEMBL2158825,CCXXDPNVVABEGJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4CC(=O)O,O=C(O)Cc1ccccc1N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
436,CHEMBL10,CDMGBJANTYXAIV-UHFFFAOYSA-N,SB-203580,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1
437,CHEMBL10,CDMGBJANTYXAIV-UHFFFAOYSA-N,SB-203580,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F,C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1
438,CHEMBL2107687,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,VALETHAMATE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1
439,CHEMBL2107687,CEJGGHKJHDHLAZ-UHFFFAOYSA-M,VALETHAMATE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)C(C1=CC=CC=C1)C(=O)OCC[N+](C)(CC)CC.[Br-],CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1
440,CHEMBL494093,CEUMRIVIGREJGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,9120.11,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.039999923502187,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)N,CN1CCN(c2nc(N)nc3c2CCc2ccccc2-3)CC1
441,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,29.7,NM,,,,,,,,,,,,,,,,,,,,7.527243550682787,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
442,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12784105.0,Ki,=,25.1,NM,,,,,,,,,,,,,,,,,,,,7.6003262785189625,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
443,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,420.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.376750709602098,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
444,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,25.1,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.6003262785189625,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
445,CHEMBL1112,CEUORZQYGODEFX-UHFFFAOYSA-N,ARIPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,7.0,C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl,O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
446,CHEMBL93321,CEXVQARQHVKRBU-RMNMTYGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,9.6,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.017728766960431,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3COC4=CC=CC=C24,CN(C)CC1C[C@@H]2c3ccccc3OCc3ccccc3[C@H]2O1
447,CHEMBL61070,CFANDXVYVGVAJZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,602.56,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.219999701663428,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CCCCC3,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)C3CCCCC3)cc2)CC1
448,CHEMBL508102,CFOYWRHIYXMDOT-UHFFFAOYSA-N,CARBIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1C=CN(C1=S)C,CCOC(=O)n1ccn(C)c1=S
449,CHEMBL508102,CFOYWRHIYXMDOT-UHFFFAOYSA-N,CARBIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N1C=CN(C1=S)C,CCOC(=O)n1ccn(C)c1=S
450,CHEMBL27979,CFUHKRLMDNFZED-SFTDATJTSA-N,"A-349,821",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12657274.0,Ki,=,2344.23,NM,,,,,,,,,,,,,,,Binding affinity towards human histaminergic (H1) receptor,Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.6299997805248845,C[C@H]1CC[C@@H](N1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCOCC4)C,C[C@H]1CC[C@H](C)N1CCCOc1ccc(-c2ccc(C(=O)N3CCOCC3)cc2)cc1
451,CHEMBL62421,CGDJUGZQGOTFLF-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,35481.34,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.449999986821809,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](C)N)CC2)cc1
452,CHEMBL6,CGIGDMFJXJATDK-UHFFFAOYSA-N,INDOMETHACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
453,CHEMBL6,CGIGDMFJXJATDK-UHFFFAOYSA-N,INDOMETHACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
454,CHEMBL95076,CGNVNXXLENQGRB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.35,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.197226274708022,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCOCC6=CC=CO6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4CCOCc4ccco4)CC3)(c3ccccc3)C2)cc(OC)c1OC
455,CHEMBL2158773,CGPUMTTUBWGRHT-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,CC1=CC(=CC=C1)C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1cccc(C[C@@H](C(=O)O)N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
457,CHEMBL560386,CHCVZZOPCAVWNV-HTAPYJJXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19520574.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,"Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@H]1[C@@H](OC2=C(C=CC=C2S1(=O)=O)OC)C3=CC=C(C=C3)OCCCN4CCCC4,COc1cccc2c1O[C@@H](c1ccc(OCCCN3CCCC3)cc1)[C@H](C)S2(=O)=O
458,CHEMBL64021,CHEGJFNZXABNBU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,380.19,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.41999931041096,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=CC(=C3)C,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)c3cccc(C)c3)cc2)CC1
460,CHEMBL2037531,CHGXPKZHRZIZSQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22520153.0,Ki,=,52.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 histamine receptor by liquid scintillation assay,Benzothiazoles as probes for the 5HT(1A) receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants.,Eur. J. Med. Chem.,PUBLICATION,,7.2839966563652,C1CN(CCC1C2=CC=CC=C2)CCCCC(=O)C3=NC4=CC=CC=C4S3,O=C(CCCCN1CCC(c2ccccc2)CC1)c1nc2ccccc2s1
462,CHEMBL56337,CHNUOJQWGUIOLD-NFZZJPOKSA-N,EPALRESTAT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1
463,CHEMBL56337,CHNUOJQWGUIOLD-NFZZJPOKSA-N,EPALRESTAT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C(=C\C1=CC=CC=C1)/C=C\2/C(=O)N(C(=S)S2)CC(=O)O,CC(/C=C1\SC(=S)N(CC(=O)O)C1=O)=C\c1ccccc1
464,CHEMBL241694,CHNXZKVNWQUJIB-CEGNMAFCSA-N,ETHISTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
465,CHEMBL241694,CHNXZKVNWQUJIB-CEGNMAFCSA-N,ETHISTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
468,CHEMBL2432039,CHZUEGVOEFMIJH-ZKRSMWHSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,4736.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.324588306285137,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC67C8C9C6C1C9C8C71,C1C2C3CC4C2C2C1C3[C@H](NCC13C5C6C7C5C1C7C63)C42
470,CHEMBL2146813,CIAWHNGOFJZBCL-MGBGTMOVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,17.38,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,7.759950227887352,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=C(C=NC=C5)C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccncc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
471,CHEMBL1572,CIDUJQMULVCIBT-MQDUPKMGSA-N,NETILMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O
472,CHEMBL1572,CIDUJQMULVCIBT-MQDUPKMGSA-N,NETILMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H]1C[C@@H]([C@H]([C@@H]([C@H]1O[C@@H]2[C@@H]([C@H]([C@@](CO2)(C)O)NC)O)O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N,CCN[C@@H]1C[C@H](N)[C@@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O
473,CHEMBL79496,CIIWLVZNBDXUIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)C(=O)C1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)C(=O)C1CC2c3ccccc3Cc3ccccc3N2O1
474,CHEMBL464811,CILDROBPHGWMGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,190.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3CCN(CC3)C4=NC5=C(C=CC(=C5)Cl)NC6=CC=CC=C64,Clc1ccc2c(c1)N=C(N1CCN(Cc3ccc(OCCCN4CCCCC4)cc3)CC1)c1ccccc1N2
476,CHEMBL156131,CISTXXCPQIZSIS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,31622776601683.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.5,C1=CC=C(C=C1)C2=NC(=CS2)CCN,NCCc1csc(-c2ccccc2)n1
478,CHEMBL196,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ASCORBATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O
479,CHEMBL196,CIWBSHSKHKDKBQ-JLAZNSOCSA-N,ASCORBATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O,O=C1O[C@H]([C@@H](O)CO)C(O)=C1O
480,CHEMBL459,CJCSPKMFHVPWAR-JTQLQIEISA-N,METHYLDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
481,CHEMBL459,CJCSPKMFHVPWAR-JTQLQIEISA-N,METHYLDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O
482,CHEMBL2105617,CJDRUOGAGYHKKD-FUIWMBJSSA-N,AJMALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O
483,CHEMBL2105617,CJDRUOGAGYHKKD-FUIWMBJSSA-N,AJMALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1C2CC3C4C5(CC(C2[C@H]5O)N3C1O)C6=CC=CC=C6N4C,CCC1C2CC3C4N(C)c5ccccc5C45CC(C2[C@H]5O)N3C1O
484,CHEMBL481153,CJGNMVAAMQAWEF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23707254.0,Ki,=,29.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.5376020021010435,C1CCN(C1)CCOC(=O)N2C3=CC=CC=C3SC4=CC=CC=C42,O=C(OCCN1CCCC1)N1c2ccccc2Sc2ccccc21
485,CHEMBL73706,CJHFYNOETGOKCU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,550.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.259637310505756,C1CN(CCN1CC2=CC=C(O2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,NC(=O)N(O)CCC#Cc1ccc(CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)o1
486,CHEMBL1767145,CJMVJEMHSLDPMO-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.501,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.300162274132754,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=CC=C4)F,CN1CCC[C@@H]1Cn1nc(Cc2cccc(F)c2)c2ccccc2c1=O
488,CHEMBL64884,CJXQVUBYAQWRHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,56.23,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.250031916490598,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CN3C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3cccn3C)CC2)cc1
491,CHEMBL157843,CKIRNALZCRYDMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1000000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.0,C1=CC=NC(=C1)CCCCCCCCCCCCN,NCCCCCCCCCCCCc1ccccn1
493,CHEMBL1082723,CKLPLPZSUQEDRT-WPCRTTGESA-N,NITD609,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20813948.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant histamine H1 receptor,"Spiroindolones, a potent compound class for the treatment of malaria.",Science,PUBLICATION,,5.0,C[C@H]1CC2=C([C@]3(N1)C4=C(C=CC(=C4)Cl)NC3=O)NC5=CC(=C(C=C25)F)Cl,C[C@H]1Cc2c([nH]c3cc(Cl)c(F)cc23)[C@@]2(N1)C(=O)Nc1ccc(Cl)cc12
496,CHEMBL274767,CKMBGNSZMPWQNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,794328234724282.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.9,C1=CC=C(C=C1)C(CCCCC2=NC=C(N2)CCN)C3=CC=CC=C3,NCCc1cnc(CCCCC(c2ccccc2)c2ccccc2)[nH]1
498,CHEMBL1923528,CLEGTFPJUAEKOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,2290.87,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.639999555020353,CNCC(CN1C2CCCCC2C3=CC=CC=C31)O,CNCC(O)CN1c2ccccc2C2CCCCC21
499,CHEMBL1200558,CLKOFPXJLQSYAH-ABRJDSQDSA-N,BACITRACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4,CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1
500,CHEMBL1200558,CLKOFPXJLQSYAH-ABRJDSQDSA-N,BACITRACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)NCCCC[C@@H](C(=O)N[C@@H](C(=O)N1)CCCN)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]2CSC(=N2)[C@H]([C@@H](C)CC)N)CC(=O)N)CC(=O)O)CC3=CN=CN3)CC4=CC=CC=C4,CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1
501,CHEMBL270602,CLKWUUNGQCSMKW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=CN=C(C=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F,Cc1cnc(-c2nnc(SCCCN3CCc4ccc5oc(C(F)(F)F)nc5c4CC3)n2C)cn1
505,CHEMBL2208432,CLQMFOOMFPNKNA-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)N3C4=CC=CC=C4NC3=O)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)n1c(=O)[nH]c2ccccc21
506,CHEMBL3357042,CLTMMUQENFHOIL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,289.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.539102157243452,CC(C)CC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CC(C)CC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
507,CHEMBL1515611,CMCCHHWTTBEZNM-UHFFFAOYSA-N,BROMISOVALUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(C(=O)NC(=O)N)Br,CC(C)C(Br)C(=O)NC(N)=O
508,CHEMBL1515611,CMCCHHWTTBEZNM-UHFFFAOYSA-N,BROMISOVALUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(C(=O)NC(=O)N)Br,CC(C)C(Br)C(=O)NC(N)=O
509,CHEMBL88,CMSMOCZEIVJLDB-UHFFFAOYSA-N,CYCLOPHOSPHAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNP(=O)(OC1)N(CCCl)CCCl,O=P1(N(CCCl)CCCl)NCCCO1
510,CHEMBL88,CMSMOCZEIVJLDB-UHFFFAOYSA-N,CYCLOPHOSPHAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CNP(=O)(OC1)N(CCCl)CCCl,O=P1(N(CCCl)CCCl)NCCCO1
511,CHEMBL154,CMWTZPSULFXXJA-VIFPVBQESA-N,NAPROXEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
512,CHEMBL154,CMWTZPSULFXXJA-VIFPVBQESA-N,NAPROXEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O,COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
515,CHEMBL2432047,CNPQMMDLXZBMLB-KPCGFGSOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CN=CC=C6,c1cncc(CN[C@H]2C3C4CC5C6C4CC3C6C52)c1
517,CHEMBL270239,COKSKIXACCXTRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCC(C)N4CCc5cc6nc(C)oc6c(C)c5CC4)n3C)cccc2n1
518,CHEMBL820,COVZYZSDYWQREU-UHFFFAOYSA-N,BUSULFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)OCCCCOS(=O)(=O)C,CS(=O)(=O)OCCCCOS(C)(=O)=O
519,CHEMBL820,COVZYZSDYWQREU-UHFFFAOYSA-N,BUSULFAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)OCCCCOS(=O)(=O)C,CS(=O)(=O)OCCCCOS(C)(=O)=O
520,CHEMBL478617,CPDKHEPGGZULPR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,635.4,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.196952789508871,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=CC=C4)O,O=C(CCCN1C2CCC1CC(O)(c1ccccc1)C2)c1ccc(F)cc1
521,CHEMBL1454946,CPEUVMUXAHMANV-UHFFFAOYSA-N,FLUBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F,COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1
522,CHEMBL1454946,CPEUVMUXAHMANV-UHFFFAOYSA-N,FLUBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F,COC(=O)Nc1nc2ccc(C(=O)c3ccc(F)cc3)cc2[nH]1
523,CHEMBL16073,CPJSUEIXXCENMM-UHFFFAOYSA-N,PHENACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC=C(C=C1)NC(=O)C,CCOc1ccc(NC(C)=O)cc1
524,CHEMBL16073,CPJSUEIXXCENMM-UHFFFAOYSA-N,PHENACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC=C(C=C1)NC(=O)C,CCOc1ccc(NC(C)=O)cc1
526,CHEMBL2432051,CPLYGLAQLNAQOI-SEDVZXITSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,5569.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.254222782110241,COC1=CC(=CC(=C1OC)OC)CN[C@H]2C3C4CC5C2C6C3CC4C56,COc1cc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc(OC)c1OC
527,CHEMBL404956,CPNTXNSOEZESIH-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=C(C=CC(=C1)F)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,Cc1cc(F)ccc1O[C@H](c1ccccc1)[C@H]1CNCCO1
531,CHEMBL1321,CPTBDICYNRMXFX-UHFFFAOYSA-N,PROCARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,CNNCc1ccc(C(=O)NC(C)C)cc1
532,CHEMBL1321,CPTBDICYNRMXFX-UHFFFAOYSA-N,PROCARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC(=O)C1=CC=C(C=C1)CNNC,CNNCc1ccc(C(=O)NC(C)C)cc1
533,CHEMBL82714,CQGTWGRGLDAJSE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,1.66,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.779891911959945,CC1(CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)CN(C)C,CN(C)CC1(C)CC2c3ccccc3Cc3ccccc3N2O1
534,CHEMBL82714,CQGTWGRGLDAJSE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,61.66,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.209996479609512,CC1(CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)CN(C)C,CN(C)CC1(C)CC2c3ccccc3Cc3ccccc3N2O1
535,CHEMBL510139,CQIUKKVOEOPUDV-IYSWYEEDSA-N,CITRININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,CC1=C2C(=CO[C@H](C)[C@H]2C)C(=O)C(C(=O)O)=C1O
536,CHEMBL510139,CQIUKKVOEOPUDV-IYSWYEEDSA-N,CITRININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H](OC=C2C1=C(C(=C(C2=O)C(=O)O)O)C)C,CC1=C2C(=CO[C@H](C)[C@H]2C)C(=O)C(C(=O)O)=C1O
538,CHEMBL310018,CQJJYGDKIDMYJM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,676.08,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.170001911302621,CN(C)CCCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CCCC1CC2c3ccccc3Cc3ccccc3N2O1
539,CHEMBL1210154,CQUWKHKELQQYRI-KGENOOAVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20591666.0,IC50,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells,A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C/C(=N\OC(=O)NC1=CC=CC=C1)/C2=CC=CC(=C2)C3=CC=CS3,C/C(=N\OC(=O)Nc1ccccc1)c1cccc(-c2cccs2)c1
540,CHEMBL102416,CRGOWMIZBWIMTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,575.44,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.239999952707271,C1CN(CCC1O)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CCC(O)CC3)cc2)cc1
542,CHEMBL486963,CSAKAHRWRJLYBQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,2900.0,NM,,,,,,,,,,,,,,,,,,,,5.537602002101044,C1=CC=C(C=C1)CCCCC(=O)NC(=NCCCC2=CN=CN2)N,NC(=NCCCc1cnc[nH]1)NC(=O)CCCCc1ccccc1
544,CHEMBL2171024,CSSKAGWIWQOQME-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC(=CC=C4)C(=O)O,O=C(O)c1cccc(C(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
545,CHEMBL1289,CTETYYAZBPJBHE-UHFFFAOYSA-N,HALOPROGIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI,Clc1cc(Cl)c(OCC#CI)cc1Cl
546,CHEMBL1289,CTETYYAZBPJBHE-UHFFFAOYSA-N,HALOPROGIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=CC(=C1Cl)Cl)Cl)OCC#CI,Clc1cc(Cl)c(OCC#CI)cc1Cl
547,CHEMBL94726,CTPOZVITFCJCLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.59,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.18111458540599,COC1=C(C(=C(C=C1)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8)OC)OC,COc1ccc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc4c(c3)OCO4)C2)c(OC)c1OC
549,CHEMBL1068,CTRLABGOLIVAIY-UHFFFAOYSA-N,OXCARBAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,NC(=O)N1c2ccccc2CC(=O)c2ccccc21
550,CHEMBL1068,CTRLABGOLIVAIY-UHFFFAOYSA-N,OXCARBAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N,NC(=O)N1c2ccccc2CC(=O)c2ccccc21
551,CHEMBL2158824,CUIDNQSCWXAPRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)C(=O)O,O=C(O)c1ccc(N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
552,CHEMBL2205822,CUIQKJJPRAKRJM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCCc1cccc(F)c1
553,CHEMBL318369,CUKBOHPSSFJJFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.02,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.220403508742175,CCOC(=O)CCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC(=C(C=C6)Cl)Cl,CCOC(=O)CCCn1c(C(=O)C2CCN(CCC3(c4ccc(Cl)c(Cl)c4)CCN(C(=O)c4cc(OC)c(OC)c(OC)c4)C3)CC2)nc2ccccc21
556,CHEMBL1123,CURUTKGFNZGFSE-UHFFFAOYSA-N,DICYCLOMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1
557,CHEMBL1123,CURUTKGFNZGFSE-UHFFFAOYSA-N,DICYCLOMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1
558,CHEMBL444353,CVHQTOGEHBNYHC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,12.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.920818753952375,CN1C=CC2=C1C(=O)CN3C=CN=C3C2=C4CCNCC4,Cn1ccc2c1C(=O)Cn1ccnc1C2=C1CCNCC1
559,CHEMBL278462,CVKJAXCQPFOAIN-VXGBXAGGSA-N,CIPRALISANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15608078.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C)(C)CCC#C[C@@H]1C[C@H]1C2=CN=CN2,CC(C)(C)CCC#C[C@@H]1C[C@H]1c1cnc[nH]1
561,CHEMBL256653,CVPRWHZDWBRVGS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CN=CC=C5,Cc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2cccnc2)n1C)CC3
562,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,3.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
563,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,3.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
564,CHEMBL550818,CVUXESFCUHCXHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,3.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(CC1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
566,CHEMBL2030631,CWEGCQIIDCZZED-UHFFFAOYSA-N,N-BENZYLPYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CC2=CC=CC=C2,c1ccc(CN2CCCC2)cc1
567,CHEMBL64334,CWMROIPYLYIONF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,660.69,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.180002266489224,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CCCC,CCCCCC(=O)c1ccc(OCCCN2CCN(CCCC)CC2)cc1
568,CHEMBL2158781,CWXOTCCLEKNUJY-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,CC1=C(C=CC(=C1)F)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O,Cc1cc(F)ccc1OC1CCN(CC2CCN([C@@H](Cc3ccc(F)cc3)C(=O)O)CC2)CC1
569,CHEMBL1231530,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,BETAMIPRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NCCC(=O)O,O=C(O)CCNC(=O)c1ccccc1
570,CHEMBL1231530,CWXYHOHYCJXYFQ-UHFFFAOYSA-N,BETAMIPRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NCCC(=O)O,O=C(O)CCNC(=O)c1ccccc1
572,CHEMBL1276948,CXDSZAINFKAKPN-AKRCKQFNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,8.199970640755867,C1C[C@@]2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
573,CHEMBL239510,CXJWCTREHRSRNG-BDQAORGHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O,C[C@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(C#N)cc3)CC2=O)cc1
574,CHEMBL239080,CXJWCTREHRSRNG-VEIFNGETSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(C#N)cc3)CC2=O)cc1
575,CHEMBL16,CXOFVDLJLONNDW-UHFFFAOYSA-N,PHENYTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
576,CHEMBL16,CXOFVDLJLONNDW-UHFFFAOYSA-N,PHENYTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3,O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1
577,CHEMBL210578,CXQUOFVDYCOSEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16621538.0,Ki,=,8780.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor by radioligand binding assay,"Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.056505484093897,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1
578,CHEMBL210578,CXQUOFVDYCOSEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,8780.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,5.056505484093897,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1
579,CHEMBL210578,CXQUOFVDYCOSEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,8780.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.056505484093897,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,O=C(CCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1ccc(F)cc1
580,CHEMBL271702,CXSFVUWINAYILW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=CN=C(C=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)C(=NO5)C,Cc1cnc(-c2nnc(SCCCN3CCc4ccc5c(C)noc5c4CC3)n2C)cn1
581,CHEMBL1201024,CXYRUNPLKGGUJF-XKTSLVMZSA-M,METHSCOPOLAMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],C[N+]1(C)[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@H]1O[C@@H]21
582,CHEMBL1201024,CXYRUNPLKGGUJF-XKTSLVMZSA-M,METHSCOPOLAMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1([C@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C.[Br-],C[N+]1(C)[C@H]2CC(OC(=O)[C@H](CO)c3ccccc3)C[C@H]1[C@H]1O[C@@H]21
583,CHEMBL2171014,CYAXTHULEFHIMG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C3CCN(CC3)C(=O)NS(=O)(=O)C4=CC=C(C=C4)N(C)C)Cl,Cc1c(Cl)ccc(OC2CCN(C3CCN(C(=O)NS(=O)(=O)c4ccc(N(C)C)cc4)CC3)CC2)c1Cl
584,CHEMBL404520,CYDMQBQPVICBEU-XRNKAMNCSA-N,CHLORTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12
585,CHEMBL404520,CYDMQBQPVICBEU-XRNKAMNCSA-N,CHLORTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C(C=CC(=C41)Cl)O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)ccc(Cl)c4[C@@](C)(O)[C@H]3C[C@@H]12
587,CHEMBL75880,CYXKNKQEMFBLER-UHFFFAOYSA-N,PERHEXILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
588,CHEMBL75880,CYXKNKQEMFBLER-UHFFFAOYSA-N,PERHEXILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3,C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1
590,CHEMBL1783961,CZCOISNXSIJAAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,650.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.187086643357143,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2cccnc2)C1
591,CHEMBL1783961,CZCOISNXSIJAAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,930.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.031517051446066,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2cccnc2)C1
592,CHEMBL311469,CZIHNRWJTSTCEX-UHFFFAOYSA-N,2-ACETYLAMINOFLUORENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2
593,CHEMBL311469,CZIHNRWJTSTCEX-UHFFFAOYSA-N,2-ACETYLAMINOFLUORENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC2=C(C=C1)C3=CC=CC=C3C2,CC(=O)Nc1ccc2c(c1)Cc1ccccc1-2
594,CHEMBL98350,CZQHHVNHHHRRDU-UHFFFAOYSA-N,LY-294002,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12
595,CHEMBL98350,CZQHHVNHHHRRDU-UHFFFAOYSA-N,LY-294002,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1C2=CC(=O)C3=C(O2)C(=CC=C3)C4=CC=CC=C4,O=c1cc(N2CCOCC2)oc2c(-c3ccccc3)cccc12
596,CHEMBL1092600,CZXWYWSRENNIBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,11.9,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.924453038607469,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)CC3=NC=CN=C3,Cc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1
597,CHEMBL1277125,DADRXTGBZRBZMD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.0,C1CN(CC(=C1)C(=O)O)C2CCC3(C2)CC4=CC=CC=C4OC5=CC=CC=C35,O=C(O)C1=CCCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1
598,CHEMBL241329,DARWEDNPGILOPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18020391.0,Ki,=,270.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.,J. Med. Chem.,PUBLICATION,,6.568636235841013,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC(=O)C3=CN=CC(=C3)C)Cl,CCOc1cc(CN2CCC(NC(=O)c3cncc(C)c3)CC2)ccc1Cl
601,CHEMBL897,DBABZHXKTCFAPX-UHFFFAOYSA-N,PROBENECID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
602,CHEMBL897,DBABZHXKTCFAPX-UHFFFAOYSA-N,PROBENECID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)S(=O)(=O)C1=CC=C(C=C1)C(=O)O,CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1
603,CHEMBL710,DBEPLOCGEIEOCV-WSBQPABSSA-N,FINASTERIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
604,CHEMBL710,DBEPLOCGEIEOCV-WSBQPABSSA-N,FINASTERIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C
605,CHEMBL1277217,DBFNYFZBHMQFLI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,158.49,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.799998134593397,C1CC2(CC1N3CCC(CC3)(C(=O)O)F)CC4=CC=CC=C4OC5=CC=CC=C25,O=C(O)C1(F)CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1
606,CHEMBL248702,DBGIVFWFUFKIQN-VIFPVBQESA-N,DEXFENFLURAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1
607,CHEMBL248702,DBGIVFWFUFKIQN-VIFPVBQESA-N,DEXFENFLURAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN[C@@H](C)CC1=CC(=CC=C1)C(F)(F)F,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1
608,CHEMBL1062,DBPWSSGDRRHUNT-CEGNMAFCSA-N,HYDROXYPROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
609,CHEMBL1062,DBPWSSGDRRHUNT-CEGNMAFCSA-N,HYDROXYPROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
610,CHEMBL871,DBVJJBKOTRCVKF-UHFFFAOYSA-N,ETIDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(O)(P(=O)(O)O)P(=O)(O)O,CC(O)(P(=O)(O)O)P(=O)(O)O
611,CHEMBL871,DBVJJBKOTRCVKF-UHFFFAOYSA-N,ETIDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(O)(P(=O)(O)O)P(=O)(O)O,CC(O)(P(=O)(O)O)P(=O)(O)O
615,CHEMBL1767140,DCGYGKIBQOAKTB-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.500312917381596,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)F,CN1CCC[C@@H]1Cn1nc(Cc2ccc(F)cc2)c2ccccc2c1=O
616,CHEMBL139,DCOPUUMXTXDBNB-UHFFFAOYSA-N,DICLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
617,CHEMBL139,DCOPUUMXTXDBNB-UHFFFAOYSA-N,DICLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl
618,CHEMBL2158817,DCPIUFZZSDRFTC-AJZOCDQUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,19.95,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@H]3CN(CCO3)C(C4=CC=CC=C4)C(=O)O,O=C(O)C(c1ccccc1)N1CCO[C@@H](CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)C1
619,CHEMBL2158818,DCPIUFZZSDRFTC-PPUHSXQSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H]3CN(CCO3)C(C4=CC=CC=C4)C(=O)O,O=C(O)C(c1ccccc1)N1CCO[C@H](CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)C1
620,CHEMBL105669,DCSHODGQAYSURK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,27.54,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.560036064079095,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=C(C=C(C=C3)C#N)C,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccc(C#N)cc3C)cc2)CC1
621,CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
622,CHEMBL1729,DCSUBABJRXZOMT-UHFFFAOYSA-N,CISAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1CN(CCC1NC(=O)C2=CC(=C(C=C2OC)N)Cl)CCCOC3=CC=C(C=C3)F,COc1cc(N)c(Cl)cc1C(=O)NC1CCN(CCCOc2ccc(F)cc2)CC1OC
623,CHEMBL40,DDBREPKUVSBGFI-UHFFFAOYSA-N,PHENOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
624,CHEMBL40,DDBREPKUVSBGFI-UHFFFAOYSA-N,PHENOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O
625,CHEMBL476323,DDDZBLNULGDPGA-UHFFFAOYSA-N,MK-0249,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18598020.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,"Synthesis, structure-activity relationships, and biological profiles of a quinazolinone class of histamine H3 receptor inverse agonists.",J. Med. Chem.,PUBLICATION,,5.0,CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OCCCN4CCCC4)C(F)(F)F,Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OCCCN2CCCC2)cc1
626,CHEMBL558467,DDHSIUUOIYFUOU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,1.8,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.744727494896694,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
627,CHEMBL2367892,DDTDNCYHLGRFBM-YZEKDTGTSA-N,TEICOPLANIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1[C@H]([C@@H]([C@@H](O[C@H]1O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O[C@@H]5[C@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C6=C(C=CC(=C6)[C@H](C(=O)N3)NC(=O)[C@H]7C8=CC(=C(C(=C8)OC9=C(C=C2C=C9)Cl)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)CO)O)O)NC(=O)C)OC1=C(C=C(C[C@@H]2C(=O)N[C@@H](C3=CC(=CC(=C3)OC3=C(C=CC(=C3)[C@H](C(=O)N2)N)O)O)C(=O)N7)C=C1)Cl)O)C(=O)O)CO)O)O,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O
628,CHEMBL2367892,DDTDNCYHLGRFBM-YZEKDTGTSA-N,TEICOPLANIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1[C@H]([C@@H]([C@@H](O[C@H]1O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O[C@@H]5[C@H]([C@@H]([C@@H]([C@H](O5)CO)O)O)O)C6=C(C=CC(=C6)[C@H](C(=O)N3)NC(=O)[C@H]7C8=CC(=C(C(=C8)OC9=C(C=C2C=C9)Cl)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)CO)O)O)NC(=O)C)OC1=C(C=C(C[C@@H]2C(=O)N[C@@H](C3=CC(=CC(=C3)OC3=C(C=CC(=C3)[C@H](C(=O)N2)N)O)O)C(=O)N7)C=C1)Cl)O)C(=O)O)CO)O)O,CC(=O)N[C@@H]1[C@H](Oc2c3cc4cc2Oc2ccc(cc2Cl)[C@@H](O[C@@H]2O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]2NC(C)=O)[C@@H]2NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H]4NC(=O)[C@@H](Cc5ccc(c(Cl)c5)O3)NC(=O)[C@H](N)c3ccc(O)c(c3)Oc3cc(O)cc4c3)c3ccc(O)c(c3)-c3c(O[C@H]4O[C@H](CO)[C@@H](O)[C@@H](O)[C@@H]4O)cc(O)cc3[C@@H](C(=O)O)NC2=O)O[C@@H](CO)[C@@H](O)[C@@H]1O
629,CHEMBL562,DDUHZTYCFQRHIY-RBHXEPJQSA-N,GRISEOFULVIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
630,CHEMBL562,DDUHZTYCFQRHIY-RBHXEPJQSA-N,GRISEOFULVIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC,COC1=CC(=O)C[C@@H](C)[C@]12Oc1c(Cl)c(OC)cc(OC)c1C2=O
634,CHEMBL3350037,DEQANNDTNATYII-JDBXKHNRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@@H](C)O)O,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
635,CHEMBL3350037,DEQANNDTNATYII-JDBXKHNRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@@H](CO)[C@@H](C)O)O,C[C@@H](O)[C@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1
636,CHEMBL43064,DERZBLKQOCDDDZ-JLHYYAGUSA-N,CINNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,74.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.130768280269023,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
637,CHEMBL43064,DERZBLKQOCDDDZ-JLHYYAGUSA-N,CINNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,8.62,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.064492734175287,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=CC=C3)C4=CC=CC=C4,C(=C/c1ccccc1)\CN1CCN(C(c2ccccc2)c2ccccc2)CC1
638,CHEMBL1923522,DFBFDRZHAVAEKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,61.66,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,7.209996479609512,CN1CCN(CC1)C2=NC3=C(C=NN3C)C(=N2)N4CCCC4,CN1CCN(c2nc(N3CCCC3)c3cnn(C)c3n2)CC1
639,CHEMBL1923522,DFBFDRZHAVAEKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,62.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,7.207608310501746,CN1CCN(CC1)C2=NC3=C(C=NN3C)C(=N2)N4CCCC4,CN1CCN(c2nc(N3CCCC3)c3cnn(C)c3n2)CC1
640,CHEMBL1873703,DFBKLUNHFCTMDC-PICURKEMSA-N,DIELDRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,ClC1=C(Cl)[C@]2(Cl)[C@@H]3[C@@H]4C[C@H]([C@@H]3[C@@]1(Cl)C2(Cl)Cl)[C@H]1O[C@@H]41
641,CHEMBL1873703,DFBKLUNHFCTMDC-PICURKEMSA-N,DIELDRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@H]3[C@@H]([C@H]1[C@H]4[C@@H]2O4)[C@]5(C(=C([C@@]3(C5(Cl)Cl)Cl)Cl)Cl)Cl,ClC1=C(Cl)[C@]2(Cl)[C@@H]3[C@@H]4C[C@H]([C@@H]3[C@@]1(Cl)C2(Cl)Cl)[C@H]1O[C@@H]41
642,CHEMBL460402,DFBYKWKCUIKCPG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,686.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.163675884293247,CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)C(=O)C4=CC=C(C=C4)OCCCN5CCCCC5,CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)c1ccc(OCCCN2CCCCC2)cc1
643,CHEMBL1935436,DFNGZIPWXHTTPA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,C1CC(CN(C1)CCO)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,OCCN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
644,CHEMBL2178582,DFOFEBXXZMVAGG-MZJWZYIUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,Ki,=,20.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.698970004336019,C1CC(CN(C1)C/C=C/2\C3=CC=CC=C3COC4=C2C=C(C=C4)CC(=O)O)CC5=CC=CC=C5,O=C(O)Cc1ccc2c(c1)/C(=C/CN1CCCC(Cc3ccccc3)C1)c1ccccc1CO2
645,CHEMBL1140,DFPAKSUCGFBDDF-UHFFFAOYSA-N,NIACINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)N,NC(=O)c1cccnc1
646,CHEMBL1140,DFPAKSUCGFBDDF-UHFFFAOYSA-N,NIACINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)N,NC(=O)c1cccnc1
647,CHEMBL451821,DFTFGLPAHCOAEP-TVSVWYSMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)N(C)C(=O)[C@@H](C(C)C)NC)C)CN1C,CN[C@@H](C(=O)N(C)[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]24CN(C)[C@@H](C)[C@H]2CC[C@@H]34)C1)C(C)C
648,CHEMBL540634,DFUGESMXMUMLJG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)Cl.Cl,O=C(c1ccc(Cl)cc1)N1CCN(c2ccc(OC3CCN(C4CCC4)CC3)cc2)C(=O)C1
649,CHEMBL452,DGBIGWXXNGSACT-UHFFFAOYSA-N,CLONAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
650,CHEMBL452,DGBIGWXXNGSACT-UHFFFAOYSA-N,CLONAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl,O=C1CN=C(c2ccccc2Cl)c2cc([N+](=O)[O-])ccc2N1
652,CHEMBL425358,DGLAILDSPYOZLT-GDLZYMKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,305.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.515700160653214,C1CN(CCN1CCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl,NC(=O)N(O)CCC#Cc1ccc(OCCN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)cc1
653,CHEMBL316561,DGMKFQYCZXERLX-UHFFFAOYSA-N,PROGLUMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1
654,CHEMBL316561,DGMKFQYCZXERLX-UHFFFAOYSA-N,PROGLUMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC=CC=C1,CCCN(CCC)C(=O)C(CCC(=O)O)NC(=O)c1ccccc1
655,CHEMBL1783890,DGWKVXVCPCPOAK-UHFFFAOYSA-N,GSK207040,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24269482.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CNC(=O)C1=CN=C(C=N1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2,CNC(=O)c1cnc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)cn1
657,CHEMBL2146812,DGZLHXBKGBELTQ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,1.29,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,8.88941028970075,CN1CCC[C@@H]1CN2C(=O)C3=NC=CN=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2nccnc2c1=O
658,CHEMBL287052,DHGUFKPZDMQBED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,1780.0,NM,,,,,,,,,,,,,,,,,,,,5.749579997691106,C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(Cl)c2)[nH]1
660,CHEMBL287052,DHGUFKPZDMQBED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1995.26,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(Cl)c2)[nH]1
661,CHEMBL287052,DHGUFKPZDMQBED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,158489319246111.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.199999999999998,C1=CC(=CC(=C1)Cl)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(Cl)c2)[nH]1
662,CHEMBL1078642,DHHDEHNHEBYRPQ-UHFFFAOYSA-N,UR-PI376,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19791743.0,Ki,=,25703.96,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells,Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.,J. Med. Chem.,PUBLICATION,,4.589999963296594,C1=CC=C(C=C1)SCCNC(=NCCCCC2=CN=CN2)NC#N,N#CNC(=NCCCCc1cnc[nH]1)NCCSc1ccccc1
667,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N,NCC(=O)O
668,CHEMBL773,DHMQDGOQFOQNFH-UHFFFAOYSA-N,GLYCINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)N,NCC(=O)O
669,CHEMBL2205821,DHQYUPWRESNGBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCCc1ccccc1
670,CHEMBL48449,DHZBEENLJMYSHQ-XCVPVQRUSA-N,CANTHARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3,C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1
671,CHEMBL48449,DHZBEENLJMYSHQ-XCVPVQRUSA-N,CANTHARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12[C@H]3CC[C@@H]([C@@]1(C(=O)OC2=O)C)O3,C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1
673,CHEMBL571390,DIADJINIBFEMEL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,16.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.795880017344076,CC1=CC=C(C=C1)CN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,Cc1ccc(CN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
674,CHEMBL1783959,DICDOOGFHQRKKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,100.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CN=CC=C4,CN1CCc2c(c3ccccc3n2CCc2cccnc2)C1
675,CHEMBL1783959,DICDOOGFHQRKKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,410.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3872161432802645,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CN=CC=C4,CN1CCc2c(c3ccccc3n2CCc2cccnc2)C1
676,CHEMBL102840,DIEXZKWJXAPYGJ-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,14000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.853871964321762,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NS(=O)(=O)C3=CC=C(C=C3)C#N,CC(=O)c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3ccc(C#N)cc3)C2)cc1
677,CHEMBL95051,DIPBPGRFGZKMEF-UHFFFAOYSA-N,MDL-28163,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,59.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.229147988357856,COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(C(=O)c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
678,CHEMBL95051,DIPBPGRFGZKMEF-UHFFFAOYSA-N,MDL-28163,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,7.23,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.14086170270547,COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(C(=O)c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
679,CHEMBL95051,DIPBPGRFGZKMEF-UHFFFAOYSA-N,MDL-28163,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,59.0,NM,,,,,,,,,,,,,,,Compound was evaluated for the antagonistic activity against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.229147988357856,COC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(C(=O)c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
680,CHEMBL240393,DIQMIXLXBUWZKA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.4999996786570655,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OCCCN4CCCCC4.C(=O)O,CS(=O)(=O)c1cccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)c1
681,CHEMBL580,DIWRORZWFLOCLC-UHFFFAOYSA-N,LORAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
682,CHEMBL580,DIWRORZWFLOCLC-UHFFFAOYSA-N,LORAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl,O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O
684,CHEMBL2208430,DIXSEWSBXAEKKY-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC4=CC=CC=C43)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c2ccccc12
685,CHEMBL487894,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,DIPYRONE SODIUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C
686,CHEMBL487894,DJGAAPFSPWAYTJ-UHFFFAOYSA-M,DIPYRONE SODIUM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)[O-].[Na+],Cc1c(N(C)CS(=O)(=O)[O-])c(=O)n(-c2ccccc2)n1C
687,CHEMBL2171016,DJGWTFPDOGEBKS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C3CCN(CC3)S(=O)(=O)NC(=O)C4=CC=CC=C4)Cl,Cc1c(Cl)ccc(OC2CCN(C3CCN(S(=O)(=O)NC(=O)c4ccccc4)CC3)CC2)c1Cl
688,CHEMBL273165,DJHAFQLSNXBKIX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCC(C)N4CCc5cc6nc(C)oc6c(Br)c5CC4)n3C)cccc2n1
689,CHEMBL1093058,DJILKXZJMQURGL-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,4.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.356547323513812,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CC=N3,C[C@H](c1c(CCN(C)C)sc2ccccc12)n1cccn1
692,CHEMBL519240,DJKJVWJQAVGLHJ-YPMHNXCESA-N,A-987306,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,Ki,=,3548.13,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,5.450000476425332,C1CC[C@H]2[C@@H](C1)C3=C(O2)CCC4=C3N=C(N=C4N5CCNCC5)N,Nc1nc2c(c(N3CCNCC3)n1)CCC1=C2[C@@H]2CCCC[C@@H]2O1
693,CHEMBL331603,DJUHRAPXNFPKDW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,171.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.767003889607847,CCCC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCCC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
694,CHEMBL267930,DKGZKTPJOSAWFA-UHFFFAOYSA-N,SPIPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,476.19,NM,,,,,,,,,,,,,,,,,,,,6.3222197290286175,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1
695,CHEMBL267930,DKGZKTPJOSAWFA-UHFFFAOYSA-N,SPIPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,480.0,NM,,,,,,,,,,,,,,,,,,,,6.3187587626244115,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CCC2(CC1)C(=O)NCN2c1ccccc1)c1ccc(F)cc1
696,CHEMBL1531134,DKMFBWQBDIGMHM-UHFFFAOYSA-N,MELPERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,580.0,NM,,,,,,,,,,,,,,,,,,,,6.236572006437062,CC1CCN(CC1)CCCC(=O)C2=CC=C(C=C2)F,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1
697,CHEMBL660,DKNWSYNQZKUICI-UHFFFAOYSA-N,AMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2CC3CC1CC(C2)(C3)N,NC12CC3CC(CC(C3)C1)C2
698,CHEMBL660,DKNWSYNQZKUICI-UHFFFAOYSA-N,AMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C2CC3CC1CC(C2)(C3)N,NC12CC3CC(CC(C3)C1)C2
699,CHEMBL321320,DKTSZKSSVLOHMC-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,3600.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,C1CN(C[C@H]1NS(=O)(=O)C2=CC(=CC=C2)Cl)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3cccc(Cl)c3)C2)cc1)C1CC1
700,CHEMBL2158830,DKVGJRLHFIQFEM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,39.81,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)OCC(=O)O,O=C(O)COc1ccc(N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
701,CHEMBL75435,DKYWVDODHFEZIM-NSHDSACASA-N,DEXKETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
702,CHEMBL75435,DKYWVDODHFEZIM-NSHDSACASA-N,DEXKETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1
703,CHEMBL571,DKYWVDODHFEZIM-UHFFFAOYSA-N,KETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
704,CHEMBL571,DKYWVDODHFEZIM-UHFFFAOYSA-N,KETOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
705,CHEMBL1909050,DLDAZIVPAOLETE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
706,CHEMBL1909050,DLDAZIVPAOLETE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,Cc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
707,CHEMBL513,DLGOEMSEDOSKAD-UHFFFAOYSA-N,CARMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCl)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NCCCl
708,CHEMBL513,DLGOEMSEDOSKAD-UHFFFAOYSA-N,CARMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCl)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NCCCl
709,CHEMBL1915535,DLKAQKCVCFAVIS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21955944.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C)(C)CCNC1=CC(=NC=N1)N2CCN(CC2)C,CN1CCN(c2cc(NCCC(C)(C)C)ncn2)CC1
710,CHEMBL288772,DLMPCEBSXNLTAT-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,398.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.400116927926312,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)C4=C(C=C(C=C4)F)C#N,CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C
711,CHEMBL2207664,DLONTNINHYMHFB-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)O)Cl,Cc1c(Cl)ccc(OC2CCN(C[C@H](O)CNC(=O)c3c[nH]c(=O)cc3C(F)(F)F)CC2)c1Cl
712,CHEMBL3233432,DLXKEWOEEPMPHX-PMACEKPBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,,C1CN(C[C@@H]2[C@H]1N3CCOC4=CC=CC2=C43)CCCC(=O)C5=CC=C(C=C5)F,O=C(CCCN1CC[C@H]2[C@@H](C1)c1cccc3c1N2CCO3)c1ccc(F)cc1
716,CHEMBL127,DMJNNHOOLUXYBV-PQTSNVLCSA-N,MEROPENEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
717,CHEMBL127,DMJNNHOOLUXYBV-PQTSNVLCSA-N,MEROPENEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)N(C)C)C(=O)O)[C@@H](C)O,C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12
719,CHEMBL1774494,DMMAFYCLHWGPBF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,128.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.892790030352131,CC(C1=CC2=C(C=C1)OCC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O,CC(C(=O)O)c1ccc2c(c1)N(CCCN1CCCN(c3cc(=O)n(C)c(=O)n3C)CC1)c1ccccc1CO2
720,CHEMBL434684,DMQAXIJUTYJHIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,28.84,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.540004743952608,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CN(C)C,CC(C1=C(CN(C)C)Cc2ccccc21)c1ccccn1
721,CHEMBL2158831,DMQWGZFKPDYZCH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)CC4=CC=CC=C4C(=O)O,O=C(O)c1ccccc1CN1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
724,CHEMBL286398,DNIAPMSPPWPWGF-UHFFFAOYSA-N,PROPYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CO)O,CC(O)CO
725,CHEMBL286398,DNIAPMSPPWPWGF-UHFFFAOYSA-N,PROPYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CO)O,CC(O)CO
726,CHEMBL570695,DNIULMBWQYTFJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,155.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.809668301829707,CC1=CC=C(C=C1)CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,Cc1ccc(CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
728,CHEMBL1200709,DNTGGZPQPQTDQF-XBXARRHUSA-N,CROTAMITON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC=C1C)C(=O)/C=C/C,C/C=C/C(=O)N(CC)c1ccccc1C
729,CHEMBL1200709,DNTGGZPQPQTDQF-XBXARRHUSA-N,CROTAMITON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC=C1C)C(=O)/C=C/C,C/C=C/C(=O)N(CC)c1ccccc1C
730,CHEMBL1405,DNXHEGUUPJUMQT-CBZIJGRNSA-N,ESTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O
731,CHEMBL1405,DNXHEGUUPJUMQT-CBZIJGRNSA-N,ESTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O
732,CHEMBL1466,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,DICUMAROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O
733,CHEMBL1466,DOBMPNYZJYQDGZ-UHFFFAOYSA-N,DICUMAROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=C(C(=O)O2)CC3=C(C4=CC=CC=C4OC3=O)O)O,O=c1oc2ccccc2c(O)c1Cc1c(O)c2ccccc2oc1=O
734,CHEMBL822,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,TERBINAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12
735,CHEMBL822,DOMXUEMWDBAQBQ-WEVVVXLNSA-N,TERBINAFINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C#C/C=C/CN(C)CC1=CC=CC2=CC=CC=C21,CN(C/C=C/C#CC(C)(C)C)Cc1cccc2ccccc12
737,CHEMBL271083,DOTHXJXYLNKQOQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C(C(F)(F)F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4nc(C(F)(F)C(F)(F)F)oc4cc3CC2)n1C
739,CHEMBL1282,DOUYETYNHWVLEO-UHFFFAOYSA-N,IMIQUIMOD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,CC(C)Cn1cnc2c(N)nc3ccccc3c21
740,CHEMBL1282,DOUYETYNHWVLEO-UHFFFAOYSA-N,IMIQUIMOD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N,CC(C)Cn1cnc2c(N)nc3ccccc3c21
743,CHEMBL74779,DOXXMQHNZRHZPH-RPBOFIJWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,660.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.180456064458133,C1C[C@H](O[C@@H]1CN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)C#CCCN(C(=O)N)O,NC(=O)N(O)CCC#C[C@@H]1CC[C@@H](CN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)O1
745,CHEMBL2208436,DPJWTHMHDTUYEX-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,501.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(CCC1NC[C@@H](COC2=CC=CC(=C2)C#N)O)CC3=CC(=C(C=C3)Cl)Cl,N#Cc1cccc(OC[C@@H](O)CNC2CCN(Cc3ccc(Cl)c(Cl)c3)CC2)c1
747,CHEMBL83220,DQAMCNMFLLPWQR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)C(=O)C(F)(F)F,CN(CC1CC2c3ccccc3Cc3ccccc3N2O1)C(=O)C(F)(F)F
748,CHEMBL19019,DQCKKXVULJGBQN-XFWGSAIBSA-N,NALTREXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
749,CHEMBL19019,DQCKKXVULJGBQN-XFWGSAIBSA-N,NALTREXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O,O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5
750,CHEMBL1198,DQKXQSGTHWVTAD-UHFFFAOYSA-N,PRAMOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2,CCCCOc1ccc(OCCCN2CCOCC2)cc1
751,CHEMBL1198,DQKXQSGTHWVTAD-UHFFFAOYSA-N,PRAMOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=CC=C(C=C1)OCCCN2CCOCC2,CCCCOc1ccc(OCCCN2CCOCC2)cc1
752,CHEMBL856,DQMZLTXERSFNPB-UHFFFAOYSA-N,PRIMIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NCNC1=O
753,CHEMBL856,DQMZLTXERSFNPB-UHFFFAOYSA-N,PRIMIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NCNC1=O)C2=CC=CC=C2,CCC1(c2ccccc2)C(=O)NCNC1=O
755,CHEMBL63002,DRCFWAFIBAFOCV-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4365.16,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.359999833093896,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC5=CC=CC=C5S4)N,N[C@H](Cc1cc2ccccc2s1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
756,CHEMBL2207278,DREBLEJJYUKNLT-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)F)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2cc(F)ccc12
759,CHEMBL45,DRLFMBDRBRZALE-UHFFFAOYSA-N,MELATONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COc1ccc2[nH]cc(CCNC(C)=O)c2c1
760,CHEMBL45,DRLFMBDRBRZALE-UHFFFAOYSA-N,MELATONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC,COc1ccc2[nH]cc(CCNC(C)=O)c2c1
761,CHEMBL1557680,DRQJSDYVORTCEY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15798001.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC(=O)N1C(CC(C2=CC=CC=C21)N(C3=CC=CC=C3)C(=O)C)C,CCC(=O)N1c2ccccc2C(N(C(C)=O)c2ccccc2)CC1C
764,CHEMBL434001,DSKGOKHOBPYUEE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,5370.32,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.269999835325842,C1CN(CCN1CCO)C2=NC=NC3=C2OC4=CC=CC=C43,OCCN1CCN(c2ncnc3c2oc2ccccc23)CC1
766,CHEMBL517407,DSRXHDAICZGTCK-ORBVJSQLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,295.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5301779840218375,CN(CC/C=C/1\C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)CC4=CC=C(C=C4)OCCCN5CCCCC5,CN(CC/C=C1\c2ccccc2Sc2ccc(Cl)cc21)Cc1ccc(OCCCN2CCCCC2)cc1
767,CHEMBL2252949,DSSYKIVIOFKYAU-OIBJUYFYSA-N,(-)-CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C1(C)C)CC2=O,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2
768,CHEMBL2252949,DSSYKIVIOFKYAU-OIBJUYFYSA-N,(-)-CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C1(C)C)CC2=O,CC1(C)[C@H]2CC[C@]1(C)C(=O)C2
769,CHEMBL504760,DSSYKIVIOFKYAU-XCBNKYQSSA-N,CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CC[C@@H](C1(C)C)CC2=O,CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2
770,CHEMBL504760,DSSYKIVIOFKYAU-XCBNKYQSSA-N,CAMPHOR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CC[C@@H](C1(C)C)CC2=O,CC1(C)[C@@H]2CC[C@@]1(C)C(=O)C2
771,CHEMBL1083162,DTGZGHPOXFQXNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20452213.0,EC50,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in human SK-N-MC cells,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)OCCCNCCC2=CN=CN2)C3=NC4=C(N3)C=CC(=C4C)F,Cc1cc(OCCCNCCc2cnc[nH]2)ccc1-c1nc2c(C)c(F)ccc2[nH]1
772,CHEMBL1092598,DTQWVENQVGQFAP-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,C[C@H](C1=C(CC2=CC=CC=C21)CCN(C)C)C3=NC=CS3,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1nccs1
773,CHEMBL238870,DTTUPIQCRQKVGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCCC3)cc2)C(=O)C1
774,CHEMBL96467,DTYAFBJXWWLRMA-QMHKHESXSA-N,SNAP-7915,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10956183.0,Ki,=,54.0,NM,,,,,,,,,,,,,,,"Binding affinity towards Histamine H1 receptor in human brain tissue preparation, using [3H]rauwolscine as radioligand.",De novo design of a novel oxazolidinone analogue as a potent and selective alpha1A adrenergic receptor antagonist with high oral bioavailability.,J. Med. Chem.,PUBLICATION,,7.267606240177032,C[C@H]1[C@@H](N(C(=O)O1)C(=O)NCCCN2CCC(CC2)C3=CC=C(C=C3)F)C4=CC(=C(C=C4)F)F,C[C@@H]1OC(=O)N(C(=O)NCCCN2CCC(c3ccc(F)cc3)CC2)[C@H]1c1ccc(F)c(F)c1
775,CHEMBL2207285,DTYDZUZTWZDAGL-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CC1NS(=O)(=O)C2=CC3=C(C=C2)C(=CNC3=O)C(=O)NC[C@H](CN4CCC(CC4)OC5=CC(=C(C=C5)Cl)Cl)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2cc(S(=O)(=O)NC3CC3)ccc12
776,CHEMBL3357049,DUCSQMQJPSZEAW-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,4647.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.332827327521132,CC(C)C[C@H](C(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1)N,CC(C)C[C@@H](N)C(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
777,CHEMBL137781,DUKNIHFTDAXJON-MUIJYRPGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,500.0,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,6.301029995663981,C[C@@H]1C[C@@H](N1C(=O)[C@H]2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C)C,C[C@H]1C[C@@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1
778,CHEMBL343755,DUKNIHFTDAXJON-ORPLUIKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,2500.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,5.6020599913279625,C[C@H]1C[C@@H](N1C(=O)[C@H]2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C)C,C[C@H]1C[C@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1
779,CHEMBL138989,DUKNIHFTDAXJON-RCZCSUKSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,1400.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,5.853871964321763,C[C@@H]1C[C@H](N1C(=O)[C@H]2CN(C3CC4=CNC5=CC=CC(=C45)C3=C2)C)C,C[C@@H]1C[C@@H](C)N1C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)CC2N(C)C1
780,CHEMBL328187,DUTDDZFCPPOWFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,1500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,5.823908740944319,CN1C=C(N=N1)C2=CC3=C(C=C2)N(C=C3C4CCN(CC4)CCN5CCNC5=O)C6=CC=C(C=C6)F,Cn1cc(-c2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)nn1
781,CHEMBL1783970,DUUHEGAGOHEODE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,320.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.494850021680094,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=NC=CN=C4,Cc1ccc2c(c1)c1c(n2CCc2cnccn2)CCN(C)C1
782,CHEMBL1783970,DUUHEGAGOHEODE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,7940.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.100179497572903,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=NC=CN=C4,Cc1ccc2c(c1)c1c(n2CCc2cnccn2)CCN(C)C1
784,CHEMBL608560,DUZFRLZTNIIHKJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccc(F)c1
785,CHEMBL608560,DUZFRLZTNIIHKJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1cccc(F)c1
787,CHEMBL334255,DVBJBNKEBPCGSY-UHFFFAOYSA-M,CETYLPYRIDINIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Br-],CCCCCCCCCCCCCCCC[n+]1ccccc1
788,CHEMBL334255,DVBJBNKEBPCGSY-UHFFFAOYSA-M,CETYLPYRIDINIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1.[Br-],CCCCCCCCCCCCCCCC[n+]1ccccc1
790,CHEMBL3104091,DVSMVUMYJDOPJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,50.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,CN1CCC2=C(C1)C3=CC=CC4=C3N2C5=CC=CC=C5CC4,CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1
791,CHEMBL3104091,DVSMVUMYJDOPJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CN1CCC2=C(C1)C3=CC=CC4=C3N2C5=CC=CC=C5CC4,CN1CCc2c(c3cccc4c3n2-c2ccccc2CC4)C1
794,CHEMBL1774499,DVZWFDDQIOLGDS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,75.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.1249387366083,CC(C)(C1=CC2=C(CCC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C=C1)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4CCc4ccc(C(C)(C)C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
795,CHEMBL273170,DWIXBLOYUJIYNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17998160.0,Ki,=,8.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.096910013008056,CC1C2=C(C=CC(=C2Cl)Cl)NC(=N1)N,CC1N=C(N)Nc2ccc(Cl)c(Cl)c21
796,CHEMBL2158815,DWNROPYUHGRJJG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(C4=CC=CC=C4)C(=O)O,O=C(O)C(c1ccccc1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
797,CHEMBL1319362,DWSGTFTVBLXELC-RDYJJYPNSA-N,HOMATROPINE HYDROBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O.Br,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(O)c1ccccc1)C2
798,CHEMBL1319362,DWSGTFTVBLXELC-RDYJJYPNSA-N,HOMATROPINE HYDROBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(C3=CC=CC=C3)O.Br,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(O)c1ccccc1)C2
799,CHEMBL120055,DWSOZYFSYVOVOC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Compound was tested for its affinity towards histaminergic (H 1) receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1N2CCN(CC2)C(=O)COC3=CC4=C(C=C3)NC=C4CCN,Cc1ccccc1N1CCN(C(=O)COc2ccc3[nH]cc(CCN)c3c2)CC1
800,CHEMBL1651208,DWTYHCYVKJONSP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23009245.0,IC50,=,8150.0,NM,,,,,,,,,,,,,,,Inhibition of radioligand binding to human histamine H1 receptor,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,5.088842391260024,C1CCC(C1)N2CC3=C(C2=O)C=CC(=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(c3)CN(C3CCCC3)C4=O)c2)ccc1Cl
803,CHEMBL272300,DXIJUOOAQKSDNE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C,Cc1ccc2c(-c3nnc(SCCC(C)N4CCc5cc6c(cc5CC4)C(=O)N(C)C6)n3C)cccc2n1
804,CHEMBL340199,DXJUCAUQIHNOAF-AEFFLSMTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,122.0,NM,,,,,,,,,,,,,,,,,,,,6.9136401693252525,CN(C)[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)[C@@H]1Cc2ccccc2[C@H](c2ccccc2)C1
805,CHEMBL340199,DXJUCAUQIHNOAF-AEFFLSMTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,129.0,NM,,,,,,,,,,,,,,,,,,,,6.889410289700751,CN(C)[C@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)[C@@H]1Cc2ccccc2[C@H](c2ccccc2)C1
806,CHEMBL127307,DXJUCAUQIHNOAF-SJLPKXTDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.65,NM,,,,,,,,,,,,,,,,,,,,8.782516055786092,CN(C)[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccccc2)C1
807,CHEMBL127307,DXJUCAUQIHNOAF-SJLPKXTDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,2.5,NM,,,,,,,,,,,,,,,,,,,,8.602059991327963,CN(C)[C@H]1C[C@@H](C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)[C@@H]1Cc2ccccc2[C@@H](c2ccccc2)C1
808,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,2.49,NM,,,,,,,,,,,,,,,,,,,,8.603800652904264,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)C1Cc2ccccc2C(c2ccccc2)C1
809,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,4.26,NM,,,,,,,,,,,,,,,,,,,,8.370590400897282,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)C1Cc2ccccc2C(c2ccccc2)C1
810,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,13.6,NM,,,,,,,,,,,,,,,,,,,,7.866461091629782,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)C1Cc2ccccc2C(c2ccccc2)C1
811,CHEMBL104945,DXJUCAUQIHNOAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,14.7,NM,,,,,,,,,,,,,,,,,,,,7.832682665251823,CN(C)C1CC(C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)C1Cc2ccccc2C(c2ccccc2)C1
812,CHEMBL3402679,DXJUCAUQIHNOAF-WMZOPIPTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,29.9,NM,,,,,,,,,,,,,,,,,,,,7.52432881167557,CN(C)[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)[C@H]1Cc2ccccc2[C@H](c2ccccc2)C1
813,CHEMBL3402679,DXJUCAUQIHNOAF-WMZOPIPTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,42.4,NM,,,,,,,,,,,,,,,,,,,,7.372634143407267,CN(C)[C@@H]1C[C@H](C2=CC=CC=C2C1)C3=CC=CC=C3,CN(C)[C@H]1Cc2ccccc2[C@H](c2ccccc2)C1
815,CHEMBL31714,DXTYGLAQRALLEG-LFYBBSHMSA-N,CP-96021,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=NC2=C(N1C3=CC=C(C=C3)OCC4=CC(=CC=C4)/C=C/C5=NC6=C(S5)C=CC(=C6)F)C=CN=C2,Cc1nc2cnccc2n1-c1ccc(OCc2cccc(/C=C/c3nc4cc(F)ccc4s3)c2)cc1
816,CHEMBL1767142,DXZJJDOMGLPHDI-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,398.11,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,6.399996913372259,CC(C)(C)C1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C,CN1CCC[C@@H]1Cn1nc(Cc2ccc(C(C)(C)C)cc2)c2ccccc2c1=O
817,CHEMBL269994,DYDLMZLLICKPBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C,CCc1nc2cc3c(c(C)c2o1)CCN(CCCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
818,CHEMBL240352,DYKCULOUGOBIOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F,O=C(c1ccc(F)cc1F)N1CCN(c2ccc(OCCCN3CCCC3)cc2)C(=O)C1
819,CHEMBL316068,DYRUSALPYKCZDY-RYLMWKJUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,1.2,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.920818753952375,CN1CCN(CC1)CC2C[C@H]3[C@H](O2)C4=CC=CC=C4SC5=CC=CC=C35,CN1CCN(CC2C[C@@H]3c4ccccc4Sc4ccccc4[C@H]3O2)CC1
820,CHEMBL196598,DZKYLEMMURXALW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)C(F)(F)F)OC,COc1ccc(NC(=O)N2CCN(c3ccc(C(F)(F)F)cc3)CC2)cc1N1CCN(C)CC1
821,CHEMBL101634,DZXOBJYKYJVJJV-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,11000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.9586073148417755,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=CSC(=N3)C4=CN=CC=C4,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)c3csc(-c4cccnc4)n3)C2)cc1
822,CHEMBL850,DZZWHBIBMUVIIW-DTORHVGOSA-N,SPARFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F,C[C@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1
823,CHEMBL850,DZZWHBIBMUVIIW-DTORHVGOSA-N,SPARFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CN(C[C@@H](N1)C)C2=C(C(=C3C(=C2F)N(C=C(C3=O)C(=O)O)C4CC4)N)F,C[C@H]1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C[C@@H](C)N1
824,CHEMBL182150,FAIMGWSOSCFGRU-IYBDPMFKSA-N,ATC-0175,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,150.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,CN(C)C1=NC(=NC2=CC=CC=C21)NC3CCC(CC3)NC(=O)C4=CC(=C(C=C4)F)F,CN(C)c1nc(NC2CCC(NC(=O)c3ccc(F)c(F)c3)CC2)nc2ccccc12
825,CHEMBL1560,FAKRSMQSSFJEIM-RQJHMYQMSA-N,CAPTOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
826,CHEMBL1560,FAKRSMQSSFJEIM-RQJHMYQMSA-N,CAPTOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O,C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O
827,CHEMBL1200600,FAOZLTXFLGPHNG-KNAQIMQKSA-N,FLUOROMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
828,CHEMBL1200600,FAOZLTXFLGPHNG-KNAQIMQKSA-N,FLUOROMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@]2([C@@]4(C1=CC(=O)C=C4)C)F)O)C)(C(=O)C)O,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
829,CHEMBL2208416,FAPBWZUNGKHHJO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,IC50,=,5011.87,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3000002024454185,C1CC(C1)C(=O)NC2=CC=CC=C2OCC(CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O,O=C(Nc1ccccc1OCC(O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)C1CCC1
830,CHEMBL1278020,FAXDKDSDNWXAIS-NASUQTAISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.799970733446231,COC(=O)C1=CCCN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35,COC(=O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
831,CHEMBL418658,FAZLRTUIRXGMGN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,724.44,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.139997578098903,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CN=CC=C3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3cccnc3)CC2)cc1
832,CHEMBL196370,FBDANPRMCCLYRK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=CC=C4OC)OC,COc1ccc(NC(=O)N2CCN(c3ccccc3OC)CC2)cc1N1CCN(C)CC1
833,CHEMBL457957,FBGLPECKCFZJFU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,559.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.252588192113577,CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)C(=O)CC4=CC=C(C=C4)OCCCN5CCCCC5,CN(CCC=C1c2ccccc2CCc2ccccc21)C(=O)Cc1ccc(OCCCN2CCCCC2)cc1
834,CHEMBL34259,FBOZXECLQNJBKD-ZDUSSCGKSA-N,METHOTREXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
835,CHEMBL34259,FBOZXECLQNJBKD-ZDUSSCGKSA-N,METHOTREXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1
836,CHEMBL689,FBPFZTCFMRRESA-KVTDHHQDSA-N,MANNITOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
837,CHEMBL689,FBPFZTCFMRRESA-KVTDHHQDSA-N,MANNITOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)O,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO
838,CHEMBL606036,FCDNLGMRDAOTCR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,98.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.008773924307505,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=C(C=C4)C(F)(F)F,Cc1ccc2c(c1)c1c(n2CCc2ccc(C(F)(F)F)cc2)CCN(C)C1
839,CHEMBL160933,FCRIMCQUUZFBDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,25.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.602059991327962,CN(C)CC1C2=CC=CC=C2CC3=CC=CC=C13,CN(C)CC1c2ccccc2Cc2ccccc21
840,CHEMBL563271,FDBNTQCFINBNNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,88.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.055517327849832,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)OCC(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(OCC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
841,CHEMBL21,FDDDEECHVMSUSB-UHFFFAOYSA-N,SULFANILAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)N,Nc1ccc(S(N)(=O)=O)cc1
842,CHEMBL21,FDDDEECHVMSUSB-UHFFFAOYSA-N,SULFANILAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)N,Nc1ccc(S(N)(=O)=O)cc1
843,CHEMBL476,FDKXTQMXEQVLRF-ZHACJKMWSA-N,DACARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)/N=N/C1=C(NC=N1)C(=O)N,CN(C)/N=N/c1nc[nH]c1C(N)=O
844,CHEMBL476,FDKXTQMXEQVLRF-ZHACJKMWSA-N,DACARBAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)/N=N/C1=C(NC=N1)C(=O)N,CN(C)/N=N/c1nc[nH]c1C(N)=O
845,CHEMBL1078745,FDVIZOQPGHRQNB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,3600.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.443697499232713,CCOC1=CC(=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)OC5CCOCC5,CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)cc(OC2CCOCC2)c1
846,CHEMBL62596,FDVYBGCVXDDGND-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)[C@@H]4CC(=O)N4,O=C1C[C@@H](N2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)CC2)N1
847,CHEMBL423666,FDVYBGCVXDDGND-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,21877.62,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6599999253499025,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)[C@H]4CC(=O)N4,O=C1C[C@H](N2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)CC2)N1
848,CHEMBL989,FEBLZLNTKCEFIT-VSXGLTOVSA-N,FLUOCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
849,CHEMBL989,FEBLZLNTKCEFIT-VSXGLTOVSA-N,FLUOCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@@]53C)F)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
851,CHEMBL1774490,FEHNLVPCVHLEHQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,140.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.853871964321763,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCN(CCCN3c4ccccc4COc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
852,CHEMBL2207276,FEIOPVQTLJUJBR-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)C)O,Cc1cc(Cl)ccc1OC1CCN(C[C@H](O)CNC(=O)c2c[nH]c(=O)c3cc(S(C)(=O)=O)ccc23)CC1
854,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
855,CHEMBL46,FELGMEQIXOGIFQ-UHFFFAOYSA-N,ONDANSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O
857,,FERVXSHGEVPGHF-UHFFFAOYSA-N,41149-66-0,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,6.0,NM,,,,,,,,,,,,,,,,,,,,8.221848749616356,CC1=CC=C(C=C1)C(C2=CC=CC=C2)OCC[N+](C)(C)C,Cc1ccc(C(OCC[N+](C)(C)C)c2ccccc2)cc1
858,CHEMBL274119,FFEARJCKVFRZRR-UHFFFAOYSA-N,RACEMETHIONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CSCCC(C(=O)O)N,CSCCC(N)C(=O)O
859,CHEMBL310604,FFFHZYDWPBMWHY-UHFFFAOYSA-N,HOMOCYSTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS)C(C(=O)O)N,NC(CCS)C(=O)O
860,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
861,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
862,CHEMBL108,FFGPTBGBLSHEPO-UHFFFAOYSA-N,CARBAMAZEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N,NC(=O)N1c2ccccc2C=Cc2ccccc21
863,CHEMBL291882,FFIKBIOXICZKHW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=C(C=CS3)Cl,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3sccc3Cl)CC2)cc1
864,CHEMBL1222728,FFNIMQCKAVUSKV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20667729.0,IC50,>,20000.0,NM,,,,,,,,,,,,,,,Antagonist activity at human histamine H1 receptor,Discovery of substituted benzyl tetrazoles as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,CN1CCN(CC1)C(C2=CC=CC=C2)C3=NN=NN3CC4=CC=CC=C4,CN1CCN(C(c2ccccc2)c2nnnn2Cc2ccccc2)CC1
865,CHEMBL1259188,FGHKCRNDQSRICR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CN1N=C(N=N1)CC2=CC3=C(C=C2)N(C=C3C4CCN(CC4)CCN5CCNC5=O)C6=CC=C(C=C6)F,Cn1nnc(Cc2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)n1
866,CHEMBL1940403,FGTGRXMIFIZGBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,115.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.939302159646387,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCSC3=CC=C(C=C3)F,OC1(c2ccc(Cl)cc2)CCN(CCCSc2ccc(F)cc2)CC1
867,CHEMBL2171034,FGWSLMPEBIIYTF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=C(C=C4)F,O=C(NS(=O)(=O)c1ccc(F)cc1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
868,CHEMBL219916,FGXWKSZFVQUSTL-UHFFFAOYSA-N,DOMPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1344.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.871600731282194,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
869,CHEMBL219916,FGXWKSZFVQUSTL-UHFFFAOYSA-N,DOMPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,156.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.806875401645539,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1
870,CHEMBL267648,FHFYDNQZQSQIAI-UHFFFAOYSA-N,PEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
871,CHEMBL267648,FHFYDNQZQSQIAI-UHFFFAOYSA-N,PEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCN(C)CC3)cc21
872,CHEMBL1125,FHPIXVHJEIZKJW-UHFFFAOYSA-N,DESMETHYLOLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,22.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.657577319177793,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCNCC4,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCNCC1
874,CHEMBL1092766,FHUODQKGUFFZJE-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,2.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.537602002101043,C[C@H](C1=C(N=CC=C1)Cl)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@H](c1cccnc1Cl)c1c(CCN(C)C)sc2ccccc12
875,CHEMBL62660,FHVOGKHFMPAIBO-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3300000383353785,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CO)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@H](N)CO)CC2)cc1
876,CHEMBL458019,FIKAKWIAUPDISJ-UHFFFAOYSA-L,PARAQUAT DICHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-],C[n+]1ccc(-c2cc[n+](C)cc2)cc1
877,CHEMBL458019,FIKAKWIAUPDISJ-UHFFFAOYSA-L,PARAQUAT DICHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C.[Cl-].[Cl-],C[n+]1ccc(-c2cc[n+](C)cc2)cc1
878,CHEMBL1278201,FIMFEAXKPOZWDG-VUNKPPBISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.799970733446231,C1C[C@@]2(CC1N3CCC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
879,CHEMBL3233411,FINYFOYZAZLCFE-FPOVZHCZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,,CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC5=NOC6=CC=CC=C65,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCc3noc4ccccc34)CC[C@@H]12
881,CHEMBL154695,FJCPGOQOVQYZGS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,15848931924611.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.199999999999998,C1=CC=C(C=C1)CC2=NC(=CS2)CCN,NCCc1csc(Cc2ccccc2)n1
883,CHEMBL3417585,FJHKZEVPGYADEG-XOKHGSTOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25827402.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human H1R,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@H]4[C@@H]3C4,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@@H]3C[C@H]23)cc1
884,CHEMBL3417586,FJHKZEVPGYADEG-XYPHTWIQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25827402.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human H1R,"3,4-Diaza-bicyclo[4.1.0]hept-4-en-2-one phenoxypropylamine analogs of irdabisant (CEP-26401) as potent histamine-3 receptor inverse agonists with robust wake-promoting activity.",Eur. J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)[C@@H]4[C@H]3C4,C[C@@H]1CCCN1CCCOc1ccc(C2=NNC(=O)[C@H]3C[C@@H]23)cc1
885,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
886,CHEMBL934,FJLBFSROUSIWMA-UHFFFAOYSA-N,METYRAPONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2,CC(C)(C(=O)c1cccnc1)c1cccnc1
887,CHEMBL2220442,FJLGEFLZQAZZCD-VAWYXSNFSA-N,FLUVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1C2=CC=CC=C2C(=C1/C=C/C(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
888,CHEMBL2220442,FJLGEFLZQAZZCD-VAWYXSNFSA-N,FLUVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)N1C2=CC=CC=C2C(=C1/C=C/C(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F,CC(C)n1c(/C=C/C(O)CC(O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21
889,CHEMBL507360,FJPDUNSHNPHJFS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18952421.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,Development of novel 2-[4-(aminoalkoxy)phenyl]-4(3H)-quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1C(=NC2=C(C1=O)C=CN=C2OC)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5,COc1nccc2c(=O)n(C)c(-c3ccc(OC4CCN(C5CCC5)CC4)cc3)nc12
891,CHEMBL312082,FJXRDARXFNFHEP-NBXNUCLWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,190.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.721246399047171,CC(C#CC1=CC=C(O1)CN2CCN(CC2)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl)N(C(=O)N)O,CC(C#Cc1ccc(CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)o1)N(O)C(N)=O
893,CHEMBL403,FKENQMMABCRJMK-RITPCOANSA-N,SULBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C,CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
894,CHEMBL403,FKENQMMABCRJMK-RITPCOANSA-N,SULBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)C,CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
895,CHEMBL282829,FKHBXKAEVUTBRK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4,CCc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
896,CHEMBL43860,FKKPXTRMLVLGJG-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.721246399047171,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)C4=CC=C(C=C4)F,CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1
898,CHEMBL2158816,FLDDBSYUKQDTDX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CC(CN(C1)C(C2=CC=CC=C2)C(=O)O)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,O=C(O)C(c1ccccc1)N1CCCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)C1
899,CHEMBL1242923,FLGSUSWMWSZVMP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20684563.0,Ki,=,780.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,"Discovery of N-{1-[3-(3-Oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.",J. Med. Chem.,PUBLICATION,,6.107905397309519,C1CN(CCC1NC(=O)CC2=CC=CC=C2)CCCN3C(=O)COC4=CC=CC=C43,O=C(Cc1ccccc1)NC1CCN(CCCN2C(=O)COc3ccccc32)CC1
900,CHEMBL94906,FLHDOLQPNXOYNQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.6,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.180456064458129,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4=O)CC5=CC(=C(C(=C5)OC)OC)OC)C6=CC=C(C=C6)F,CCOCCn1c(C(=O)C2CCN(CCC3(c4ccc(F)cc4)CCN(Cc4cc(OC)c(OC)c(OC)c4)C3=O)CC2)nc2ccccc21
901,CHEMBL401576,FLIIXHVRMXEDPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.19999817218203,CC1=NOC2=C1C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC=C(C=C5)C(F)(F)F,Cc1noc2cc3c(cc12)CCN(CCCSc1nnc(-c2ccc(C(F)(F)F)cc2)n1C)CC3
902,CHEMBL16192,FLNYLINBEZROPL-NSOVKSMOSA-N,CP-96345,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,~,10000.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=CC=C1CN[C@@H]2[C@@H](N3CCC2CC3)C(C4=CC=CC=C4)C5=CC=CC=C5,COc1ccccc1CN[C@H]1C2CCN(CC2)[C@H]1C(c1ccccc1)c1ccccc1
904,CHEMBL2207665,FLTAIVXWWOKLBO-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,CN1C=C(C(=CC1=O)C(F)(F)F)C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O,Cn1cc(C(=O)NC[C@@H](O)CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)c(C(F)(F)F)cc1=O
905,CHEMBL10971,FLTBEMVEAFMWDD-UHFFFAOYSA-N,SCH-37370,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,100.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.0,CC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
906,CHEMBL550337,FLZIWHXEHDCVMN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.657577319177793,CN(CCOC)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,COCCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
907,CHEMBL1475,FMHHVULEAZTJMA-UHFFFAOYSA-N,TRIOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
908,CHEMBL1475,FMHHVULEAZTJMA-UHFFFAOYSA-N,TRIOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)OC2=C1C=C3C=C(OC3=C2C)C,Cc1cc2cc3c(C)cc(=O)oc3c(C)c2o1
910,CHEMBL31184,FMMWHPNWAFZXNH-UHFFFAOYSA-N,BENZO[DEF]CHRYSENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34
911,CHEMBL31184,FMMWHPNWAFZXNH-UHFFFAOYSA-N,BENZO[DEF]CHRYSENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C3=C4C(=CC2=C1)C=CC5=C4C(=CC=C5)C=C3,c1ccc2c(c1)cc1ccc3cccc4ccc2c1c34
912,CHEMBL2146810,FNEORDYLRZOEEP-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.631,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.199970640755863,CCCCN1CCC[C@@H]1CN2C(=O)C3=C(C(=N2)CC4=CC=C(C=C4)Cl)N=CC=C3,CCCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ncccc2c1=O
914,CHEMBL359122,FNLZNEYPJNEYFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,2511.89,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1=CN=CC=C1CCCCCCCCCCN,NCCCCCCCCCCc1ccncc1
915,CHEMBL359122,FNLZNEYPJNEYFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,199526231496888.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.3,C1=CN=CC=C1CCCCCCCCCCN,NCCCCCCCCCCc1ccncc1
918,CHEMBL585,FNYLWPVRPXGIIP-UHFFFAOYSA-N,TRIAMTERENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
919,CHEMBL585,FNYLWPVRPXGIIP-UHFFFAOYSA-N,TRIAMTERENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=NC3=C(N=C(N=C3N=C2N)N)N,Nc1nc(N)c2nc(-c3ccccc3)c(N)nc2n1
920,CHEMBL238872,FOCPBTUUAJZSNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,O=C(c1ccc(F)cc1F)N1CCN(c2ccc(OCCCN3CCCCCC3)cc2)C(=O)C1
922,CHEMBL2158827,FOQNONLDPFMOKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,19.95,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=C(C=C4)CC(=O)O,O=C(O)Cc1ccc(N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
924,CHEMBL1077908,FPAJMJGGDZGJPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,199.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7011469235902945,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)NS(=O)(=O)C5=CC=CC=C5)OC,CCOc1cc(CN2CCC(Nc3nc4cc(NS(=O)(=O)c5ccccc5)ccc4o3)CC2)ccc1OC
925,CHEMBL51,FPCCSQOGAWCVBH-UHFFFAOYSA-N,KETANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22694093.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.,J. Med. Chem.,PUBLICATION,,8.698970004336019,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CCN3C(=O)C4=CC=CC=C4NC3=O,O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1
926,CHEMBL100454,FPDIERBPQFAFSI-UHFFFAOYSA-N,2-HYDROXY-METHYLOLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,6.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(S4)CO,CN1CCN(C2=Nc3ccccc3Nc3sc(CO)cc32)CC1
927,CHEMBL2205835,FPHVMMXTLGSYHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccc1
928,CHEMBL2205835,FPHVMMXTLGSYHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccccc1
929,CHEMBL519609,FPUKGJMTLUQGFZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23707254.0,Ki,=,430.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor (unknown origin) by PDSP assay,Selectivity of phenothiazine cholinesterase inhibitors for neurotransmitter systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.366531544420414,CCN(CC)CCCOC(=O)N1C2=CC=CC=C2SC3=CC=CC=C31,CCN(CC)CCCOC(=O)N1c2ccccc2Sc2ccccc21
931,CHEMBL255619,FQKBVZIGJYRJIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)CC6CC6,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4nc(CC5CC5)oc4cc3CC2)n1C
932,CHEMBL1370561,FQPFAHBPWDRTLU-UHFFFAOYSA-N,AMINOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,Cn1c(=O)c2[nH]cnc2n(C)c1=O
933,CHEMBL1370561,FQPFAHBPWDRTLU-UHFFFAOYSA-N,AMINOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N,Cn1c(=O)c2[nH]cnc2n(C)c1=O
935,CHEMBL3311308,FQUAFMNPXPXOJE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24881566.0,IC50,>,39810.72,NM,,,,,,,,,,,,,,,Antagonist activity at human histamine H1 receptor by luminescence assay,Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.399999967876858,CC1=CC(=C(C(=C1)C)NS(=O)(=O)C2=CC=C(C=C2)OC)C,COc1ccc(S(=O)(=O)Nc2c(C)cc(C)cc2C)cc1
936,CHEMBL1082036,FRDOPYUUNJUZKI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,38400.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.4156687756324695,CCOC1=CC(=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)S(=O)(=O)CC)OC5CCOCC5,CCOc1cc(CN2CCC(Nc3nc4cc(S(=O)(=O)CC)ccc4o3)CC2)cc(OC2CCOCC2)c1
937,CHEMBL427836,FRHJULSNWZOUMW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CCC1=NC2=C(O1)C=CC3=C2CCN(CC3)CCCSC4=NN=C(N4C)C5=C(N=CO5)C,CCc1nc2c3c(ccc2o1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
938,CHEMBL1767156,FRUMSZUUBXPHHF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.0,CN1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
939,CHEMBL560741,FRXWLMMHSBOBJK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,0.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,9.221848749616356,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=CC=C(C=C3)F,CN(C)CCC1=C(Cc2ccc(F)cc2)c2ccccc2C1
940,CHEMBL1909049,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,COc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
941,CHEMBL1909049,FSIWGHXVLYRBFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1C(=O)N2CCC(CC2)CC3=CC=CC=C3,COc1ccccc1C(=O)N1CCC(Cc2ccccc2)CC1
942,CHEMBL1076211,FSKFPVLPFLJRQB-UHFFFAOYSA-N,TOLPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1
943,CHEMBL1076211,FSKFPVLPFLJRQB-UHFFFAOYSA-N,TOLPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1
944,CHEMBL1222625,FSQHSKMGRAIYLO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C=C(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4)C(=O)O,C=C(CN1CCN(C2=Cc3ccccc3Cn3ccnc32)CC1)C(=O)O
945,CHEMBL189171,FSQKKOOTNAMONP-UHFFFAOYSA-N,ACEMETACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
946,CHEMBL189171,FSQKKOOTNAMONP-UHFFFAOYSA-N,ACEMETACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)OCC(=O)O,COc1ccc2c(c1)c(CC(=O)OCC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1
948,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16854056.0,EC50,=,6.76,NM,,,cell_based,,,,,,,,,,,,Activity at human histamine H1 receptor transfected in COS7 cells by NF-kappaB luciferase reporter assay,Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.,J. Med. Chem.,PUBLICATION,,8.170053304058364,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42,CN1CCN(C2=Nc3ccc(Cl)cc3Oc3ccccc32)CC1
949,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16854056.0,Ki,=,7.76,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.,J. Med. Chem.,PUBLICATION,,8.110138278741811,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42,CN1CCN(C2=Nc3ccc(Cl)cc3Oc3ccccc32)CC1
951,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19053770.0,Ki,=,7.76,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.,J. Med. Chem.,PUBLICATION,,8.110138278741811,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42,CN1CCN(C2=Nc3ccc(Cl)cc3Oc3ccccc32)CC1
952,CHEMBL213912,FSRSEANZUZHDHK-UHFFFAOYSA-N,VUF-6884,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,8.318,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.079981083971084,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)OC4=CC=CC=C42,CN1CCN(C2=Nc3ccc(Cl)cc3Oc3ccccc32)CC1
953,CHEMBL976,FSVJFNAIGNNGKK-UHFFFAOYSA-N,PRAZIQUANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1
954,CHEMBL976,FSVJFNAIGNNGKK-UHFFFAOYSA-N,PRAZIQUANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1
955,CHEMBL744,FTALBRSUTCGOEG-UHFFFAOYSA-N,RILUZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,Nc1nc2ccc(OC(F)(F)F)cc2s1
956,CHEMBL744,FTALBRSUTCGOEG-UHFFFAOYSA-N,RILUZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1OC(F)(F)F)SC(=N2)N,Nc1nc2ccc(OC(F)(F)F)cc2s1
957,,FTCWKSGDHXCEMZ-UHFFFAOYSA-N,K117,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15798001.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1CC(C2=CC=CC=C2N1C(=O)C3=CC=CC=C3)N(C4=CC=CC=C4)C(=O)C(C)C,CC(C)C(=O)N(c1ccccc1)C1CC(C)N(C(=O)c2ccccc2)c2ccccc21
961,CHEMBL83668,FUSNMLFNXJSCDI-UHFFFAOYSA-N,TOLNAFTATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2,Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1
962,CHEMBL83668,FUSNMLFNXJSCDI-UHFFFAOYSA-N,TOLNAFTATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)N(C)C(=S)OC2=CC3=CC=CC=C3C=C2,Cc1cccc(N(C)C(=S)Oc2ccc3ccccc3c2)c1
964,CHEMBL105567,FUYGZJGUDRONJU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,758.58,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.119998611678232,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CSC=C3,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccsc3)cc2)CC1
966,CHEMBL12948,FVLVBPDQNARYJU-UHFFFAOYSA-N,SEMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CCC(CC1)NC(=O)N(CCCl)N=O,CC1CCC(NC(=O)N(CCCl)N=O)CC1
967,CHEMBL12948,FVLVBPDQNARYJU-UHFFFAOYSA-N,SEMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CCC(CC1)NC(=O)N(CCCl)N=O,CC1CCC(NC(=O)N(CCCl)N=O)CC1
968,CHEMBL1946253,FVMDOYQNOWAVCQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,1247.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,5.904133546521457,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCCC3=CC=C(C=C3)F,Fc1ccc(CCCCN2CCCN(c3ccc(Cl)cc3)CC2)cc1
969,CHEMBL3094215,FVUHMXKJJTVQKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1995.26,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC3=C(CCN(CC3)CC4CC4)C=C2,c1cc2c(cc1OCCCN1CCCCC1)CCN(CC1CC1)CC2
971,CHEMBL594721,FWRAMRVPMYVJMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)C2=NC(=NC(=C2)NCC3=CC=CC=C3Cl)N,CN1CCN(c2cc(NCc3ccccc3Cl)nc(N)n2)CC1
972,CHEMBL64773,FWXQEINBRJTOSP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1202.26,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.920001601921648,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)NC(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)NC(C)C)CC2)cc1
973,CHEMBL256477,FXBRDXOXJHZPDA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.19999817218203,CCC1=NN(C2=C1C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C,CCc1nn(C)c2cc3c(cc12)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
974,CHEMBL193435,FXHLGRYCQSRFHY-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,42.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.376750709602098,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Br)OC4=CC=CC=C24,CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1
975,CHEMBL195856,FXHLGRYCQSRFHY-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor; Not tested,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Br)OC4=CC=CC=C24,CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Br)cc3[C@H]2O1
976,CHEMBL319000,FXIPXWLVYIHFEP-OAQYLSRUSA-N,A-331440,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,1905.46,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,CN(C)[C@@H]1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,CN(C)[C@@H]1CCN(CCCOc2ccc(-c3ccc(C#N)cc3)cc2)C1
977,CHEMBL160581,FYCXANKHKYEXTR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Compound was tested for its affinity towards histaminergic (H 1) receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1C2=CC=CC3=CC=CC=C32)C(=O)COC4=CC5=C(C=C4)NC=C5CCN,NCCc1c[nH]c2ccc(OCC(=O)N3CCN(c4cccc5ccccc45)CC3)cc12
979,CHEMBL602850,FYGREZKTJIXWIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1cccc(F)c1
980,CHEMBL602850,FYGREZKTJIXWIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1cccc(F)c1
981,CHEMBL608,FYPMFJGVHOHGLL-UHFFFAOYSA-N,PROBUCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
982,CHEMBL608,FYPMFJGVHOHGLL-UHFFFAOYSA-N,PROBUCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC(=CC(=C1O)C(C)(C)C)SC(C)(C)SC2=CC(=C(C(=C2)C(C)(C)C)O)C(C)(C)C,CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1
984,CHEMBL1923521,FZBQOBOSIQUVSG-UHFFFAOYSA-N,4-(2-BENZYLPHENOXY)PIPERIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,6.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,8.221848749616356,C1CNCCC1OC2=CC=CC=C2CC3=CC=CC=C3,c1ccc(Cc2ccccc2OC2CCNCC2)cc1
985,CHEMBL1923521,FZBQOBOSIQUVSG-UHFFFAOYSA-N,4-(2-BENZYLPHENOXY)PIPERIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,6.31,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,8.199970640755867,C1CNCCC1OC2=CC=CC=C2CC3=CC=CC=C3,c1ccc(Cc2ccccc2OC2CCNCC2)cc1
986,CHEMBL1643900,FZIIBLBHXXRTMG-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21146989.0,Ki,=,2376.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.624153563690844,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC(=CC=C6)F,Fc1cccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)c1
987,CHEMBL1643900,FZIIBLBHXXRTMG-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,2376.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.624153563690844,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCC6=CC(=CC=C6)F,Fc1cccc(CCN[C@H]2C3C4CC5C6C4CC3C6C52)c1
989,CHEMBL1643901,GACBJAOXQGFNDL-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21146989.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor at 10 uM,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(CC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
990,CHEMBL1643901,GACBJAOXQGFNDL-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(Cc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
992,CHEMBL116463,GALCSZPFCCZIBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,454.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.342944147142896,C1CN(CCC1NC(=O)OCCC2=CC=C(C=C2)C#N)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,N#Cc1ccc(CCOC(=O)NC2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
993,CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
994,CHEMBL553025,GBABOYUKABKIAF-IELIFDKJSA-N,VINORELBINE BASE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C[C@H]2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2
995,CHEMBL578,GBXSMTUPTTWBMN-XIRDDKMYSA-N,ENALAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
996,CHEMBL578,GBXSMTUPTTWBMN-XIRDDKMYSA-N,ENALAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
998,CHEMBL471724,GCEYKTZXUXSFFO-UHFFFAOYSA-N,UR-PI287,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,2570.4,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.589999287456538,CC(C)C(=O)NC(=NCCCC1=CN=CN1)N,CC(C)C(=O)NC(N)=NCCCc1cnc[nH]1
999,CHEMBL1395,GCKMFJBGXUYNAG-HLXURNFRSA-N,METHYLTESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
1000,CHEMBL1395,GCKMFJBGXUYNAG-HLXURNFRSA-N,METHYLTESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
1001,CHEMBL1783962,GDGRKDCFXHOMEX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,>,10000.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)C(F)(F)F,CN1CCc2c(c3cc(C(F)(F)F)ccc3n2CCc2cccnc2)C1
1002,CHEMBL1783962,GDGRKDCFXHOMEX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CN=CC=C4)C=CC(=C3)C(F)(F)F,CN1CCc2c(c3cc(C(F)(F)F)ccc3n2CCc2cccnc2)C1
1003,CHEMBL181,GDLBFKVLRPITMI-UHFFFAOYSA-N,DIAZOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,CC1=NS(=O)(=O)c2cc(Cl)ccc2N1
1004,CHEMBL181,GDLBFKVLRPITMI-UHFFFAOYSA-N,DIAZOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl,CC1=NS(=O)(=O)c2cc(Cl)ccc2N1
1005,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,85.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.070581074285707,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1006,CHEMBL415,GDLIGKIOYRNHDA-UHFFFAOYSA-N,CLOMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,9.83,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.007446482167865,CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21
1007,CHEMBL2171037,GDRRHBZSXZXDLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,CN(C)C1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,CN(C)c1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
1008,CHEMBL1091774,GDVOQNXWYQVYJH-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,6100.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.214670164989234,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCCC4,C[C@@H](c1ccccn1)c1c(CCN2CCCC2)sc2ccccc12
1010,CHEMBL314107,GEDGEGJCGBTAON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,16.98,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.770062314092066,CN(C)CC1CC2C3=C(CC4=C(N2O1)C=C(C=C4)F)C=CC(=C3)F,CN(C)CC1CC2c3cc(F)ccc3Cc3ccc(F)cc3N2O1
1011,CHEMBL47482,GEICAQNIOJFRQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,197.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.705533773838407,C1C2=CC=CC=C2C(C3=CC=CC=C31)CN,NCC1c2ccccc2Cc2ccccc21
1012,CHEMBL2158785,GEMBQNHUTJFAFL-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CC1=C(C=CC(=C1Cl)C#N)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O,Cc1c(OC2CCN(CC3CCN([C@@H](Cc4ccc(F)cc4)C(=O)O)CC3)CC2)ccc(C#N)c1Cl
1013,CHEMBL1092377,GETROLYXSDDSDH-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,2.7,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841014,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)F,C[C@@H](c1ncccc1F)c1c(CCN(C)C)sc2ccccc12
1014,CHEMBL2355126,GFBKORZTTCHDGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,,,,,,8.397940008672037,CN1CCN(CC1)CCC=C2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,CN1CCN(CCC=C2c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
1015,CHEMBL1201,GFBKORZTTCHDGY-UWVJOHFNSA-N,THIOTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,5.88,NM,,,,,,,,,,,,,,,,,,,,8.230622673923861,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
1016,CHEMBL1201,GFBKORZTTCHDGY-UWVJOHFNSA-N,THIOTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,4.4,NM,,,,,,,,,,,,,,,,,,,,8.356547323513812,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
1017,CHEMBL1201,GFBKORZTTCHDGY-UWVJOHFNSA-N,THIOTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,6.0,NM,,,,,,,,,,,,,,,,,,,,8.221848749616356,CN1CCN(CC1)CC/C=C\2/C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)(=O)N(C)C,CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
1018,CHEMBL556782,GFGGZTNVJUNZEE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CC1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5.Cl,Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1
1020,CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
1021,CHEMBL1451,GFNANZIMVAIWHM-OBYCQNJPSA-N,TRIAMCINOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@H]([C@@]2(C(=O)CO)O)O)CCC4=CC(=O)C=C[C@@]43C)F)O,C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO
1022,CHEMBL1767149,GFOPLENUCATIPC-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.251,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.600326278518963,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=C(C=C4)F)F,CN1CCC[C@@H]1Cn1nc(Cc2ccc(F)c(F)c2)c2ccccc2c1=O
1024,CHEMBL404363,GGTFAVLCBBVKHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)N=C(O6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc6nc(C(F)(F)F)oc6c5CC4)n3C)cccc2n1
1025,CHEMBL561981,GGTPJIUWVNXICI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,>,500.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=CC=CC(=C53)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4cccc(C(=O)O)c43)CC2)cc(=O)n(C)c1=O
1026,CHEMBL880,GGXKWVWZWMLJEH-UHFFFAOYSA-N,FAMCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O
1027,CHEMBL880,GGXKWVWZWMLJEH-UHFFFAOYSA-N,FAMCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O
1028,CHEMBL185,GHASVSINZRGABV-UHFFFAOYSA-N,FLUOROURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=O)NC(=O)N1)F,O=c1[nH]cc(F)c(=O)[nH]1
1029,CHEMBL185,GHASVSINZRGABV-UHFFFAOYSA-N,FLUOROURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C(=O)NC(=O)N1)F,O=c1[nH]cc(F)c(=O)[nH]1
1030,CHEMBL319535,GHVPKFCDNOFWEW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.6,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.180456064458129,CC(C)OC1=CC=CC(=C1)CC(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8,CC(C)Oc1cccc(CC(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc4c(c3)OCO4)C2)c1
1031,CHEMBL559060,GHZHZIJXYOTTAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,4.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.346787486224656,C1CN(CCC1NCC2CCOCC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1
1032,CHEMBL558468,GIEBQTVDYXTBCS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,CN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,COc1ccc(Cn2c(N3CCC(N(C)C)CC3)nc3ccccc32)cc1
1034,CHEMBL152221,GIGMUWUHKTVYOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,3981.07,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.40000018605658,C1CCN(C1)CCCCCCCCCCCCC2=CN=CN2,c1ncc(CCCCCCCCCCCCN2CCCC2)[nH]1
1035,CHEMBL152221,GIGMUWUHKTVYOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,501187233627271.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.699999999999998,C1CCN(C1)CCCCCCCCCCCCC2=CN=CN2,c1ncc(CCCCCCCCCCCCN2CCCC2)[nH]1
1036,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.18,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.497572880015568,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1[C@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2
1037,CHEMBL1201203,GIJXKZJWITVLHI-PMOLBWCYSA-N,BENZTROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.37,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.431798275933003,CN1[C@@H]2CC[C@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1[C@H]2CC[C@@H]1CC(OC(c1ccccc1)c1ccccc1)C2
1038,CHEMBL116590,GIJXKZJWITVLHI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1.1,NM,,,,,,,,,,,,,,,,,,,,8.958607314841776,CN1C2CCC1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CN1C2CCC1CC(OC(c1ccccc1)c1ccccc1)C2
1039,CHEMBL1277035,GIZCWMURBFLMON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.699991797446188,C1CC2(CC1N3CC(=CC(=O)O)C3)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C=C1CN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)C1
1040,CHEMBL2207277,GJJRSPSNZFRQIQ-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=C(C=C4)S(=O)(=O)C)O,Cc1cc(Cl)ccc1OC1CCN(C[C@H](O)CNC(=O)c2c[nH]c(=O)c3ccc(S(C)(=O)=O)cc23)CC1
1041,CHEMBL1277584,GJQONOYIKURBSD-IYRGYZHQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.700057099977232,C1C[C@H](CN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)C(=O)O,O=C(O)[C@@H]1CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
1042,CHEMBL328250,GJSLOMWRLALDCT-UHFFFAOYSA-N,ADINAZOLAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
1043,CHEMBL134,GJSURZIOUXUGAL-UHFFFAOYSA-N,CLONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,Clc1cccc(Cl)c1NC1=NCCN1
1044,CHEMBL134,GJSURZIOUXUGAL-UHFFFAOYSA-N,CLONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl,Clc1cccc(Cl)c1NC1=NCCN1
1045,CHEMBL698,GKCBAIGFKIBETG-UHFFFAOYSA-N,TETRACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,CCCCNc1ccc(C(=O)OCCN(C)C)cc1
1046,CHEMBL698,GKCBAIGFKIBETG-UHFFFAOYSA-N,TETRACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCNC1=CC=C(C=C1)C(=O)OCCN(C)C,CCCCNc1ccc(C(=O)OCCN(C)C)cc1
1047,CHEMBL194837,GKDBTHSYQZTDAJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16134937.0,IC50,=,3.5,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,PUBLICATION,,8.455931955649724,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)COC3=C(C=C(C=C3)Cl)Cl)OCCN(C)C,Cc1cc(OCCN(C)C)nc2ccc(NC(=O)COc3ccc(Cl)cc3Cl)cc12
1048,CHEMBL256016,GKDLNLYIGUXYSK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C(C)C,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4nc(C(C)C)oc4cc3CC2)n1C
1050,CHEMBL954,GKIRPKYJQBWNGO-OCEACIFDSA-N,ENCLOMIPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1
1051,CHEMBL954,GKIRPKYJQBWNGO-OCEACIFDSA-N,ENCLOMIPHENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC1=CC=C(C=C1)/C(=C(\C2=CC=CC=C2)/Cl)/C3=CC=CC=C3,CCN(CC)CCOc1ccc(/C(=C(/Cl)c2ccccc2)c2ccccc2)cc1
1052,CHEMBL2158772,GKKOWDZJMOVEBY-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CC1=CC=CC=C1C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1ccccc1C[C@@H](C(=O)O)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1053,CHEMBL2171050,GKKYKABOCZBQRA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,1000.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)F)F,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(F)c(F)c4)CC3)CC2)cc1
1056,CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C
1057,CHEMBL460291,GKQPCPXONLDCMU-CCEZHUSRSA-N,LACIDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1c1ccccc1/C=C/C(=O)OC(C)(C)C
1058,CHEMBL199824,GKTQBPYMIGXPKG-JVVVGQRLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16392798.0,Ki,=,150.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.",J. Med. Chem.,PUBLICATION,,6.823908740944319,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC4=C3C=C(C=C4)O[11CH3],COc1ccc2cccc(N3CCN(CCCCn4ncc(=O)n(C)c4=O)CC3)c2c1
1059,CHEMBL1771,GKTWGGQPFAXNFI-HNNXBMFYSA-N,CLOPIDOGREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
1060,CHEMBL1771,GKTWGGQPFAXNFI-HNNXBMFYSA-N,CLOPIDOGREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3,COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1
1062,CHEMBL1783975,GLNBRPIPBOSSGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,7570.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.120904120499927,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=NC=C5,Cc1ccc2c(c1)c1c(n2CCc2ccncc2)CCN(C2CCN(C)CC2)C1
1063,CHEMBL1783975,GLNBRPIPBOSSGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=NC=C5,Cc1ccc2c(c1)c1c(n2CCc2ccncc2)CCN(C2CCN(C)CC2)C1
1064,CHEMBL1425,GLVAUDGFNGKCSF-UHFFFAOYSA-N,MERCAPTOPURINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=CN2,S=c1nc[nH]c2nc[nH]c12
1065,CHEMBL1425,GLVAUDGFNGKCSF-UHFFFAOYSA-N,MERCAPTOPURINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=CN2,S=c1nc[nH]c2nc[nH]c12
1066,CHEMBL73135,GLXQEUGDWMYWCC-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,150.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.823908740944319,C1CN(CCN1CC2=CC=C(O2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl,NC(=O)N(O)CCC#Cc1ccc(CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)o1
1067,CHEMBL73135,GLXQEUGDWMYWCC-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,150.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,6.823908740944319,C1CN(CCN1CC2=CC=C(O2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl,NC(=O)N(O)CCC#Cc1ccc(CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)o1
1068,CHEMBL25719,GLZPCOQZEFWAFX-JXMROGBWSA-N,GERANIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=CCC/C(=C/CO)/C)C,CC(C)=CCC/C(C)=C/CO
1069,CHEMBL25719,GLZPCOQZEFWAFX-JXMROGBWSA-N,GERANIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=CCC/C(=C/CO)/C)C,CC(C)=CCC/C(C)=C/CO
1070,CHEMBL330462,GMDILGHWZUFMEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.8,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.167491087293763,CCOC1=CC(=CC(=C1OCC)OCC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)OC)OC,CCOc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(OC)c(OC)c3)C2)cc(OCC)c1OCC
1071,CHEMBL323562,GMFZCHLJVCOHAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,426.58,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.369999510099088,CC1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,CC1CCN(CCCOc2ccc(-c3ccc(C#N)cc3)cc2)CC1
1073,CHEMBL350878,GMNSEVXCXMPGAC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=CC=C(C=C1)CCCCC2=NC=C(N2)CCN,NCCc1cnc(CCCCc2ccccc2)[nH]1
1075,CHEMBL36715,GMZVRMREEHBGGF-UHFFFAOYSA-N,PIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)N(C1)CC(=O)N,NC(=O)CN1CCCC1=O
1076,CHEMBL36715,GMZVRMREEHBGGF-UHFFFAOYSA-N,PIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)N(C1)CC(=O)N,NC(=O)CN1CCCC1=O
1077,CHEMBL256471,GNAFTHDBPJUMAT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)SC(=N5)C,Cc1nc2cc3c(cc2s1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
1078,CHEMBL11553,GNBOIGBQIBQOIA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,400.0,NM,,,,,,,,,,,,,,,,,,,,6.3979400086720375,CN(C)CCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3,CN(C)CCc1cnc(CCC(c2ccccc2)c2ccccc2)[nH]1
1079,CHEMBL304027,GNMIPEYDMWERLO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1023.29,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9900012699519385,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=C(C(=CC=C3)F)F,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)c3cccc(F)c3F)cc2)CC1
1080,CHEMBL1201117,GNXFOGHNGIVQEH-UHFFFAOYSA-N,METHOCARBAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(COC(=O)N)O,COc1ccccc1OCC(O)COC(N)=O
1081,CHEMBL1201117,GNXFOGHNGIVQEH-UHFFFAOYSA-N,METHOCARBAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(COC(=O)N)O,COc1ccccc1OCC(O)COC(N)=O
1082,CHEMBL642,GOEMGAFJFRBGGG-UHFFFAOYSA-N,ACEBUTOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
1083,CHEMBL642,GOEMGAFJFRBGGG-UHFFFAOYSA-N,ACEBUTOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C,CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(C(C)=O)c1
1084,CHEMBL64124,GOVWCMLTQFJSCR-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,45708.82,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.339999990132752,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC#N)N,N#CC[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1085,CHEMBL2205819,GOYQRMVWIWPDFU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCc1ccccc1
1086,CHEMBL7568,GPKJTRJOBQGKQK-UHFFFAOYSA-N,QUINACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12
1087,CHEMBL7568,GPKJTRJOBQGKQK-UHFFFAOYSA-N,QUINACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCCC(C)NC1=C2C=C(C=CC2=NC3=C1C=CC(=C3)Cl)OC,CCN(CC)CCCC(C)Nc1c2ccc(Cl)cc2nc2ccc(OC)cc12
1088,CHEMBL191703,GPLGAQQQNWMVMM-MYAJQUOBSA-N,CONESSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C[C@H]1[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC=C5[C@@]4(CC[C@@H](C5)N(C)C)C)CN1C,C[C@H]1[C@H]2CC[C@H]3[C@@H]4CC=C5C[C@@H](N(C)C)CC[C@]5(C)[C@H]4CC[C@]23CN1C
1089,CHEMBL1730,GPRBEKHLDVQUJE-QSWIMTSFSA-N,CEFOTAXIME,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
1090,CHEMBL1730,GPRBEKHLDVQUJE-QSWIMTSFSA-N,CEFOTAXIME,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O,CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(C)=O)CS[C@H]12)c1csc(N)n1
1092,CHEMBL2208427,GPRHHSZIXIDKDN-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,COC1=C(C=CC(=C1)C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O)N,COc1cc(C(=O)NC[C@@H](O)CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)ccc1N
1093,CHEMBL96429,GPVDPKZTACUYNW-IPKCRJEZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,2.36,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.627087997029893,C1COCCN1CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35,c1ccc2c(c1)Cc1ccccc1[C@H]1CC(CN3CCOCC3)O[C@H]21
1094,CHEMBL1276947,GPWMNUXSJDSCAV-NZICPMOKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.500038134403809,C1C[C@@]2(CC1N3C[C@@H]4C[C@@]4(C3)C(=O)O)CC5=CC=CC=C5CC6=CC=CC=C26,O=C(O)[C@]12C[C@H]1CN(C1CC[C@]3(Cc4ccccc4Cc4ccccc43)C1)C2
1095,CHEMBL2031737,GPZMWOXSIRVXQW-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313227.0,Ki,=,7055.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant H1 receptor,Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.,J. Med. Chem.,PUBLICATION,,5.1515029819096325,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C(=O)C4=CC=C(C=C4)[N+](=O)[O-],C[C@@H]1CCCN1CCc1cc2cc(C(=O)c3ccc([N+](=O)[O-])cc3)ccc2o1
1099,CHEMBL1767167,GQWSXILTLUTBAJ-PGUFJCEWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.899974269892138,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCCc1ccc(OCCCN2CCCCCC2)cc1
1100,CHEMBL514,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,LOMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NC1CCCCC1
1101,CHEMBL514,GQYIWUVLTXOXAJ-UHFFFAOYSA-N,LOMUSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)NC(=O)N(CCCl)N=O,O=NN(CCCl)C(=O)NC1CCCCC1
1102,CHEMBL303369,GRAGHFIYRPTBJY-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16595.87,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.779999975777493,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C(C)C)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@H](N)C(C)C)CC2)cc1
1103,CHEMBL62592,GRAGHFIYRPTBJY-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,19054.61,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.719999935717911,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](C(C)C)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](N)C(C)C)CC2)cc1
1104,CHEMBL1910380,GREREVYRUNFCTM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,602.56,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.219999701663428,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)C(=O)C3=NC4=CC=CC=C4N3)C5=CC=CC=N5,COc1ccc(CN(CCN2CCN(C(=O)c3nc4ccccc4[nH]3)CC2)c2ccccn2)cc1
1105,CHEMBL485958,GRHNPETZKNATKG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,7000.0,NM,,,,,,,,,,,,,,,,,,,,5.154901959985743,C1CCC(CC1)CC(=O)NC(=NCCCC2=CN=CN2)N,NC(=NCCCc1cnc[nH]1)NC(=O)CC1CCCCC1
1107,CHEMBL102452,GRJGKRWJSKONHR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3548.13,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.450000476425332,C1CN(CCC1N)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CCC(N)CC3)cc2)cc1
1108,CHEMBL594138,GRKYNTKPAFRLLZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,386.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.413412695328245,CNCCCC(C1=CC=CC=C1)C2=CC=CC=C2,CNCCCC(c1ccccc1)c1ccccc1
1110,CHEMBL303824,GRWARSULWXLZOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN1CCCC1CCNC2=C3CCCCCC3=NC4=CC=CC=C42,CN1CCCC1CCNc1c2c(nc3ccccc13)CCCCC2
1111,CHEMBL81977,GSCPDZHWVNUUFI-UHFFFAOYSA-N,3-AMINOBENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)N)C(=O)N,NC(=O)c1cccc(N)c1
1112,CHEMBL81977,GSCPDZHWVNUUFI-UHFFFAOYSA-N,3-AMINOBENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)N)C(=O)N,NC(=O)c1cccc(N)c1
1113,CHEMBL33,GSDSWSVVBLHKDQ-JTQLQIEISA-N,LEVOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1114,CHEMBL33,GSDSWSVVBLHKDQ-JTQLQIEISA-N,LEVOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1115,CHEMBL4,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,OFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1116,CHEMBL4,GSDSWSVVBLHKDQ-UHFFFAOYSA-N,OFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O,CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
1117,CHEMBL2171041,GSQPHXFZLYFUQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CN(C)C1=CC=CC=C1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,CN(C)c1ccccc1S(=O)(=O)NC(=O)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1118,CHEMBL1277491,GSUXFSXZSCBDQK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.699991797446188,C1CC2(CC1N3CCC(CC3)C(=O)O)C4=CC=CC=C4SC5=C(C2=O)C=C(C=C5)F,O=C(O)C1CCN(C2CCC3(C2)C(=O)c2cc(F)ccc2Sc2ccccc23)CC1
1122,CHEMBL434785,GUDHMDVRURNAHL-SNVBAGLBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10715.19,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.970000123715015,C1C(CC2=CC=CC=C21)[C@H](C(=O)O)N,N[C@@H](C(=O)O)C1Cc2ccccc2C1
1124,CHEMBL303454,GUGOEEXESWIERI-SSEXGKCCSA-N,R-TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,3.16,NM,,,,,,,,,,,,,,,,,,,,8.500312917381597,CC(C)(C)C1=CC=C(C=C1)[C@@H](CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc([C@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1125,CHEMBL303454,GUGOEEXESWIERI-SSEXGKCCSA-N,R-TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CC(C)(C)C1=CC=C(C=C1)[C@@H](CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc([C@H](O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1126,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12747773.0,Ki,=,58.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor,Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.,J. Med. Chem.,PUBLICATION,,7.236572006437062,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1127,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,40.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.397940008672037,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1128,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25494650.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),CNS drug design: balancing physicochemical properties for optimal brain exposure.,J. Med. Chem.,PUBLICATION,,9.0,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1129,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,22.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.657577319177793,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1130,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,563.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.249491605148653,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1131,CHEMBL17157,GUGOEEXESWIERI-UHFFFAOYSA-N,TERFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2.59,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.586700235918746,CC(C)(C)C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O,CC(C)(C)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1132,CHEMBL1091782,GUNAZEDORZMWRN-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,4.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.337242168318426,C[C@@H](C1=CSC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@@H](c1cscn1)c1c(CCN(C)C)sc2ccccc12
1133,CHEMBL1940412,GUOQPFNLBAXWIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,62.9,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,7.201349354554732,C1CN(CCN1CCCOC2=CC=C(C=C2)F)C3=CC=CC=C3,Fc1ccc(OCCCN2CCN(c3ccccc3)CC2)cc1
1135,CHEMBL360202,GUUFVYCRQBZPLO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,50.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CCCCOC4=CC=C(C=C4)C#CCCN(C(=O)N)O)C5=C1C=CC=N5,NC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)cc1
1137,CHEMBL1774492,GUYGSIXDIXLGLA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,255.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.5934598195660445,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCN(CCCN3c4ccccc4COc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
1139,CHEMBL345185,GVDNUYAKHMLSKZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1995.26,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1=C(NC=N1)CCCCCCCCCN,NCCCCCCCCCc1cnc[nH]1
1140,CHEMBL345185,GVDNUYAKHMLSKZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,50118723362727.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.699999999999998,C1=C(NC=N1)CCCCCCCCCN,NCCCCCCCCCc1cnc[nH]1
1141,CHEMBL1096430,GVGOZYJHWUIVHV-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,89.13,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0499760934766735,C[C@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2,C[C@H](CC(=O)NC(N)=NCCCc1cnc[nH]1)C1CCCCC1
1143,CHEMBL486965,GVGOZYJHWUIVHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,280.0,NM,,,,,,,,,,,,,,,,,,,,6.552841968657781,CC(CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2,CC(CC(=O)NC(N)=NCCCc1cnc[nH]1)C1CCCCC1
1144,CHEMBL486965,GVGOZYJHWUIVHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,910.0,NM,,,,,,,,,,,,,,,,,,,,6.040958607678906,CC(CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2,CC(CC(=O)NC(N)=NCCCc1cnc[nH]1)C1CCCCC1
1145,CHEMBL486965,GVGOZYJHWUIVHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,5300.0,NM,,,,,,,,,,,,,,,,,,,,5.275724130399211,CC(CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2,CC(CC(=O)NC(N)=NCCCc1cnc[nH]1)C1CCCCC1
1147,CHEMBL1096431,GVGOZYJHWUIVHV-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,66.07,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.179995693191682,C[C@@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2CCCCC2,C[C@@H](CC(=O)NC(N)=NCCCc1cnc[nH]1)C1CCCCC1
1149,CHEMBL47,GVJHHUAWPYXKBD-IEOSBIPESA-N,VITAMIN E,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
1150,CHEMBL47,GVJHHUAWPYXKBD-IEOSBIPESA-N,VITAMIN E,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2
1151,CHEMBL561690,GWLKWIJXTVRQMT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,IC50,=,80.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.094204119632131,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=CC=CC=C5,CN(c1ccccc1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
1153,CHEMBL1078240,GWSJPOPJXLJSLF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,1013.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.994390554639718,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC(=C(C=C4O3)S(=O)(=O)N)Cl)OC,CCOc1cc(CN2CCC(Nc3nc4cc(Cl)c(S(N)(=O)=O)cc4o3)CC2)ccc1OC
1154,CHEMBL13341,GWUSZQUVEVMBPI-UHFFFAOYSA-N,NIMETAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc21
1155,CHEMBL13341,GWUSZQUVEVMBPI-UHFFFAOYSA-N,NIMETAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3,CN1C(=O)CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc21
1156,CHEMBL2207657,GWVFJNPANMKQSY-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518963,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC=C4F)O,Cc1cc(Cl)ccc1OC1CCN(C[C@H](O)CNC(=O)c2c[nH]c(=O)c3c(F)cccc23)CC1
1159,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,,,,,,9.096910013008056,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
1160,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12747773.0,Ki,=,3.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor,Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.,J. Med. Chem.,PUBLICATION,,8.522878745280337,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
1161,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,2.09,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.679853713888948,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
1162,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,14.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.853871964321763,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
1163,CHEMBL296419,GXDALQBWZGODGZ-UHFFFAOYSA-N,ASTEMIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.61,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.79317412396815,COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,COc1ccc(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
1164,CHEMBL239975,GXILWBIQFGWJQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
1167,CHEMBL408,GXPHKUHSUJUWKP-UHFFFAOYSA-N,TROGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
1168,CHEMBL408,GXPHKUHSUJUWKP-UHFFFAOYSA-N,TROGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C2=C(CCC(O2)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(COc1ccc(CC3SC(=O)NC3=O)cc1)O2
1170,CHEMBL3290012,GXZWKZAOGQRNTL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24805037.0,Ki,=,69.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant H1 receptor expressed in HEK293 cells,Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia.,J. Med. Chem.,PUBLICATION,,7.161150909262744,C1CN(CCC1C2=NOC3=C2C=CC(=C3)F)CCCCNS(=O)(=O)C4=CC5=CC=CC=C5S4,O=S(=O)(NCCCCN1CCC(c2noc3cc(F)ccc23)CC1)c1cc2ccccc2s1
1171,CHEMBL293033,GYCWHNUGCXMJDF-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16218.1,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.790000026071144,CC(C)(C)OC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,CC(C)(C)OC[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1172,CHEMBL877,GYDJEQRTZSCIOI-LJGSYFOKSA-N,TRANEXAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)O,NCC1CCC(C(=O)O)CC1
1173,CHEMBL877,GYDJEQRTZSCIOI-LJGSYFOKSA-N,TRANEXAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)O,NCC1CCC(C(=O)O)CC1
1176,CHEMBL25688,GZAZQKHMIYBBFL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,5011.87,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3000002024454185,C1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CCCC3)cc2)cc1
1177,CHEMBL62312,GZGINHDPANJTJY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,398.11,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CO3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3ccco3)CC2)cc1
1178,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,130.0,NM,,,,,,,,,,,,,,,,,,,,6.886056647693162,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
1179,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,320.0,NM,,,,,,,,,,,,,,,,,,,,6.494850021680094,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
1180,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,130.0,NM,,,,,,,,,,,,,,,,,,,,6.886056647693162,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
1181,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,570.0,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,6.2441251443275085,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
1182,CHEMBL12713,GZKLJWGUPQBVJQ-UHFFFAOYSA-N,SERTINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,0.51,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,9.292429823902065,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)Cl)C4=CC=C(C=C4)F)CCN5CCNC5=O,O=C1NCCN1CCN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(Cl)cc23)CC1
1183,CHEMBL81,GZUITABIAKMVPG-UHFFFAOYSA-N,RALOXIFENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
1184,CHEMBL81,GZUITABIAKMVPG-UHFFFAOYSA-N,RALOXIFENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O,O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12
1185,CHEMBL1910382,GZUNLKUPHLSRKX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,100.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CN(CCN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl)CCN(CC4=CC=C(C=C4)OC)C5=CC=CC=N5,COc1ccc(CN(CCN(C)CCN2CCN(C(=O)c3cc4cc(Cl)ccc4[nH]3)CC2)c2ccccn2)cc1
1186,CHEMBL257536,HAJIPROMBKTILW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OCC(=O)N5,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4c(cc3CC2)OCC(=O)N4)n1C
1187,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1(CC(=O)NC1=O)C,CCC1(C)CC(=O)NC1=O
1188,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CC(=O)NC1=O)C,CCC1(C)CC(=O)NC1=O
1189,CHEMBL696,HAPOVYFOVVWLRS-UHFFFAOYSA-N,ETHOSUXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CC(=O)NC1=O)C,CCC1(C)CC(=O)NC1=O
1190,CHEMBL433257,HAVJATCHLFRDHY-KSZYUSJVSA-N,HARRINGTONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O,COC(=O)C[C@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
1191,CHEMBL433257,HAVJATCHLFRDHY-KSZYUSJVSA-N,HARRINGTONINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CC[C@@](CC(=O)OC)(C(=O)O[C@H]1[C@H]2C3=CC4=C(C=C3CCN5[C@@]2(CCC5)C=C1OC)OCO4)O)O,COC(=O)C[C@](O)(CCC(C)(C)O)C(=O)O[C@@H]1C(OC)=C[C@]23CCCN2CCc2cc4c(cc2[C@H]13)OCO4
1194,CHEMBL90997,HBMJQYDGBNSZMC-UHFFFAOYSA-N,S-34324,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,C1C(CC2=C1C=CC(=C2)F)CC3CN=CN3,Fc1ccc2c(c1)CC(CC1CN=CN1)C2
1195,CHEMBL129,HBOMLICNUCNMMY-XLPZGREQSA-N,ZIDOVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
1196,CHEMBL129,HBOMLICNUCNMMY-XLPZGREQSA-N,ZIDOVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-],Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O
1197,CHEMBL352375,HBRHULDGKNIFGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,218.78,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.6599923820033275,CC(C)N(CCC1=C(C2=CC=CC=C2C1)C(C)C3=CC=CC=N3)C(C)C,CC(C1=C(CCN(C(C)C)C(C)C)Cc2ccccc21)c1ccccn1
1198,CHEMBL352375,HBRHULDGKNIFGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,2454.71,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.6099998081597775,CC(C)N(CCC1=C(C2=CC=CC=C2C1)C(C)C3=CC=CC=N3)C(C)C,CC(C1=C(CCN(C(C)C)C(C)C)Cc2ccccc21)c1ccccn1
1200,CHEMBL1568,HBUBKKRHXORPQB-FJFJXFQQSA-N,FLUDARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
1201,CHEMBL1568,HBUBKKRHXORPQB-FJFJXFQQSA-N,FLUDARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)F)N,Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
1202,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,120.0,NM,,,,,,,,,,,,,,,,,,,,6.920818753952375,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1203,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,60.0,NM,,,,,,,,,,,,,,,,,,,,7.221848749616356,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1204,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1205,CHEMBL72,HCYAFALTSJYZDH-UHFFFAOYSA-N,DESIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCCN1c2ccccc2CCc2ccccc21
1206,CHEMBL1168,HDACQVRGBOVJII-JBDAPHQKSA-N,RAMIPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
1207,CHEMBL1168,HDACQVRGBOVJII-JBDAPHQKSA-N,RAMIPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@H]3CCC[C@H]3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21
1208,CHEMBL1277769,HDDLHPPRMNRBQB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,CC1(CCN(CC1)C2CCC3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)C(=O)O,CC1(C(=O)O)CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1
1210,CHEMBL37161,HDDSHPAODJUKPD-UHFFFAOYSA-N,FENBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1
1211,CHEMBL37161,HDDSHPAODJUKPD-UHFFFAOYSA-N,FENBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)SC3=CC=CC=C3,COC(=O)Nc1nc2ccc(Sc3ccccc3)cc2[nH]1
1213,CHEMBL1349,HDOVUKNUBWVHOX-QMMMGPOBSA-N,VALACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21
1214,CHEMBL1349,HDOVUKNUBWVHOX-QMMMGPOBSA-N,VALACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@H](C(=O)OCCOCN1C=NC2=C1N=C(NC2=O)N)N,CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)[nH]c(N)nc21
1215,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.62,NM,,,,,,,,,,,,,,,,,,,,9.207608310501746,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21
1216,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,3.3,NM,,,,,,,,,,,,,,,,,,,,8.481486060122112,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21
1217,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,0.62,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,9.207608310501746,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21
1218,CHEMBL285802,HDOZVRUNCMBHFH-UHFFFAOYSA-N,ZOTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,3.4,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.468521082957745,CN(C)CCOC1=CC2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc21
1219,CHEMBL237087,HDRIBIYPLKZUDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19524331.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]N-alpha-methylhistamine from histamine H1 receptor expressed in SK-N-MC cells,Diamine-based human histamine H3 receptor antagonists: (4-aminobutyn-1-yl)benzylamines.,Eur. J. Med. Chem.,PUBLICATION,,5.0,C1CCN(CC1)CCC#CC2=CC=CC(=C2)CN3CCOCC3,C(#Cc1cccc(CN2CCOCC2)c1)CCN1CCCCC1
1220,CHEMBL2205820,HDZWTAJVYGVJEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCc1cccc(F)c1
1221,CHEMBL2205820,HDZWTAJVYGVJEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC7=CC(=CC=C7)F)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCCc1cccc(F)c1
1222,CHEMBL44618,HEDRZPFGACZZDS-UHFFFAOYSA-N,CHLOROFORM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)Cl,ClC(Cl)Cl
1223,CHEMBL44618,HEDRZPFGACZZDS-UHFFFAOYSA-N,CHLOROFORM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)Cl,ClC(Cl)Cl
1224,CHEMBL561489,HEFAAVYYGFTJLY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,75.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.123782159408357,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC=N5,CN(c1ncccn1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
1225,CHEMBL175,HEFNNWSXXWATRW-JTQLQIEISA-N,DEXIBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
1226,CHEMBL175,HEFNNWSXXWATRW-JTQLQIEISA-N,DEXIBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@H](C)C(=O)O)cc1
1227,CHEMBL427526,HEFNNWSXXWATRW-SNVBAGLBSA-N,(R)-IBUPROPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1
1228,CHEMBL427526,HEFNNWSXXWATRW-SNVBAGLBSA-N,(R)-IBUPROPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1=CC=C(C=C1)CC(C)C)C(=O)O,CC(C)Cc1ccc([C@@H](C)C(=O)O)cc1
1229,CHEMBL521,HEFNNWSXXWATRW-UHFFFAOYSA-N,IBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)Cc1ccc(C(C)C(=O)O)cc1
1230,CHEMBL521,HEFNNWSXXWATRW-UHFFFAOYSA-N,IBUPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC1=CC=C(C=C1)C(C)C(=O)O,CC(C)Cc1ccc(C(C)C(=O)O)cc1
1231,CHEMBL457,HEMJJKBWTPKOJG-UHFFFAOYSA-N,GEMFIBROZIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1
1232,CHEMBL457,HEMJJKBWTPKOJG-UHFFFAOYSA-N,GEMFIBROZIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1
1233,CHEMBL34139,HFGZFHCWKKQGIS-NOZJJQNGSA-N,GENACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C,C[C@H]([C@](O)(Cn1cncn1)c1ccc(F)cc1F)S(C)(=O)=O
1234,CHEMBL34139,HFGZFHCWKKQGIS-NOZJJQNGSA-N,GENACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]([C@](CN1C=NC=N1)(C2=C(C=C(C=C2)F)F)O)S(=O)(=O)C,C[C@H]([C@](O)(Cn1cncn1)c1ccc(F)cc1F)S(C)(=O)=O
1235,CHEMBL1230813,HFHDHCJBZVLPGP-RWMJIURBSA-N,ALFADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
1236,CHEMBL1230813,HFHDHCJBZVLPGP-RWMJIURBSA-N,ALFADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@H](O2)[C@@H]([C@H]7O)O)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
1239,CHEMBL1091791,HFLPUFFCCFMOMB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,390.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,CC1=CC(=NC=C1)C(C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1ccnc(C(C)c2c(CCN(C)C)sc3ccccc23)c1
1240,CHEMBL2171047,HFWLILWGBZWYRI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=C(C(=C(C=C4)Cl)C)Cl,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(C)c4Cl)CC3)CC2)cc1
1241,CHEMBL1669421,HGLDEVLFUAEPJC-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,162.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.790484985457369,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CO4,C[C@H](C1=C(CCN(C)Cc2ncco2)Cc2ccccc21)c1cnccn1
1242,CHEMBL1243394,HGLGWLWXYRAXPK-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,=,280.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,6.552841968657781,C1CNCCC1[C@H](CSC2=CC=C(C=C2)C(F)(F)F)C3=CN=CN3,FC(F)(F)c1ccc(SC[C@H](c2cnc[nH]2)C2CCNCC2)cc1
1243,CHEMBL1243395,HGLGWLWXYRAXPK-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,=,48.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,7.3187587626244115,C1CNCCC1[C@@H](CSC2=CC=C(C=C2)C(F)(F)F)C3=CN=CN3,FC(F)(F)c1ccc(SC[C@@H](c2cnc[nH]2)C2CCNCC2)cc1
1245,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23602445.0,Ki,=,936.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.028724151261895,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1246,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23602445.0,Ki,=,1258.93,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1247,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1248,CHEMBL2391541,HGRHWEAUHXYNNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,COC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(OC)cc12
1250,CHEMBL401777,HGTGAIQIJPCZMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C,CCc1nc2cc3c(c(C)c2o1)CCN(CCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
1251,CHEMBL30327,HGUFODBRKLSHSI-UHFFFAOYSA-N,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2
1252,CHEMBL30327,HGUFODBRKLSHSI-UHFFFAOYSA-N,"2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)Cl)OC3=CC(=C(C=C3O2)Cl)Cl,Clc1cc2c(cc1Cl)Oc1cc(Cl)c(Cl)cc1O2
1253,CHEMBL29808,HGWVDBLPHYBBTH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4,C=Cc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
1254,CHEMBL219146,HHJUWIANJFBDHT-KOTLKJBCSA-N,VINDESINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
1255,CHEMBL219146,HHJUWIANJFBDHT-KOTLKJBCSA-N,VINDESINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)N)O)O)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
1258,CHEMBL748,HIGSLXSBYYMVKI-UHFFFAOYSA-N,PRALIDOXIME CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=CC=C1/C=N/O.[Cl-],C[n+]1ccccc1/C=N/O
1259,CHEMBL748,HIGSLXSBYYMVKI-UHFFFAOYSA-N,PRALIDOXIME CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+]1=CC=CC=C1/C=N/O.[Cl-],C[n+]1ccccc1/C=N/O
1260,CHEMBL563920,HILDNLJIJXAVHA-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,0.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,9.045757490560677,C[C@@H](C1=CC=CC=N1)C2=C(OC3=CC=CC=C32)CCN(C)C,C[C@@H](c1ccccn1)c1c(CCN(C)C)oc2ccccc12
1262,CHEMBL11584,HJHFHKLECBMBFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,125892541179417.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.100000000000001,C1=CC=C(C=C1)C(CC2=NC=C(N2)CCN)C3=CC=CC=C3,NCCc1cnc(CC(c2ccccc2)c2ccccc2)[nH]1
1264,CHEMBL1779058,HJKLOGARPBXZTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21555222.0,Ki,=,2372.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,"Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.624885315307775,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC(=O)C7=CC=C(C=C7)F)O,O=C(CCCN1C2C3C4CC5C6C4C2C6C1(O)C53)c1ccc(F)cc1
1265,CHEMBL1779058,HJKLOGARPBXZTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,2372.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.624885315307775,C1C2C3C4C1C5C2C6C3C4C5(N6CCCC(=O)C7=CC=C(C=C7)F)O,O=C(CCCN1C2C3C4CC5C6C4C2C6C1(O)C53)c1ccc(F)cc1
1266,CHEMBL1220,HJLSLZFTEKNLFI-UHFFFAOYSA-N,TINIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
1267,CHEMBL1220,HJLSLZFTEKNLFI-UHFFFAOYSA-N,TINIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C,CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C
1268,CHEMBL1669408,HJNGVQMITVXZEN-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,13.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693162,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCF,C[C@H](C1=C(CCN(C)CCF)Cc2ccccc21)c1cnccn1
1269,CHEMBL2030623,HJOLMLNXMCFYQQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CC3=CC(=CC=C3)F,Fc1cccc(CN2C3CCC2CC3)c1
1270,CHEMBL1783969,HJSAIEMTRYMFMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,>,10000.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(=O)O,CN1CCc2c(c3cc(C(=O)O)ccc3n2CCc2ccncc2)C1
1271,CHEMBL1783969,HJSAIEMTRYMFMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(=O)O,CN1CCc2c(c3cc(C(=O)O)ccc3n2CCc2ccncc2)C1
1272,CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NN,NNc1ccccc1
1273,CHEMBL456807,HKOOXMFOFWEVGF-UHFFFAOYSA-N,PHENYLHYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NN,NNc1ccccc1
1275,CHEMBL446885,HKYLTVCKKUPKSQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,436.52,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.359995853468939,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccc(OC(F)(F)F)cc3)cc2)CC1
1277,CHEMBL11879,HKZSTMPUPMSPLU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,398107170553497.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.6,C1CCN(C1)CCC2=CN=C(N2)CCC(C3=CC=CC=C3)C4=CC=CC=C4,c1ccc(C(CCc2ncc(CCN3CCCC3)[nH]2)c2ccccc2)cc1
1279,CHEMBL238456,HLBPILNTTPELKS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.4999996786570655,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O,CC(C)N1CCC(Oc2ccc(N3CCN(C(=O)c4ccc(C#N)cc4)CC3=O)cc2)CC1
1282,CHEMBL1454,HLFSDGLLUJUHTE-SNVBAGLBSA-N,LEVAMISOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSC2=N[C@H](CN21)C3=CC=CC=C3,c1ccc([C@H]2CN3CCSC3=N2)cc1
1283,CHEMBL1454,HLFSDGLLUJUHTE-SNVBAGLBSA-N,LEVAMISOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CSC2=N[C@H](CN21)C3=CC=CC=C3,c1ccc([C@H]2CN3CCSC3=N2)cc1
1292,CHEMBL2158782,HLXZPGHNFUSVMT-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=C(C=CC(=C1)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O)Cl,Cc1cc(OC2CCN(CC3CCN([C@@H](Cc4ccc(F)cc4)C(=O)O)CC3)CC2)ccc1Cl
1293,CHEMBL3221637,HMPMHACJMYGXPE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,>,4000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,,MedChemComm,PUBLICATION,,5.3979400086720375,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)C3(CCOCC3)C(=O)N,CC(C)N1CCC(Oc2ccc(C3(C(N)=O)CCOCC3)cc2)CC1
1294,CHEMBL64775,HMRCFAPWUJGFPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5600045260461926,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)OCC(C)C)CC2)cc1
1295,CHEMBL348302,HMWYNGSUVFCIHB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,3.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,8.522878745280337,CNCCCC1C2=CC=CC=C2CC3=CC=CC=C13,CNCCCC1c2ccccc2Cc2ccccc21
1296,CHEMBL189676,HMXDWDSNPRNUKI-UHFFFAOYSA-N,SURINABANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15131245.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,,,,,,6.0,CCC1=C(N(N=C1C(=O)NN2CCCCC2)C3=C(C=C(C=C3)Cl)Cl)C4=CC=C(C=C4)Br,CCc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1
1299,CHEMBL28997,HNCAIEASLRMRKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)F,Fc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
1300,CHEMBL2207632,HNCOLMVXXZHGHT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)C#C,C#Cc1cc(CN2CCN(c3ccccc3OC)CC2)c2cccccc1-2
1301,CHEMBL317524,HNDKQQSKDXJMDG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,204.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.690369832574103,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8.CS(=O)(=O)O,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc4c(c3)OCO4)C2)cc(OC)c1OC
1302,CHEMBL1411979,HNJJXZKZRAWDPF-UHFFFAOYSA-N,METHAPYRILENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,16.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.795880017344076,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2,CN(C)CCN(Cc1cccs1)c1ccccn1
1303,CHEMBL1411979,HNJJXZKZRAWDPF-UHFFFAOYSA-N,METHAPYRILENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.8,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.744727494896694,CN(C)CCN(CC1=CC=CS1)C2=CC=CC=N2,CN(C)CCN(Cc1cccs1)c1ccccn1
1304,CHEMBL1767157,HNLNXYUSMGCHFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.199970640755867,CN1CCCC1CCN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCCC1CCn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
1305,CHEMBL1024,HOMGKSMUEGBAAB-UHFFFAOYSA-N,IFOSFAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(P(=O)(OC1)NCCCl)CCCl,O=P1(NCCCl)OCCCN1CCCl
1306,CHEMBL1024,HOMGKSMUEGBAAB-UHFFFAOYSA-N,IFOSFAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(P(=O)(OC1)NCCCl)CCCl,O=P1(NCCCl)OCCCN1CCCl
1308,CHEMBL1092813,HOUUGSUKNBXWNT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,17.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.769551078621726,CC1=C(C=CC=N1)[C@@H](C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12
1309,CHEMBL1669413,HOXVEGPFZJNLIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,2.8,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.55284196865778,C1CCN(C1)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,c1ccc2c(c1)CC(CCN1CCCC1)=C2Cc1cnccn1
1310,CHEMBL483400,HOYKNPXNYUOCRM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18841880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.,J. Med. Chem.,PUBLICATION,,5.0,CC1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5,Cc1nc2cccc(F)c2c(=O)n1-c1ccc(OC2CCN(C3CCC3)CC2)cc1
1311,CHEMBL1444,HPJKCIUCZWXJDR-UHFFFAOYSA-N,LETROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
1312,CHEMBL1444,HPJKCIUCZWXJDR-UHFFFAOYSA-N,LETROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
1313,CHEMBL866,HPNSFSBZBAHARI-RUDMXATFSA-N,MYCOPHENOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2
1314,CHEMBL866,HPNSFSBZBAHARI-RUDMXATFSA-N,MYCOPHENOLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)O)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)O)C(=O)OC2
1315,CHEMBL2323582,HPRWHXGAJGUOCP-UHFFFAOYSA-N,BODILISANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1662.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells,,ACS Med. Chem. Lett.,PUBLICATION,,5.779368980551907,[B-]1(N2C(=CC(=C2C(=C3[N+]1=C(C=C3C)C)C4=CC=C(C=C4)OCCCN5CCCCC5)C)C)(F)F,CC1=CC(C)=[N+]2C1=C(c1ccc(OCCCN3CCCCC3)cc1)c1c(C)cc(C)n1[B-]2(F)F
1316,CHEMBL1092651,HPVUAGMZZRSSHI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3OC,COc1nccnc1CC1=C(CCN(C)C)Cc2cc(F)ccc21
1317,CHEMBL493677,HQZBFDAIHIKVRO-CXAGYDPISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18817368.0,IC50,=,6000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,"Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels.",J. Med. Chem.,PUBLICATION,,5.221848749616356,CC(C)(C)CCN1CC[C@@H]([C@@H](C1)F)CNC(=O)C2=CC(=CC(=C2)Cl)Cl,CC(C)(C)CCN1CC[C@H](CNC(=O)c2cc(Cl)cc(Cl)c2)[C@H](F)C1
1318,CHEMBL271844,HRBGKICNPOCYPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC=N6,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6ncoc6cc5CC4)n3C)cccc2n1
1319,CHEMBL2207637,HRHSURDPAJFNRA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,2600.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,CN(C)CC1=C2C=CC=CC=C2C(=C1)CN3CCN(CC3)C4=CC=CC=C4OC,COc1ccccc1N1CCN(Cc2cc(CN(C)C)c3cccccc2-3)CC1
1320,CHEMBL534737,HRQFLVPRFGMKJO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4CC4.Cl,O=C(C1CC1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
1322,CHEMBL2146805,HRSYZRFBUGIVHN-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.34700000000000003,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.459670525209127,CN1CCC[C@@H]1CN2C(=O)C3=C(C=NC=C3)C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2cnccc2c1=O
1323,CHEMBL270227,HRUTWQCXFHLYSD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C(F)(F)F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C(F)(F)C(F)(F)F)oc6cc5CC4)n3C)cccc2n1
1324,CHEMBL980,HSRJKNPTNIJEKV-UHFFFAOYSA-N,GUAIFENESIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(CO)O,COc1ccccc1OCC(O)CO
1325,CHEMBL980,HSRJKNPTNIJEKV-UHFFFAOYSA-N,GUAIFENESIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCC(CO)O,COc1ccccc1OCC(O)CO
1326,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
1327,CHEMBL23,HSUGRBWQSSZJOP-RTWAWAEBSA-N,DILTIAZEM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC,COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1
1328,CHEMBL272511,HTADTAUIMFMPFI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc6oc(C)nc6c5CC4)n3C)cccc2n1
1329,CHEMBL239101,HTCLEEXSMMUUES-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.800000874803202,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC(=CC(=C5)F)F.C(=O)O,O=C(c1cc(F)cc(F)c1)N1CCN(c2ccc(OC3CCN(C4CCC4)CC3)cc2)C(=O)C1
1330,CHEMBL1767141,HTHMMDLGLVQHEM-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.2,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.69897000433602,CC1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C,Cc1ccc(Cc2nn(C[C@H]3CCCN3C)c(=O)c3ccccc23)cc1
1331,CHEMBL1491,HTIQEAQVCYTUBX-UHFFFAOYSA-N,AMLODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl
1332,CHEMBL1491,HTIQEAQVCYTUBX-UHFFFAOYSA-N,AMLODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl
1333,CHEMBL2376803,HTLDHQKBLGJBRF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,16595.87,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.779999975777493,CNC1CN(C1)C2=NC(=NC3=C2N=CC(=C3)C4CCCC4)N,CNC1CN(c2nc(N)nc3cc(C4CCCC4)cnc23)C1
1334,CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
1335,CHEMBL1016,HTQMVQVXFRQIKW-UHFFFAOYSA-N,CANDESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O,CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
1337,CHEMBL403815,HULQLOOBDVQQSC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(C=C6C(=C5CC4)N=C(O6)C)Cl,Cc1ccc2c(-c3nnc(SCCCN4CCc5c(Cl)cc6oc(C)nc6c5CC4)n3C)cccc2n1
1338,CHEMBL1521,HUNXMJYCHXQEGX-UHFFFAOYSA-N,ZALEPLON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
1339,CHEMBL1521,HUNXMJYCHXQEGX-UHFFFAOYSA-N,ZALEPLON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C,CCN(C(C)=O)c1cccc(-c2ccnc3c(C#N)cnn23)c1
1340,CHEMBL898,HUPFGZXOMWLGNK-UHFFFAOYSA-N,DIFLUNISAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
1341,CHEMBL898,HUPFGZXOMWLGNK-UHFFFAOYSA-N,DIFLUNISAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O,O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O
1342,CHEMBL1669427,HUPZZDHJGMFMTN-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,15.2,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.818156412055227,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4CCOCC4,C[C@H](C1=C(CCN(C)CC2CCOCC2)Cc2ccccc21)c1cnccn1
1343,CHEMBL129198,HUQJRYMLJBBEDO-UHFFFAOYSA-N,JNJ-7777120,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14722321.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl,CN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1
1344,CHEMBL129198,HUQJRYMLJBBEDO-UHFFFAOYSA-N,JNJ-7777120,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,Ki,=,977.24,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,6.009998764965339,CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl,CN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1
1345,CHEMBL129198,HUQJRYMLJBBEDO-UHFFFAOYSA-N,JNJ-7777120,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,46773.51,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3300000383353785,CN1CCN(CC1)C(=O)C2=CC3=C(N2)C=CC(=C3)Cl,CN1CCN(C(=O)c2cc3cc(Cl)ccc3[nH]2)CC1
1346,CHEMBL1084132,HVBAGGJDXDXSAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20153647.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Activity at histamine H1 receptor,"The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,C1CCNC(C1)CN2CCN(C2)C3=CC=CC=C3,c1ccc(N2CCN(CC3CCCCN3)C2)cc1
1347,CHEMBL2207641,HVGNYVOUQOKFLU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)CN5CCN(CC5)C6=CC=CC=C6OC,COc1ccccc1N1CCN(Cc2cc(CN3CCN(c4ccccc4OC)CC3)c3cccccc2-3)CC1
1348,CHEMBL516088,HVJOIRMQZXEGPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,944.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.025028005701932,COC1=C(C=CC=C1OCCF)C(=O)C2CCN(CC2)CCC3=CC=C(C=C3)F,COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(F)cc2)CC1
1349,CHEMBL1085672,HVSRNYNPOUFDNJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20153647.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Activity at histamine H1 receptor,"The identification of a selective dopamine D2 partial agonist, D3 antagonist displaying high levels of brain exposure.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCNC(C1)CN2CCN(C2=O)C3=CC(=CC=C3)Cl,O=C1N(CC2CCCCN2)CCN1c1cccc(Cl)c1
1350,CHEMBL1490,HWHLPVGTWGOCJO-UHFFFAOYSA-N,TRIHEXYPHENIDYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1
1351,CHEMBL1490,HWHLPVGTWGOCJO-UHFFFAOYSA-N,TRIHEXYPHENIDYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)C(CCN2CCCCC2)(C3=CC=CC=C3)O,OC(CCN1CCCCC1)(c1ccccc1)C1CCCCC1
1352,CHEMBL398812,HWRLDLIRHAWZST-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,O=C(c1ccc(F)cc1F)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
1353,CHEMBL239963,HWSMMNKRBIFEDV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)F.C(=O)O,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OC3CCN(C4CCCC4)CC3)cc2)C(=O)C1
1354,CHEMBL1527608,HWXIGFIVGWUZAO-UHFFFAOYSA-N,DOXOFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
1355,CHEMBL1527608,HWXIGFIVGWUZAO-UHFFFAOYSA-N,DOXOFYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3,Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O
1356,CHEMBL106545,HWYZEJDWSUNZPS-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3715.35,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4300002677960535,CN[C@@H]1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,CN[C@@H]1CCN(CCCOc2ccc(-c3ccc(C#N)cc3)cc2)C1
1357,CHEMBL309904,HXBMOXWVYIRYHK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,151.36,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.819988880942283,CC(C)N(CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1)C(C)C,CC(C)N(CC1CC2c3ccccc3Cc3ccccc3N2O1)C(C)C
1358,CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
1359,CHEMBL1483,HXHWSAZORRCQMX-UHFFFAOYSA-N,ALBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC,CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
1360,CHEMBL1824784,HXOMGUPFBWZKBK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)N3CC4=CC=CC=C4.Cl,c1ccc(CN2C3CC4CC(C3)CC2C4)cc1
1363,CHEMBL74355,HXTGXYRHXAGCFP-OAQYLSRUSA-N,VOLINANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.0,COC1=CC=CC(=C1OC)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O,COc1cccc([C@H](O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC
1364,,HXTGXYRHXAGCFP-UHFFFAOYSA-N,MDL 100907,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15999145.0,Ki,=,66.7,NM,,,,,,,,,,,,,,,,,,,,7.175874166083451,COC1=CC=CC(=C1OC)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O,COc1cccc(C(O)C2CCN(CCc3ccc(F)cc3)CC2)c1OC
1365,CHEMBL595,HYAFETHFCAUJAY-UHFFFAOYSA-N,PIOGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
1366,CHEMBL595,HYAFETHFCAUJAY-UHFFFAOYSA-N,PIOGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1
1367,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
1368,CHEMBL193,HYIMSNHJOBLJNT-UHFFFAOYSA-N,NIFEDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
1369,CHEMBL56367,HYWYRSMBCFDLJT-UHFFFAOYSA-N,NIMESULIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1
1370,CHEMBL56367,HYWYRSMBCFDLJT-UHFFFAOYSA-N,NIMESULIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2,CS(=O)(=O)Nc1ccc([N+](=O)[O-])cc1Oc1ccccc1
1372,CHEMBL686,HYYBABOKPJLUIN-UHFFFAOYSA-N,MEFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,Cc1cccc(Nc2ccccc2C(=O)O)c1C
1373,CHEMBL686,HYYBABOKPJLUIN-UHFFFAOYSA-N,MEFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C,Cc1cccc(Nc2ccccc2C(=O)O)c1C
1374,CHEMBL64100,HZCFDQSTHWNXEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4500041484693496,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3CCC3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)C3CCC3)CC2)cc1
1376,CHEMBL568400,HZPGVFKYDDQWIZ-GASCZTMLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,390.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,CC1=CC(=NC(=N1)NC2CCC(CC2)NC(=O)C3=CC(=C(C=C3)Cl)Cl)N(C)C,Cc1cc(N(C)C)nc(NC2CCC(NC(=O)c3ccc(Cl)c(Cl)c3)CC2)n1
1379,CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
1380,CHEMBL107,IAKHMKGGTNLKSZ-INIZCTEOSA-N,COLCHICINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC,COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
1382,CHEMBL504,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,DIMETHYL SULFOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C,C[S+](C)[O-]
1383,CHEMBL504,IAZDPXIOMUYVGZ-UHFFFAOYSA-N,DIMETHYL SULFOXIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)C,C[S+](C)[O-]
1384,CHEMBL239099,IBEQZETWFPHMMF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)C#N.C(=O)O,N#Cc1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)C(=O)C2)cc1
1385,CHEMBL1090527,IBILQKIYEWGQDQ-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,0.3,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.522878745280336,C[C@H](C1=C(CC2=C1C=CC(=C2)F)CCN(C)C)C3=NC=CS3,C[C@H](C1=C(CCN(C)C)Cc2cc(F)ccc21)c1nccs1
1386,CHEMBL3215298,IBSREHMXUMOFBB-JFUDTMANSA-N,ABAMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
1387,CHEMBL3215298,IBSREHMXUMOFBB-JFUDTMANSA-N,ABAMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](C=C[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1/C=C/C=C/2\CO[C@H]3[C@@]2([C@@H](C=C([C@H]3O)C)C(=O)O[C@H]4C[C@@H](C/C=C(/[C@H]1O[C@H]5C[C@@H]([C@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O)OC)OC)\C)O[C@]7(C4)C=C[C@@H]([C@H](O7)C(C)C)C)O,CC[C@H](C)[C@H]1O[C@]2(C=C[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
1388,CHEMBL2207660,IBTMKWBYOYIWBF-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=C(NN=C3)C(F)(F)F)O)Cl,Cc1c(Cl)ccc(OC2CCN(C[C@H](O)CNC(=O)c3cn[nH]c3C(F)(F)F)CC2)c1Cl
1389,CHEMBL592752,IBUHDDLETPJVGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,40.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.397940008672037,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4,Cc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1
1390,CHEMBL592752,IBUHDDLETPJVGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,146.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.835647144215562,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=C4,Cc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1
1391,CHEMBL104994,IBVAFMSEJOGFLC-RDJZCZTQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,43000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.366531544420414,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)[C@H](CO)N,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)[C@@H](N)CO)C2)cc1
1392,CHEMBL608151,IBZJKEOJOGAMGJ-COPLHBTASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20170186.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors.,J. Med. Chem.,PUBLICATION,,6.0,CCOC[C@H]1[C@H]2[C@@]1(CNC2)C3=CC(=C(C=C3)Cl)Cl,CCOC[C@H]1[C@@H]2CNC[C@@]21c1ccc(Cl)c(Cl)c1
1393,CHEMBL595180,ICAQZJCLBRKWBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)C2=NC(=NC(=C2)NCC3=C(C=CC=C3Cl)Cl)N,CN1CCN(c2cc(NCc3c(Cl)cccc3Cl)nc(N)n2)CC1
1394,CHEMBL101748,ICDXLEXUWOLRPG-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,8900.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.050609993355088,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC(=C2)C#N)CCCOC3=CC=C(C=C3)C(=O)C4CC4,N#Cc1cccc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)c1
1396,CHEMBL1935573,ICIGFIHEQAKGAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,6422.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.192329698769516,CN1CCN(CC1)C2=NC(=NC3=C2C=CC(=C3)C4=CC=CO4)N,CN1CCN(c2nc(N)nc3cc(-c4ccco4)ccc23)CC1
1398,CHEMBL1200585,ICMWWNHDUZJFDW-DHODBPELSA-N,OXYMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
1399,CHEMBL1200585,ICMWWNHDUZJFDW-DHODBPELSA-N,OXYMETHOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C,C[C@]12C/C(=C/O)C(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
1401,CHEMBL435949,IDBBDQXTEVOOKW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=CC=C1N2CCN(CC2)CC3=CNC4=C3C=CC=N4,COc1ccccc1N1CCN(Cc2c[nH]c3ncccc23)CC1
1403,CHEMBL1910383,IDNLJMLLYBSJEB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,223.87,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.650004100737144,C1CN(CCN1CCOC(C2=CC=CC=C2)C3=CC=CC=C3)C(=O)C4=CC5=CC=CC=C5N4,O=C(c1cc2ccccc2[nH]1)N1CCN(CCOC(c2ccccc2)c2ccccc2)CC1
1405,CHEMBL826,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,ENOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21
1406,CHEMBL826,IDYZIJYBMGIQMJ-UHFFFAOYSA-N,ENOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(N=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21
1407,CHEMBL2106399,IEMDOFXTVAPVLX-YWQHLDGFSA-N,KITASAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O
1408,CHEMBL2106399,IEMDOFXTVAPVLX-YWQHLDGFSA-N,KITASAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O[C@H]3C[C@@]([C@H]([C@@H](O3)C)OC(=O)CC(C)C)(C)O)N(C)C)O)CC=O)C)O,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O
1409,CHEMBL85735,IEMJYQZKJFERDW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,5.89,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.229884705212896,CC1=CC2=C(CC3=CC=CC=C3C4N2OC(C4)CN(C)C)C=C1,Cc1ccc2c(c1)N1OC(CN(C)C)CC1c1ccccc1C2
1410,CHEMBL2,IENZQIKPVFGBNW-UHFFFAOYSA-N,PRAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
1411,CHEMBL2,IENZQIKPVFGBNW-UHFFFAOYSA-N,PRAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
1412,CHEMBL1940419,IESJRUUOIHDONG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,212.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.6736641390712474,C1CN(CCN1CCCSC2=CC=C(C=C2)F)C3=CC=CC=N3,Fc1ccc(SCCCN2CCN(c3ccccn3)CC2)cc1
1413,CHEMBL591568,IESQFAFNQAYROM-SDNWHVSQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,345.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4621809049267265,CN1CCC2C(C1)C3=CC=CC=C3N2/C=C/C4=CC=CC=C4,CN1CCC2C(C1)c1ccccc1N2/C=C/c1ccccc1
1414,CHEMBL591568,IESQFAFNQAYROM-SDNWHVSQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,2130.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.671620396561263,CN1CCC2C(C1)C3=CC=CC=C3N2/C=C/C4=CC=CC=C4,CN1CCC2C(C1)c1ccccc1N2/C=C/c1ccccc1
1416,CHEMBL153062,IGFHQQFPSIBGKE-UHFFFAOYSA-N,4-NONYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCCc1ccc(O)cc1
1417,CHEMBL153062,IGFHQQFPSIBGKE-UHFFFAOYSA-N,4-NONYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCCc1ccc(O)cc1
1418,CHEMBL2171038,IGLADUDHPDHSRD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=CC=CC=C1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1ccccc1S(=O)(=O)NC(=O)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1419,CHEMBL1935441,IGUBZXXWVQQSPY-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2[C@H]4CNCCO4,Cc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1
1420,CHEMBL2171048,IGXXJZSHANKJAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=C(C=C(C=C4)Cl)C,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)cc4C)CC3)CC2)cc1
1421,CHEMBL2207658,IGYNNXYCDMNULT-LLVKDONJSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=C(NN=C3)C(F)(F)F)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1cn[nH]c1C(F)(F)F
1422,CHEMBL1767151,IGZMIXBCHNOMPG-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.100015437450608,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4CCCCC4,CN1CCC[C@@H]1Cn1nc(CC2CCCCC2)c2ccccc2c1=O
1423,CHEMBL179166,IHIXIJGXTJIKRB-UHFFFAOYSA-N,SODIUM ORTHOVANAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+],[V+5]
1424,CHEMBL179166,IHIXIJGXTJIKRB-UHFFFAOYSA-N,SODIUM ORTHOVANAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][V](=O)([O-])[O-].[Na+].[Na+].[Na+],[V+5]
1425,CHEMBL264374,IIBYAHWJQTYFKB-UHFFFAOYSA-N,BEZAFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
1426,CHEMBL264374,IIBYAHWJQTYFKB-UHFFFAOYSA-N,BEZAFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)CCNC(=O)C2=CC=C(C=C2)Cl,CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
1427,CHEMBL923,IIDJRNMFWXDHID-UHFFFAOYSA-N,RISEDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
1428,CHEMBL923,IIDJRNMFWXDHID-UHFFFAOYSA-N,RISEDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O,O=P(O)(O)C(O)(Cc1cccnc1)P(=O)(O)O
1429,CHEMBL1222692,IIRIKFXWBJTDCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,C1CC(CCC1C(=O)O)N2CCN(CC2)C3=CC4=CC=CC=C4CN5C3=NC=C5,O=C(O)C1CCC(N2CCN(C3=Cc4ccccc4Cn4ccnc43)CC2)CC1
1430,CHEMBL1222692,IIRIKFXWBJTDCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CC(CCC1C(=O)O)N2CCN(CC2)C3=CC4=CC=CC=C4CN5C3=NC=C5,O=C(O)C1CCC(N2CCN(C3=Cc4ccccc4Cn4ccnc43)CC2)CC1
1431,CHEMBL418971,IISBACLAFKSPIT-UHFFFAOYSA-N,BISPHENOL A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1
1432,CHEMBL418971,IISBACLAFKSPIT-UHFFFAOYSA-N,BISPHENOL A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1
1434,CHEMBL1669414,IIVFRUJVDGTOEB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,49.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.309803919971486,C1C(CN1CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4)F,FC1CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
1435,CHEMBL1669424,IJFPVAYNHAMKAK-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,13.9,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.856985199745905,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CC=N4,C[C@H](C1=C(CCN(C)Cc2ccccn2)Cc2ccccc21)c1cnccn1
1437,CHEMBL138458,IJKYJDDNDXAREJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11784148.0,IC50,=,8000.0,NM,,,,,,,,,,,,,,,Inhibition of mepyramine binding to Histamine H1 receptor,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,PUBLICATION,,5.096910013008057,COC1CC2=CC=CC=C2C3(O1)CCN(CC3)CCCC4=CC=CC=C4,COC1Cc2ccccc2C2(CCN(CCCc3ccccc3)CC2)O1
1438,CHEMBL264418,IJMPFBJUROFOGZ-NVXWUHKLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CO[C@H](CN1)[C@@H](C2=CC=CC=C2)OC3=C(C(=CC=C3)F)F,Fc1cccc(O[C@H](c2ccccc2)[C@H]2CNCCO2)c1F
1440,CHEMBL589147,IJQSFAYWVZPICY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,66.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.180456064458133,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=C(C=C4)OC,COc1ccc(CCn2c3c(c4cc(C)ccc42)CN(C)CC3)cc1
1441,CHEMBL2207279,IKBGPCPPFWCFRO-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)F)O,Cc1cc(Cl)ccc1OC1CCN(C[C@H](O)CNC(=O)c2c[nH]c(=O)c3cc(F)ccc23)CC1
1442,CHEMBL255566,IKHRYIGPRIAKFA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(C)(C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C(C)(C)C)oc6c(Br)c5CC4)n3C)cccc2n1
1444,CHEMBL2208424,IKNJHFAJDYZLNM-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.500312917381596,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)CC[C@@H](COC3=CC=CC(=C3)C#N)O,N#Cc1cccc(OC[C@@H](O)CCN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)c1
1445,CHEMBL257525,ILAPINSYTQOSTH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCC(C)N4CCc5cc6nc(C(F)(F)F)oc6c(C)c5CC4)n3C)cccc2n1
1446,CHEMBL274525,ILLGYRJAYAAAEW-QMMMGPOBSA-N,ABT-418,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7518514.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1=NOC(=C1)[C@@H]2CCCN2C,Cc1cc([C@@H]2CCCN2C)on1
1447,CHEMBL595449,ILPANLYEJQKXKY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19646882.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Novel delta opioid receptor agonists exhibit differential stimulation of signaling pathways.,Bioorg. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)C2=NC(=NN2C3=CC(=CC=C3)O)CN(C)C,CN(C)Cc1nc(-c2ccc(C(C)(C)C)cc2)n(-c2cccc(O)c2)n1
1448,CHEMBL476934,ILSADQLMJBGMFK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2CN(C1CN2C3=CC=C(C=C3)Cl)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CC2CC1CN2c1ccc(Cl)cc1)c1ccc(F)cc1
1449,CHEMBL255220,IMFZWBPHAPCFAZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)N=C(S5)C,Cc1nc2ccc3c(c2s1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
1452,CHEMBL1767166,IMKMPTLRTHMERW-MGBGTMOVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.899974269892138,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)O,O=c1c2ccccc2c(Cc2ccc(O)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
1453,CHEMBL1201146,IMONTRJLAWHYGT-ZCPXKWAGSA-N,NORETHINDRONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
1454,CHEMBL1201146,IMONTRJLAWHYGT-ZCPXKWAGSA-N,NORETHINDRONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@H]34)C)C#C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
1455,CHEMBL1201151,IMSSROKUHAOUJS-MJCUULBUSA-N,MESTRANOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C
1456,CHEMBL1201151,IMSSROKUHAOUJS-MJCUULBUSA-N,MESTRANOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=C3C=CC(=C4)OC,C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C
1457,CHEMBL428880,IMZMKUWMOSJXDT-UHFFFAOYSA-N,CROMOLYN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1
1458,CHEMBL428880,IMZMKUWMOSJXDT-UHFFFAOYSA-N,CROMOLYN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)OCC(COC3=CC=CC4=C3C(=O)C=C(O4)C(=O)O)O)C(=O)C=C(O2)C(=O)O,O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1
1459,CHEMBL506,INDBQLZJXZLFIT-UHFFFAOYSA-N,PRIMAQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,COc1cc(NC(C)CCCN)c2ncccc2c1
1460,CHEMBL506,INDBQLZJXZLFIT-UHFFFAOYSA-N,PRIMAQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2,COc1cc(NC(C)CCCN)c2ncccc2c1
1462,CHEMBL862,INJOMKTZOLKMBF-UHFFFAOYSA-N,GUANFACINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,NC(N)=NC(=O)Cc1c(Cl)cccc1Cl
1463,CHEMBL862,INJOMKTZOLKMBF-UHFFFAOYSA-N,GUANFACINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl,NC(N)=NC(=O)Cc1c(Cl)cccc1Cl
1464,CHEMBL1923523,INKZIWWVJYBNOA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,426.58,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.369999510099088,C1=CC=C(C=C1)C2N=C(NC3=NC4=CC=CC=C4N23)N,NC1=NC(c2ccccc2)n2c(nc3ccccc32)N1
1465,CHEMBL101691,INULYJUFVOFQOR-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,9100.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.040958607678906,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3ccccc3)C2)cc1)C1CC1
1466,CHEMBL1087,INWLQCZOYSRPNW-UHFFFAOYSA-N,MEPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,Cc1cccc(C)c1NC(=O)C1CCCCN1C
1467,CHEMBL1087,INWLQCZOYSRPNW-UHFFFAOYSA-N,MEPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C,Cc1cccc(C)c1NC(=O)C1CCCCN1C
1468,CHEMBL3094214,IOCXEAYYBZJHHK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1000.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CCN(CC1)CCCOC2=CC3=C(CCN(CC3)C4=CC=CC=C4)C=C2,c1ccc(N2CCc3ccc(OCCCN4CCCCC4)cc3CC2)cc1
1469,CHEMBL2207638,IOFOPIMDJBEBFZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,5500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,COC1=CC=CC=C1N2CCN(CC2)CC3=C4C=CC=CC=C4C(=C3)CN5CCCCC5,COc1ccccc1N1CCN(Cc2cc(CN3CCCCC3)c3cccccc2-3)CC1
1470,CHEMBL429132,IOJIPFCHEXMFMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,5011.87,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3000002024454185,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C)(C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C(C)(C)C)oc6cc5CC4)n3C)cccc2n1
1472,CHEMBL614,IPEHBUMCGVEMRF-UHFFFAOYSA-N,PYRAZINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(C=N1)C(=O)N,NC(=O)c1cnccn1
1473,CHEMBL614,IPEHBUMCGVEMRF-UHFFFAOYSA-N,PYRAZINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(C=N1)C(=O)N,NC(=O)c1cnccn1
1476,CHEMBL1201346,IPOKCKJONYRRHP-FMQUCBEESA-N,BALSALAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1
1477,CHEMBL1201346,IPOKCKJONYRRHP-FMQUCBEESA-N,BALSALAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)NCCC(=O)O)N=NC2=CC(=C(C=C2)O)C(=O)O,O=C(O)CCNC(=O)c1ccc(N=Nc2ccc(O)c(C(=O)O)c2)cc1
1478,CHEMBL93556,IPQSEKMUUNQIQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,309.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,6.5100415205751645,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)C2)cc1OC
1479,CHEMBL93556,IPQSEKMUUNQIQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.48,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.188424994129406,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)C2)cc1OC
1480,CHEMBL93556,IPQSEKMUUNQIQD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,309.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5100415205751645,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)C2)cc1OC
1482,CHEMBL155188,IPTWWGFBGODTAQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.0,C1=C(NC=N1)CCCCCCCCCCCCN,NCCCCCCCCCCCCc1cnc[nH]1
1483,CHEMBL155188,IPTWWGFBGODTAQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1000000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.0,C1=C(NC=N1)CCCCCCCCCCCCN,NCCCCCCCCCCCCc1cnc[nH]1
1484,CHEMBL64608,IPWACKIXHGZBDD-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,1513.56,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.820000358220838,C[C@@H](CN)C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3,C[C@@H](CN)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1485,CHEMBL61288,IPWACKIXHGZBDD-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,1737.8,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.760000207113127,C[C@H](CN)C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3,C[C@H](CN)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1486,CHEMBL255158,IQFXDOJWHPEPAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(C=CC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F,Cc1ncccc1-c1nnc(SCCCN2CCc3ccc4oc(C(F)(F)F)nc4c3CC2)n1C
1487,CHEMBL1277311,IQNSUCJNGFOYPQ-JNDNBTNTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.900008766455317,C1C[C@H](CN(C1)C2CCC3(C2)CC4=CC=CC=C4OC5=CC=CC=C35)C(=O)O,O=C(O)[C@@H]1CCCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1
1488,CHEMBL1502,IQPSEEYGBUAQFF-UHFFFAOYSA-N,PANTOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,COc1ccnc(C[S+]([O-])c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
1489,CHEMBL1502,IQPSEEYGBUAQFF-UHFFFAOYSA-N,PANTOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC,COc1ccnc(C[S+]([O-])c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
1490,CHEMBL1091775,IQWBKNWLBVZZLG-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,3.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.4089353929735,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN4CCC4,C[C@@H](c1ccccn1)c1c(CCN2CCC2)sc2ccccc12
1491,CHEMBL1277312,IRGGYSVFJCBILG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CC2(CC1N3CC(C3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25,O=C(O)C1CN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)C1
1492,CHEMBL313604,IRIGJBAWLKWASO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,15.49,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.809948582240794,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C(=CC=C4)Cl,CN(C)CC1CC2c3ccccc3Cc3cccc(Cl)c3N2O1
1493,CHEMBL182,IRSCQMHQWWYFCW-UHFFFAOYSA-N,GANCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
1494,CHEMBL182,IRSCQMHQWWYFCW-UHFFFAOYSA-N,GANCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1
1495,CHEMBL695,IRYJRGCIQBGHIV-UHFFFAOYSA-N,TRIMETHADIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C(=O)N(C(=O)O1)C)C,CN1C(=O)OC(C)(C)C1=O
1496,CHEMBL695,IRYJRGCIQBGHIV-UHFFFAOYSA-N,TRIMETHADIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C(=O)N(C(=O)O1)C)C,CN1C(=O)OC(C)(C)C1=O
1498,CHEMBL14060,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,PHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)O,Oc1ccccc1
1499,CHEMBL14060,ISWSIDIOOBJBQZ-UHFFFAOYSA-N,PHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)O,Oc1ccccc1
1500,CHEMBL592753,ITLPFSDCSSQVPC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,30.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=C(C=C4)F,Cc1ccc2c(c1)c1c(n2CCc2ccc(F)cc2)CCN(C)C1
1501,CHEMBL1774491,ITNVSKVARAVDNB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,41.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.387216143280264,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4COc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
1502,CHEMBL1650,ITRJWOMZKQRYTA-RFZYENFJSA-N,CORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
1503,CHEMBL1650,ITRJWOMZKQRYTA-RFZYENFJSA-N,CORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C
1504,CHEMBL272480,ITTGLZWHTWLHSG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6c(cc5CC4)C(=O)N(C)C6)n3C)cccc2n1
1505,CHEMBL2030622,ITUMTGGIBOPIJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CC3=CC=CC=C3,c1ccc(CN2C3CCC2CC3)cc1
1506,CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,COCCc1ccc(OCC(O)CNC(C)C)cc1
1507,CHEMBL13,IUBSYMUCCVWXPE-UHFFFAOYSA-N,METOPROLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CCOC)O,COCCc1ccc(OCC(O)CNC(C)C)cc1
1508,CHEMBL499815,IUCNQFHEWLYECJ-CXCSZTQTSA-L,ATRACTYLOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CCC4[C@@]3(C2)C)C(=C)[C@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+],C=C1[C@@H]2CCC3[C@]4(C)C[C@H](O[C@@H]5O[C@H](CO)[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]5OC(=O)CC(C)C)C[C@@H](C(=O)O)[C@H]4CC[C@]3(C2)[C@@H]1O
1509,CHEMBL499815,IUCNQFHEWLYECJ-CXCSZTQTSA-L,ATRACTYLOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(=O)O[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@@H]2C[C@H]([C@H]3CC[C@@]45C[C@@H](CCC4[C@@]3(C2)C)C(=C)[C@H]5O)C(=O)O)CO)OS(=O)(=O)[O-])OS(=O)(=O)[O-].[K+].[K+],C=C1[C@@H]2CCC3[C@]4(C)C[C@H](O[C@@H]5O[C@H](CO)[C@@H](OS(=O)(=O)[O-])[C@H](OS(=O)(=O)[O-])[C@H]5OC(=O)CC(C)C)C[C@@H](C(=O)O)[C@H]4CC[C@]3(C2)[C@@H]1O
1511,CHEMBL2158837,IUIGATKKQCOBAF-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4Cl)C(=O)O,O=C(O)[C@H](Cc1ccccc1Cl)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1512,CHEMBL127516,IUWVALYLNVXWKX-UHFFFAOYSA-N,BUTAMBEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC(=O)C1=CC=C(C=C1)N,CCCCOC(=O)c1ccc(N)cc1
1513,CHEMBL127516,IUWVALYLNVXWKX-UHFFFAOYSA-N,BUTAMBEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC(=O)C1=CC=C(C=C1)N,CCCCOC(=O)c1ccc(N)cc1
1514,CHEMBL702,IVBHGBMCVLDMKU-GXNBUGAJSA-N,PIPERACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O
1515,CHEMBL702,IVBHGBMCVLDMKU-GXNBUGAJSA-N,PIPERACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(C(=O)C1=O)C(=O)N[C@H](C2=CC=CC=C2)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O
1516,CHEMBL59715,IVCVMDSHKKVJIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,524.81,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.279997898282849,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CN=CN3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3cnc[nH]3)CC2)cc1
1517,CHEMBL421026,IVRXDSYEBGHJBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,2884.03,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.540000226349733,C1C2CN(CC2CN1)CCCOC3=CC=C(C=C3)C4=CC=C(C=C4)C#N,N#Cc1ccc(-c2ccc(OCCCN3CC4CNCC4C3)cc2)cc1
1518,CHEMBL1088882,IVVSQFRLZUQKBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,12.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CC1=CN=CC(=N1)CC2=C(CC3=CC=CC=C32)CCN(C)C,Cc1cncc(CC2=C(CCN(C)C)Cc3ccccc32)n1
1519,CHEMBL589148,IWEWIZBBORJKBV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,40.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.397940008672037,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2ccccc2)C1
1520,CHEMBL589148,IWEWIZBBORJKBV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,131.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.8827287043442364,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2ccccc2)C1
1523,CHEMBL1643,IWUCXVSUMQZMFG-AFCXAGJDSA-N,RIBAVIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
1524,CHEMBL1643,IWUCXVSUMQZMFG-AFCXAGJDSA-N,RIBAVIRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NN1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N,NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1
1525,CHEMBL1517,IWVCMVBTMGNXQD-PXOLEDIWSA-N,OXYTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12
1526,CHEMBL1517,IWVCMVBTMGNXQD-PXOLEDIWSA-N,OXYTETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3[C@H](O)[C@@H]12
1527,CHEMBL256488,IWYNZVSUMFYFCF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)N=C(O6)C(C)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc6nc(C(C)(F)F)oc6c5CC4)n3C)cccc2n1
1528,CHEMBL1201237,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,LEVOBUNOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
1529,CHEMBL1201237,IXHBTMCLRNMKHZ-LBPRGKRZSA-N,LEVOBUNOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC[C@@H](COC1=CC=CC2=C1CCCC2=O)O,CC(C)(C)NC[C@H](O)COc1cccc2c1CCCC2=O
1531,CHEMBL90063,IXZDLPYKIIELLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,3162.28,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.4999996786570655,C1=C(NC=N1)CCCCCCCCN,NCCCCCCCCc1cnc[nH]1
1532,CHEMBL90063,IXZDLPYKIIELLK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,25118864315095.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.4,C1=C(NC=N1)CCCCCCCCN,NCCCCCCCCc1cnc[nH]1
1533,CHEMBL1277679,IYAJUPFWKMPDJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CC2(CC1N3CCC(CC3)(C(=O)O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1(O)CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1
1534,CHEMBL1278116,IYDOAHOHMRQFTJ-QWAKEFERSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,8.400116927926312,CN(C)C1CC[C@@]2(C1)CC3=CC=CC=C3CC4=CC=CC=C24,CN(C)C1CC[C@]2(Cc3ccccc3Cc3ccccc32)C1
1535,CHEMBL60189,IYDTWLIGTRMAPG-SSEXGKCCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,12022.64,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.920000156997056,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=C(C=C4)C5=CC=CC=C5)N,N[C@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1536,CHEMBL327497,IYGHJULMISLCJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.62,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.1791420105603,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC=CC=C3)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)CCN(C(=O)c3ccccc3)C2)cc1OC
1537,CHEMBL327497,IYGHJULMISLCJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,240.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.619788758288393,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC=CC=C3)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)F)OC,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)CCN(C(=O)c3ccccc3)C2)cc1OC
1538,CHEMBL417990,IYGYMKDQCDOMRE-ZWKOTPCHSA-N,BICUCULLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN1CCC2=CC3=C(C=C2[C@H]1[C@H]4C5=C(C6=C(C=C5)OCO6)C(=O)O4)OCO3,CN1CCc2cc3c(cc2[C@H]1[C@@H]1OC(=O)c2c1ccc1c2OCO1)OCO3
1539,CHEMBL633,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,AMIODARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
1540,CHEMBL633,IYIKLHRQXLHMJQ-UHFFFAOYSA-N,AMIODARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I,CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1
1541,CHEMBL559147,IYOZTVGMEWJPKR-IJLUTSLNSA-N,Y-27632,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N,C[C@@H](N)C1CCC(C(=O)Nc2ccncc2)CC1
1542,CHEMBL559147,IYOZTVGMEWJPKR-IJLUTSLNSA-N,Y-27632,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](C1CCC(CC1)C(=O)NC2=CC=NC=C2)N,C[C@@H](N)C1CCC(C(=O)Nc2ccncc2)CC1
1543,CHEMBL1743259,IZBNNCFOBMGTQX-UHFFFAOYSA-N,ETOPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,3100.0,NM,,,,,,,,,,,,,,,,,,,,5.508638306165726,CCC1=NN(C(=O)N1CC)CCCN2CCN(CC2)C3=CC(=CC=C3)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CC
1544,CHEMBL932,IZEKFCXSFNUWAM-UHFFFAOYSA-N,DIPYRIDAMOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
1545,CHEMBL932,IZEKFCXSFNUWAM-UHFFFAOYSA-N,DIPYRIDAMOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO,OCCN(CCO)c1nc(N2CCCCC2)c2nc(N(CCO)CCO)nc(N3CCCCC3)c2n1
1548,CHEMBL11603,IZVUQTNTFFLRBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=CC=C(C=C1)C(C2=CC=CC=C2)C3=NC=C(N3)CCN,NCCc1cnc(C(c2ccccc2)c2ccccc2)[nH]1
1551,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,16000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.795880017344076,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
1552,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,0.97,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.013228265733757,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
1553,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,9.98,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.000869458712629,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
1554,CHEMBL1172,JAUOIFJMECXRGI-UHFFFAOYSA-N,DESLORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.16,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.935542010773082,C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4,Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1
1555,CHEMBL440864,JAUZYQXKUMRTOO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,208.93,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.679999195735272,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)F,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)c3ccc(F)cc3)cc2)CC1
1556,CHEMBL1222694,JAWGTZDKZCZPKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=CN2CC3=CC=CC=C3C=C(C2=N1)N4CCN(CC4)CC(C)(C)C(=O)O,Cc1cn2c(n1)C(N1CCN(CC(C)(C)C(=O)O)CC1)=Cc1ccccc1C2
1558,CHEMBL152122,JAXLDMXXLBSGOC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198647,C1=CC(=CN=C1)CCCCCCCCCCCCN,NCCCCCCCCCCCCc1cccnc1
1559,CHEMBL152122,JAXLDMXXLBSGOC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1=CC(=CN=C1)CCCCCCCCCCCCN,NCCCCCCCCCCCCc1cccnc1
1560,CHEMBL153479,JBDGDEWWOUBZPM-XYPYZODXSA-N,AMBROXOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,Nc1c(Br)cc(Br)cc1CNC1CCC(O)CC1
1561,CHEMBL153479,JBDGDEWWOUBZPM-XYPYZODXSA-N,AMBROXOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1NCC2=C(C(=CC(=C2)Br)Br)N)O,Nc1c(Br)cc(Br)cc1CNC1CCC(O)CC1
1562,CHEMBL1381098,JBDOSUUXMYMWQH-UHFFFAOYSA-N,1-NAPHTHYLISOTHIOCYANATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC=C2N=C=S,S=C=Nc1cccc2ccccc12
1563,CHEMBL1381098,JBDOSUUXMYMWQH-UHFFFAOYSA-N,1-NAPHTHYLISOTHIOCYANATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC=C2N=C=S,S=C=Nc1cccc2ccccc12
1564,CHEMBL1433,JBIWCJUYHHGXTC-AKNGSSGZSA-N,DOXYCYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
1565,CHEMBL1433,JBIWCJUYHHGXTC-AKNGSSGZSA-N,DOXYCYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,C[C@H]1c2cccc(O)c2C(O)=C2C(=O)[C@]3(O)C(O)=C(C(N)=O)C(=O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21
1566,CHEMBL272899,JCCIEQKRVYXDHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,311.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 (unknown origin),,Med Chem Res,PUBLICATION,,6.507239610973163,CCCC1=CC2=C(C=C1)N(C(=O)S2)CCN3CCCCCC3,CCCc1ccc2c(c1)sc(=O)n2CCN1CCCCCC1
1567,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,1500000.0,NM,,,,binding,,,,,,,,,,,,,,,,2.8239087409443187,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
1568,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,414.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.382999658879101,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
1569,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,37.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.431798275933005,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
1570,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,290.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,6.5376020021010435,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
1571,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,311.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.507239610973163,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
1572,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,170.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.769551078621726,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
1573,CHEMBL998,JCCNYMKQOSZNPW-UHFFFAOYSA-N,LORATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,20.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.698970004336019,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
1574,CHEMBL571391,JCHIUKROMYHWKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,64.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.1938200260161125,CC1=CC=C(C=C1)CCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,Cc1ccc(CCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1575,CHEMBL515,JCKYGMPEJWAADB-UHFFFAOYSA-N,CHLORAMBUCIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
1576,CHEMBL515,JCKYGMPEJWAADB-UHFFFAOYSA-N,CHLORAMBUCIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl,O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1
1577,CHEMBL567791,JCSAJCBJJWFNIO-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,800.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.096910013008057,CC1=CC(=NC(=N1)NC2CCC(CC2)NC(=O)C3=CC=C(C=C3)Cl)N(C)C,Cc1cc(N(C)C)nc(NC2CCC(NC(=O)c3ccc(Cl)cc3)CC2)n1
1578,CHEMBL256651,JCUBTYXXBDFOHF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC(=C(C=C5)F)F,CCc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2ccc(F)c(F)c2)n1C)CC3
1579,CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=NN2N,Nn1nnc2ccccc21
1580,CHEMBL101168,JCXKHYLLVKZPKE-UHFFFAOYSA-N,1-AMINOBENZOTRIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)N=NN2N,Nn1nnc2ccccc21
1583,CHEMBL302445,JDYFFOLXVFGXNI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,6025.6,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.219999701663428,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCNCC2,CCCCCC(=O)c1ccc(OCCCN2CCNCC2)cc1
1584,CHEMBL1455766,JEJWQCTZDAJWOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24690494.0,Ki,<,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),Antagonists of the kappa opioid receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=CC=C(C=C1)S(=O)(=O)NCC2=CC=C(C=C2)C(=O)NCCN(CC3=CC=CC=C3)C(C)C,Cc1ccc(S(=O)(=O)NCc2ccc(C(=O)NCCN(Cc3ccccc3)C(C)C)cc2)cc1
1588,CHEMBL290106,JFIOVJDNOJYLKP-UHFFFAOYSA-N,BITHIONOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
1589,CHEMBL290106,JFIOVJDNOJYLKP-UHFFFAOYSA-N,BITHIONOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1SC2=C(C(=CC(=C2)Cl)Cl)O)O)Cl)Cl,Oc1c(Cl)cc(Cl)cc1Sc1cc(Cl)cc(Cl)c1O
1590,CHEMBL589389,JGJNEIOIBJGSFV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,104.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.982966660701218,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)OC,COc1ccc2c(c1)c1c(n2CCc2ccccc2)CCN(C)C1
1591,CHEMBL353846,JGOAIQNSOGZNBX-UHFFFAOYSA-N,ADIPHENINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,112201.85,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,3.9499999823118728,CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2,CCN(CC)CCOC(=O)C(c1ccccc1)c1ccccc1
1592,CHEMBL240187,JGPLBVWXJOJNGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OCCCN4CCCCC4,CS(=O)(=O)c1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1
1593,CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
1594,CHEMBL252556,JGPMMRGNQUBGND-UHFFFAOYSA-N,IDEBENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO,COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O
1596,CHEMBL102925,JGRFHTWWWXEAHZ-QFIPXVFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.638272163982407,CCC1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,CCc1ccc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)cc1
1597,CHEMBL29,JGSARLDLIJGVTE-MBNYWOFBSA-N,BENZYLPENICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O
1598,CHEMBL29,JGSARLDLIJGVTE-MBNYWOFBSA-N,BENZYLPENICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)CC3=CC=CC=C3)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O
1603,CHEMBL2158820,JHJPBZPNRYMQKP-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,25.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](C4=CC=CC=C4)C(=O)O,O=C(O)[C@H](c1ccccc1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1604,CHEMBL2158819,JHJPBZPNRYMQKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(C4=CC=CC=C4)C(=O)O,O=C(O)C(c1ccccc1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1605,CHEMBL2158821,JHJPBZPNRYMQKP-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@H](C4=CC=CC=C4)C(=O)O,O=C(O)[C@@H](c1ccccc1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1608,CHEMBL394144,JHRLWHBYMHILPR-FSRHSHDFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3)CC2=O)cc1
1609,CHEMBL239300,JHRLWHBYMHILPR-FYZYNONXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,C[C@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3)CC2=O)cc1
1610,CHEMBL1200679,JIAARYAFYJHUJI-UHFFFAOYSA-L,ZINC CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[Cl-].[Cl-].[Zn+2],[Zn+2]
1611,CHEMBL1200679,JIAARYAFYJHUJI-UHFFFAOYSA-L,ZINC CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[Cl-].[Cl-].[Zn+2],[Zn+2]
1612,CHEMBL1055,JIVPVXMEBJLZRO-UHFFFAOYSA-N,CHLORTHALIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl
1613,CHEMBL1055,JIVPVXMEBJLZRO-UHFFFAOYSA-N,CHLORTHALIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O,NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl
1614,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,0.06,NM,,,,,,,,,,,,,,,,,,,,10.221848749616356,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
1616,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.7,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.431798275933005,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
1617,CHEMBL516,JJCFRYNCJDLXIK-UHFFFAOYSA-N,CYPROHEPTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.43,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.366531544420411,CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1,CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1
1618,CHEMBL326263,JJKPSOUEWPDPFS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,795.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.0996328713435295,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)C#N,N#Cc1ccc(CCOC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
1619,CHEMBL2030627,JJTSIVODPMDGBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCC3=CC=CC=C3,c1ccc(CCN2C3CCC2CC3)cc1
1620,CHEMBL1006,JKOQGQFVAUAYPM-UHFFFAOYSA-N,AMIFOSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CN)CNCCSP(=O)(O)O,NCCCNCCSP(=O)(O)O
1621,CHEMBL1006,JKOQGQFVAUAYPM-UHFFFAOYSA-N,AMIFOSTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CN)CNCCSP(=O)(O)O,NCCCNCCSP(=O)(O)O
1622,CHEMBL443,JLKIGFTWXXRPMT-UHFFFAOYSA-N,SULFAMETHOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
1623,CHEMBL443,JLKIGFTWXXRPMT-UHFFFAOYSA-N,SULFAMETHOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=NO1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1
1625,CHEMBL2208428,JMGBVGDZPLNFAE-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,CS(=O)(=O)C1=CC=CC=C1C(=O)NC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O,CS(=O)(=O)c1ccccc1C(=O)NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1
1626,CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O
1627,CHEMBL12131,JMPFSEBWVLAJKM-UHFFFAOYSA-N,CLOSANTEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)I)I)O)Cl)C(C#N)C3=CC=C(C=C3)Cl,Cc1cc(C(C#N)c2ccc(Cl)cc2)c(Cl)cc1NC(=O)c1cc(I)cc(I)c1O
1628,CHEMBL437,JNMRHUJNCSQMMB-UHFFFAOYSA-N,SULFATHIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
1629,CHEMBL437,JNMRHUJNCSQMMB-UHFFFAOYSA-N,SULFATHIAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2,Nc1ccc(S(=O)(=O)Nc2nccs2)cc1
1630,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,160.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344076,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C,Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1
1631,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1580.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.801342913045577,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C,Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1
1632,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,158.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.801342913045577,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C,Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1
1633,CHEMBL589390,JNODQFNWMXFMEV-UHFFFAOYSA-N,LATREPIRDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,1580.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.801342913045577,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=C(C=C4)C,Cc1ccc2c(c1)c1c(n2CCc2ccc(C)nc2)CCN(C)C1
1634,CHEMBL1540,JNTOCHDNEULJHD-UHFFFAOYSA-N,PENCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2CCC(CO)CO)c(=O)[nH]1
1635,CHEMBL1540,JNTOCHDNEULJHD-UHFFFAOYSA-N,PENCICLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1CCC(CO)CO)N=C(NC2=O)N,Nc1nc2c(ncn2CCC(CO)CO)c(=O)[nH]1
1636,CHEMBL255567,JNTWHFOMVSHHKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(S1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C(N=CO5)C,CCc1nc2cc3c(cc2s1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
1637,CHEMBL590241,JNUCCWMHZZUFKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,242.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.616184634019568,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCCC4=CC=CC=C4,c1ccc(CCNCC2c3ccccc3Cc3ccccc32)cc1
1638,CHEMBL418666,JOFVFDZMGRFHQG-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4677.35,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.330000131185909,CC[C@@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,CC[C@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1639,CHEMBL302829,JOFVFDZMGRFHQG-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,2089.3,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.679999195735272,CC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,CC[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1640,CHEMBL302829,JOFVFDZMGRFHQG-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,70794.58,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.149999990420337,CC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,CC[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1641,CHEMBL2204360,JOJYHYRCIYAVHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21486038.0,Ki,=,180.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder.",J. Med. Chem.,PUBLICATION,,6.7447274948966935,CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C.Cl,Cc1ccc(Sc2ccccc2N2CCNCC2)c(C)c1
1642,CHEMBL560517,JONUVZHQXKYZDL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,>,500.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C(C=CC=C53)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4c(C(=O)O)cccc43)CC2)cc(=O)n(C)c1=O
1643,CHEMBL462547,JOYRKODLDBILNP-UHFFFAOYSA-N,URETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N,CCOC(N)=O
1644,CHEMBL462547,JOYRKODLDBILNP-UHFFFAOYSA-N,URETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)N,CCOC(N)=O
1645,CHEMBL271909,JOZMHQIYXRYITJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,251.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)N=C(S6)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc6nc(C)sc6c5CC4)n3C)cccc2n1
1646,CHEMBL2207286,JPDUMUHTXIBGHJ-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,CN(C)S(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O,CN(C)S(=O)(=O)c1ccc2c(C(=O)NC[C@@H](O)CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)c[nH]c(=O)c2c1
1647,CHEMBL1940404,JPTSMZMSIACDAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,698.6,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.155771418698372,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCOC3=CC=C(C=C3)F,OC1(c2ccc(Cl)cc2)CCN(CCCOc2ccc(F)cc2)CC1
1648,CHEMBL96141,JPUGXAMECQJERZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.47,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.1890957193313,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC(=C(C=C6)Cl)Cl,CCOCCn1c(C(=O)C2CCN(CCC3(c4ccc(Cl)c(Cl)c4)CCN(C(=O)c4cc(OC)c(OC)c(OC)c4)C3)CC2)nc2ccccc21
1649,CHEMBL271066,JQEQULOLEPTBRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OCC(=O)N6,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6c(cc5CC4)OCC(=O)N6)n3C)cccc2n1
1650,CHEMBL392713,JQJNQYUMEBRJKC-FERBBOLQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O,C[C@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3cc(F)cc(F)c3)CC2=O)cc1
1651,CHEMBL239081,JQJNQYUMEBRJKC-GMUIIQOCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3cc(F)cc(F)c3)CC2=O)cc1
1654,CHEMBL270852,JQVYPXIHEOFUGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C(C)C,Cc1ccc2c(-c3nnc(SCCCCN4CCc5cc6c(cc5CC4)C(=O)N(C(C)C)C6)n3C)cccc2n1
1655,CHEMBL374478,JQXXHWHPUNPDRT-WLSIYKJHSA-N,RIFAMPICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
1656,CHEMBL374478,JQXXHWHPUNPDRT-WLSIYKJHSA-N,RIFAMPICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
1657,CHEMBL926,JRWZLRBJNMZMFE-UHFFFAOYSA-N,DOBUTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1
1658,CHEMBL926,JRWZLRBJNMZMFE-UHFFFAOYSA-N,DOBUTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O,CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1
1659,CHEMBL1592,JSDRRTOADPPCHY-HSQYWUDLSA-N,QUINAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
1660,CHEMBL1592,JSDRRTOADPPCHY-HSQYWUDLSA-N,QUINAPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2ccccc2C[C@H]1C(=O)O
1661,CHEMBL323517,JSPIFTWKMOPKHZ-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,37000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.431798275933005,C1CN(C[C@H]1NC(=O)C2=CSC(=N2)C3=CN=CC=C3)CCCOC4=CC=C(C=C4)C(=O)C5CC5,O=C(N[C@H]1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)C1)c1csc(-c2cccnc2)n1
1662,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
1663,CHEMBL1110,JSWZEAMFRNKZNL-UHFFFAOYSA-N,ALOSETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C,Cc1[nH]cnc1CN1CCc2c(c3ccccc3n2C)C1=O
1665,CHEMBL258930,JTCQOAITNDJYSA-IEBWSBKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1COC2=C1C=CC=C2O[C@@H]([C@H]3CNCCO3)C4=CC=CC=C4,c1ccc([C@@H](Oc2cccc3c2OCC3)[C@H]2CNCCO2)cc1
1666,CHEMBL141,JTEGQNOMFQHVDC-NKWVEPMBSA-N,LAMIVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1
1667,CHEMBL141,JTEGQNOMFQHVDC-NKWVEPMBSA-N,LAMIVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N,Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1
1668,CHEMBL315772,JTLCTTWVUAIQHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,2.34,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.630784142589858,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)Cl,CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1
1669,CHEMBL315772,JTLCTTWVUAIQHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,=,2.34,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.630784142589858,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)Cl,CN(C)CC1CC2c3ccccc3Cc3ccc(Cl)cc3N2O1
1670,CHEMBL84158,JTVPZMFULRWINT-UHFFFAOYSA-N,TIAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC,CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC
1671,CHEMBL84158,JTVPZMFULRWINT-UHFFFAOYSA-N,TIAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=C(C=CC(=C1)S(=O)(=O)C)OC,CCN(CC)CCNC(=O)c1cc(S(C)(=O)=O)ccc1OC
1672,CHEMBL1537,JTWOMNBEOCYFNV-NFFDBFGFSA-N,AZLOCILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
1673,CHEMBL1537,JTWOMNBEOCYFNV-NFFDBFGFSA-N,AZLOCILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)NC(=O)N4CCNC4=O)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
1675,CHEMBL102984,JUQYDUYFGBPURU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3467.37,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.459999812689,CC1CCCCN1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,CC1CCCCN1CCCOc1ccc(-c2ccc(C#N)cc2)cc1
1676,CHEMBL255417,JURMKPGGUGOQIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)C(C)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br,CCc1nc2cc3c(c(Br)c2o1)CCN(C(C)CCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
1677,CHEMBL429023,JUVIOZPCNVVQFO-HBGVWJBISA-N,ROTENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1
1678,CHEMBL429023,JUVIOZPCNVVQFO-HBGVWJBISA-N,ROTENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC,C=C(C)[C@H]1Cc2c(ccc3c2O[C@@H]2COc4cc(OC)c(OC)cc4[C@@H]2C3=O)O1
1680,CHEMBL2203551,JUWUZLUBIRHYMM-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor after 1.5 hrs by microbeta scintillation counting analysis,,ACS Med. Chem. Lett.,PUBLICATION,,5.0,C1C[C@H](NC1)COC2=NOC(=C2)COC3=CC=CC=C3,c1ccc(OCc2cc(OC[C@@H]3CCCN3)no2)cc1
1681,CHEMBL236610,JVCJWEYSNNCGKX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,266.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.575118363368933,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)Cl,CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1Cl
1682,CHEMBL2158832,JVDFBAQLTSMMBQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)CC4=CC(=CC=C4)C(=O)O,O=C(O)c1cccc(CN2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
1684,CHEMBL1783968,JVIRLKXDBNCSGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,220.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.657577319177793,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(F)(F)F,CN1CCc2c(c3cc(C(F)(F)F)ccc3n2CCc2ccncc2)C1
1685,CHEMBL1783968,JVIRLKXDBNCSGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)C(F)(F)F,CN1CCc2c(c3cc(C(F)(F)F)ccc3n2CCc2ccncc2)C1
1688,CHEMBL591803,JVPBPESGJIUWIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,35.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CN1CCC2=C(C1)C3=C(N2CCC4=CC=C(C=C4)C(F)(F)F)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2ccc(C(F)(F)F)cc2)C1
1689,CHEMBL1200559,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,LACTIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)O)O,CC(O)C(=O)O
1690,CHEMBL1200559,JVTAAEKCZFNVCJ-UHFFFAOYSA-N,LACTIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)O)O,CC(O)C(=O)O
1691,CHEMBL1670,JWBOIMRXGHLCPP-UHFFFAOYSA-N,MITOTANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1
1692,CHEMBL1670,JWBOIMRXGHLCPP-UHFFFAOYSA-N,MITOTANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(C2=CC=C(C=C2)Cl)C(Cl)Cl)Cl,Clc1ccc(C(c2ccccc2Cl)C(Cl)Cl)cc1
1693,CHEMBL1767147,JWDZDXFXHWMSGR-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,2.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.698970004336019,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=CC=C4)OC,COc1cccc(Cc2nn(C[C@H]3CCCN3C)c(=O)c3ccccc23)c1
1694,CHEMBL631,JWHAUXFOSRPERK-UHFFFAOYSA-N,PROPAFENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1
1695,CHEMBL631,JWHAUXFOSRPERK-UHFFFAOYSA-N,PROPAFENONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNCC(COC1=CC=CC=C1C(=O)CCC2=CC=CC=C2)O,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1
1696,CHEMBL240395,JWVDVKRDYUKSCG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C(=O)N5CCC5.C(=O)O,O=C(c1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1)N1CCC1
1697,CHEMBL103828,JWVSNNPXFZNTNU-APWZRJJASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,56000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.251811972993798,C[C@H](C(=O)N[C@H]1CCN(C1)CCCOC2=CC=C(C=C2)C(=O)C)NC(=O)OC(C)(C)C,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)[C@@H](C)NC(=O)OC(C)(C)C)C2)cc1
1698,CHEMBL320174,JWVSNNPXFZNTNU-LPHOPBHVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,60000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.221848749616356,C[C@@H](C(=O)N[C@H]1CCN(C1)CCCOC2=CC=C(C=C2)C(=O)C)NC(=O)OC(C)(C)C,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)[C@H](C)NC(=O)OC(C)(C)C)C2)cc1
1699,CHEMBL91157,JWYUBODPEUBFLH-FSTMKDAKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,=,113.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.946921556516581,C/C(=C\C1=CC=CC=C1)/CN2CCN(CC2)C[C@H]3[C@@H]4COC5=CC(=C(C=C5C4=NO3)OC)OC,COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccccc4)CC3)[C@@H]1CO2
1700,CHEMBL434,JWZZKOKVBUJMES-UHFFFAOYSA-N,ISOPROTERENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,CC(C)NCC(O)c1ccc(O)c(O)c1
1701,CHEMBL434,JWZZKOKVBUJMES-UHFFFAOYSA-N,ISOPROTERENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC(=C(C=C1)O)O)O,CC(C)NCC(O)c1ccc(O)c(O)c1
1702,CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
1703,CHEMBL159,JXLYSJRDGCGARV-CFWMRBGOSA-N,VINBLASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
1704,CHEMBL305338,JXOCVUPTHGIJET-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,56.23,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.250031916490598,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CC3=CC=CC=C3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)Cc3ccccc3)CC2)cc1
1705,CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
1706,CHEMBL389621,JYGXADMDTFJGBT-VWUMJDOOSA-N,HYDROCORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
1708,CHEMBL1090197,JYRXHQCPLUTCMM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,7.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.113509274827518,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NN=CC=C3,CN(C)CCC1=C(Cc2cccnn2)c2ccccc2C1
1709,CHEMBL63323,JZFPYUNJRRFVQU-UHFFFAOYSA-N,NIFLUMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1
1710,CHEMBL63323,JZFPYUNJRRFVQU-UHFFFAOYSA-N,NIFLUMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC(=C1)NC2=C(C=CC=N2)C(=O)O)C(F)(F)F,O=C(O)c1cccnc1Nc1cccc(C(F)(F)F)c1
1711,CHEMBL64461,JZOQPCYGADPKSS-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,37153.52,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.430000034012231,C1C[C@@H](NC1)C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CCN(C(=O)[C@H]3CCCN3)CC2)cc1)C1CC1
1712,CHEMBL117405,JZQKKSLKJUAGIC-NSHDSACASA-N,S(-)-PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=C1C=CN2)O,CC(C)NC[C@H](O)COc1cccc2[nH]ccc12
1713,CHEMBL117405,JZQKKSLKJUAGIC-NSHDSACASA-N,S(-)-PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NC[C@@H](COC1=CC=CC2=C1C=CN2)O,CC(C)NC[C@H](O)COc1cccc2[nH]ccc12
1714,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CC(C)NCC(O)COc1cccc2[nH]ccc12
1715,CHEMBL500,JZQKKSLKJUAGIC-UHFFFAOYSA-N,PINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=CC2=C1C=CN2)O,CC(C)NCC(O)COc1cccc2[nH]ccc12
1716,CHEMBL435,JZUFKLXOESDKRF-UHFFFAOYSA-N,HYDROCHLOROTHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
1717,CHEMBL435,JZUFKLXOESDKRF-UHFFFAOYSA-N,HYDROCHLOROTHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O
1718,CHEMBL1091778,KAWDUHFGBOIYCO-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,79000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.102372908709558,C[C@@H](C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12
1719,CHEMBL1091777,KAWDUHFGBOIYCO-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,3500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.455931955649724,C[C@H](C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@H](c1cccnc1)c1c(CCN(C)C)sc2ccccc12
1720,CHEMBL1091776,KAWDUHFGBOIYCO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,10000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(C1=CN=CC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccnc1)c1c(CCN(C)C)sc2ccccc12
1721,CHEMBL42335,KAXNWVHHUKHNDK-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,91.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.040958607678906,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)C#N,CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1
1723,CHEMBL408208,KBAMXOZNCXYSJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCN4CCc5cc6nc(C(F)(F)F)oc6c(Br)c5CC4)n3C)cccc2n1
1728,CHEMBL272588,KCFSZIDRLPEDRQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)N5C=CC(=CC5=N4)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3nc4cc(C(F)(F)F)ccn4c3CC2)n1C
1729,CHEMBL1196,KCLANYCVBBTKTO-UHFFFAOYSA-N,PROPARACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N
1730,CHEMBL1196,KCLANYCVBBTKTO-UHFFFAOYSA-N,PROPARACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=C(C=C(C=C1)C(=O)OCCN(CC)CC)N,CCCOc1ccc(C(=O)OCCN(CC)CC)cc1N
1731,CHEMBL271729,KCLMHEWINSXASY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=C(C=CC6=N5)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5nc6ccc(C(F)(F)F)cn6c5CC4)n3C)cccc2n1
1732,CHEMBL2158838,KCLONPRRKHVPLU-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)Cl)C(=O)O,O=C(O)[C@H](Cc1ccc(Cl)cc1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1733,CHEMBL1092494,KCSVGYHUQTUHTM-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,8.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.096910013008056,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)Cl,C[C@@H](c1ncccc1Cl)c1c(CCN(C)C)sc2ccccc12
1735,CHEMBL1753,KDLRVYVGXIQJDK-AWPVFWJPSA-N,CLINDAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
1736,CHEMBL1753,KDLRVYVGXIQJDK-AWPVFWJPSA-N,CLINDAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@H](C)Cl,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
1737,CHEMBL1092118,KEDAYBZXXNOGOP-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,5.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.2839966563652,C[C@@H](C1=CN=CS1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@@H](c1cncs1)c1c(CCN(C)C)sc2ccccc12
1738,CHEMBL1259187,KEEXCUUQRQNRNF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,64.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.1938200260161125,CC(=O)NCC1=CC2=C(C=C1)N(C=C2C3CCN(CC3)CCN4CCNC4=O)C5=CC=C(C=C5)F,CC(=O)NCc1ccc2c(c1)c(C1CCN(CCN3CCNC3=O)CC1)cn2-c1ccc(F)cc1
1740,CHEMBL400612,KENVEDVQQZAGDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O,N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCCC4)cc3)C(=O)C2)cc1
1742,CHEMBL392532,KEQCAAQBOMIVCB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,CC(C)N1CCC(Oc2ccc(N3CCN(C(=O)c4ccc(F)cc4F)CC3=O)cc2)CC1
1745,CHEMBL351231,KFHYZKCRXNRKRC-MRXNPFEDSA-N,ABT-239,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15608078.0,Ki,=,1621.81,NM,,,,,,,,,,,,,,,,,,,,5.790000026071144,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C4=CC=C(C=C4)C#N,C[C@@H]1CCCN1CCc1cc2cc(-c3ccc(C#N)cc3)ccc2o1
1746,CHEMBL273166,KFMDKMLEGDZMCX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)CC7CC7,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(CC7CC7)oc6cc5CC4)n3C)cccc2n1
1747,CHEMBL101692,KGDAOALFCOEYFT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CNC=C3,CCOC(=O)N1CCN(CCCOc2ccc(-c3cc[nH]c3)cc2)CC1
1748,CHEMBL256474,KGDPFNITOFAOLP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C(C)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4nc(C(C)(F)F)oc4cc3CC2)n1C
1750,CHEMBL287671,KGZWRXWYLPRJCF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)C5=CC=CC=C5,c1ccc(-c2ccc(N3CCN(Cc4c[nH]c5ncccc45)CC3)cc2)cc1
1751,CHEMBL942,KHOITXIGCFIULA-UHFFFAOYSA-N,BISACODYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
1752,CHEMBL942,KHOITXIGCFIULA-UHFFFAOYSA-N,BISACODYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC1=CC=C(C=C1)C(C2=CC=C(C=C2)OC(=O)C)C3=CC=CC=N3,CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1
1753,CHEMBL272297,KHTUQDQSUXMHQA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NN(C(=C1)C2=NC3=C(O2)C=CC4=C3CCN(CC4)CCCSC5=NN=C(N5C)C6=C(N=CO6)C)C,Cc1cc(-c2nc3c4c(ccc3o2)CCN(CCCSc2nnc(-c3ocnc3C)n2C)CC4)n(C)n1
1754,CHEMBL175782,KIAVPENCSGKVQP-UHFFFAOYSA-N,METHIMEPIP,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771452.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine binding to COS-7 cell membranes expressing human histamine H1 receptor,N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist.,J. Med. Chem.,PUBLICATION,,5.0,CN1CCC(CC1)CC2=CN=CN2,CN1CCC(Cc2cnc[nH]2)CC1
1755,CHEMBL2376804,KICLSPYVVBSUFF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,20892.96,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.68000002720016,CNC1CN(C1)C2=NC(=NC3=C2N=CC(=C3)C4CC4)N,CNC1CN(c2nc(N)nc3cc(C4CC4)cnc23)C1
1756,CHEMBL26880,KINYVKAOICLKCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12657274.0,Ki,<,1905.46,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine (H1) receptor,Synthesis and SAR of aminoalkoxy-biaryl-4-carboxamides: novel and selective histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,C1CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N4CCCC4,O=C(c1ccc(-c2ccc(OCCCN3CCCC3)cc2)cc1)N1CCCC1
1757,CHEMBL609579,KISZTEOELCMZPY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,2758.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.559405738160169,C1=CC=C(C=C1)C(CCN)C2=CC=CC=C2,NCCC(c1ccccc1)c1ccccc1
1758,CHEMBL64120,KIUNCIUUHAZFFW-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3300000383353785,CC(C)(C)OC(=O)N1CCC[C@@H]1C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,CC(C)(C)OC(=O)N1CCC[C@@H]1C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1759,,KIWQWJKWBHZMDT-GSVOUGTGSA-N,D-HOMOCYSTEINE THIOLACTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CSC(=O)[C@@H]1N,N[C@@H]1CCSC1=O
1760,CHEMBL568892,KIZHXXNZJUOENQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,20.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.698970004336019,COC(=O)C1=CC=C(C=C1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,COC(=O)c1ccc(CCCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
1764,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
1765,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
1766,CHEMBL13209,KJONHKAYOJNZEC-UHFFFAOYSA-N,NITRAZEPAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3,O=C1CN=C(c2ccccc2)c2cc([N+](=O)[O-])ccc2N1
1767,CHEMBL293492,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,CINNAMALDEHYDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)/C=C/C=O,O=C/C=C/c1ccccc1
1768,CHEMBL293492,KJPRLNWUNMBNBZ-QPJJXVBHSA-N,CINNAMALDEHYDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)/C=C/C=O,O=C/C=C/c1ccccc1
1769,CHEMBL1092126,KJQCJXUDPPZASI-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,9.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.031517051446064,CC1=C(N=CC=C1)[C@H](C)C2=C(SC3=CC=CC=C32)CCN(C)C,Cc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12
1772,CHEMBL63631,KJWJYNTUXOGLFR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,11220.18,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.950000175844591,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)S(=O)(=O)C(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(S(=O)(=O)C(C)C)CC2)cc1
1773,CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CN2C=CN=C2,c1ccc(Cn2ccnc2)cc1
1774,CHEMBL14192,KKKDZZRICRFGSD-UHFFFAOYSA-N,BENZYLIMIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CN2C=CN=C2,c1ccc(Cn2ccnc2)cc1
1777,CHEMBL58,KKZJGLLVHKMTCM-UHFFFAOYSA-N,MITOXANTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
1778,CHEMBL58,KKZJGLLVHKMTCM-UHFFFAOYSA-N,MITOXANTRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
1779,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,16.12,NM,,,,,,,,,,,,,,,,,,,,7.7926349625309275,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
1780,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,16.0,NM,,,,,,,,,,,,,,,,,,,,7.795880017344076,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
1781,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,,,,,,7.721246399047171,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
1782,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,72.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.142667503568733,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
1783,CHEMBL479,KLBQZWRITKRQQV-UHFFFAOYSA-N,THIORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,8.41,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.075204004202089,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC,CSc1ccc2c(c1)N(CCC1CCCCN1C)c1ccccc1S2
1784,CHEMBL1092765,KLFVGKSTNOVPOR-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,1.7,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,C[C@H](C1=C(N=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@H](c1cccnc1F)c1c(CCN(C)C)sc2ccccc12
1786,CHEMBL321709,KLHSXAZZKUOFFG-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,1500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.823908740944319,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)Br)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3ccc(Br)cc3)C2)cc1)C1CC1
1788,CHEMBL2207668,KLPJSXVRXSMWBK-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,501.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(CCC1OC2=CC=C(C=C2)C#N)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O,N#Cc1ccc(OC2CCN(C[C@H](O)CNC(=O)c3c[nH]c(=O)c4ccccc34)CC2)cc1
1789,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2
1790,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2
1791,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2
1792,CHEMBL460,KLPWJLBORRMFGK-UHFFFAOYSA-N,MOLINDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,2130.0,NM,,,,,,,,,,,,,,,,,,,,5.671620396561263,CCC1=C(NC2=C1C(=O)C(CC2)CN3CCOCC3)C,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2
1793,CHEMBL2030635,KLUCWWVQVUXBSE-UHFFFAOYSA-N,N-(2-PHENYLETHYL)PYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCC2=CC=CC=C2,c1ccc(CCN2CCCC2)cc1
1794,CHEMBL64896,KMEARAZYHMRMGA-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN[C@@H]1C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CCN(C(=O)[C@@H]3CCN3)CC2)cc1)C1CC1
1795,CHEMBL305144,KMEARAZYHMRMGA-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,12589.25,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.900000142057633,C1CN[C@H]1C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CCN(C(=O)[C@H]3CCN3)CC2)cc1)C1CC1
1796,CHEMBL2146803,KMFDXNUGIFDFHQ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.513,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.289882634888183,COCCN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,COCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
1797,CHEMBL2207633,KMVWYPYWHLOVLW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)C#CC5=CC=CC=C5,COc1ccccc1N1CCN(Cc2cc(C#Cc3ccccc3)c3cccccc2-3)CC1
1798,CHEMBL1518,KNAHARQHSZJURB-UHFFFAOYSA-N,PROPYLTHIOURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=CC(=O)NC(=S)N1,CCCc1cc(=O)[nH]c(=S)[nH]1
1799,CHEMBL1518,KNAHARQHSZJURB-UHFFFAOYSA-N,PROPYLTHIOURACIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1=CC(=O)NC(=S)N1,CCCc1cc(=O)[nH]c(=S)[nH]1
1800,CHEMBL2432046,KNBHNNRMMAKKFI-SEDVZXITSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,1359.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.866780543267506,COC1=C(C=C(C=C1)CN[C@H]2C3C4CC5C2C6C3CC4C56)OC,COc1ccc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc1OC
1802,CHEMBL565,KNHUKKLJHYUCFP-UHFFFAOYSA-N,CLOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
1803,CHEMBL565,KNHUKKLJHYUCFP-UHFFFAOYSA-N,CLOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl,CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1
1804,CHEMBL105952,KNMJAZUTBMPTPA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,162.18,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.790002703917631,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=CC=C3[N+](=O)[O-],CCOC(=O)N1CCN(CCCOc2ccc(-c3ccccc3[N+](=O)[O-])cc2)CC1
1806,CHEMBL429136,KNZNKJDEMHGXSO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18023344.0,Ki,=,18.3,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.73754891026957,CC1C2=C(C=CC(=C2Cl)Cl)NC(=NCC(F)F)N1,CC1NC(=NCC(F)F)Nc2ccc(Cl)c(Cl)c21
1807,CHEMBL256694,KNZNKJDEMHGXSO-YFKPBYRVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18023344.0,Ki,=,2.6,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: optimising brain penetration.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.585026652029184,C[C@H]1C2=C(C=CC(=C2Cl)Cl)NC(=NCC(F)F)N1,C[C@@H]1NC(=NCC(F)F)Nc2ccc(Cl)c(Cl)c21
1809,CHEMBL2208417,KOACYGPEOVSJCA-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,501.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,C1CN(CCC1NC[C@@H](COC2=CC=C(C=C2)C#N)O)CC3=CC(=C(C=C3)Cl)Cl,N#Cc1ccc(OC[C@@H](O)CNC2CCN(Cc3ccc(Cl)c(Cl)c3)CC2)cc1
1814,CHEMBL2208435,KOUMCBHTVFDPSI-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CN=NC4=CC=CC=C43)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1cnnc2ccccc12
1815,CHEMBL1065,KPJZHOPZRAFDTN-ZRGWGRIASA-N,METHYSERGIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
1816,CHEMBL1065,KPJZHOPZRAFDTN-ZRGWGRIASA-N,METHYSERGIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CN(C4=CC=CC(=C34)C2=C1)C)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4c3c(cn4C)C[C@H]2N(C)C1
1817,CHEMBL498847,KPQZUUQMTUIKBP-UHFFFAOYSA-N,SECNIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CC(C)O
1818,CHEMBL498847,KPQZUUQMTUIKBP-UHFFFAOYSA-N,SECNIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CC(C)O)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CC(C)O
1819,CHEMBL557555,KPSRODZRAIWAKH-UHFFFAOYSA-N,CIPROFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O
1820,CHEMBL557555,KPSRODZRAIWAKH-UHFFFAOYSA-N,CIPROFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CC2(Cl)Cl,CC(C)(Oc1ccc(C2CC2(Cl)Cl)cc1)C(=O)O
1821,CHEMBL62804,KPXVCGPCRXEDLT-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,53703.18,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.2699999970646445,C[C@@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,C[C@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1822,CHEMBL302196,KPXVCGPCRXEDLT-OAHLLOKOSA-N,A-304121,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,69183.1,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.159999981744464,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,C[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1823,CHEMBL302196,KPXVCGPCRXEDLT-OAHLLOKOSA-N,A-304121,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,C[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
1824,CHEMBL701,KPYSYYIEGFHWSV-UHFFFAOYSA-N,BACLOFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,NCC(CC(=O)O)c1ccc(Cl)cc1
1825,CHEMBL701,KPYSYYIEGFHWSV-UHFFFAOYSA-N,BACLOFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(CC(=O)O)CN)Cl,NCC(CC(=O)O)c1ccc(Cl)cc1
1826,CHEMBL141343,KPZQRBACZSLMPH-UHFFFAOYSA-N,U-78517F,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,14791.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,4.83000246293343,CC1=C(C2=C(CCC(O2)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2
1827,CHEMBL141343,KPZQRBACZSLMPH-UHFFFAOYSA-N,U-78517F,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1718.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.764976840504778,CC1=C(C2=C(CCC(O2)(C)CN3CCN(CC3)C4=NC(=NC(=C4)N5CCCC5)N6CCCC6)C(=C1O)C)C,Cc1c(C)c2c(c(C)c1O)CCC(C)(CN1CCN(c3cc(N4CCCC4)nc(N4CCCC4)n3)CC1)O2
1828,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
1829,CHEMBL128,KQKPFRSPSRPDEB-UHFFFAOYSA-N,SUMATRIPTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNS(=O)(=O)CC1=CC2=C(C=C1)NC=C2CCN(C)C,CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1
1832,CHEMBL447,KQPKPCNLIDLUMF-UHFFFAOYSA-N,SECOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O
1833,CHEMBL447,KQPKPCNLIDLUMF-UHFFFAOYSA-N,SECOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC=C,C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O
1834,CHEMBL1208572,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,SALINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O,CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C
1835,CHEMBL1208572,KQXDHUJYNAXLNZ-XQSDOZFQSA-N,SALINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O,CC[C@@H](C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H]1O[C@@H]([C@@H](CC)C(=O)O)CC[C@@H]1C)[C@H]1O[C@]2(C=C[C@@H](O)[C@]3(CC[C@@](C)([C@H]4CC[C@](O)(CC)[C@H](C)O4)O3)O2)[C@H](C)C[C@@H]1C
1837,CHEMBL1261,KRKNYBCHXYNGOX-UHFFFAOYSA-N,CITRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,O=C(O)CC(O)(CC(=O)O)C(=O)O
1838,CHEMBL1261,KRKNYBCHXYNGOX-UHFFFAOYSA-N,CITRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)C(CC(=O)O)(C(=O)O)O,O=C(O)CC(O)(CC(=O)O)C(=O)O
1839,CHEMBL1669423,KRLJKEOQHOYBSK-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,28.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.552841968657781,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4C,C[C@H](C1=C(CCN(C)Cc2nccn2C)Cc2ccccc21)c1cnccn1
1840,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.67,NM,,,,,,,,,,,,,,,,,,,,9.173925197299171,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
1841,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,0.95,NM,,,,,,,,,,,,,,,,,,,,9.022276394711152,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
1842,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,1.12,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.950781977329818,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
1843,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.78,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.320572103387883,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
1844,CHEMBL629,KRMDCWKBEZIMAB-UHFFFAOYSA-N,AMITRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.555,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.255707016877325,CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2CCc2ccccc21
1845,CHEMBL605081,KRPHBUMURAALTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,112.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.950781977329817,CC1=CC=C(C=C1)CCN2C3=C(CN(CC3)C)C4=C2C=CC(=C4)C,Cc1ccc(CCn2c3c(c4cc(C)ccc42)CN(C)CC3)cc1
1846,CHEMBL1752,KSCFJBIXMNOVSH-UHFFFAOYSA-N,DYPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
1847,CHEMBL1752,KSCFJBIXMNOVSH-UHFFFAOYSA-N,DYPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O,Cn1c(=O)c2c(ncn2CC(O)CO)n(C)c1=O
1848,CHEMBL32749,KSEBMYQBYZTDHS-HWKANZROSA-N,FERULIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,COc1cc(/C=C/C(=O)O)ccc1O
1849,CHEMBL32749,KSEBMYQBYZTDHS-HWKANZROSA-N,FERULIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)/C=C/C(=O)O)O,COc1cc(/C=C/C(=O)O)ccc1O
1850,CHEMBL540445,KTEXNACQROZXEV-SLXBATTESA-N,PARTHENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CCC[C@@]2([C@@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,C=C1C(=O)O[C@H]2[C@H]1CCC(C)=CCC[C@@]1(C)O[C@@H]21
1851,CHEMBL540445,KTEXNACQROZXEV-SLXBATTESA-N,PARTHENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CCC[C@@]2([C@@H](O2)[C@@H]3[C@@H](CC1)C(=C)C(=O)O3)C,C=C1C(=O)O[C@H]2[C@H]1CCC(C)=CCC[C@@]1(C)O[C@@H]21
1852,CHEMBL941,KTUFNOKKBVMGRW-UHFFFAOYSA-N,IMATINIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
1853,CHEMBL941,KTUFNOKKBVMGRW-UHFFFAOYSA-N,IMATINIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
1854,CHEMBL82635,KTWZXHKXAGXWOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,6.03,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.219682687859848,CC1=C2CC3=CC=CC=C3C4CC(ON4C2=CC=C1)CN(C)C,Cc1cccc2c1Cc1ccccc1C1CC(CN(C)C)ON21
1856,CHEMBL330719,KUAJFMGQGXJNCK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.55,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.183758700008218,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=NC=C6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccncc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
1857,CHEMBL330719,KUAJFMGQGXJNCK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,285.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.54515513999149,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=NC=C6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccncc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
1858,CHEMBL96158,KUCRPWOVGMMXDP-FDMCOVCTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321763,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3OC4=CC=CC=C24,CN(C)CC1C[C@@H]2c3ccccc3Oc3ccccc3[C@H]2O1
1859,CHEMBL330713,KUCRPWOVGMMXDP-MRJVUNAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,32.6,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.4867823999320615,CN(C)CC1C[C@@H]2[C@H](O1)C3=CC=CC=C3OC4=CC=CC=C24,CN(C)CC1C[C@H]2c3ccccc3Oc3ccccc3[C@H]2O1
1861,CHEMBL61396,KUPWVSPABUWQQB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,104.71,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.980011840408715,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=C(C=CO3)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3occc3C)CC2)cc1
1862,CHEMBL24944,KVSKGMLNBAPGKH-UHFFFAOYSA-N,TRIBROMSALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br,O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O
1863,CHEMBL24944,KVSKGMLNBAPGKH-UHFFFAOYSA-N,TRIBROMSALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1NC(=O)C2=C(C(=CC(=C2)Br)Br)O)Br,O=C(Nc1ccc(Br)cc1)c1cc(Br)cc(Br)c1O
1864,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.65,NM,,,,,,,,,,,,,,,,,,,,9.187086643357144,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1865,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,0.087,NM,,,,,,,,,,,,,,,,,,,,10.060480747381384,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1866,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,5.6,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,8.2518119729938,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1867,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1868,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,3.5,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.455931955649724,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1869,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.920818753952375,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1870,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,2.8,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,8.55284196865778,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1872,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,8.698970004336019,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1873,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,13.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.886056647693162,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1874,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.47,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.832682665251824,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1875,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,7.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.154901959985743,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1876,CHEMBL715,KVWDHTXUZHCGIO-UHFFFAOYSA-N,OLANZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.0,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1
1877,CHEMBL94788,KVYXGCNCFPIESF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.0,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCC(=O)O)C6=CC(=C(C=C6)Cl)Cl,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4CCCC(=O)O)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
1879,CHEMBL327306,KWUQZAPLAOREKL-FDMCOVCTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,4.3,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.366531544420411,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3SC4=CC=CC=C24,CN(C)CC1C[C@@H]2c3ccccc3Sc3ccccc3[C@H]2O1
1881,CHEMBL3409256,KWZBJWOQFABHPF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25557493.0,Ki,=,160.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in HEK-293 cells,Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.,Eur. J. Med. Chem.,PUBLICATION,,6.795880017344076,C1CN(CCN1CCCOC2=CC=CC=C2C(=O)N)C3=CC=CC4=C3C=CN4S(=O)(=O)C5=CC=CC=C5,NC(=O)c1ccccc1OCCCN1CCN(c2cccc3c2ccn3S(=O)(=O)c2ccccc2)CC1
1884,CHEMBL2208437,KXSMUDWNWWFRRE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,1258.93,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,CS(=O)(=O)C1=CC=CC=C1C(=O)NCC(CNC2CCN(CC2)CC3=CC(=C(C=C3)Cl)Cl)O,CS(=O)(=O)c1ccccc1C(=O)NCC(O)CNC1CCN(Cc2ccc(Cl)c(Cl)c2)CC1
1885,CHEMBL9514,KYRVNWMVYQXFEU-UHFFFAOYSA-N,NOCODAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3,COC(=O)Nc1nc2ccc(C(=O)c3cccs3)cc2[nH]1
1886,CHEMBL9514,KYRVNWMVYQXFEU-UHFFFAOYSA-N,NOCODAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CS3,COC(=O)Nc1nc2ccc(C(=O)c3cccs3)cc2[nH]1
1888,CHEMBL1118,KYYIDSXMWOZKMP-UHFFFAOYSA-N,DESVENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16675639.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1
1889,CHEMBL304714,KZBINGTZAGPLQP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,741.31,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.130000141365475,CCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC,CCCC(=O)c1ccc(OCCCN2CCN(C(=O)OCC)CC2)cc1
1890,CHEMBL1910384,KZGYBDPASGTNOZ-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,457.09,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3399982798971175,COC1=CC=C(C=C1)CN(CCN[C@H]2CCN(C2)C(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=N5,COc1ccc(CN(CCN[C@H]2CCN(C(=O)c3cc4ccccc4[nH]3)C2)c2ccccn2)cc1
1892,CHEMBL468176,KZPYBMNBUZPMKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18640038.0,EC50,>,50000.0,NM,,,,,,,,,,,,,,,Agonist activity at histamine H1 receptor,Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN(CCC1C2=NC(=NO2)C3=C(C=C(C=C3)F)Cl)C4=CN=C5C=CC(=CC5=C4)Cl,Fc1ccc(-c2noc(C3CCN(c4cnc5ccc(Cl)cc5c4)CC3)n2)c(Cl)c1
1893,CHEMBL468176,KZPYBMNBUZPMKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18640038.0,IC50,>,50000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.301029995663981,C1CN(CCC1C2=NC(=NO2)C3=C(C=C(C=C3)F)Cl)C4=CN=C5C=CC(=CC5=C4)Cl,Fc1ccc(-c2noc(C3CCN(c4cnc5ccc(Cl)cc5c4)CC3)n2)c(Cl)c1
1895,CHEMBL293802,KZZIVOLMJPSDEP-UHFFFAOYSA-N,ARPROMIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,353.0,NM,,,,,,,,,,,,,,,,,,,,6.452225294612178,C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC=C(C=C3)F,NC(=NCCCc1cnc[nH]1)NCCC(c1ccc(F)cc1)c1ccccn1
1896,CHEMBL3094130,LABRWGKKPFQRIQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1258.93,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,C1CCN(CC1)CCCOC2=CC3=C(CCNCC3)C=C2,c1cc2c(cc1OCCCN1CCCCC1)CCNCC2
1897,CHEMBL258090,LAGGNVKIMAMGMQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)CC(F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(CC(F)(F)F)oc6cc5CC4)n3C)cccc2n1
1899,CHEMBL1910378,LAKQJOXTAMPPOO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,169.82,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.770011163455188,COC1=CC=C(C=C1)CN(CCN2CCN(CC2)C(=O)C3=CC4=CC=CC=C4N3)C5=CC=CC=N5,COc1ccc(CN(CCN2CCN(C(=O)c3cc4ccccc4[nH]3)CC2)c2ccccn2)cc1
1900,CHEMBL2031884,LBAKRWRQQGNMEB-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,7230.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.140861702705468,CCNC(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=O)N(CC3)CCN4CCC[C@H]4C,CCNC(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCC[C@H]2C)C3=O)cc1
1901,CHEMBL64321,LBCXFPZCIKKGSB-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,3311.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.480000159330324,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC3=CC=NC=C3)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@H](N)Cc3ccncc3)CC2)cc1
1902,CHEMBL62808,LBCXFPZCIKKGSB-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,2290.87,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.639999555020353,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC3=CC=NC=C3)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](N)Cc3ccncc3)CC2)cc1
1903,CHEMBL2030630,LCBQDWKMNGEPLD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCCC3=CC(=CC=C3)F,Fc1cccc(CCCN2C3CCC2CC3)c1
1904,CHEMBL1088899,LCEUDZGEEHIOMS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,35.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CC1=CN=C(C=N1)CC2=C(CC3=CC=CC=C32)CCN(C)C,Cc1cnc(CC2=C(CCN(C)C)Cc3ccccc32)cn1
1909,CHEMBL81485,LCKBEOTXTNWYRG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,10.72,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.96980521464325,CNCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CNCC1CC2c3ccccc3Cc3ccccc3N2O1
1910,CHEMBL179590,LDAIZSJPULESPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,5.89,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.229884705212896,CCOC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O,CCOC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
1911,CHEMBL1094510,LDKQFEPUPKIHCG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4,CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1
1912,CHEMBL549599,LDMXQNXCFMLIER-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,CNC1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CNC1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
1913,CHEMBL360666,LDPRUJUFFYEDJC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,17.8,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.749579997691106,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)OCC3=CC=CC=C3)O)C(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=C(OCc1ccccc1)N(O)CCC#Cc1ccc(OCCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
1914,CHEMBL85155,LDUDMYAXGOQOGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,CC1=CC2=C(C=C1)C3CC(ON3C4=CC=CC=C4C2)CN(C)C,Cc1ccc2c(c1)Cc1ccccc1N1OC(CN(C)C)CC21
1915,CHEMBL1201193,LEBVLXFERQHONN-INIZCTEOSA-N,LEVOBUPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
1916,CHEMBL1201193,LEBVLXFERQHONN-INIZCTEOSA-N,LEVOBUPIVACAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C,CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
1917,CHEMBL340816,LECUUDCCVOYUHG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,973.5,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.0116640441439495,C1CC2CC(CC1N2CCCC(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4,O=C(CCCN1C2CCC1CC(c1ccccc1)C2)c1ccc(F)cc1
1918,CHEMBL2158792,LEHDCEDFGAFVGX-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=C(C=CC(=C1)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O)Cl,Cc1cc(OC2CCN(CC3CCN([C@@](C)(Cc4ccc(F)cc4)C(=O)O)CC3)CC2)ccc1Cl
1921,CHEMBL1200391,LENZDBCJOHFCAS-UHFFFAOYSA-N,TROMETHAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(CO)(CO)N)O,NC(CO)(CO)CO
1922,CHEMBL1200391,LENZDBCJOHFCAS-UHFFFAOYSA-N,TROMETHAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(CO)(CO)N)O,NC(CO)(CO)CO
1923,CHEMBL61231,LESFXMYDPQCDFJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,933.25,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.030002001401657,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)CC(C)C,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)CC(C)C)cc2)CC1
1924,CHEMBL43594,LEVRYVCMBBJQLU-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,616.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.210419287835576,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)C#N,CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C
1925,CHEMBL437002,LEVTWCPGXIVKEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F,O=C(c1ccccc1F)N1CCC(Cc2ccccc2)CC1
1926,CHEMBL437002,LEVTWCPGXIVKEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3F,O=C(c1ccccc1F)N1CCC(Cc2ccccc2)CC1
1927,CHEMBL366563,LEVWYRKDKASIDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)SSCC(C(=O)O)N,NC(CSSCC(N)C(=O)O)C(=O)O
1928,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
1929,CHEMBL808,LEZWWPYKPKIXLL-UHFFFAOYSA-N,ECONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1COC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl,Clc1ccc(COC(Cn2ccnc2)c2ccc(Cl)cc2Cl)cc1
1930,CHEMBL63036,LFKNMWWWQLOXKE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,416.87,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3799993576999325,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CC=N3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3ccccn3)CC2)cc1
1931,CHEMBL545,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCO,CCO
1932,CHEMBL545,LFQSCWFLJHTTHZ-UHFFFAOYSA-N,ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCO,CCO
1933,CHEMBL557210,LFSBNTMFCXGIEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,3.2,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.494850021680094,CN(CCO)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(CCO)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
1934,CHEMBL18797,LFWHFZJPXXOYNR-MFOYZWKCSA-N,SULINDAC SULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(=C2)F)CC(=O)O,CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1
1935,CHEMBL18797,LFWHFZJPXXOYNR-MFOYZWKCSA-N,SULINDAC SULFIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)SC)C=CC(=C2)F)CC(=O)O,CSc1ccc(/C=C2/C(C)=C(CC(=O)O)c3cc(F)ccc32)cc1
1936,CHEMBL102390,LGBGBJRXINUEFH-AZUAARDMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,80000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.096910013008056,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)[C@@H](CO)NC(=O)OC(C)(C)C,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)[C@@H](CO)NC(=O)OC(C)(C)C)C2)cc1
1937,CHEMBL316968,LGBGBJRXINUEFH-ICSRJNTNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,75000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.1249387366083,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)[C@H](CO)NC(=O)OC(C)(C)C,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)[C@H](CO)NC(=O)OC(C)(C)C)C2)cc1
1938,CHEMBL194659,LGHLMADLDHUIJY-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,7.5,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.1249387366083,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)OC4=CC=CC=C24,CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1
1939,CHEMBL195706,LGHLMADLDHUIJY-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,33.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.481486060122112,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)F)OC4=CC=CC=C24,CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(F)cc3[C@H]2O1
1940,CHEMBL593988,LGIIUKGHECNJNZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,6.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,8.221848749616356,CN(C)CCC1C2=CC=CC=C2CC3=CC=CC=C13,CN(C)CCC1c2ccccc2Cc2ccccc21
1941,CHEMBL2171029,LGNOCEJCJLXMEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=C(C=C4)C5=NN(N=N5)CCCCC(=O)O,O=C(O)CCCCn1nnc(-c2ccc(C(=O)N3CCC(N4CCC(Oc5ccc(Cl)c(Cl)c5)CC4)CC3)cc2)n1
1944,CHEMBL156455,LGXVIGDEPROXKC-UHFFFAOYSA-N,"1,1-DICHLOROETHENE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=C(Cl)Cl,C=C(Cl)Cl
1945,CHEMBL156455,LGXVIGDEPROXKC-UHFFFAOYSA-N,"1,1-DICHLOROETHENE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=C(Cl)Cl,C=C(Cl)Cl
1946,CHEMBL1643902,LGZPNSXZRKGUES-DKSPCFMDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21146989.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor at 10 uM,Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
1947,CHEMBL1643902,LGZPNSXZRKGUES-DKSPCFMDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C2C6C3CC4C56,CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C5C3CC2C5C41
1948,CHEMBL3233142,LHAPOGAFBLSJJQ-GUTACTQSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,6.0,CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCC(=O)c3ccc(F)cc3)CC[C@@H]12
1950,CHEMBL82966,LHTXSHOSMCEFFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,2.29,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.640164517660113,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)F,CN(C)CC1CC2c3cccc(F)c3Cc3ccccc3N2O1
1951,CHEMBL293762,LHVRFUVVRXGZPV-UHFFFAOYSA-N,AMTHAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,15848.93,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.800000052738446,CC1=C(SC(=N1)N)CCN,Cc1nc(N)sc1CCN
1952,CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841014,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3OC,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21
1953,CHEMBL1090176,LHYWGVZKOTTYSZ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,2.7,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841014,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3OC,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2cc(C)ccc21
1954,CHEMBL2037604,LIEAKONJVOLXFZ-LSDHHAIUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22578490.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1C[C@H](C)COC2=CC=C(C=C2)C3=CC(=O)NN=C3,C[C@H](COc1ccc(-c2cn[nH]c(=O)c2)cc1)CN1CCC[C@H]1C
1956,CHEMBL271631,LJDQESSYTJNKOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CCC1=NC2=C(S1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C,CCc1nc2cc3c(cc2s1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
1958,CHEMBL440512,LJVNYCDXBXGQIK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,87.0,NM,,,,,,,,,,,,,,,In vitro binding affinity of compound against histamine H1 neuronal receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0604807473813835,CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CC[N+](CC4)(C)[O-],Cc1cc2c(s1)Nc1ccccc1N=C2N1CC[N+](C)([O-])CC1
1959,CHEMBL2079587,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,STANOZOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C,C[C@]12Cc3cn[nH]c3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
1960,CHEMBL2079587,LKAJKIOFIWVMDJ-IYRCEVNGSA-N,STANOZOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C,C[C@]12Cc3cn[nH]c3C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O
1961,CHEMBL177,LKCWBDHBTVXHDL-RMDFUYIESA-N,AMIKACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
1962,CHEMBL177,LKCWBDHBTVXHDL-RMDFUYIESA-N,AMIKACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N,NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O
1965,CHEMBL2171035,LKFICSFQSQYFJF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=C(C=C4)Cl,O=C(NS(=O)(=O)c1ccc(Cl)cc1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
1967,CHEMBL63560,LKJPYSCBVHEWIU-KRWDZBQOSA-N,(R)-BICALUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
1968,CHEMBL63560,LKJPYSCBVHEWIU-KRWDZBQOSA-N,(R)-BICALUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1
1969,CHEMBL1910386,LLBZLFNYOYVBFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,5.5,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.259637310505756,C1CN(CCC1NC2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)CCN5CCN(CC5)C(=O)C6=CC7=CC=CC=C7N6,O=C(c1cc2ccccc2[nH]1)N1CCN(CCN2CCC(Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)CC1
1970,CHEMBL2158793,LLEJNWFSXZIFMW-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CC1=C(C=CC(=C1)F)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=C(C=C4)F)C(=O)O,Cc1cc(F)ccc1OC1CCN(CC2CCN([C@@](C)(Cc3ccc(F)cc3)C(=O)O)CC2)CC1
1973,CHEMBL1088898,LLKGAHXEIBHUNC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.200659450546419,CC1=NC=CN=C1CC2=C(CC3=CC=CC=C32)CCN(C)C,Cc1nccnc1CC1=C(CCN(C)C)Cc2ccccc21
1974,CHEMBL1542,LMEKQMALGUDUQG-UHFFFAOYSA-N,AZATHIOPRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
1975,CHEMBL1542,LMEKQMALGUDUQG-UHFFFAOYSA-N,AZATHIOPRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-],Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12
1976,CHEMBL302231,LMFNLINKCDGRTE-NTSWFWBYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@@H]1C2=CN=CN2)CN,NC[C@@H]1C[C@H]1c1cnc[nH]1
1977,CHEMBL292924,LMFNLINKCDGRTE-PHDIDXHHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@@H]1C2=CN=CN2)CN,NC[C@H]1C[C@H]1c1cnc[nH]1
1978,CHEMBL292558,LMFNLINKCDGRTE-RITPCOANSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@H]1C2=CN=CN2)CN,NC[C@H]1C[C@@H]1c1cnc[nH]1
1979,CHEMBL305135,LMFNLINKCDGRTE-WDSKDSINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@H]1C2=CN=CN2)CN,NC[C@@H]1C[C@@H]1c1cnc[nH]1
1980,CHEMBL1054,LMJSLTNSBFUCMU-UHFFFAOYSA-N,TRICHLORMETHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
1981,CHEMBL1054,LMJSLTNSBFUCMU-UHFFFAOYSA-N,TRICHLORMETHIAZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)NC(N2)C(Cl)Cl,NS(=O)(=O)c1cc2c(cc1Cl)NC(C(Cl)Cl)NS2(=O)=O
1982,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,1886.79,NM,,,,,,,,,,,,,,,,,,,,5.724276434183983,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1983,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1700.0,NM,,,,,,,,,,,,,,,,,,,,5.769551078621726,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1984,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,1900.0,NM,,,,,,,,,,,,,,,,,,,,5.721246399047171,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1985,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,790.0,NM,,,,,,,,,,,,,,,,,,,,6.102372908709557,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1986,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,260.0,NM,,,,,,,,,,,,,,,,,,,,6.585026652029183,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1987,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,1800.0,NM,,,,,,,,,,,,,,,,,,,,5.7447274948966935,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1988,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,730.0,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,6.136677139879544,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1989,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,440.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.356547323513813,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1990,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,440.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.356547323513813,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1991,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,440.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.356547323513813,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1992,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,2781.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.55579901113584,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1993,CHEMBL54,LNEPOXFFQSENCJ-UHFFFAOYSA-N,HALOPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,323.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.490797477668897,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCC(O)(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
1994,CHEMBL865,LNPDTQAFDNKSHK-UHFFFAOYSA-N,VALDECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
1995,CHEMBL865,LNPDTQAFDNKSHK-UHFFFAOYSA-N,VALDECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N,Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1
1998,CHEMBL1744448,LOLFAJUUOFBGSF-KYIYJVAASA-N,BLEOMYCIN A2,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@H]([C@@H](C)NC(=O)[C@H](C(C1=CN=CN1)O[C@H]2[C@H]([C@H]([C@@H]([C@@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)OC(=O)N)O)NC(=O)C4=CC(=NC(=N4)C(CC(=O)N)NCC(C(=O)N)N)N)O)C(=O)N[C@@H](C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.[Br-],CC(O)[C@H](NC(=O)[C@@H](C)[C@@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1cc(N)nc(C(CC(N)=O)NCC(N)C(N)=O)n1)C(O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1
1999,CHEMBL1744448,LOLFAJUUOFBGSF-KYIYJVAASA-N,BLEOMYCIN A2,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]([C@H]([C@@H](C)NC(=O)[C@H](C(C1=CN=CN1)O[C@H]2[C@H]([C@H]([C@@H]([C@@H](O2)CO)O)O)O[C@@H]3[C@H]([C@H]([C@@H]([C@H](O3)CO)O)OC(=O)N)O)NC(=O)C4=CC(=NC(=N4)C(CC(=O)N)NCC(C(=O)N)N)N)O)C(=O)N[C@@H](C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C.[Br-],CC(O)[C@H](NC(=O)[C@@H](C)[C@@H](O)[C@@H](C)NC(=O)[C@@H](NC(=O)c1cc(N)nc(C(CC(N)=O)NCC(N)C(N)=O)n1)C(O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1cnc[nH]1)C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1
2001,CHEMBL1824778,LPAMOYXJLQSGRI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)(N3CC4=CC(=CC=C4)F)O.Cl,OC12CC3CC(CC(C3)N1Cc1cccc(F)c1)C2
2002,CHEMBL2171013,LPHIWCBAJGQIIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518963,CC1=CC=C(C=C1)S(=O)(=O)N(C)C(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1ccc(S(=O)(=O)N(C)C(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
2003,CHEMBL441687,LPLVUJXQOOQHMX-QWBHMCJMSA-N,GLYCYRRHIZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C
2004,CHEMBL441687,LPLVUJXQOOQHMX-QWBHMCJMSA-N,GLYCYRRHIZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O,CC1(C)[C@@H](O[C@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@@](C)(C(=O)O)CC[C@]3(C)CC[C@]21C
2005,CHEMBL222863,LPMXVESGRSUGHW-HBYQJFLCSA-N,OUABAIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O
2006,CHEMBL222863,LPMXVESGRSUGHW-HBYQJFLCSA-N,OUABAIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2C[C@H]([C@@]3([C@@H]4[C@@H](CC[C@@]3(C2)O)[C@]5(CC[C@@H]([C@]5(C[C@H]4O)C)C6=CC(=O)OC6)O)CO)O)O)O)O,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@H]4[C@H](O)C[C@]5(C)[C@@H](C6=CC(=O)OC6)CC[C@]5(O)[C@@H]4CC[C@]3(O)C2)[C@H](O)[C@H](O)[C@H]1O
2007,CHEMBL404,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,TAZOBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
2008,CHEMBL404,LPQZKKCYTLCDGQ-WEDXCCLWSA-N,TAZOBACTAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3,C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
2009,CHEMBL111861,LPYXTAPPNYMYOP-XDBTXSBWSA-N,CORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
2010,CHEMBL111861,LPYXTAPPNYMYOP-XDBTXSBWSA-N,CORTISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C=C1CC[C@@H]3[C@@H]2C(=O)C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
2011,CHEMBL2207672,LQCZDIMQFUOGJG-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)C)O)Cl,Cc1c(Cl)ccc(OC2CCN(C[C@H](O)CNC(=O)c3c[nH]c(=O)c4cc(S(C)(=O)=O)ccc34)CC2)c1Cl
2012,CHEMBL2207636,LQGNDHYNCHVOGU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)C#N,COc1ccccc1N1CCN(Cc2cc(C#N)c3cccccc2-3)CC1
2013,CHEMBL94480,LQNLNHOIPAAEJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.25,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.204119982655925,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC=C(C=C7)F,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccccn4)CC3)(c3ccc(F)cc3)C2)cc(OC)c1OC
2014,CHEMBL891,LQOLIRLGBULYKD-JKIFEVAISA-N,CLOXACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12
2015,CHEMBL891,LQOLIRLGBULYKD-JKIFEVAISA-N,CLOXACILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O,Cc1onc(-c2ccccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@H]12
2019,CHEMBL506247,LRBQNJMCXXYXIU-PPKXGCFTSA-N,TANNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1
2020,CHEMBL506247,LRBQNJMCXXYXIU-PPKXGCFTSA-N,TANNIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O,O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1
2023,CHEMBL346230,LRTHKJMSTYBFFO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,0.5,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,9.30102999566398,CN(C)CCCC1C2=CC=CC=C2CC3=CC=CC=C13,CN(C)CCCC1c2ccccc2Cc2ccccc21
2026,CHEMBL2207659,LSHDMKHXFDYKLP-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=C(NN=C3)C(F)(F)F)O,Cc1cc(Cl)ccc1OC1CCN(C[C@H](O)CNC(=O)c2cn[nH]c2C(F)(F)F)CC1
2027,CHEMBL158595,LSLKPVQOFVGVSL-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14741266.0,Ki,=,890.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor of human colon cells was determined,"Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 3: 5-Substituted 3-phenyl-1,2,4-oxadiazoles as potent antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0506099933550885,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC(=C(C=C2)C3=NOC(=N3)CC4CCCC4)F)NC(=O)C5=CC=C(C=C5)N(C)C,C[C@@H](NC(=O)c1ccc(N(C)C)cc1)C(=O)N1CCN(CCCOc2ccc(-c3noc(CC4CCCC4)n3)c(F)c2)CC1
2028,CHEMBL1566249,LSNWBKACGXCGAJ-UHFFFAOYSA-N,AMPIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3,CCOC(=O)OC(C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21
2029,CHEMBL1566249,LSNWBKACGXCGAJ-UHFFFAOYSA-N,AMPIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)OC(C)OC1=C(N(S(=O)(=O)C2=CC=CC=C21)C)C(=O)NC3=CC=CC=N3,CCOC(=O)OC(C)OC1=C(C(=O)Nc2ccccn2)N(C)S(=O)(=O)c2ccccc21
2030,CHEMBL549598,LSOVNGNFKVHURS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,IC50,=,4.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.356547323513812,CN(CC1CCCCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(CC1CCCCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
2031,CHEMBL1082,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,AMOXICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
2032,CHEMBL1082,LSQZJLSUYDQPKJ-NJBDSQKTSA-N,AMOXICILLIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O
2033,CHEMBL62949,LSVDVSGWHKKGEU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCCCCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC,CCCCCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)OCC)CC2)cc1
2035,CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
2036,CHEMBL1751,LTMHDMANZUZIPE-PUGKRICDSA-N,DIGOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6C[C@@H](O)[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
2039,CHEMBL1935435,LUFOXAFMTZDQHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,8.1,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.09151498112135,C1CC(CN(C1)CC2=NC=CO2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(C3CCCN(Cc4ncco4)C3)nc3ccccc32)cc1
2040,CHEMBL1935435,LUFOXAFMTZDQHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,13.1,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.8827287043442364,C1CC(CN(C1)CC2=NC=CO2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(C3CCCN(Cc4ncco4)C3)nc3ccccc32)cc1
2041,CHEMBL1909051,LUHHARLTABWBTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1
2042,CHEMBL1909051,LUHHARLTABWBTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3C(F)(F)F,O=C(c1ccccc1C(F)(F)F)N1CCC(Cc2ccccc2)CC1
2043,CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
2044,CHEMBL165,LUKBXSAWLPMMSZ-OWOJBTEDSA-N,RESVERATROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O,Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1
2045,CHEMBL54126,LULNWZDBKTWDGK-UHFFFAOYSA-M,NEOSTIGMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-],CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
2046,CHEMBL54126,LULNWZDBKTWDGK-UHFFFAOYSA-M,NEOSTIGMINE BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C.[Br-],CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1
2048,CHEMBL552026,LUSFVKKEBIMJTI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,6.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.180456064458129,C1CCN(C(=O)C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,O=C1CCCCN1C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
2049,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
2050,CHEMBL1732,LUZRJRNZXALNLM-JGRZULCMSA-N,DIHYDROERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
2051,CHEMBL64259,LVCDOFXANXULSM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,309.03,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.509999358109048,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OC(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)OC(C)C)CC2)cc1
2052,CHEMBL1231107,LVQDKIWDGQRHTE-UHFFFAOYSA-N,CYROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1NC2=NC(=NC(=N2)N)N,Nc1nc(N)nc(NC2CC2)n1
2053,CHEMBL1231107,LVQDKIWDGQRHTE-UHFFFAOYSA-N,CYROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1NC2=NC(=NC(=N2)N)N,Nc1nc(N)nc(NC2CC2)n1
2054,CHEMBL560061,LVQDPXHGLLUJTK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,69.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.161150909262744,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CCC(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(CCC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2055,CHEMBL105967,LVTJCSTYQPNIJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3890.45,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.410000161858409,C1CNCCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CCCNCC3)cc2)cc1
2056,CHEMBL1672288,LVXAMCKZCLWWTF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21207959.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Syntheses of 2-amino and 2-halothiazole derivatives as high-affinity metabotropic glutamate receptor subtype 5 ligands and potential radioligands for in vivo imaging.,J. Med. Chem.,PUBLICATION,,5.0,C1=C(C=C(C=C1C#N)F)C#CC2=CSC(=N2)F,N#Cc1cc(F)cc(C#Cc2csc(F)n2)c1
2059,CHEMBL187264,LWOMEPYLSGEMDX-SSEXGKCCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,9.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.045757490560675,C1CN(CCN1CCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl,NC(=O)N(O)CCC#Cc1ccc(OCCCN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)cc1
2060,CHEMBL325372,LXCFILQKKLGQFO-UHFFFAOYSA-N,METHYLPARABEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=C(C=C1)O,COC(=O)c1ccc(O)cc1
2061,CHEMBL325372,LXCFILQKKLGQFO-UHFFFAOYSA-N,METHYLPARABEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=C(C=C1)O,COC(=O)c1ccc(O)cc1
2062,CHEMBL1908355,LXIKEPCNDFVJKC-QXMHVHEDSA-N,TENIDAP,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O,NC(=O)n1c(O)c(C(=O)c2cccs2)c2cc(Cl)ccc21
2063,CHEMBL1908355,LXIKEPCNDFVJKC-QXMHVHEDSA-N,TENIDAP,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)C(=O)C2=C(N(C3=C2C=C(C=C3)Cl)C(=O)N)O,NC(=O)n1c(O)c(C(=O)c2cccs2)c2cc(Cl)ccc21
2064,CHEMBL1393,LXMSZDCAJNLERA-ZHYRCANASA-N,SPIRONOLACTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21
2065,CHEMBL1393,LXMSZDCAJNLERA-ZHYRCANASA-N,SPIRONOLACTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21
2066,CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.721246399047171,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C
2067,CHEMBL1935443,LXOHJARDVFSOPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,365.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.437707135543525,CC1=C(C=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCO4)C,Cc1ccc(Cn2c(C3CNCCO3)nc3ccccc32)cc1C
2068,CHEMBL457299,LYCAIKOWRPUZTN-UHFFFAOYSA-N,ETHYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CO)O,OCCO
2069,CHEMBL457299,LYCAIKOWRPUZTN-UHFFFAOYSA-N,ETHYLENE GLYCOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CO)O,OCCO
2073,CHEMBL59931,LYZKHJXQSGMRGZ-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10232.93,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.989999996723885,CC(C)(C)C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,CC(C)(C)C[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
2074,CHEMBL302795,LZNWYQJJBLGYLT-UHFFFAOYSA-N,TENOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O
2075,CHEMBL302795,LZNWYQJJBLGYLT-UHFFFAOYSA-N,TENOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=C(S1(=O)=O)C=CS2)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O
2076,CHEMBL1935434,LZTBBMYTELVXQM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,16.6,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.779891911959945,C1CC(CN(C1)CC(=O)N2CCOCC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,O=C(CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1)N1CCOCC1
2077,CHEMBL2112451,LZZBODFOSOSLCF-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,20000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.698970004336019,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)C#N)CCCOC3=CC=C(C=C3)C(=O)C4CC4,N#Cc1ccc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)cc1
2078,CHEMBL593734,MAAQGZFMFXQVOG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,1670.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.777283528852418,C1=CC=C(C=C1)C(CCCN)C2=CC=CC=C2,NCCCC(c1ccccc1)c1ccccc1
2079,CHEMBL2158840,MANRLQSCJCTMOZ-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC(=CC=C4)F)C(=O)O,O=C(O)[C@H](Cc1cccc(F)c1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
2081,CHEMBL2208434,MAWNODXTLNGOAA-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CC(=O)NC4=CC=CC=C43)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1cc(=O)[nH]c2ccccc12
2082,CHEMBL313493,MBABOKRGFJTBAE-UHFFFAOYSA-N,METHANESULFONIC ACID METHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COS(=O)(=O)C,COS(C)(=O)=O
2083,CHEMBL313493,MBABOKRGFJTBAE-UHFFFAOYSA-N,METHANESULFONIC ACID METHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COS(=O)(=O)C,COS(C)(=O)=O
2085,CHEMBL832,MBGGBVCUIVRRBF-UHFFFAOYSA-N,SULFINPYRAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
2086,CHEMBL832,MBGGBVCUIVRRBF-UHFFFAOYSA-N,SULFINPYRAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=O)C(C(=O)N2C3=CC=CC=C3)CCS(=O)C4=CC=CC=C4,O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
2087,CHEMBL2207670,MBMAQWYADJFPMU-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,251.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,CS(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)C#N)Cl)O,CS(=O)(=O)c1ccc2c(C(=O)NC[C@@H](O)CN3CCC(Oc4ccc(C#N)c(Cl)c4)CC3)c[nH]c(=O)c2c1
2088,CHEMBL186125,MBQMCWRJVSGZMF-WJOKGBTCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,30.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.522878745280337,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl,NC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)cc1
2091,CHEMBL639,MBUVEWMHONZEQD-UHFFFAOYSA-N,AZELASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.899629454882437,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
2093,CHEMBL639,MBUVEWMHONZEQD-UHFFFAOYSA-N,AZELASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,1.2,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,8.920818753952375,CN1CCCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1
2094,CHEMBL1767137,MBVVVQZOMZFVJF-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,10.0,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)OC,COc1ccc(Cc2nn(C[C@H]3CCCN3C)c(=O)c3ccccc23)cc1
2098,CHEMBL1222623,MCEBFAPNLMTKDG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,CC(C)(CN1CCCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4)C(=O)O,CC(C)(CN1CCCN(C2=Cc3ccccc3Cn3ccnc32)CC1)C(=O)O
2099,CHEMBL310555,MCJGNVYPOGVAJF-UHFFFAOYSA-N,OXYQUINOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)O)N=CC=C2,Oc1cccc2cccnc12
2100,CHEMBL310555,MCJGNVYPOGVAJF-UHFFFAOYSA-N,OXYQUINOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C1)O)N=CC=C2,Oc1cccc2cccnc12
2101,CHEMBL1923729,MCNAJLPLCULBOJ-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22014551.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Synthesis and evaluation of pyridone-phenoxypropyl-R-2-methylpyrrolidine analogues as histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CN(C(=O)C=C3)C,C[C@@H]1CCCN1CCCOc1ccc(-c2ccc(=O)n(C)c2)cc1
2105,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
2106,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.5,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
2107,CHEMBL1935444,MCVGJQYUOLRXOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.200659450546419,CC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,Cc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
2108,CHEMBL1091790,MDTGYTUAMOVSAG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,23000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.638272163982408,CC(C1=CC=NC=C1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccncc1)c1c(CCN(C)C)sc2ccccc12
2109,CHEMBL272702,MDWSQWMMLXSJIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OCCN6C(=O)C,CC(=O)N1CCOc2cc3c(cc21)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
2111,CHEMBL1536,MECHNRXZTMCUDQ-RKHKHRCZSA-N,ERGOCALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C
2112,CHEMBL1536,MECHNRXZTMCUDQ-RKHKHRCZSA-N,ERGOCALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C
2113,CHEMBL2413154,MEKSQRMXWZHFIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17221184.0,Ki,=,1030.0,NM,,,,,,,,,,,,,,,,,,,,5.987162775294827,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC=C3OC,COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1
2114,CHEMBL2413154,MEKSQRMXWZHFIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23816046.0,Ki,=,1030.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),"Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.",Bioorg. Med. Chem.,PUBLICATION,,5.987162775294827,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC=C3OC,COc1ccccc1N1CCN(CCCCn2ncc(=O)n(C)c2=O)CC1
2115,CHEMBL24,METKIMKYRPQLGS-UHFFFAOYSA-N,ATENOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
2116,CHEMBL24,METKIMKYRPQLGS-UHFFFAOYSA-N,ATENOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O,CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
2117,CHEMBL1222626,MEWLTRGECZFZDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,C1CN(CCN1C2CC(C2)C(=O)O)C3=CC4=CC=CC=C4CN5C3=NC=C5,O=C(O)C1CC(N2CCN(C3=Cc4ccccc4Cn4ccnc43)CC2)C1
2118,CHEMBL1222626,MEWLTRGECZFZDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,C1CN(CCN1C2CC(C2)C(=O)O)C3=CC4=CC=CC=C4CN5C3=NC=C5,O=C(O)C1CC(N2CCN(C3=Cc4ccccc4Cn4ccnc43)CC2)C1
2119,CHEMBL972,MEZLKOACVSPNER-GFCCVEGCSA-N,SELEGILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C#CCN(C)[C@H](C)Cc1ccccc1
2120,CHEMBL972,MEZLKOACVSPNER-GFCCVEGCSA-N,SELEGILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CC1=CC=CC=C1)N(C)CC#C,C#CCN(C)[C@H](C)Cc1ccccc1
2121,CHEMBL569,MFDFERRIHVXMIY-UHFFFAOYSA-N,PROCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,CCN(CC)CCOC(=O)c1ccc(N)cc1
2122,CHEMBL569,MFDFERRIHVXMIY-UHFFFAOYSA-N,PROCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCOC(=O)C1=CC=C(C=C1)N,CCN(CC)CCOC(=O)c1ccc(N)cc1
2124,CHEMBL2171033,MFJWXRIWIGLCGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC=C4,O=C(NS(=O)(=O)c1ccccc1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
2125,CHEMBL2030624,MFKYGKXYJBKSQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CN2C3CCC2CC3)OC,COc1ccc(CN2C3CCC2CC3)cc1OC
2126,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
2127,CHEMBL289469,MFWNKCLOYSRHCJ-UHFFFAOYSA-N,GRANISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C,CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2
2128,CHEMBL1086105,MGPIMNVSULKFFK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20452213.0,EC50,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in human SK-N-MC cells,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)OCCCN2CCC3=C(C2)NC=N3)C4=NC5=C(N4)C=CC(=C5C)F,Cc1cc(OCCCN2CCc3nc[nH]c3C2)ccc1-c1nc2c(C)c(F)ccc2[nH]1
2131,CHEMBL2207667,MHAQTEBGBYFXKL-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,251.19,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,C1CN(CCC1OC2=C(C(=C(C=C2)Cl)Cl)C(=O)N)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O,NC(=O)c1c(OC2CCN(C[C@H](O)CNC(=O)c3c[nH]c(=O)c4ccccc34)CC2)ccc(Cl)c1Cl
2132,CHEMBL268258,MHPMXTGKTXJIDI-IBGZPJMESA-N,A-80426,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,CN(CCC1=CC2=C(C=C1)C=CO2)C[C@@H]3CCCC4=C3C=CC=C4OC,COc1cccc2c1CCC[C@H]2CN(C)CCc1ccc2ccoc2c1
2133,CHEMBL1687,MHXYWXHKLBMJKL-QBYKQQEBSA-N,TUBOCURARINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.[Cl-],COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
2134,CHEMBL1687,MHXYWXHKLBMJKL-QBYKQQEBSA-N,TUBOCURARINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC2=CC(=C3C=C2[C@@H]1CC4=CC=C(C=C4)OC5=C6[C@@H](CC7=CC(=C(C=C7)O)O3)[N+](CCC6=CC(=C5O)OC)(C)C)OC.[Cl-],COc1cc2c3cc1Oc1cc(ccc1O)C[C@@H]1c4c(cc(OC)c(O)c4Oc4ccc(cc4)C[C@@H]3N(C)CC2)CC[N+]1(C)C
2135,CHEMBL407030,MIFVTYPADKEWAV-HGRQBIKSSA-N,GAMMA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)O)OC6[C@H](OC([C@@H]([C@H]6O)O)C7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CO)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1OC2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)OC(OC9[C@@H](CO)OC(C1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
2136,CHEMBL407030,MIFVTYPADKEWAV-HGRQBIKSSA-N,GAMMA-CYCLODEXTRIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](OC([C@@H]([C@H]5O)O)OC6[C@H](OC([C@@H]([C@H]6O)O)C7[C@H](OC([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@@H]([C@@H]([C@H]8O)O)O[C@@H]9[C@H](O[C@H](O2)[C@@H]([C@H]9O)O)CO)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1OC2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)OC(OC9[C@@H](CO)OC(C1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
2137,CHEMBL340978,MITFXPHMIHQXPI-UHFFFAOYSA-N,BENOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
2138,CHEMBL340978,MITFXPHMIHQXPI-UHFFFAOYSA-N,BENOXAPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O,CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1
2139,CHEMBL2030633,MIZXZRHARATZMK-UHFFFAOYSA-N,"N-(3,4-DIMETHOXYBENZYL)PYRROLIDINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CN2CCCC2)OC,COc1ccc(CN2CCCC2)cc1OC
2141,CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
2142,CHEMBL480,MJIHNNLFOKEZEW-UHFFFAOYSA-N,LANSOPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F,Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1
2143,CHEMBL305660,MJJALKDDGIKVBE-UHFFFAOYSA-N,EBASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,28.3,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.548213564475709,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
2144,CHEMBL305660,MJJALKDDGIKVBE-UHFFFAOYSA-N,EBASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3.29,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.482804102050025,CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN2CCC(CC2)OC(C3=CC=CC=C3)C4=CC=CC=C4,CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1
2145,CHEMBL322873,MJKGHXXXMDVBEW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5600045260461926,CC1CCCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,CC1CCCN(CCCOc2ccc(-c3ccc(C#N)cc3)cc2)C1
2146,CHEMBL476839,MJKRYUCQHJLOIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,439.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.357535479757877,CC1=CC=C(C=C1)CCN2CCC(CC2)C(C3=C(C(=CC=C3)OCCF)OC)O,COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(C)cc2)CC1
2147,CHEMBL402087,MJLHCRFMFPSGBF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(C)(C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C(C)(C)C)oc6c(C)c5CC4)n3C)cccc2n1
2152,CHEMBL563647,MKKJPIHSAMRGEO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,41.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.387216143280264,CCC(C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O,CCC(C(=O)O)c1ccc2c(c1)N(CCCN1CCCN(c3cc(=O)n(C)c(=O)n3C)CC1)c1ccccc1S2
2153,CHEMBL184,MKUXAQIIEYXACX-UHFFFAOYSA-N,ACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Nc1nc2c(ncn2COCCO)c(=O)[nH]1
2154,CHEMBL184,MKUXAQIIEYXACX-UHFFFAOYSA-N,ACYCLOVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1COCCO)N=C(NC2=O)N,Nc1nc2c(ncn2COCCO)c(=O)[nH]1
2155,CHEMBL806,MKXKFYHWDHIYRV-UHFFFAOYSA-N,FLUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
2156,CHEMBL806,MKXKFYHWDHIYRV-UHFFFAOYSA-N,FLUTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
2157,CHEMBL52440,MKXZASYAUGDDCJ-NJAFHUGGSA-N,DEXTROMETHORPHAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
2158,CHEMBL52440,MKXZASYAUGDDCJ-NJAFHUGGSA-N,DEXTROMETHORPHAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CC[C@@]23CCCC[C@@H]2[C@@H]1CC4=C3C=C(C=C4)OC,COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3
2159,CHEMBL271072,MLGRCKZMFCALCK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCCCN4CCc5cc6nc(C)oc6c(Br)c5CC4)n3C)cccc2n1
2160,CHEMBL15770,MLKXDPUZXIRXEP-MFOYZWKCSA-N,SULINDAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
2161,CHEMBL15770,MLKXDPUZXIRXEP-MFOYZWKCSA-N,SULINDAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc([S+](C)[O-])cc1
2163,CHEMBL256473,MMAVGOXTOMTHGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C(C)(F)F)oc6cc5CC4)n3C)cccc2n1
2164,CHEMBL83073,MMEQHMVQEKIHIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,37.15,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.430041181903406,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)C(F)(F)F,CN(C)CC1CC2c3cccc(C(F)(F)F)c3Cc3ccccc3N2O1
2166,CHEMBL561377,MMKZIPYPZZNRTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,53.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.275724130399211,CN1C(=CC(=O)N(C1=O)C)N(C)CCCN2CCC(CC2)CN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O,CN(CCCN1CCC(CN2c3ccccc3Sc3ccc(C(=O)O)cc32)CC1)c1cc(=O)n(C)c(=O)n1C
2168,CHEMBL238871,MMRPNJJCBOGWTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O,O=C(c1cc(F)cc(F)c1)N1CCN(c2ccc(OCCCN3CCCCCC3)cc2)C(=O)C1
2169,CHEMBL1923531,MMWJPRSBOSCWBE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,4168.69,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.380000399499542,C1CCN(CC1)CCN2C3=CC=CC=C3N4C2=NC=N4,c1ccc2c(c1)n(CCN1CCCCC1)c1ncnn21
2170,CHEMBL560120,MMXKXXGRZUAQGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,28.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.552841968657781,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl,Cn1c(NCCCN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)cc(=O)n(C)c1=O
2171,CHEMBL560120,MMXKXXGRZUAQGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,58.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.236572006437062,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl,Cn1c(NCCCN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)cc(=O)n(C)c1=O
2174,CHEMBL93645,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,ACECLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
2175,CHEMBL93645,MNIPYSSQXLZQLJ-UHFFFAOYSA-N,ACECLOFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)CC(=O)OCC(=O)O)NC2=C(C=CC=C2Cl)Cl,O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl
2176,CHEMBL539093,MNOZJGDIRIYZSQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.4999996786570655,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)Cl.Cl,CC(C)N1CCC(Oc2ccc(N3CCN(C(=O)c4ccc(Cl)cc4)CC3=O)cc2)CC1
2177,CHEMBL2158828,MNSGCVNHLLGCDG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4OCC(=O)O,O=C(O)COc1ccccc1N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
2178,CHEMBL2207643,MNVDCQLMHFFYCU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC=CC=C1N2CCN(CC2)CC3=C4C=CC=CC=C4C=C3,COc1ccccc1N1CCN(Cc2ccc3cccccc2-3)CC1
2180,CHEMBL2208418,MNXRFTOYSSFEST-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,316.23,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.499996931948306,C1CN(CCC1NC[C@@H](COC2=CC3=C(C=C2)N=CS3)O)CC4=CC(=C(C=C4)Cl)Cl,O[C@@H](CNC1CCN(Cc2ccc(Cl)c(Cl)c2)CC1)COc1ccc2ncsc2c1
2181,CHEMBL3357041,MOFVGVFZWIHAPO-DUXPYHPUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,153.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.815308569182402,C/C=C/C(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,C/C=C/C(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
2182,CHEMBL2158780,MOHMWXTYADLKCG-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O,Cc1cc(Cl)ccc1OC1CCN(CC2CCN([C@@H](Cc3ccc(F)cc3)C(=O)O)CC2)CC1
2186,CHEMBL3321790,MPWWGTFDWDZHRM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,977.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.010105436281228,C1CC2CC(CC1N2CCCSC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccc(F)cc1
2187,CHEMBL1632411,MQAUVLYNYCPXHD-ICFOKQHNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC(CC1)/C(=N/O)/C2=CC3=CC=CC=C3N2,CN1CCC(/C(=N/O)c2cc3ccccc3[nH]2)CC1
2188,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
2189,CHEMBL529,MQTOSJVFKKJCRP-BICOPXKESA-N,AZITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O
2190,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,4000.0,NM,,,,,,,,,,,,,,,,,,,,5.3979400086720375,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
2191,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,316227.77,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,3.4999999945296856,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
2192,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
2193,CHEMBL597,MRBDMNSDAVCSSF-UHFFFAOYSA-N,PHENTOLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O,Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1
2195,CHEMBL62066,MRYDVIQPLWEQDJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1659.59,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.779999190713338,CCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)CC)cc2)CC1
2196,CHEMBL330367,MRZJFWSFVDADTA-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,158.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.801342913045577,CCOC1=CC(=CC(=C1OCC)OCC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)OC)OC.C(=C/C(=O)O)\C(=O)O,CCOc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(OC)c(OC)c3)C2)cc(OCC)c1OCC
2197,CHEMBL1669418,MSDXVUCMHKOWGT-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,8.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.09151498112135,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CO4,C[C@H](C1=C(CCN(C)Cc2ccco2)Cc2ccccc21)c1cnccn1
2200,CHEMBL1669406,MSMKOTVNTGCTFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,41.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.387216143280264,CCCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CCCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
2201,CHEMBL65849,MSNSHZJXNNLNOS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,7696.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.113734940970243,CN(C)CCCNC1=C2CCCCCC2=NC3=CC=CC=C31,CN(C)CCCNc1c2c(nc3ccccc13)CCCCC2
2202,CHEMBL1093607,MSPFRPWEGPBFTC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,122.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.9136401693252525,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)N3C=CN=C3,CC(c1c(CCN(C)C)sc2ccccc12)n1ccnc1
2203,CHEMBL84931,MSQRTETUBFIHMP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,2.57,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.590066876668706,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)F,CN(C)CC1CC2c3ccccc3Cc3ccc(F)cc3N2O1
2208,CHEMBL116735,MUAYITOFLINYIL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1660.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.779891911959945,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCC4=CC=C(C=C4)F,O=C(CCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
2209,CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
2210,CHEMBL386630,MUMGGOZAMZWBJJ-DYKIIFRCSA-N,TESTOSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
2211,CHEMBL2207282,MUPZZNZQFUCJBT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)N)O,NS(=O)(=O)c1ccc2c(C(=O)NC[C@@H](O)CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)c[nH]c(=O)c2c1
2212,CHEMBL1200845,MUQNGPZZQDCDFT-JNQJZLCISA-N,HALCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
2213,CHEMBL1200845,MUQNGPZZQDCDFT-JNQJZLCISA-N,HALCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CCl)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CCl)O1
2214,CHEMBL2037608,MURCULVYVOMYIO-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22578490.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Synthesis and evaluation of 4- and 5-pyridazin-3-one phenoxypropylamine analogues as histamine-3 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=CC(=O)N(N=C3)COC,COCn1ncc(-c2ccc(OCCCN3CCC[C@H]3C)cc2)cc1=O
2215,CHEMBL1194,MVFGUOIZUNYYSO-UHFFFAOYSA-N,PRILOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(C)C(=O)NC1=CC=CC=C1C,CCCNC(C)C(=O)Nc1ccccc1C
2216,CHEMBL1194,MVFGUOIZUNYYSO-UHFFFAOYSA-N,PRILOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(C)C(=O)NC1=CC=CC=C1C,CCCNC(C)C(=O)Nc1ccccc1C
2217,CHEMBL488025,MVGSNCBCUWPVDA-MFOYZWKCSA-N,EXISULIND,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)(=O)=O)cc1
2218,CHEMBL488025,MVGSNCBCUWPVDA-MFOYZWKCSA-N,EXISULIND,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC\1=C(C2=C(/C1=C\C3=CC=C(C=C3)S(=O)(=O)C)C=CC(=C2)F)CC(=O)O,CC1=C(CC(=O)O)c2cc(F)ccc2/C1=C\c1ccc(S(C)(=O)=O)cc1
2219,CHEMBL476108,MVKKLGNVARQKRP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,188.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.724458311598691,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
2220,CHEMBL564226,MVMQESMQSYOVGV-HNNXBMFYSA-N,(S)-(+)-DIMETHINDENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,0.4370000000000001,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,9.359518563029578,C[C@@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1
2221,CHEMBL564226,MVMQESMQSYOVGV-HNNXBMFYSA-N,(S)-(+)-DIMETHINDENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,0.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,9.397940008672037,C[C@@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C,C[C@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1
2222,CHEMBL1493369,MVMQESMQSYOVGV-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,69.18,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.160019442321657,C[C@H](C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C,C[C@@H](C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1
2223,CHEMBL22108,MVMQESMQSYOVGV-UHFFFAOYSA-N,DIMETHINDENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,0.6920000000000001,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,9.159893905543242,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)C,CC(C1=C(CCN(C)C)Cc2ccccc21)c1ccccn1
2224,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,,,,,,7.823908740944319,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
2225,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,4.6,NM,,,,,,,,,,,,,,,,,,,,8.337242168318426,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
2226,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,510.0,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,6.292429823902062,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
2227,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,43.0,NM,,,,,,,,,,,,,,,,,,,,7.366531544420414,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
2228,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,5.3,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.275724130399214,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
2229,CHEMBL708,MVWVFYHBGMAFLY-UHFFFAOYSA-N,ZIPRASIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,47.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,7.327902142064282,C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54,O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1
2232,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,,,,Not Determined,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells; not tested,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,CC(c1cc2ccccc2s1)N(O)C(N)=O
2233,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,CC(c1cc2ccccc2s1)N(O)C(N)=O
2234,CHEMBL93,MWLSOWXNZPKENC-UHFFFAOYSA-N,ZILEUTON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O,CC(c1cc2ccccc2s1)N(O)C(N)=O
2237,CHEMBL3238447,MXRUKGSLFINORK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,2238.72,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.650000220873455,C1CCN(CC1)CCCOC2=CC=C(C=C2)CN3C(=O)C(NC3=O)(C4=CC=CC=C4)C5=CC=CC=C5,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1Cc1ccc(OCCCN2CCCCC2)cc1
2238,CHEMBL271632,MXYJVPGKILUPBU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)SC(=N6)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C)sc6cc5CC4)n3C)cccc2n1
2239,CHEMBL2103769,MXYUKLILVYORSK-HKBOAZHASA-N,LOBELINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,44668.36,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,4.349999992368662,CN1[C@H](CCC[C@H]1CC(=O)C2=CC=CC=C2)C[C@@H](C3=CC=CC=C3)O,CN1[C@H](CC(=O)c2ccccc2)CCC[C@@H]1C[C@H](O)c1ccccc1
2240,CHEMBL600325,MYEJFUXQJGHEQK-ALRJYLEOSA-N,PROSCILLARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,C[C@@H]1O[C@@H](O[C@@H]2C=C3CC[C@@H]4[C@H](CC[C@]5(C)[C@@H](c6ccc(=O)oc6)CC[C@]45O)[C@@]3(C)CC2)[C@H](O)[C@H](O)[C@H]1O
2241,CHEMBL600325,MYEJFUXQJGHEQK-ALRJYLEOSA-N,PROSCILLARIDIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@H]2CC[C@@]3([C@H]4CC[C@@]5([C@H](CC[C@@]5([C@@H]4CCC3=C2)O)C6=COC(=O)C=C6)C)C)O)O)O,C[C@@H]1O[C@@H](O[C@@H]2C=C3CC[C@@H]4[C@H](CC[C@]5(C)[C@@H](c6ccc(=O)oc6)CC[C@]45O)[C@@]3(C)CC2)[C@H](O)[C@H](O)[C@H]1O
2242,CHEMBL262777,MYPYJXKWCTUITO-LYRMYLQWSA-N,VANCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
2243,CHEMBL262777,MYPYJXKWCTUITO-LYRMYLQWSA-N,VANCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H]([C@H](C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9O)O)[C@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)CO)O)O)(C)N)O,CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
2244,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
2245,CHEMBL8,MYSWGUAQZAJSOK-UHFFFAOYSA-N,CIPROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O,O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
2247,CHEMBL417215,MYYDLAXWFPHASV-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9332.54,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.030000139977383,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=C(C=C4)F)N,N[C@H](Cc1ccc(F)cc1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
2250,CHEMBL2205815,MYZBXDLMEOAPIJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC8=C(C=C7)OCO8)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccc2c(c1)OCO2
2251,CHEMBL2158788,MYZGZNJBQOQRTJ-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=CC=C4)C(=O)O,Cc1c(OC2CCN(CC3CCN([C@@H](Cc4ccccc4)C(=O)O)CC3)CC2)ccc(Cl)c1Cl
2252,CHEMBL1095699,MZZGOOYMKKIOOX-VKHMYHEASA-N,AZASERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-],[N-]=[N+]=CC(=O)OC[C@H](N)C(=O)O
2253,CHEMBL1095699,MZZGOOYMKKIOOX-VKHMYHEASA-N,AZASERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H](C(=O)O)N)OC(=O)C=[N+]=[N-],[N-]=[N+]=CC(=O)OC[C@H](N)C(=O)O
2254,CHEMBL257717,NAFIXABLSKOHPB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=CC2=NC3=C(N2C=C1)CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C,Cc1ccn2c3c(nc2c1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
2255,CHEMBL558339,NAGKIWFBALBSMD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,59.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.226945306635737,C1CN(CCC1N2C=CC=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(n4cccc4)CC3)nc3ccccc32)cc1
2256,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,4.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,8.397940008672037,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12
2257,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,4000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3979400086720375,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12
2258,CHEMBL564144,NANQRVOKMXDMNL-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12
2259,CHEMBL1090433,NANQRVOKMXDMNL-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,IC50,=,256000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,3.5917600346881504,C[C@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@H](c1ccccn1)c1c(CCN(C)C)sc2ccccc12
2260,CHEMBL1090432,NANQRVOKMXDMNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,12.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.920818753952375,CC(C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1ccccn1)c1c(CCN(C)C)sc2ccccc12
2262,CHEMBL157328,NAQBCIUOBUOYRD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,79432823472428.2,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.9,C1=CC(=CC(=C1)C(F)(F)F)C2=NC(=CS2)CCN,NCCc1csc(-c2cccc(C(F)(F)F)c2)n1
2264,CHEMBL62115,NAVVYTVXMQUKNO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,2041.74,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.689999562814496,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=NC=CN=C3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3cnccn3)CC2)cc1
2266,CHEMBL1586,NBMKJKDGKREAPL-DVTGEIKXSA-N,BECLOMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
2267,CHEMBL1586,NBMKJKDGKREAPL-DVTGEIKXSA-N,BECLOMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)Cl)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
2268,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
2269,CHEMBL163,NCDNCNXCDXHOMX-XGKFQTDJSA-N,RITONAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=NC(=CS1)CN(C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=CC=C2)C[C@@H]([C@H](CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O,CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1
2270,CHEMBL421,NCEXYHBECQHGNR-QZQOTICOSA-N,SULFASALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
2271,CHEMBL421,NCEXYHBECQHGNR-QZQOTICOSA-N,SULFASALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O,O=C(O)c1cc(N=Nc2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O
2274,CHEMBL1200656,NCXMLFZGDNKEPB-FFPOYIOWSA-N,NATAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O
2275,CHEMBL1200656,NCXMLFZGDNKEPB-FFPOYIOWSA-N,NATAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@@H]3[C@H](O3)/C=C/C(=O)O1)O)O)O)C(=O)O)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)C)O)N)O,C[C@@H]1C/C=C/C=C/C=C/C=C/[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N)[C@@H]2O)C[C@@H]2O[C@](O)(C[C@@H](O)C[C@H]3O[C@@H]3/C=C/C(=O)O1)C[C@H](O)[C@H]2C(=O)O
2276,CHEMBL714,NDAUXUAQIAJITI-UHFFFAOYSA-N,ALBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
2277,CHEMBL714,NDAUXUAQIAJITI-UHFFFAOYSA-N,ALBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1
2278,CHEMBL406,NDDAHWYSQHTHNT-UHFFFAOYSA-N,INDAPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
2279,CHEMBL406,NDDAHWYSQHTHNT-UHFFFAOYSA-N,INDAPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N,CC1Cc2ccccc2N1NC(=O)c1ccc(Cl)c(S(N)(=O)=O)c1
2281,CHEMBL475621,NDEWHFAPFGGMKU-UHFFFAOYSA-N,UR-PI294,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,3467.37,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.459999812689,CCC(=O)NC(=NCCCC1=CN=CN1)N,CCC(=O)NC(N)=NCCCc1cnc[nH]1
2284,CHEMBL187637,NDNBZMHADGKSLT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,295.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5301779840218375,C1CN(CCN1CCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,NC(=O)N(O)CCC#Cc1ccc(OCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2285,CHEMBL578170,NDWXGJDJKXDMOV-HDICACEKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,170.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.769551078621726,CC1=CC=C(C=C1)C(=O)NC2CCC(CC2)NC3=NC=C(C(=N3)N(C)C)C,Cc1ccc(C(=O)NC2CCC(Nc3ncc(C)c(N(C)C)n3)CC2)cc1
2286,CHEMBL2207661,NDXPOARUSJMOJN-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.899974269892138,C1CC1C2=C(C=NN2)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1cn[nH]c1C1CC1
2287,CHEMBL214312,NESASFDNMLPZIR-KBPBESRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)CNCC[C@H]2C[C@@H]2C3=CN=CN3,c1ncc([C@H]2C[C@@H]2CCNCC2CCCCC2)[nH]1
2288,CHEMBL214312,NESASFDNMLPZIR-KBPBESRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,IC50,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human H1 receptor expressed in 293-EBNA cells assessed as inhibition of histamine agonist activity by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)CNCC[C@H]2C[C@@H]2C3=CN=CN3,c1ncc([C@H]2C[C@@H]2CCNCC2CCCCC2)[nH]1
2289,CHEMBL895,NETZHAKZCGBWSS-CEDHKZHLSA-N,NALBUPHINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
2290,CHEMBL895,NETZHAKZCGBWSS-CEDHKZHLSA-N,NALBUPHINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(C1)CN2CC[C@]34[C@@H]5[C@H](CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O)O,Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314
2291,CHEMBL325516,NEUFWHZAVWYYSZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1280.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.892790030352131,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)OCCC4=CC=C(C=C4)F,O=C(OCCc1ccc(F)cc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
2292,CHEMBL711,NFBAXHOPROOJAW-UHFFFAOYSA-N,PHENINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,O=C1c2ccccc2C(=O)C1c1ccccc1
2293,CHEMBL711,NFBAXHOPROOJAW-UHFFFAOYSA-N,PHENINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,O=C1c2ccccc2C(=O)C1c1ccccc1
2294,CHEMBL113956,NFBNIRNKYJTDIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1820.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.739928612014924,CCOC1=CC=C(C=C1)CCNC(=O)N2CCN(CC2)CCCC(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,CCOc1ccc(CCNC(=O)N2CCN(CCCC(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2296,CHEMBL1200406,NFLLKCVHYJRNRH-UHFFFAOYSA-N,DIMENHYDRINATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,319.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.496209316942818,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
2297,CHEMBL1200406,NFLLKCVHYJRNRH-UHFFFAOYSA-N,DIMENHYDRINATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,37.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.431798275933005,CN1C2=C(C(=O)N(C1=O)C)NC(=N2)Cl.CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
2298,CHEMBL577904,NFQWOMAFZMZYOX-FZNQNYSPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,920.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.036212172654443,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)CNC(=O)C3=CC(=C(C=C3)F)F,Cc1cnc(NC2CCC(CNC(=O)c3ccc(F)c(F)c3)CC2)nc1N(C)C
2300,CHEMBL24665,NFUYVKMAGIJYKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.0,C1=CC(=CC(=C1)C(F)(F)F)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(C(F)(F)F)c2)[nH]1
2301,CHEMBL24665,NFUYVKMAGIJYKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1=CC(=CC(=C1)C(F)(F)F)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(C(F)(F)F)c2)[nH]1
2302,CHEMBL24665,NFUYVKMAGIJYKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,251.19,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,C1=CC(=CC(=C1)C(F)(F)F)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(C(F)(F)F)c2)[nH]1
2304,CHEMBL1148,NGBFQHCMQULJNZ-UHFFFAOYSA-N,TORSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
2305,CHEMBL1148,NGBFQHCMQULJNZ-UHFFFAOYSA-N,TORSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C,Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1
2306,CHEMBL2158779,NHOMRPYETSURDH-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1CN2CCC(CC2)OC3=C(C=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)F)C(=O)O,O=C(O)[C@H](Cc1ccc(F)cc1)N1CCC(CN2CCC(Oc3ccc(Cl)cc3Cl)CC2)CC1
2307,CHEMBL1200862,NHTGHBARYWONDQ-JTQLQIEISA-N,METYROSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)cc1)C(=O)O
2308,CHEMBL1200862,NHTGHBARYWONDQ-JTQLQIEISA-N,METYROSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N,C[C@](N)(Cc1ccc(O)cc1)C(=O)O
2309,CHEMBL453,NHUHCSRWZMLRLA-UHFFFAOYSA-N,SULFISOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C
2310,CHEMBL453,NHUHCSRWZMLRLA-UHFFFAOYSA-N,SULFISOXAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(ON=C1C)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C
2313,CHEMBL109,NIJJYAXOARWZEE-UHFFFAOYSA-N,VALPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(CCC)C(=O)O,CCCC(CCC)C(=O)O
2314,CHEMBL109,NIJJYAXOARWZEE-UHFFFAOYSA-N,VALPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC(CCC)C(=O)O,CCCC(CCC)C(=O)O
2315,CHEMBL1774501,NIKHLOHBEKSSNM-LIMNOBDPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,540.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.267606240177032,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C/3\C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCN(CC/C=C3\c4ccccc4COc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2316,CHEMBL1774500,NIKHLOHBEKSSNM-NYAPKIOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,84.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.075720713938117,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCN(CC/C=C3/c4ccccc4COc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2321,CHEMBL486962,NJDNYPJEXDZZKT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC=C(C=C1)CCCC(=O)NC(=NCCCC2=CN=CN2)N,NC(=NCCCc1cnc[nH]1)NC(=O)CCCc1ccccc1
2323,CHEMBL406678,NJIAHBGDDDILFN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=CC=CC6=N5,Cc1ccc2c(-c3nnc(SCCCN4CCc5nc6ccccn6c5CC4)n3C)cccc2n1
2324,CHEMBL322678,NJOYBVVACVXAAZ-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,91000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.040958607678906,CN1C=C(N=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,Cn1cnc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)c1
2325,CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
2326,CHEMBL83,NKANXQFJJICGDU-QPLCGJKRSA-N,TAMOXIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3,CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1
2328,CHEMBL1946126,NLEQSFUEJXECJY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,509.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.293282217663242,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCOC3=CC=C(C=C3)F,Fc1ccc(OCCCN2CCCN(c3ccc(Cl)cc3)CC2)cc1
2330,CHEMBL1747,NLVFBUXFDBBNBW-PBSUHMDJSA-N,TOBRAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
2331,CHEMBL1747,NLVFBUXFDBBNBW-PBSUHMDJSA-N,TOBRAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H](C[C@@H]([C@H](O3)CN)O)N)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
2332,CHEMBL563055,NMEALLMQARPNTN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,14.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.85078088734462,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2N4CCC(CC4)NCC5CCOCC5,COc1ccc(Cn2c(N3CCC(NCC4CCOCC4)CC3)nc3ccccc32)cc1
2334,CHEMBL2158777,NMLHPAJBQUFHAV-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC(=CC=C4)C(F)(F)F)C(=O)O,O=C(O)[C@H](Cc1cccc(C(F)(F)F)c1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
2335,CHEMBL104808,NMOWFTXQHLZDDV-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,9200.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0362121726544435,C1CN(C[C@H]1NS(=O)(=O)C2=CC=C(C=C2)F)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3ccc(F)cc3)C2)cc1)C1CC1
2336,CHEMBL59798,NMTPIRAMYOPHIO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,457.09,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3399982798971175,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CC(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(CC(C)C)CC2)cc1
2337,CHEMBL1489,NMUSYJAQQFHJEW-KVTDHHQDSA-N,AZACITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
2338,CHEMBL1489,NMUSYJAQQFHJEW-KVTDHHQDSA-N,AZACITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N,Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1
2339,CHEMBL462605,NNACHAUCXXVJSP-UHFFFAOYSA-N,TIPROLISANT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,1148.15,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.940001369850307,C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl,Clc1ccc(CCCOCCCN2CCCCC2)cc1
2340,CHEMBL28607,NNGCXJPRHBHODU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4,COc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
2341,CHEMBL79,NNJVILVZKWQKPM-UHFFFAOYSA-N,LIDOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CCN(CC)CC(=O)Nc1c(C)cccc1C
2342,CHEMBL79,NNJVILVZKWQKPM-UHFFFAOYSA-N,LIDOCAINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC(=O)NC1=C(C=CC=C1C)C,CCN(CC)CC(=O)Nc1c(C)cccc1C
2343,CHEMBL622,NNYBQONXHNTVIJ-UHFFFAOYSA-N,ETODOLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
2344,CHEMBL622,NNYBQONXHNTVIJ-UHFFFAOYSA-N,ETODOLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2C(=CC=C1)C3=C(N2)C(OCC3)(CC)CC(=O)O,CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3
2345,CHEMBL394015,NOBSINPJDRJYCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F,O=C(c1cc(F)cc(F)c1)N1CCN(c2ccc(OCCCN3CCCC3)cc2)C(=O)C1
2348,CHEMBL757,NPAGDVCDWIYMMC-IZPLOLCNSA-N,NANDROLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O
2349,CHEMBL757,NPAGDVCDWIYMMC-IZPLOLCNSA-N,NANDROLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@H]34,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O
2350,CHEMBL3039597,NPEFREDMMVQEPL-RWPARATISA-N,GENTAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1
2351,CHEMBL3039597,NPEFREDMMVQEPL-RWPARATISA-N,GENTAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)N.CC([C@@H]1CC[C@H]([C@H](O1)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@](CO3)(C)O)NC)O)N)N)N)NC.C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC[C@H](O3)CN)N)N)N)O,CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1
2352,CHEMBL57,NQDJXKOVJZTUJA-UHFFFAOYSA-N,NEVIRAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1
2353,CHEMBL57,NQDJXKOVJZTUJA-UHFFFAOYSA-N,NEVIRAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4,Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1
2354,CHEMBL238503,NQEWRKQNDSWJNM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=NC=C4.C(=O)O,O=C(c1ccncc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
2355,CHEMBL418691,NQLCAHXYVYXKBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,812.83,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.090000275786017,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)OC,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)c3ccc(OC)cc3)cc2)CC1
2357,CHEMBL2171026,NQTXEWZDVUMZDO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=C(C=C4)C5=NNN=N5,O=C(c1ccc(-c2nn[nH]n2)cc1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
2358,CHEMBL62050,NQVNEFLFZVEJSK-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,13489.63,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.869999962200743,CN[C@H](CC1=CC=CC=C1)C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,CN[C@H](Cc1ccccc1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
2359,CHEMBL291394,NQWIESOLCWAUTM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,478.63,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.320000083770781,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=NC=C3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3ccncc3)CC2)cc1
2360,CHEMBL1177,NRNCYVBFPDDJNE-UHFFFAOYSA-N,PEMOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,NC1=NC(=O)C(c2ccccc2)O1
2361,CHEMBL1177,NRNCYVBFPDDJNE-UHFFFAOYSA-N,PEMOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2C(=O)N=C(O2)N,NC1=NC(=O)C(c2ccccc2)O1
2362,CHEMBL1092650,NRNPLYWFPSCQAF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.5,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.823908740944319,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3OC,COc1nccnc1CC1=C(CCN(C)C)Cc2cc(Cl)ccc21
2363,CHEMBL256015,NRQJARQPULKWBG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C(C)C)oc6cc5CC4)n3C)cccc2n1
2365,CHEMBL1940418,NSMCYUMPIGJKHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,167.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.777283528852418,C1CN(CCN1CCCCC2=CC=C(C=C2)F)C3=CC=CC=N3,Fc1ccc(CCCCN2CCN(c3ccccn3)CC2)cc1
2366,CHEMBL256658,NSOOFJHAXVGHFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=CN2C3=C(CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)N=C2C=C1,Cc1ccc2nc3c(n2c1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
2367,CHEMBL1222552,NSRMKMSTPLJNHM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,0.631,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.199970640755863,C1CN(CCN1)C2=CC3=CC=CC=C3CN4C2=NC=C4,C1=C(N2CCNCC2)c2nccn2Cc2ccccc21
2368,CHEMBL96471,NTBSVMCWAHSWAK-YLOCQQLVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,29.7,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.527243550682787,C1CN(CCC1C2=CC=CC=C2)CC3C[C@H]4[C@H](O3)C5=CC=CC=C5CC6=CC=CC=C46,c1ccc(C2CCN(CC3C[C@@H]4c5ccccc5Cc5ccccc5[C@H]4O3)CC2)cc1
2369,CHEMBL195437,NTDQQZYCCIDJRK-UHFFFAOYSA-N,4-OCTYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCc1ccc(O)cc1
2370,CHEMBL195437,NTDQQZYCCIDJRK-UHFFFAOYSA-N,4-OCTYLPHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCCCCC1=CC=C(C=C1)O,CCCCCCCCc1ccc(O)cc1
2371,CHEMBL1096428,NTHUVTORAXKPJS-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,6165.95,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.210000001311122,C[C@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2=CC=CC=C2,C[C@H](CC(=O)NC(N)=NCCCc1cnc[nH]1)c1ccccc1
2381,CHEMBL1096429,NTHUVTORAXKPJS-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,831.76,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.080001969035981,C[C@@H](CC(=O)NC(=NCCCC1=CN=CN1)N)C2=CC=CC=C2,C[C@@H](CC(=O)NC(N)=NCCCc1cnc[nH]1)c1ccccc1
2383,CHEMBL243712,NTJOBXMMWNYJFB-UHFFFAOYSA-N,AMISULPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19337725.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCN1CCCC1CNC(=O)C2=CC(=C(C=C2OC)N)S(=O)(=O)CC,CCN1CCCC1CNC(=O)c1cc(S(=O)(=O)CC)c(N)cc1OC
2384,CHEMBL534512,NTMBNTAWSSELPH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)Cl.Cl,O=C(c1ccc(Cl)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
2385,CHEMBL2205830,NTRDOPDLDNCOHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=CC(=C1OC)OC)CN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc(OC)c1OC
2386,CHEMBL2205830,NTRDOPDLDNCOHJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,COC1=CC(=CC(=C1OC)OC)CN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc(OC)c1OC
2389,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2390,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,1258.92,NM,,,,,,,,,,,,,,,,,,,,5.900001866923468,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2391,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2392,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,1258.92,NM,,,,,,,,,,,,,,,,,,,,5.900001866923468,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2393,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,,,,,,5.899998417198647,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2394,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2395,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,2060.0,NM,,,,,,,,,,,,,,,,,,,,5.6861327796308485,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2396,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,=,13.0,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,7.886056647693162,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2398,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,158.49,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.799998134593397,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2399,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,15848931924611.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.199999999999998,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2400,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,7010.0,NM,,,,,,,,,,,,,,,,,,,,5.154281982033341,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2401,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16408006.0,Ki,=,79432.82,NM,,,cell_based,,,,,COS-7,,,,,,,Displacement of [3H]mepyramine from human wild-type histamine H1 receptor expressed in COS-7 cells by liquid scintillation counting,Linking agonist binding to histamine H1 receptor activation.,Nat. Chem. Biol.,PUBLICATION,,4.100000018985305,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2402,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,190.0,NM,,,,,,,,,,,,,,,,,,,,6.721246399047171,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2403,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16942032.0,EC50,=,45.0,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in 293-EBNA cells by luciferase reporter gene assay,Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.,J. Med. Chem.,PUBLICATION,,7.346787486224656,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2404,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18950149.0,EC50,=,190.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,"Acylguanidines as bioisosteres of guanidines: NG-acylated imidazolylpropylguanidines, a new class of histamine H2 receptor agonists.",J. Med. Chem.,PUBLICATION,,6.721246399047171,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2405,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,190.55,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,6.719991046891813,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2406,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19791743.0,EC50,=,190.55,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase assay,Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.,J. Med. Chem.,PUBLICATION,,6.719991046891813,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2407,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,=,190.55,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.719991046891813,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2409,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,199.53,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2410,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25993395.0,Ki,=,6000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.,J. Med. Chem.,PUBLICATION,,5.221848749616356,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2411,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,EC50,=,190.0,NM,,,,,,,,,,,,,,,Agonist activity at human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 or RGS9 assessed as increase in 32Pi level incubated for 20 mins by liquid scintillation counting in presence of [gamma32P]GTP,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,6.721246399047171,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2412,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,EC50,=,190.55,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 preincubated for 2 mins before [gamma32P]GTP addition measured after 20 mins by steady-state GTPase activity assay,,MedChemComm,PUBLICATION,,6.719991046891813,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2413,CHEMBL90,NTYJJOPFIAHURM-UHFFFAOYSA-N,HISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,~,1000.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1=C(NC=N1)CCN,NCCc1cnc[nH]1
2415,CHEMBL154047,NTZJIQAKZMLDFO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,79432823472428.2,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.9,C1=CC=NC(=C1)CCCCCCCCCCN,NCCCCCCCCCCc1ccccn1
2417,CHEMBL2207635,NUTCIQIPIDPFOT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,1400.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.853871964321763,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)CO,COc1ccccc1N1CCN(Cc2cc(CO)c3cccccc2-3)CC1
2419,CHEMBL27769,NVKAWKQGWWIWPM-ABEVXSGRSA-N,STANOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
2420,CHEMBL27769,NVKAWKQGWWIWPM-ABEVXSGRSA-N,STANOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4O)C,C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O
2423,CHEMBL1278115,NWCYKTKORNLIRC-AVKWCDSFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.599980364934843,C1C[C@]2(CC1NCCC(=O)O)CC3=CC=CC=C3CC4=CC=CC=C24,O=C(O)CCNC1CC[C@@]2(Cc3ccccc3Cc3ccccc32)C1
2424,CHEMBL1278114,NWCYKTKORNLIRC-BPARTEKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,8.0,C1C[C@@]2(CC1NCCC(=O)O)CC3=CC=CC=C3CC4=CC=CC=C24,O=C(O)CCNC1CC[C@]2(Cc3ccccc3Cc3ccccc32)C1
2425,CHEMBL105,NWIBSHFKIJFRCO-WUDYKRTCSA-N,MITOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
2426,CHEMBL105,NWIBSHFKIJFRCO-WUDYKRTCSA-N,MITOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
2427,CHEMBL2171044,NWUBEEIEKUQVJL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC(=C4)C#N,N#Cc1cccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
2429,CHEMBL155314,NWWFCAFBMXDHNK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1995.26,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1=C(NC=N1)CCCCCCCCCCCCCCN,NCCCCCCCCCCCCCCc1cnc[nH]1
2430,CHEMBL155314,NWWFCAFBMXDHNK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,3981071705534969.5,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.6,C1=C(NC=N1)CCCCCCCCCCCCCCN,NCCCCCCCCCCCCCCc1cnc[nH]1
2431,CHEMBL572,NXFQHRVNIOXGAQ-YCRREMRBSA-N,NITROFURANTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
2432,CHEMBL572,NXFQHRVNIOXGAQ-YCRREMRBSA-N,NITROFURANTOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(=O)NC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
2433,CHEMBL2171032,NXHYSNCNFYHMIU-NFBKMPQASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,199.53,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CC[C@H]([C@@H](C2)C(=O)O)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,CS(=O)(=O)c1cccc(C(=O)N2CC[C@@H](N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)[C@H](C(=O)O)C2)c1
2434,CHEMBL3094216,NXSLQNZNLLDVBI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,=,1995.26,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC3=C(CCN(CC3)CC4CCCO4)C=C2,c1cc2c(cc1OCCCN1CCCCC1)CCN(CC1CCCO1)CC2
2435,CHEMBL393436,NYAIYQKWZFWRCU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,826.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.083019952679617,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)F,CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1F
2437,CHEMBL70586,NYKCGQQJNVPOLU-ONTIZHBOSA-N,SPIRADOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
2438,CHEMBL70586,NYKCGQQJNVPOLU-ONTIZHBOSA-N,SPIRADOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN([C@H]1CC[C@@]2(CCCO2)C[C@@H]1N3CCCC3)C(=O)CC4=CC(=C(C=C4)Cl)Cl,CN(C(=O)Cc1ccc(Cl)c(Cl)c1)[C@H]1CC[C@@]2(CCCO2)C[C@@H]1N1CCCC1
2439,CHEMBL92401,NYMGNSNKLVNMIA-UHFFFAOYSA-N,IPRONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NNC(=O)C1=CC=NC=C1,CC(C)NNC(=O)c1ccncc1
2440,CHEMBL92401,NYMGNSNKLVNMIA-UHFFFAOYSA-N,IPRONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NNC(=O)C1=CC=NC=C1,CC(C)NNC(=O)c1ccncc1
2441,CHEMBL1079686,NYMPDEKHLLUZPU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,5000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CCOC1=CC(=CC(=C1N2C=CC=C2)OCC)CN3CCC(CC3)NC4=NC5=C(O4)C=CC(=C5)S(=O)(=O)N(C)C,CCOc1cc(CN2CCC(Nc3nc4cc(S(=O)(=O)N(C)C)ccc4o3)CC2)cc(OCC)c1-n1cccc1
2442,CHEMBL1277126,NYWUAMYWDNANQG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CC2(CC1N3CCC(=CC3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25,O=C(O)C1=CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1
2443,CHEMBL2207654,NZFSPDVTABQASR-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518963,C1CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=CNC3=O)C(=O)NC[C@H](CN4CCC(CC4)OC5=CC(=C(C=C5)Cl)Cl)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2cc(S(=O)(=O)N3CCC3)ccc12
2444,CHEMBL415324,NZHGWWWHIYHZNX-CSKARUKUSA-N,TRANILAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC,COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC
2445,CHEMBL415324,NZHGWWWHIYHZNX-CSKARUKUSA-N,TRANILAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC,COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC
2446,CHEMBL402853,NZPLLWYDJFVQEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C7=CC(=NN7C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc6oc(-c7cc(C)nn7C)nc6c5CC4)n3C)cccc2n1
2447,CHEMBL1237174,OAKJQQAXSVQMHS-UHFFFAOYSA-N,HYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,NN,NN
2448,CHEMBL1237174,OAKJQQAXSVQMHS-UHFFFAOYSA-N,HYDRAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,NN,NN
2449,CHEMBL59733,OBMUCKQULKBRME-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,100000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=NC=CS4)N,N[C@H](Cc1nccs1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
2450,CHEMBL445332,OBSYBRPAKCASQB-AGQYDFLVSA-N,SALVINORIN A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12192085.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(=O)O[C@H]1C[C@H]([C@@]2(CC[C@H]3C(=O)O[C@@H](C[C@@]3([C@H]2C1=O)C)C4=COC=C4)C)C(=O)OC,COC(=O)[C@@H]1C[C@H](OC(C)=O)C(=O)[C@H]2[C@@]1(C)CC[C@H]1C(=O)O[C@H](c3ccoc3)C[C@]21C
2452,CHEMBL1774502,ODFDIJBCTCNYMX-OPVMPGTRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,92.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.036212172654443,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCCN(CC/C=C3/c4ccccc4COc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2453,CHEMBL314968,ODJIGTDOQQQJKM-JKRBJUMTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,47.1,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.326979092871103,C1CN(CCC1C2=CC=CC=C2)CC3C[C@H]4[C@H](O3)C5=CC=CC=C5SC6=CC=CC=C46,c1ccc(C2CCN(CC3C[C@@H]4c5ccccc5Sc5ccccc5[C@H]4O3)CC2)cc1
2454,CHEMBL917,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,FLOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F
2455,CHEMBL917,ODKNJVUHOIMIIZ-RRKCRQDMSA-N,FLOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1F
2456,CHEMBL2207663,ODKRBJGIPOQDPJ-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,CC1=C(C=CC(=C1)Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)O,Cc1cc(Cl)ccc1OC1CCN(C[C@H](O)CNC(=O)c2c[nH]c(=O)cc2C(F)(F)F)CC1
2457,CHEMBL1632174,ODMLUIATXKBXOW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21075638.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine receptor H1,Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.0,C1CN2C3=CC=CC=C3C(=C2OC1)C(=O)NCC4CCN(CC4)CCCCCC(=O)O,O=C(O)CCCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1
2458,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.49,NM,,,,,,,,,,,,,,,,,,,,9.309803919971486,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CC/C=C1/c2ccccc2COc2ccccc21
2459,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,0.17,NM,,,,,,,,,,,,,,,,,,,,9.769551078621726,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CC/C=C1/c2ccccc2COc2ccccc21
2460,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,0.09,NM,,,,,,,,,,,,,,,,,,,,10.045757490560677,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CC/C=C1/c2ccccc2COc2ccccc21
2461,CHEMBL101740,ODQWQRRAPPTVAG-BOPFTXTBSA-N,CIDOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,0.32,NM,,,,,,,,,,,,,,,,,,,,9.494850021680094,CN(C)CC/C=C\1/C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CC/C=C1/c2ccccc2COc2ccccc21
2463,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,0.17800000000000002,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,9.749579997691106,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2COc2ccccc21
2464,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,0.57,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.244125144327509,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2COc2ccccc21
2465,CHEMBL1628227,ODQWQRRAPPTVAG-UHFFFAOYSA-N,DOXEPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.066,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,10.18045606445813,CN(C)CCC=C1C2=CC=CC=C2COC3=CC=CC=C31,CN(C)CCC=C1c2ccccc2COc2ccccc21
2466,CHEMBL514217,ODRJZKUJAYVKSJ-VVOJOOEHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18768318.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and evaluation of a spiro-isobenzofuranone class of histamine H3 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN(CCN1CCCCC1)C(=O)C2CCC3(CC2)C4=CC=CC=C4C(=O)O3,CN(CCN1CCCCC1)C(=O)C1CCC2(CC1)OC(=O)c1ccccc12
2467,CHEMBL167911,OEBRKCOSUFCWJD-UHFFFAOYSA-N,DICHLORVOS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COP(=O)(OC)OC=C(Cl)Cl,COP(=O)(OC)OC=C(Cl)Cl
2468,CHEMBL167911,OEBRKCOSUFCWJD-UHFFFAOYSA-N,DICHLORVOS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COP(=O)(OC)OC=C(Cl)Cl,COP(=O)(OC)OC=C(Cl)Cl
2469,CHEMBL327888,OEJHRMYSNOPXGZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.2,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.207608310501746,CCOCCN1C2=CC=CC=C2N=C1C(=O)C3CCN(CC3)CCC4(CCN(C4)C(=O)C5=CC(=C(C(=C5)OC)OC)OC)C6=CC(=C(C=C6)OC)OC,CCOCCn1c(C(=O)C2CCN(CCC3(c4ccc(OC)c(OC)c4)CCN(C(=O)c4cc(OC)c(OC)c(OC)c4)C3)CC2)nc2ccccc21
2470,CHEMBL783,OELFLUMRDSZNSF-BRWVUGGUSA-N,NATEGLINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,CC(C)C1CCC(C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
2471,CHEMBL783,OELFLUMRDSZNSF-BRWVUGGUSA-N,NATEGLINIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1CCC(CC1)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)O,CC(C)C1CCC(C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
2473,CHEMBL1767158,OEYDBWKMXFZENQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.600326278518963,CN1CCCCC(C1)N2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)C1
2474,CHEMBL407,OFBIFZUFASYYRE-UHFFFAOYSA-N,FLUMAZENIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
2475,CHEMBL407,OFBIFZUFASYYRE-UHFFFAOYSA-N,FLUMAZENIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C,CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
2476,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NNC2=C1C(=O)NC=N2,O=c1[nH]cnc2[nH]ncc12
2477,CHEMBL1467,OFCNXPDARWKPPY-UHFFFAOYSA-N,ALLOPURINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NNC2=C1C(=O)NC=N2,O=c1[nH]cnc2[nH]ncc12
2478,CHEMBL236788,OFGZKSUTEKHHAS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,2600.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.585026652029182,CCOC1=CC(=CC(=C1N)OCC)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)S(=O)(=O)N,CCOc1cc(CN2CCC(Nc3nc4cc(S(N)(=O)=O)ccc4o3)CC2)cc(OCC)c1N
2479,CHEMBL1601669,OFHCOWSQAMBJIW-AVJTYSNKSA-N,ALFACALCIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
2480,CHEMBL1601669,OFHCOWSQAMBJIW-AVJTYSNKSA-N,ALFACALCIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O
2483,CHEMBL95029,OFMHVSNETOZSQH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.0,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCCOC6=CC=CC=C6C(=O)OC)C7=CC=CC=C7,COC(=O)c1ccccc1OCCCCn1c(C(=O)C2CCN(CCC3(c4ccccc4)CCN(C(=O)c4cc(OC)c(OC)c(OC)c4)C3)CC2)nc2ccccc21
2484,CHEMBL1071,OFPXSFXSNFPTHF-UHFFFAOYSA-N,OXAPROZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
2485,CHEMBL1071,OFPXSFXSNFPTHF-UHFFFAOYSA-N,OXAPROZIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3,O=C(O)CCc1nc(-c2ccccc2)c(-c2ccccc2)o1
2486,CHEMBL1440,OFVLGDICTFRJMM-WESIUVDSSA-N,TETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
2487,CHEMBL1440,OFVLGDICTFRJMM-WESIUVDSSA-N,TETRACYCLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1([C@H]2C[C@H]3[C@@H](C(=O)C(=C([C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)O)C(=O)N)N(C)C)O,CN(C)[C@@H]1C(=O)C(C(N)=O)=C(O)[C@@]2(O)C(=O)C3=C(O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12
2488,CHEMBL936,OGAKLTJNUQRZJU-UHFFFAOYSA-N,DIPHENIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
2489,CHEMBL936,OGAKLTJNUQRZJU-UHFFFAOYSA-N,DIPHENIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)CCCC(C2=CC=CC=C2)(C3=CC=CC=C3)O,OC(CCCN1CCCCC1)(c1ccccc1)c1ccccc1
2491,CHEMBL70598,OGEAASSLWZDQBM-UHFFFAOYSA-N,TEMELASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,3.2,NM,,,,,,,,,,,,,,,,,,,,8.494850021680094,CC1=NC=C(C=C1)CC2=CN=C(NC2=O)NCCCCC3=NC=C(C=C3C)Br,Cc1ccc(Cc2cnc(NCCCCc3ncc(Br)cc3C)[nH]c2=O)cn1
2492,CHEMBL723,OGHNVEJMJSYVRP-UHFFFAOYSA-N,CARVEDILOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
2493,CHEMBL723,OGHNVEJMJSYVRP-UHFFFAOYSA-N,CARVEDILOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O,COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
2494,CHEMBL267014,OGJGQVFWEPNYSB-UHFFFAOYSA-N,L-745870,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=C(C=C4)Cl,Clc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
2495,CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
2496,CHEMBL9,OGJPXUAPXNRGGI-UHFFFAOYSA-N,NORFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)cc21
2497,CHEMBL264761,OGLKHSQISDJZCG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,977.24,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.009998764965339,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C(=C)C,C=C(C)C(=O)c1ccc(OCCCN2CCN(C(=O)OCC)CC2)cc1
2498,CHEMBL1669416,OGQADGYHVAQLNE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,249.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.603800652904264,C1CN(CC1(F)F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,FC1(F)CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
2499,CHEMBL870,OGSPWJRAVKPPFI-UHFFFAOYSA-N,ALENDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,NCCCC(O)(P(=O)(O)O)P(=O)(O)O
2500,CHEMBL870,OGSPWJRAVKPPFI-UHFFFAOYSA-N,ALENDRONIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN,NCCCC(O)(P(=O)(O)O)P(=O)(O)O
2501,CHEMBL1669409,OGTGPRXXTIEASF-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,32.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.494850021680094,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC#N,C[C@H](C1=C(CCN(C)CC#N)Cc2ccccc21)c1cnccn1
2502,CHEMBL372453,OGWAJJGAXANYMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)Cl)OC,COc1ccc(NC(=O)N2CCN(c3ccc(Cl)cc3)CC2)cc1N1CCN(C)CC1
2503,CHEMBL90555,OGWKCGZFUXNPDA-XQKSVPLYSA-N,VINCRISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
2504,CHEMBL90555,OGWKCGZFUXNPDA-XQKSVPLYSA-N,VINCRISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O,CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
2506,CHEMBL181085,OHBPVXVMMZZMKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,7.59,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.119758224104519,CC(C)COC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O,CC(C)COC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2507,CHEMBL370128,OHBRURMYVYWCLY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=CC=C4Cl)OC,COc1ccc(NC(=O)N2CCN(c3ccccc3Cl)CC2)cc1N1CCN(C)CC1
2508,CHEMBL444307,OHFUDGRGQOZMIF-IZZDOVSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,426.58,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.369999510099088,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)/C=C/C3=CN=CC=C3,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)/C=C/c3cccnc3)cc2)CC1
2509,CHEMBL1783965,OHKBLWVRXBNICP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,160.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.795880017344076,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=NC=C4,Cc1ccc2c(c1)c1c(n2CCc2ccncc2)CCN(C)C1
2510,CHEMBL1783965,OHKBLWVRXBNICP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,3980.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4001169279263115,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=NC=C4,Cc1ccc2c(c1)c1c(n2CCc2ccncc2)CCN(C)C1
2512,CHEMBL131,OIGNJSKKLXVSLS-VWUMJDOOSA-N,PREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
2513,CHEMBL131,OIGNJSKKLXVSLS-VWUMJDOOSA-N,PREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
2516,CHEMBL3609372,OINGHOPGNMYCAB-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26191365.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human histamine H1 receptor,,ACS Med. Chem. Lett.,PUBLICATION,,4.5228787452803365,CC(C)NC(=O)N1CC[C@@H](C1)N=C2C3=C(C=CC(=C3)Cl)N(C4=C(N2)C=C(C=C4)F)CC(F)F,CC(C)NC(=O)N1CC[C@H](N=C2Nc3cc(F)ccc3N(CC(F)F)c3ccc(Cl)cc32)C1
2517,CHEMBL2178580,OIXSYJAHIPQFMO-RUZDIDTESA-N,YM-344484,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,Ki,=,47.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at histamine H1 receptor expressed in human PC3 cells inhibition of histamine-induced calcium influx by cell based assay,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.327902142064282,CC1=NN=C(C=C1)C(=O)N2CCC(=CC(=O)N[C@@H]3CCN(C3)CC4=CC5=C(C=C4)C=C(C=C5)F)CC2,Cc1ccc(C(=O)N2CCC(=CC(=O)N[C@@H]3CCN(Cc4ccc5cc(F)ccc5c4)C3)CC2)nn1
2518,CHEMBL1767155,OIZYYUJMNZAXNN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.199970640755867,CN1CCC(C1)CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC(Cn2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)C1
2519,CHEMBL253376,OJGDCBLYJGHCIH-UHFFFAOYSA-N,BROMHEXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
2520,CHEMBL253376,OJGDCBLYJGHCIH-UHFFFAOYSA-N,BROMHEXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CC1=C(C(=CC(=C1)Br)Br)N)C2CCCCC2,CN(Cc1cc(Br)cc(Br)c1N)C1CCCCC1
2522,CHEMBL1447,OJMMVQQUTAEWLP-KIDUDLJLSA-N,LINCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
2523,CHEMBL1447,OJMMVQQUTAEWLP-KIDUDLJLSA-N,LINCOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC[C@@H]1C[C@H](N(C1)C)C(=O)N[C@@H]([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)[C@@H](C)O,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@@H](C)O)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1
2524,CHEMBL94739,OJSFTALXCYKKFQ-YLJYHZDGSA-N,FEMOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,4200.0,NM,,,,,,,,,,,,,,,,,,,,5.376750709602098,CN1CC[C@@H]([C@H](C1)COC2=CC=C(C=C2)OC)C3=CC=CC=C3,COc1ccc(OC[C@H]2CN(C)CC[C@@H]2c2ccccc2)cc1
2527,CHEMBL598753,OKSDPUBPIUWZPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,2640.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.578396073130169,COC1=CC2=C(C=C1)C3=C(CC4=CC=CC=C4C3CN)C=C2,COc1ccc2c3c(ccc2c1)Cc1ccccc1C3CN
2529,CHEMBL526,OLBCVFGFOZPWHH-UHFFFAOYSA-N,PROPOFOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=CC=C1)C(C)C)O,CC(C)c1cccc(C(C)C)c1O
2530,CHEMBL526,OLBCVFGFOZPWHH-UHFFFAOYSA-N,PROPOFOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=CC=C1)C(C)C)O,CC(C)c1cccc(C(C)C)c1O
2531,CHEMBL452847,OLJSGKYQYTWQNJ-UHFFFAOYSA-N,VUF-10497,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19053770.0,Ki,=,19.95,NM,,,cell_based,,,,,NIH3T3,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in NIH3T3 cells,Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.,J. Med. Chem.,PUBLICATION,,7.700057099977232,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=CC=CS4,CN1CCN(c2nc(NCc3cccs3)c3cc(Cl)ccc3n2)CC1
2532,CHEMBL452847,OLJSGKYQYTWQNJ-UHFFFAOYSA-N,VUF-10497,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,549.54,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.260000690598033,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=CC=CS4,CN1CCN(c2nc(NCc3cccs3)c3cc(Cl)ccc3n2)CC1
2535,CHEMBL85606,OLWRVVHPJFLNPW-LSNLESRRSA-N,SB-277011,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.19999817218203,C1CC(CCC1CCN2CCC3=C(C2)C=CC(=C3)C#N)NC(=O)C4=CC=NC5=CC=CC=C45,N#Cc1ccc2c(c1)CCN(CCC1CCC(NC(=O)c3ccnc4ccccc34)CC1)C2
2536,CHEMBL85606,OLWRVVHPJFLNPW-LSNLESRRSA-N,SB-277011,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,630.96,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.19999817218203,C1CC(CCC1CCN2CCC3=C(C2)C=CC(=C3)C#N)NC(=O)C4=CC=NC5=CC=CC=C45,N#Cc1ccc2c(c1)CCN(CCC1CCC(NC(=O)c3ccnc4ccccc34)CC1)C2
2538,CHEMBL3233067,ONISVGVNTCDONI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,6165.95,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.210000001311122,C1CCN(CC1)CCCN2C(=O)C(NC2=O)(C3=CC=CC=C3)C4=CC=CC=C4,O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1CCCN1CCCCC1
2539,CHEMBL1200624,ONKUMRGIYFNPJW-KIEAKMPYSA-N,ETHYNODIOL DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C
2540,CHEMBL1200624,ONKUMRGIYFNPJW-KIEAKMPYSA-N,ETHYNODIOL DIACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1CC[C@@H]2[C@H]3CC[C@]4([C@H]([C@@H]3CCC2=C1)CC[C@]4(C#C)OC(=O)C)C,C#C[C@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=C[C@@H](OC(C)=O)CC[C@@H]4[C@H]3CC[C@@]21C
2542,CHEMBL1617548,ONRXABULYAHOMS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,10715.19,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,4.970000123715015,C=CCN1C2=CC=CC=C2N(C1=N)CC(=O)C3=CC=CC=C3,C=CCn1c(=N)n(CC(=O)c2ccccc2)c2ccccc21
2543,CHEMBL565833,ONUBXRCAOBQBRS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19632840.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CCCNCC1=CN=C(C=C1)CCN2C=CC(=CC2=O)OCC3=CC=C(C=C3)F,CCCNCc1ccc(CCn2ccc(OCc3ccc(F)cc3)cc2=O)nc1
2544,CHEMBL311231,ONUZLDLDGNZGFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1)CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2,c1ccc2c(c1)Cc1ccccc1N1OC(CN3CCNCC3)CC21
2546,CHEMBL282424,OOKNJSVAHXTYKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CN(CCN1CC2=CNC3=C2C=CC=N3)C4=CC=CC=C4F,Fc1ccccc1N1CCN(Cc2c[nH]c3ncccc23)CC1
2547,CHEMBL1783956,OORNIOGZQUYGRW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,610.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.214670164989233,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2ccccn2)C1
2548,CHEMBL1783956,OORNIOGZQUYGRW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,940.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0268721464003026,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2ccccn2)C1
2549,CHEMBL566075,OOUPDYBXVFKJRL-UJKQEGAGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)CNC(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F,Cc1cnc(NC2CCC(CNC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC2)nc1N(C)C
2550,CHEMBL287367,OPICWPJAKDPOOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,1760.0,NM,,,,,,,,,,,,,,,,,,,,5.7544873321858505,C1=CC(=CC(=C1)I)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(I)c2)[nH]1
2551,CHEMBL685,OPXLLQIJSORQAM-UHFFFAOYSA-N,MEBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
2552,CHEMBL685,OPXLLQIJSORQAM-UHFFFAOYSA-N,MEBENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3,COC(=O)Nc1nc2ccc(C(=O)c3ccccc3)cc2[nH]1
2554,CHEMBL1697694,OQIQSTLJSLGHID-WNWIJWBNSA-N,AFLATOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2
2555,CHEMBL1697694,OQIQSTLJSLGHID-WNWIJWBNSA-N,AFLATOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C3=C(C(=O)CC3)C(=O)OC2=C4[C@@H]5C=CO[C@@H]5OC4=C1,COc1cc2c(c3oc(=O)c4c(c13)CCC4=O)[C@@H]1C=CO[C@@H]1O2
2557,CHEMBL1669415,OQSOOFROGDVPSV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4605.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.336770365467133,C1C2=CC=CC=C2C(=C1CCN3CC(C3)(F)F)CC4=NC=CN=C4,FC1(F)CN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
2559,CHEMBL97240,ORBDOXUKPRMJQT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.26,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.20342566678957,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCN6CCOCC6)C7=CC(=C(C=C7)Cl)Cl,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4CCN4CCOCC4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
2561,CHEMBL410270,ORMPNUUVYNSLES-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,500.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,COC1=CC=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=CC=N7.C(=C/C(=O)O)\C(=O)O,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccccn4)CC3)CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)C2)cc1
2563,CHEMBL398440,OSDLLIBGSJNGJE-UHFFFAOYSA-N,CHLOROXYLENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC(=C1Cl)C)O,Cc1cc(O)cc(C)c1Cl
2564,CHEMBL398440,OSDLLIBGSJNGJE-UHFFFAOYSA-N,CHLOROXYLENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=CC(=C1Cl)C)O,Cc1cc(O)cc(C)c1Cl
2565,CHEMBL64317,OSENGOVQGXZHHZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,575.44,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.239999952707271,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCCCC,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)OCCCC)CC2)cc1
2567,CHEMBL1909072,OSJJYEUEJRVVOD-UHFFFAOYSA-N,PIPAMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,9.94,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.002613615602687,C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
2568,CHEMBL1909072,OSJJYEUEJRVVOD-UHFFFAOYSA-N,PIPAMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.15,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.939302159646386,C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
2569,CHEMBL2171039,OSUVEVWOPQLILG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC=CC=C4Cl,O=C(NS(=O)(=O)c1ccccc1Cl)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
2570,CHEMBL1277401,OSWDQWCAAIWPDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.0,C1CC2(CC1N3CCC(CC3)C(=O)O)C4=CC=CC=C4OC5=C(C2=O)C=C(C=C5)Cl,O=C(O)C1CCN(C2CCC3(C2)C(=O)c2cc(Cl)ccc2Oc2ccccc23)CC1
2571,CHEMBL108545,OSWPMRLSEDHDFF-UHFFFAOYSA-N,METHYL SALICYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=CC=C1O,COC(=O)c1ccccc1O
2572,CHEMBL108545,OSWPMRLSEDHDFF-UHFFFAOYSA-N,METHYL SALICYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC(=O)C1=CC=CC=C1O,COC(=O)c1ccccc1O
2573,CHEMBL418470,OTBYLNCJHFPRTL-NKWVEPMBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@@H]1C2=CN=CN2)CCN,NCC[C@H]1C[C@H]1c1cnc[nH]1
2574,CHEMBL60716,OTBYLNCJHFPRTL-RQJHMYQMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@H]1C2=CN=CN2)CCN,NCC[C@@H]1C[C@@H]1c1cnc[nH]1
2575,CHEMBL1236282,OTVAEFIXJLOWRX-NXEZZACHSA-N,THIAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O,CS(=O)(=O)c1ccc([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)cc1
2576,CHEMBL1236282,OTVAEFIXJLOWRX-NXEZZACHSA-N,THIAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O,CS(=O)(=O)c1ccc([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)cc1
2577,CHEMBL597528,OUBNFHMJUXSZKL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,964.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.015922966097169,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCCCCC4=CC=CC=C4,c1ccc(CCCCNCC2c3ccccc3Cc3ccccc32)cc1
2578,CHEMBL817,OUDSBRTVNLOZBN-UHFFFAOYSA-N,TOLAZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
2579,CHEMBL817,OUDSBRTVNLOZBN-UHFFFAOYSA-N,TOLAZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2,Cc1ccc(S(=O)(=O)NC(=O)NN2CCCCCC2)cc1
2581,CHEMBL2146809,OUEZWZJJIKBFFV-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.500312917381596,CN1CCC[C@@H]1CN2C(=O)C3=C(C(=N2)CC4=CC=C(C=C4)Cl)N=CC=C3,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ncccc2c1=O
2582,CHEMBL26260,OUGIDAPQYNCXRA-UHFFFAOYSA-N,BETA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43,O=c1cc(-c2ccccc2)oc2ccc3ccccc3c12
2583,CHEMBL26260,OUGIDAPQYNCXRA-UHFFFAOYSA-N,BETA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=CC4=CC=CC=C43,O=c1cc(-c2ccccc2)oc2ccc3ccccc3c12
2584,CHEMBL3358509,OURPZJJZFFKVJH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25343529.0,Ki,=,110.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Targeting Dopamine D3 and Serotonin 5-HT1A and 5-HT2A Receptors for Developing Effective Antipsychotics: Synthesis, Biological Characterization, and Behavioral Studies.",J. Med. Chem.,PUBLICATION,,6.9586073148417755,C1CN(CCN1CCCCNC(=O)C2=CC3=C(C=C2)N=CC=C3)C4=CC=CC=C4,O=C(NCCCCN1CCN(c2ccccc2)CC1)c1ccc2ncccc2c1
2585,CHEMBL1946255,OUSOPIMSKOMYQI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,665.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.177178354696896,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCC3=NC4=CC=CC=C4S3,Clc1ccc(N2CCCN(CCCc3nc4ccccc4s3)CC2)cc1
2587,CHEMBL157264,OUVNPGHJCOISPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,100000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.0,C1CCC(CC1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3,NCCc1cnc(CCC(c2ccccc2)C2CCCCC2)[nH]1
2590,CHEMBL1092767,OVTUKEYYZWXZMJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,35.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CC(C1=C(SC2=CC=CC=C21)CCN(C)C)C3=NC=CS3,CC(c1nccs1)c1c(CCN(C)C)sc2ccccc12
2591,CHEMBL1092663,OWMBYQVIMDTSAW-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,4.2,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.3767507096021,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CN=C3,Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1
2592,CHEMBL476933,OWMYGKYXZFSRMD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,,C1CC2CN(CC1N2C3=CC=CC=C3)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CC2CCC(C1)N2c1ccccc1)c1ccc(F)cc1
2593,CHEMBL160893,OWPHKTVZEZNCMB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,137.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.863279432843593,C1C2=CC=CC=C2C(C3=CC=CC=C31)CCN,NCCC1c2ccccc2Cc2ccccc21
2594,CHEMBL77675,OWRCNXZUPFZXOS-UHFFFAOYSA-N,"N,N'-DIPHENYL-GUANIDINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)N,NC(=Nc1ccccc1)Nc1ccccc1
2595,CHEMBL77675,OWRCNXZUPFZXOS-UHFFFAOYSA-N,"N,N'-DIPHENYL-GUANIDINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC(=NC2=CC=CC=C2)N,NC(=Nc1ccccc1)Nc1ccccc1
2596,CHEMBL59389,OWWNABDDYQLERE-CRCLSJGQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@@H]([C@@H]1N)C2=CN=CN2,N[C@@H]1C[C@@H]1c1cnc[nH]1
2597,CHEMBL13559,OWWNABDDYQLERE-RFZPGFLSSA-N,VUF-5296,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@@H]1N)C2=CN=CN2,N[C@@H]1C[C@H]1c1cnc[nH]1
2598,CHEMBL294061,OWWNABDDYQLERE-UHNVWZDZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,>,0.0001,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,13.0,C1[C@H]([C@H]1N)C2=CN=CN2,N[C@H]1C[C@H]1c1cnc[nH]1
2599,CHEMBL13795,OWWNABDDYQLERE-WHFBIAKZSA-N,VUF-5297,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12723960.0,EC50,=,864.0,NM,,,,,,,,,,,,,,,Inhibition of human Histamine H1 receptor using [3H]pyrilamine,"Cyclopropane-based conformational restriction of histamine. (1S,2S)-2-(2-aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane, a highly selective agonist for the histamine H3 receptor, having a cis-cyclopropane structure.",J. Med. Chem.,PUBLICATION,,6.063486257521107,C1[C@@H]([C@H]1N)C2=CN=CN2,N[C@H]1C[C@@H]1c1cnc[nH]1
2600,CHEMBL188921,OWYLAEYXIQKAOL-UHFFFAOYSA-N,BUFLOMEDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1
2601,CHEMBL188921,OWYLAEYXIQKAOL-UHFFFAOYSA-N,BUFLOMEDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=C(C(=C1)OC)C(=O)CCCN2CCCC2)OC,COc1cc(OC)c(C(=O)CCCN2CCCC2)c(OC)c1
2602,CHEMBL429458,OXAGECQHLDNVCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCC3)cc2)C(=O)C1
2603,CHEMBL270595,OXEFHEYEQUISKC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCC2=CC=CC=N2,c1ccc(CCN2CCCC2)nc1
2604,CHEMBL455288,OXJGPZFAZUEPIX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,390.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,C1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)OCCN3CCN(CC3)CCCN4C5=CC=CC=C5SC6=C4C=C(C=C6)C(F)(F)F,O=C(OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1)c1ccc(OCCCN2CCCCC2)cc1
2605,CHEMBL392354,OXLSTDPYCCQCDK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=C(C=C(C=C5)F)F.C(=O)O,O=C(c1ccc(F)cc1F)N1CCN(c2ccc(OC3CCN(C4CCCC4)CC3)cc2)C(=O)C1
2606,CHEMBL564168,OYGQVRYZRZJCQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,124.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.906578314837764,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCN(CCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2609,CHEMBL255827,OYUFXMRRZYKKDL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C,Cc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
2610,CHEMBL79838,OZETYYSIKGRYTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2)C6=CC(=CC=C6)Cl,Clc1cccc(N2CCN(CC3CC4c5ccccc5Cc5ccccc5N4O3)CC2)c1
2611,CHEMBL1935425,OZMRAMSUYZLMIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153342.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC(C1)N2CCC3(CCC4=C(O3)C=CC(=C4)OC5CCS(=O)(=O)CC5)CC2,O=S1(=O)CCC(Oc2ccc3c(c2)CCC2(CCN(C4CCC4)CC2)O3)CC1
2612,CHEMBL1923535,OZUNHSMQAVTNLW-UHFFFAOYSA-N,2-(2-PHENOXYPHENYL)ETHANAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,10964.78,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,4.960000077688648,C1=CC=C(C=C1)OC2=CC=CC=C2CCN,NCCc1ccccc1Oc1ccccc1
2613,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
2614,CHEMBL493,OZVBMTJYIDMWIL-AYFBDAFISA-N,BROMOCRIPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
2615,CHEMBL469,OZWKMVRBQXNZKK-UHFFFAOYSA-N,KETOROLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
2616,CHEMBL469,OZWKMVRBQXNZKK-UHFFFAOYSA-N,KETOROLAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O,O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O
2617,CHEMBL257946,OZZLMZAQJKSGCB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)ON=C6C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6onc(C)c6cc5CC4)n3C)cccc2n1
2618,CHEMBL431850,PARRBDIQICRPTM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,437.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.359518563029578,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC(=C(C=C7)Cl)Cl.CS(=O)(=O)O,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccccn4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
2619,CHEMBL1243,PBCZLFBEBARBBI-UHFFFAOYSA-N,SULFABENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1
2620,CHEMBL1243,PBCZLFBEBARBBI-UHFFFAOYSA-N,SULFABENZAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)NC(=O)c2ccccc2)cc1
2621,CHEMBL1259172,PBYSLXLVOFLVAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,64.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.1938200260161125,C1CN(CCC1C2=CN(C3=C2C=C(C=C3)CN)C4=CC=C(C=C4)F)CCN5CCNC5=O,NCc1ccc2c(c1)c(C1CCN(CCN3CCNC3=O)CC1)cn2-c1ccc(F)cc1
2623,CHEMBL2208425,PCRWWFINVOSHRN-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CN4C=C(C=CC4=N3)F)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1cn2cc(F)ccc2n1
2624,CHEMBL503,PCZOHLXUXFIOCF-BXMDZJJMSA-N,LOVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
2625,CHEMBL503,PCZOHLXUXFIOCF-BXMDZJJMSA-N,LOVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
2627,CHEMBL2171027,PDJBLXDNFLXACI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC(=CC=C4)S(=O)(=O)CCCC(=O)O,O=C(O)CCCS(=O)(=O)c1cccc(C(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
2628,CHEMBL18701,PDMUULPVBYQBBK-UHFFFAOYSA-N,RO-201724,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC
2629,CHEMBL18701,PDMUULPVBYQBBK-UHFFFAOYSA-N,RO-201724,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCOC1=C(C=CC(=C1)CC2CNC(=O)N2)OC,CCCCOc1cc(CC2CNC(=O)N2)ccc1OC
2630,,PDNJLMZEGXHSCU-GSVOUGTGSA-N,D-HOMOCYSTEINE SULFINIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)O)[C@H](C(=O)O)N,N[C@H](CCS(=O)O)C(=O)O
2631,CHEMBL1516176,PDNJLMZEGXHSCU-VKHMYHEASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCS(=O)O)C(=O)O
2633,CHEMBL291166,PEDXQUUSXXYPJU-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,355.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.449771646944907,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=CC=C(C=C4)F,CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C
2634,CHEMBL106483,PFEJJOZKVMFZED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3235.94,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.489999539566098,C1COCCN1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CCOCC3)cc2)cc1
2635,CHEMBL107293,PFSYJJKLBNXBAA-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,5500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.259637310505756,CC1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,Cc1ccc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)cc1
2636,CHEMBL196169,PGAUZNVGTNAJSV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=CC=C4F)OC,COc1ccc(NC(=O)N2CCN(c3ccccc3F)CC2)cc1N1CCN(C)CC1
2637,CHEMBL184618,PGBHMTALBVVCIT-VCIWKGPPSA-N,NEOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
2638,CHEMBL184618,PGBHMTALBVVCIT-VCIWKGPPSA-N,NEOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N,NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O
2639,CHEMBL426317,PGGCRGAETLNAJC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16458504.0,Ki,=,839.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor by radioligand binding assay,"Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0762380391713,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC(=CC=C3)OC,COc1cccc(N2CCN(CCCCn3ncc(=O)n(C)c3=O)CC2)c1
2642,CHEMBL1201190,PGLIUCLTXOYQMV-GHVWMZMZSA-N,LEVOCETIRIZINE DIHYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,50.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.301029995663981,C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl.Cl.Cl,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1
2643,CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N,CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS
2644,CHEMBL1221512,PGOKBMWPBDRDGN-IBXSQZDTSA-N,L-744832,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H](CO[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCS(=O)(=O)C)C(=O)OC(C)C)NC[C@H](CS)N,CC[C@H](C)[C@@H](CO[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCS(C)(=O)=O)C(=O)OC(C)C)NC[C@@H](N)CS
2645,CHEMBL2171042,PHHPFXWDLDXLPN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CC1=CC(=CC=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1cccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
2646,CHEMBL1149,PHIQHXFUZVPYII-ZCFIWIBFSA-N,LEVOCARNITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,C[N+](C)(C)C[C@H](O)CC(=O)[O-]
2647,CHEMBL1149,PHIQHXFUZVPYII-ZCFIWIBFSA-N,LEVOCARNITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)C[C@@H](CC(=O)[O-])O,C[N+](C)(C)C[C@H](O)CC(=O)[O-]
2648,CHEMBL1105,PHJFLPMVEFKEPL-UHFFFAOYSA-N,6-METHOXY-2-NAPHTHYLACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O,COc1ccc2cc(CC(=O)O)ccc2c1
2649,CHEMBL1105,PHJFLPMVEFKEPL-UHFFFAOYSA-N,6-METHOXY-2-NAPHTHYLACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC2=C(C=C1)C=C(C=C2)CC(=O)O,COc1ccc2cc(CC(=O)O)ccc2c1
2650,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,1100.0,NM,,,,,,,,,,,,,,,,,,,,5.9586073148417755,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
2651,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,361.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.442492798094343,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
2652,CHEMBL621,PHLBKPHSAVXXEF-UHFFFAOYSA-N,TRAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,42.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.376750709602098,C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12
2653,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,NC(=O)N1c2ccccc2CCc2ccccc21
2654,CHEMBL41543,PHNLCHMJDSSPDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC2=CC=CC=C2N(C3=CC=CC=C31)C(=O)N,NC(=O)N1c2ccccc2CCc2ccccc21
2655,CHEMBL319231,PHNZBVSSQHIXIP-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,90000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.045757490560675,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)N,CC(=O)c1ccc(OCCCN2CC[C@H](N)C2)cc1
2656,CHEMBL319231,PHNZBVSSQHIXIP-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,100000.0,NM,,,,,,,,,,,,,,,Binding affinity towards human Histamine H1 receptor (For compound 11),Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)N,CC(=O)c1ccc(OCCCN2CC[C@H](N)C2)cc1
2658,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,8.4,NM,,,,,,,,,,,,,,,,,,,,8.075720713938116,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
2659,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,6.3,NM,,,,,,,,,,,,,,,,,,,,8.200659450546418,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
2660,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,50.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.301029995663981,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
2661,CHEMBL445,PHVGLTMQBUFIQQ-UHFFFAOYSA-N,NORTRIPTYLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,5.86,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.23210238398191,CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31,CNCCC=C1c2ccccc2CCc2ccccc21
2662,CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,Clc1ccccc1CN1CCc2sccc2C1
2663,CHEMBL833,PHWBOXQYWZNQIN-UHFFFAOYSA-N,TICLOPIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl,Clc1ccccc1CN1CCc2sccc2C1
2664,CHEMBL1090175,PIHREWZGYZJCNQ-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,3.1,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.508638306165727,C[C@@H](C1=NC=CN=C1)C2=C(CC3=C2C=CC(=C3)OC)CCN(C)C,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1cnccn1
2665,CHEMBL302468,PIIKAHNRVYTSPK-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4570.88,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3400001801593495,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](C4=CC=CC=C4)N,N[C@@H](C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1)c1ccccc1
2666,CHEMBL94,PIJVFDBKTWXHHD-HIFRSBDPSA-N,PHYSOSTIGMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C
2667,CHEMBL94,PIJVFDBKTWXHHD-HIFRSBDPSA-N,PHYSOSTIGMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C,CNC(=O)Oc1ccc2c(c1)[C@]1(C)CCN(C)[C@@H]1N2C
2668,CHEMBL47244,PIMZUZSSNYHVCU-YKWPQBAZSA-N,PICROTOXININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,C=C(C)[C@H]1[C@@H]2C(=O)O[C@H]1[C@H]1OC(=O)[C@@]34O[C@@H]3C[C@]2(O)[C@@]14C
2669,CHEMBL47244,PIMZUZSSNYHVCU-YKWPQBAZSA-N,PICROTOXININ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)[C@@H]1[C@@H]2[C@@H]3[C@@]4([C@]([C@H]1C(=O)O2)(C[C@@H]5[C@]4(O5)C(=O)O3)O)C,C=C(C)[C@H]1[C@@H]2C(=O)O[C@H]1[C@H]1OC(=O)[C@@]34O[C@@H]3C[C@]2(O)[C@@]14C
2672,CHEMBL534958,PJJQGSLLJOVYBM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.Cl,N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1
2673,CHEMBL1712923,PJLVTVAIERNDEQ-BTJKTKAUSA-N,IRSOGLADINE MALEATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O,Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1
2674,CHEMBL1712923,PJLVTVAIERNDEQ-BTJKTKAUSA-N,IRSOGLADINE MALEATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)C2=NC(=NC(=N2)N)N)Cl.C(=C\C(=O)O)\C(=O)O,Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1
2675,CHEMBL349543,PJLWLZAKVLPHRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCC4=CC=CC=C4,c1ccc(CNCC2c3ccccc3Cc3ccccc32)cc1
2676,CHEMBL596,PJMPHNIQZUBGLI-UHFFFAOYSA-N,FENTANYL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,147910.84,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,3.82999999652596,CCC(=O)N(C1CCN(CC1)CCC2=CC=CC=C2)C3=CC=CC=C3,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1
2677,CHEMBL1539,PJSFRIWCGOHTNF-UHFFFAOYSA-N,SULFADOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC
2678,CHEMBL1539,PJSFRIWCGOHTNF-UHFFFAOYSA-N,SULFADOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(N=CN=C1OC)NS(=O)(=O)C2=CC=C(C=C2)N,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC
2679,CHEMBL1464,PJVWKTKQMONHTI-UHFFFAOYSA-N,WARFARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
2680,CHEMBL1464,PJVWKTKQMONHTI-UHFFFAOYSA-N,WARFARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)CC(C1=CC=CC=C1)C2=C(C3=CC=CC=C3OC2=O)O,CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O
2682,CHEMBL1090528,PKONXOYDGGORHO-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.657577319177793,CC1=CC2=C(C=C1)C(=C(C2)CCN(C)C)[C@@H](C)C3=NC=CS3,Cc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1
2683,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,20.83,NM,,,,,,,,,,,,,,,,,,,,7.681310730052254,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
2684,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,21.0,NM,,,,,,,,,,,,,,,,,,,,7.67778070526608,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
2685,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,21.0,NM,,,,,,,,,,,,,,,,,,,,7.67778070526608,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
2686,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,40.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.397940008672037,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
2687,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,40.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.397940008672037,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
2688,CHEMBL726,PLDUPXSUYLZYBN-UHFFFAOYSA-N,FLUPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,4.66,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.331614083309999,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
2689,CHEMBL1103,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,FURAZOLIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1
2690,CHEMBL1103,PLHJDBGFXBMTGZ-WEVVVXLNSA-N,FURAZOLIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COC(=O)N1/N=C/C2=CC=C(O2)[N+](=O)[O-],O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1
2691,CHEMBL126224,PLIGPBGDXASWPX-UHFFFAOYSA-N,IPRINDOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,120.0,NM,,,,,,,,,,,,,,,,,,,,6.920818753952375,CN(C)CCCN1C2=C(CCCCCC2)C3=CC=CC=C31,CN(C)CCCn1c2c(c3ccccc31)CCCCCC2
2693,CHEMBL2207640,PLYQWXWXIUOYQJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)CC2=CC(=C3C2=CC=CC=C3)CN4CCN(CC4)C5=CC=CC=C5OC,COc1ccccc1N1CCN(Cc2cc(CN3CCN(C)CC3)c3cccccc2-3)CC1
2694,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
2695,CHEMBL160,PMATZTZNYRCHOR-CGLBZJNRSA-N,CYCLOSPORINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H]1C(=O)N(CC(=O)N([C@H](C(=O)N[C@H](C(=O)N([C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N([C@H](C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C,C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C
2699,CHEMBL1783954,PMLYIGFXJXRZKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,500.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=N4,Cc1ccc2c(c1)c1c(n2CCc2ccccn2)CCN(C)C1
2700,CHEMBL1783954,PMLYIGFXJXRZKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,10000.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CC=CC=N4,Cc1ccc2c(c1)c1c(n2CCc2ccccn2)CCN(C)C1
2701,CHEMBL270387,PMOFOATUAABMTD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,CN1C(=NN=C1SCCCN2CCC3=C(CC2)C4=C(C=C3)OC(=N4)C(F)(F)F)C5=CC=CC=C5,Cn1c(SCCCN2CCc3ccc4oc(C(F)(F)F)nc4c3CC2)nnc1-c1ccccc1
2702,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=CNC1=S,Cn1cc[nH]c1=S
2703,CHEMBL1515,PMRYVIKBURPHAH-UHFFFAOYSA-N,METHIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=CNC1=S,Cn1cc[nH]c1=S
2704,CHEMBL1729417,PMTIWRPLQBVEMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24690494.0,Ki,<,1000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),Antagonists of the kappa opioid receptor.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=C2C(=NC=C1)N(C(=O)C3=CC=CN32)CC(=O)NCCCN4CCN(CC4)C5=CC=C(C=C5)OC,COc1ccc(N2CCN(CCCNC(=O)Cn3c(=O)c4cccn4c4c(C)ccnc43)CC2)cc1
2707,CHEMBL1621,PMXMIIMHBWHSKN-UHFFFAOYSA-N,PALIPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,32.0,NM,,,,,,,,,,,,,,,,,,,,7.494850021680094,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O
2708,CHEMBL1621,PMXMIIMHBWHSKN-UHFFFAOYSA-N,PALIPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,3.4,NM,,,,,,,,,,,,,,,,,,,,8.468521082957745,CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2O
2711,CHEMBL1669407,PNSJAJNXVSKCBP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,24.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.619788758288393,CN(CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3)CCF,CN(CCF)CCC1=C(Cc2cnccn2)c2ccccc2C1
2712,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
2713,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11750180.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
2714,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
2715,CHEMBL637,PNVNVHUZROJLTJ-UHFFFAOYSA-N,VENLAFAXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O,COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1
2717,CHEMBL141209,POOPPNNSPMKABZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11784148.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of mepyramine binding to Histamine H1 receptor,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,PUBLICATION,,5.0,COC1CC2=CC=CC=C2C3(O1)CCN(CC3)CC4=CC=CC=C4,COC1Cc2ccccc2C2(CCN(Cc3ccccc3)CC2)O1
2718,CHEMBL1201012,POPFMWWJOGLOIF-XWCQMRHXSA-N,FLURANDRENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
2719,CHEMBL1201012,POPFMWWJOGLOIF-XWCQMRHXSA-N,FLURANDRENOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CCC(=O)C=C1[C@H](C[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3C[C@@H]5[C@]4(OC(O5)(C)C)C(=O)CO)C)O)F,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
2722,CHEMBL1091874,POXFWGOYGQTRMD-SECBINFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20299215.0,IC50,>,30000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5228787452803365,CN[C@@H]1CCN(C1)C2=NC(=NC3=C2OC4=C3C=C(C=C4)Cl)N,CN[C@@H]1CCN(c2nc(N)nc3c2oc2ccc(Cl)cc23)C1
2723,CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
2724,CHEMBL1479,POZRVZJJTULAOH-LHZXLZLDSA-N,DANAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C
2725,CHEMBL372588,PPABRKQHBMJESP-VYYCAZPPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,20.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.698970004336019,C1CN(CCC1CC2=CC=CC=C2)C/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O,O=C(O)Cc1ccc2c(c1)/C(=C\CN1CCC(Cc3ccccc3)CC1)c1ccccc1CO2
2726,CHEMBL551457,PPLDJNZKOFVZGW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,37.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.431798275933005,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCN(CCCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2727,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
2728,CHEMBL40583,PPQNQXQZIWHJRB-UHFFFAOYSA-N,3-METHYLCHOLANTHRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2CCC3=C2C(=CC4=C3C=CC5=CC=CC=C54)C=C1,Cc1ccc2cc3c(ccc4ccccc43)c3c2c1CC3
2729,CHEMBL431172,PPWTZQUEISGLGF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,26302.68,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.579999998661814,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)S(=O)(=O)C,CCCCCC(=O)c1ccc(OCCCN2CCN(S(C)(=O)=O)CC2)cc1
2730,CHEMBL490632,PPXOTGGYVKBLCQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,665.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.177178354696896,CC1=CC=C(C=C1)CCN2CCC(CC2)C(=O)C3=C(C(=CC=C3)OCCF)OC,COc1c(OCCF)cccc1C(=O)C1CCN(CCc2ccc(C)cc2)CC1
2731,CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20384344.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active histamine type 3 receptor agonist and evaluation of its antistress activity in mice.,J. Med. Chem.,PUBLICATION,,6.0,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2,CC(C)(C)c1ccc(SCCc2cnc[nH]2)cc1
2732,CHEMBL1098230,PQPVHIHIJVIEQG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20541426.0,Ki,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]rilamine from human histamine H1 receptor expressed in CHO cells after 1 hr by liquid scintillation counting,Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.,Bioorg. Med. Chem.,PUBLICATION,,6.0,CC(C)(C)C1=CC=C(C=C1)SCCC2=CN=CN2,CC(C)(C)c1ccc(SCCc2cnc[nH]2)cc1
2736,CHEMBL261551,PQQUQVYOCGJWAX-UHFFFAOYSA-N,VUF-10148,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18357976.0,Ki,=,741.31,NM,,,cell_based,,,,,NIH3T3,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in NIH3T3 cells,Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo.,J. Med. Chem.,PUBLICATION,,6.130000141365475,CN1CCN(CC1)C2=NC3=CC=CC=C3N=C2CC4=CC=CC=C4,CN1CCN(c2nc3ccccc3nc2Cc2ccccc2)CC1
2738,CHEMBL3289656,PQVQCEDGSJVHMK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24800940.0,Ki,=,724.44,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor by PDSP assay,Identification of a new selective dopamine D4 receptor ligand.,Bioorg. Med. Chem.,PUBLICATION,,6.139997578098903,C1CN(CCN1CCCC2=NC3=CC=CC=C3S2)C4=NC=CC=N4,c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1
2739,CHEMBL3289656,PQVQCEDGSJVHMK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24800940.0,Ki,=,730.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor by PDSP assay,Identification of a new selective dopamine D4 receptor ligand.,Bioorg. Med. Chem.,PUBLICATION,,6.136677139879544,C1CN(CCN1CCCC2=NC3=CC=CC=C3S2)C4=NC=CC=N4,c1cnc(N2CCN(CCCc3nc4ccccc4s3)CC2)nc1
2740,CHEMBL2207669,PREVLKLSVWYCAY-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CN(CCC1OC2=CC(=C(C=C2)C#N)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O,N#Cc1ccc(OC2CCN(C[C@H](O)CNC(=O)c3c[nH]c(=O)c4ccccc34)CC2)cc1Cl
2741,CHEMBL2376800,PREVTMRNRJIUDH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,33884.42,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.469999943783888,CCC1=CC2=C(C(=NC(=N2)N)N3CC(C3)NC)N=C1,CCc1cnc2c(N3CC(NC)C3)nc(N)nc2c1
2742,CHEMBL2030632,PRKCBGIXZFUCEF-UHFFFAOYSA-N,N-(3-FLUOROBENZYL)PYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CC2=CC(=CC=C2)F,Fc1cccc(CN2CCCC2)c1
2743,CHEMBL193482,PROQIPRRNZUXQM-ZXXIGWHRSA-N,ESTRIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O
2744,CHEMBL193482,PROQIPRRNZUXQM-ZXXIGWHRSA-N,ESTRIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1C[C@@H](O)[C@@H]2O
2745,CHEMBL488248,PRPSMPHMELIHFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553110.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Development of a selective and potent radioactive ligand for histamine H(3) receptors: A compound potentially useful for receptor occupancy studies.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1C(=NC2=CC=CC=C2C1=O)C3=CC=C(C=C3)OCCCN4CCCC4,Cn1c(-c2ccc(OCCCN3CCCC3)cc2)nc2ccccc2c1=O
2746,CHEMBL1783967,PRSVXRUERNSVCI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,120.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2ccncc2)C1
2747,CHEMBL1783967,PRSVXRUERNSVCI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,470.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.327902142064282,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)F,CN1CCc2c(c3cc(F)ccc3n2CCc2ccncc2)C1
2748,CHEMBL1935572,PRWLDKKWXOINJS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,2800.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.552841968657781,CN1CCN(CC1)C2=NC(=NC3=C2C=CC(=C3)C4=CSC=C4)N,CN1CCN(c2nc(N)nc3cc(-c4ccsc4)ccc23)CC1
2749,CHEMBL2205836,PSBBAGWMKGXQRW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,3727.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4286406072461615,COC1=CC=CC=C1CCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccccc1CCN1C2C3C4CC5C6C4C2C6C1(O)C53
2750,CHEMBL717,PSGAAPLEWMOORI-PEINSRQWSA-N,MEDROXYPROGESTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
2751,CHEMBL717,PSGAAPLEWMOORI-PEINSRQWSA-N,MEDROXYPROGESTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
2752,CHEMBL191,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,LOSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
2753,CHEMBL191,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,LOSARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl,CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
2754,CHEMBL255621,PSMOCFUMBCKOPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,5011.87,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3000002024454185,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC=N5,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4ncoc4cc3CC2)n1C
2755,CHEMBL402377,PSTMOSWQMHZABO-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18077160.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by [35S]GTP-gamma-S binding assay,In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C[C@H]1CCCN1CCC2=CC3=CC=CC=C3C=C2,C[C@H]1CCCN1CCc1ccc2ccccc2c1
2757,CHEMBL84081,PSVLBKXIZLIMQR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,1.29,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.88941028970075,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=CC(=C4)F,CN(C)CC1CC2c3ccccc3Cc3cc(F)ccc3N2O1
2763,CHEMBL1909078,PTLRDCMBXHILCL-UHFFFAOYSA-M,SODIUM ARSENITE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][As]=O.[Na+],O=[As][O-]
2764,CHEMBL1909078,PTLRDCMBXHILCL-UHFFFAOYSA-M,SODIUM ARSENITE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,[O-][As]=O.[Na+],O=[As][O-]
2765,CHEMBL1619,PTOAARAWEBMLNO-KVQBGUIXSA-N,CLADRIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
2766,CHEMBL1619,PTOAARAWEBMLNO-KVQBGUIXSA-N,CLADRIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O,Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
2767,CHEMBL328662,PTZUOUKVZMOWMQ-NFOSLFKVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,1.9,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.721246399047171,C1CN(CCC1C(=O)C2=CC=C(C=C2)F)CC3C[C@H]4[C@H](O3)C5=CC=CC=C5CC6=CC=CC=C46,O=C(c1ccc(F)cc1)C1CCN(CC2C[C@@H]3c4ccccc4Cc4ccccc4[C@H]3O2)CC1
2769,CHEMBL562894,PUYPQZLPNDWKQC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,7.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.148741651280925,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC,COc1ccc(Cn2c(N3CCC(n4cc(C)cn4)CC3)nc3ccccc32)cc1
2770,CHEMBL475534,PVHUJELLJLJGLN-UHFFFAOYSA-N,NITRENDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1
2771,CHEMBL475534,PVHUJELLJLJGLN-UHFFFAOYSA-N,NITRENDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc([N+](=O)[O-])c1
2772,CHEMBL408868,PVISFTMIHRDVDS-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,26.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029183,COC1=C(C=CC(=C1)Cl)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,COc1cc(Cl)ccc1O[C@H](c1ccccc1)[C@H]1CNCCO1
2774,CHEMBL94454,PVLJETXTTWAYEW-UHFFFAOYSA-N,MIZOLASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.7,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.568636235841014,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5=NC=CC(=O)N5,CN(c1nccc(=O)[nH]1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
2775,CHEMBL573,PVNIIMVLHYAWGP-UHFFFAOYSA-N,NIACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)O,O=C(O)c1cccnc1
2776,CHEMBL573,PVNIIMVLHYAWGP-UHFFFAOYSA-N,NIACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CN=C1)C(=O)O,O=C(O)c1cccnc1
2777,CHEMBL264007,PVOZTVLKZYEWDB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.36,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.196542884351587,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=C(C=C(C=C7)F)F,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(F)cc3F)C2)cc(OC)c1OC
2778,CHEMBL264007,PVOZTVLKZYEWDB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,436.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.360513510731415,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=C(C=C(C=C7)F)F,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(F)cc3F)C2)cc(OC)c1OC
2779,CHEMBL256482,PVPUOHNCMSOAEE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br,CCc1nc2cc3c(c(Br)c2o1)CCN(CCCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
2781,CHEMBL595158,PVWQFOKNAQZORV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,48.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.3187587626244115,CNCCC1C2=CC=CC=C2CC3=CC=CC=C13,CNCCC1c2ccccc2Cc2ccccc21
2782,CHEMBL3238445,PWBFJEIJPADHLX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,10471.29,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,4.979999812555049,CC1=NN=C(N1C2=CC=C(C=C2)OCCCN3CCCCC3)C4=CN=CC=C4,Cc1nnc(-c2cccnc2)n1-c1ccc(OCCCN2CCCCC2)cc1
2785,CHEMBL443896,PWESNUDCWDBFNS-UHFFFAOYSA-N,UR-PI288,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,12882.5,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,4.8899998488668865,CC(=O)NC(=NCCCC1=CN=CN1)N,CC(=O)NC(N)=NCCCc1cnc[nH]1
2786,CHEMBL314885,PWJDUASUWRTROR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,3.8,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.42021640338319,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)F,CN(C)CC1CC2c3cc(F)ccc3Cc3ccccc3N2O1
2787,CHEMBL317900,PWKIXUGLRAVBKW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,181.97,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.740000204918113,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)Br,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccc(Br)cc3)cc2)CC1
2788,CHEMBL2391166,PWLRRJAFPMHNQH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23591112.0,Ki,>,9300.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=CC=CC=C4F)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1ccccc1F
2789,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23919353.0,IC50,=,5.4,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Polypharmacology - foe or friend?,J. Med. Chem.,PUBLICATION,,8.267606240177031,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
2790,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,2.87,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.542118103266008,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
2791,CHEMBL643,PWWVAXIEGOYWEE-UHFFFAOYSA-N,PROMETHAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.334,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.476253533188435,CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C,CC(CN1c2ccccc2Sc2ccccc21)N(C)C
2792,CHEMBL589150,PWXLJFASAVPIDI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,32.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.494850021680094,CN1CCC2=C(C1)C3=C(N2CCC4=CC=C(C=C4)OC)C=CC(=C3)F,COc1ccc(CCn2c3c(c4cc(F)ccc42)CN(C)CC3)cc1
2793,CHEMBL2030636,PXBKRGXXBYALIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCC2=CC(=CC=C2)F,Fc1cccc(CCN2CCCC2)c1
2794,CHEMBL66660,PXCSHWXWJPYMAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12798320.0,Ki,=,15733.0,NM,,,,,,,,,,,,,,,Compound was tested for its binding affinity towards human H1 receptor,"A new class of histamine H(3)-receptor antagonists: synthesis and structure-activity relationships of 7,8,9,10-tetrahydro-6H-cyclohepta[b]quinolines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.803188457337323,C1CCC2=C(C3=CC=CC=C3N=C2CC1)C#CCCN4CCCCC4,C(#Cc1c2c(nc3ccccc13)CCCCC2)CCN1CCCCC1
2795,CHEMBL1277855,PXJLHYOGLFJGQN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415903,C1CN(CC(=C1)C(=O)O)C2CCC3(C2)CC4=C(CC5=CC=CC=C35)C=CC(=C4)F,O=C(O)C1=CCCN(C2CCC3(Cc4cc(F)ccc4Cc4ccccc43)C2)C1
2797,CHEMBL401728,PXMXBPLOQSHMBE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NN(C(=C1)C2=NC3=C(O2)C=C4CCN(CCC4=C3)CCCSC5=NN=C(N5C)C6=C(N=CO6)C)C,Cc1cc(-c2nc3cc4c(cc3o2)CCN(CCCSc2nnc(-c3ocnc3C)n2C)CC4)n(C)n1
2799,CHEMBL2208423,PXQMPHKMJWQPRD-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CC=CC(=C3)C#N)O,N#Cc1cccc(C(=O)NC[C@@H](O)CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)c1
2800,CHEMBL1946125,PXQSRAWVKJTJBP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,800.2,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.096801452957021,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCSC3=CC=C(C=C3)F,Fc1ccc(SCCCN2CCCN(c3ccc(Cl)cc3)CC2)cc1
2805,CHEMBL3609328,PYSIAKZWZJNMNM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26191365.0,IC50,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of recombinant human histamine H1 receptor,,ACS Med. Chem. Lett.,PUBLICATION,,9.0,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)F)NC4=C2C=C(C=C4)F,CN1CCN(C2=Nc3cc(F)ccc3Nc3ccc(F)cc32)CC1
2808,CHEMBL741,PYZRQGJRPPTADH-UHFFFAOYSA-N,LAMOTRIGINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
2809,CHEMBL741,PYZRQGJRPPTADH-UHFFFAOYSA-N,LAMOTRIGINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N,Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1
2813,CHEMBL189,PZRHRDRVRGEVNW-UHFFFAOYSA-N,MILRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1
2814,CHEMBL189,PZRHRDRVRGEVNW-UHFFFAOYSA-N,MILRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2,Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1
2815,CHEMBL309981,PZVJEHWECRAJMM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1CN(CCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2)C6=CC=CC=C6,c1ccc(N2CCN(CC3CC4c5ccccc5Cc5ccccc5N4O3)CC2)cc1
2816,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
2817,CHEMBL584,QAGYKUNXZHXKMR-HKWSIXNMSA-N,NELFINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C
2818,CHEMBL103027,QAPJOZONDSMYPF-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,6600.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.180456064458132,CC1=CC(=CC=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,Cc1cccc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)c1
2819,CHEMBL16068,QARVLSVVCXYDNA-UHFFFAOYSA-N,BROMOBENZENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)Br,Brc1ccccc1
2820,CHEMBL16068,QARVLSVVCXYDNA-UHFFFAOYSA-N,BROMOBENZENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)Br,Brc1ccccc1
2821,CHEMBL2171025,QAXGZLPJWOSHHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=C(C=C4)C5=NOC(=O)N5,O=C(c1ccc(-c2noc(=O)[nH]2)cc1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
2822,CHEMBL536991,QBEYTQZMQMRCRI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CC1=CC=C(C=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OCCCN4CCCCC4.Cl,Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCCC4)cc3)C(=O)C2)cc1
2824,CHEMBL315834,QBPDZEVGAGDUQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,1.74,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.7594507517174,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=CC=C4F,CN(C)CC1CC2c3ccccc3Cc3c(F)cccc3N2O1
2826,CHEMBL551888,QBUBIPIOMZYFEI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,3.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.443697499232712,CN(CC1=CC=CC=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(Cc1ccccc1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
2827,CHEMBL3357027,QCAINJLOQVFTKT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.0,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=C(C=C4)C(=O)OC)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3ccc(C(=O)OC)nc32)CC1
2828,CHEMBL1779059,QCBXRMVDVAHCPR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21555222.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,"Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O)OCCC8=CC=CC=C8,COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OCCc1ccccc1
2829,CHEMBL1779059,QCBXRMVDVAHCPR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=C(C=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O)OCCC8=CC=CC=C8,COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1OCCc1ccccc1
2830,CHEMBL515472,QCFZUTYIUYQTPW-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,509.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.293282217663242,COC1=C(C=CC=C1OCCF)[C@@H](C2CCN(CC2)CCC3=CC=C(C=C3)F)O,COc1c(OCCF)cccc1[C@H](O)C1CCN(CCc2ccc(F)cc2)CC1
2831,CHEMBL402143,QCFZUTYIUYQTPW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19329329.0,Ki,=,374.0,NM,,,,,,,,,,,,,,,Inhibition of human cloned histamine H1 receptor by competitive binding experiment,Synthesis and in vitro affinities of various MDL 100907 derivatives as potential 18F-radioligands for 5-HT2A receptor imaging with PET.,Bioorg. Med. Chem.,PUBLICATION,,6.427128397799519,COC1=C(C=CC=C1OCCF)C(C2CCN(CC2)CCC3=CC=C(C=C3)F)O,COc1c(OCCF)cccc1C(O)C1CCN(CCc2ccc(F)cc2)CC1
2836,CHEMBL554031,QDMPFGBUXBHFTH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1995262314968.88,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-3.3,C1=C(NC=N1)CCCCCCN,NCCCCCCc1cnc[nH]1
2838,CHEMBL2376801,QEDDBMMRWNQKSG-SNVBAGLBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23558237.0,Ki,=,11220.18,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human histamine H1 receptor expressed in HEK cells,"A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787.",Bioorg. Med. Chem. Lett.,PUBLICATION,,4.950000175844591,CCC1=CC2=C(C(=NC(=N2)N)N3CC[C@H](C3)NC)N=C1,CCc1cnc2c(N3CC[C@@H](NC)C3)nc(N)nc2c1
2839,CHEMBL290916,QELUYTUMUWHWMC-UHFFFAOYSA-N,EDARAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN(C(=O)C1)C2=CC=CC=C2,CC1=NN(c2ccccc2)C(=O)C1
2840,CHEMBL290916,QELUYTUMUWHWMC-UHFFFAOYSA-N,EDARAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN(C(=O)C1)C2=CC=CC=C2,CC1=NN(c2ccccc2)C(=O)C1
2841,CHEMBL2113241,QENBLMVKRYFDIR-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16821797.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"(R)-3'-(3-methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3,5'-oxazolidin]-2'-one, a novel and potent alpha7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties.",J. Med. Chem.,PUBLICATION,,5.0,CC1=COC2=C1C=C(C=C2)N3C[C@@]4(CN5CCC4CC5)OC3=O,Cc1coc2ccc(N3C[C@@]4(CN5CCC4CC5)OC3=O)cc12
2842,CHEMBL772,QEVHRUUCFGRFIF-MDEJGZGSSA-N,RESERPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
2843,CHEMBL772,QEVHRUUCFGRFIF-MDEJGZGSSA-N,RESERPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)C6=CC(=C(C(=C6)OC)OC)OC,COC(=O)[C@H]1[C@H]2C[C@@H]3c4[nH]c5cc(OC)ccc5c4CCN3C[C@H]2C[C@@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)[C@@H]1OC
2844,CHEMBL1935416,QEWJHGKQGHFKCH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153342.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,"Synthesis and evaluation of 4-alkoxy-[1'-cyclobutyl-spiro(3,4-dihydrobenzopyran-2,4'-piperidine)] analogues as histamine-3 receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CS(=O)(=O)CCCOC1=CC2=C(C=C1)OC3(CC2)CCN(CC3)C4CCC4,CS(=O)(=O)CCCOc1ccc2c(c1)CCC1(CCN(C3CCC3)CC1)O2
2845,CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
2846,CHEMBL413,QFJCIRLUMZQUOT-HPLJOQBZSA-N,SIROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C
2847,CHEMBL1098441,QFKNUCVKOWGNCX-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@@H](C)C2=CC=CC=C2,Cc1nc(N)sc1CCCN=C(N)NC(=O)C[C@@H](C)c1ccccc1
2848,CHEMBL1098442,QFKNUCVKOWGNCX-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@H](C)C2=CC=CC=C2,Cc1nc(N)sc1CCCN=C(N)NC(=O)C[C@H](C)c1ccccc1
2849,CHEMBL1098110,QFKNUCVKOWGNCX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)CC(C)C2=CC=CC=C2,Cc1nc(N)sc1CCCN=C(N)NC(=O)CC(C)c1ccccc1
2850,CHEMBL2205834,QFMGHZDEZHDVJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=NC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccncc1
2851,CHEMBL2436555,QFNMPNWOYBWECY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24035337.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK cells after 90 mins by scintillation counting analysis,"2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2=C(C=CC(=C2)Cl)NC(=N1)N.Cl,NC1=NCc2cc(Cl)ccc2N1
2852,CHEMBL420108,QFTNRJFCJNHEPW-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,6200.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2076083105017466,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2C#N)CCCOC3=CC=C(C=C3)C(=O)C4CC4,N#Cc1ccccc1S(=O)(=O)N[C@H]1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)C1
2853,CHEMBL240565,QGFBWPZGQZAHLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCN(C(=O)C2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCCC5.C(=O)O,CS(=O)(=O)c1cccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCCC5)CC4)cc3)C(=O)C2)c1
2858,CHEMBL87285,QGXBDMJGAMFCBF-HLUDHZFRSA-N,ANDROSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@@]43C)[C@@H]1CCC2=O
2859,CHEMBL87285,QGXBDMJGAMFCBF-HLUDHZFRSA-N,ANDROSTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CCC4=O)C)O,C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@H](O)CC[C@@]43C)[C@@H]1CCC2=O
2860,CHEMBL3321792,QHLAPIQLWATZKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,1009.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.996108833763089,C1CC2CC(CC1N2CCCSC3=CC=CC=C3F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1ccccc1F
2864,CHEMBL430502,QIPPGLRRKJCTOV-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,13000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.886056647693163,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=CC=C(C=C3)C#N,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)c3ccc(C#N)cc3)C2)cc1
2865,CHEMBL2158770,QIUVHPATBGGVRR-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,25.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC(=CC=C4)C#N)C(=O)O,N#Cc1cccc(C[C@@H](C(=O)O)N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
2866,CHEMBL105762,QJFIAPPKZLXTPP-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,562.34,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2500010234416505,C[C@@H]1CC[C@H](N1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)C,C[C@@H]1CC[C@@H](C)N1CCCOc1ccc(-c2ccc(C#N)cc2)cc1
2867,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
2868,CHEMBL269732,QJJXYPPXXYFBGM-LFZNUXCKSA-N,TACROLIMUS,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC,C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC
2869,CHEMBL594731,QJNCEPWQQYZJCX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CC1=CC=CC=C1CNC2=CC(=NC(=N2)N)N3CCN(CC3)C,Cc1ccccc1CNc1cc(N2CCN(C)CC2)nc(N)n1
2870,CHEMBL437792,QJNRRDWLNVGLID-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(C)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3ccc4oc(C(C)(F)F)nc4c3CC2)n1C
2871,CHEMBL292195,QJPBTFRGWJLPSI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,8.154901959985743,CN(CCCCC1=CN=CN1)CCC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3,CN(CCCCc1cnc[nH]1)CCC(c1ccc(Cl)cc1)c1ccccn1
2872,CHEMBL292195,QJPBTFRGWJLPSI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,8.154901959985743,CN(CCCCC1=CN=CN1)CCC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3,CN(CCCCc1cnc[nH]1)CCC(c1ccc(Cl)cc1)c1ccccn1
2873,CHEMBL330430,QJSGTTMHFKBELN-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,124.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.906578314837764,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)Cl)Cl.C(=C/C(=O)O)\C(=O)O,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
2874,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
2875,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
2876,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
2877,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18683917.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor,The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
2879,CHEMBL260374,QKDDJDBFONZGBW-UHFFFAOYSA-N,THIOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,5.0,C1CCC(CC1)NC(=S)N2CCC(CC2)C3=CN=CN3,S=C(NC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
2881,CHEMBL277100,QKDHBVNJCZBTMR-UHFFFAOYSA-N,TEMAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F,CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1
2882,CHEMBL277100,QKDHBVNJCZBTMR-UHFFFAOYSA-N,TEMAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=C(C=C(C=C4)F)F)F,CC1CN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)CCN1
2883,CHEMBL1088900,QKNADAQNYDFJFJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.657577319177793,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3OC,COc1nccnc1CC1=C(CCN(C)C)Cc2ccccc21
2884,CHEMBL2031877,QKNQLRSRULGFBA-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,7010.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.154281982033341,C[C@H]1CCCN1C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5,C[C@H]1CCCN1C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
2885,CHEMBL2031876,QKNQLRSRULGFBA-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,C[C@@H]1CCCN1C(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5,C[C@@H]1CCCN1C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
2886,CHEMBL1669426,QLDMAQDSTHZTSU-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,24.7,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.607303046740334,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN=C4,C[C@H](C1=C(CCN(C)Cc2cnccn2)Cc2ccccc21)c1cnccn1
2887,CHEMBL2158774,QLGIWKYNMSCERQ-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,CC1=CC=C(C=C1)C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1ccc(C[C@@H](C(=O)O)N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
2888,CHEMBL1669410,QLIYPKVJEXOVDM-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,109.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.962573502059376,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC#N,C[C@H](C1=C(CCN(C)CCC#N)Cc2ccccc21)c1cnccn1
2889,CHEMBL9419,QLNWXBAGRTUKKI-UHFFFAOYSA-N,METACETAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC(=CC=C1)O,CC(=O)Nc1cccc(O)c1
2890,CHEMBL9419,QLNWXBAGRTUKKI-UHFFFAOYSA-N,METACETAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC(=CC=C1)O,CC(=O)Nc1cccc(O)c1
2891,CHEMBL1767161,QLOCEFPHCAKSLE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.700057099977232,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C1CCCN(CCCCc2ccc(OCCCN3CCCCCC3)cc2)CC1
2892,CHEMBL1946257,QLTASWSCCMMISJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,129.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.889410289700751,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCCC(=O)C3=NC4=CC=CC=C4S3,O=C(CCCCN1CCCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1
2893,CHEMBL110691,QMBJSIBWORFWQT-DFXBJWIESA-N,CHLORMADINONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
2894,CHEMBL110691,QMBJSIBWORFWQT-DFXBJWIESA-N,CHLORMADINONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)CC[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
2895,CHEMBL227934,QMGVPVSNSZLJIA-FVWCLLPLSA-N,STRYCHNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75,O=C1C[C@@H]2OCC=C3CN4CC[C@]56c7ccccc7N1[C@H]5[C@H]2[C@H]3C[C@H]46
2896,CHEMBL227934,QMGVPVSNSZLJIA-FVWCLLPLSA-N,STRYCHNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN2CC3=CCO[C@H]4CC(=O)N5[C@H]6[C@H]4[C@H]3C[C@H]2[C@@]61C7=CC=CC=C75,O=C1C[C@@H]2OCC=C3CN4CC[C@]56c7ccccc7N1[C@H]5[C@H]2[C@H]3C[C@H]46
2897,CHEMBL157548,QMLVECGLEOSESV-RYUDHWBXSA-N,DANOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F,CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1
2898,CHEMBL157548,QMLVECGLEOSESV-RYUDHWBXSA-N,DANOFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C[C@@H]2C[C@H]1CN2C3=C(C=C4C(=C3)N(C=C(C4=O)C(=O)O)C5CC5)F,CN1C[C@@H]2C[C@H]1CN2c1cc2c(cc1F)c(=O)c(C(=O)O)cn2C1CC1
2899,CHEMBL64235,QMUNKLLETTWTBJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1096.48,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9599992855266795,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)CSCC,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)CSCC)CC2)cc1
2902,CHEMBL366925,QNNXKPSMUIHGIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,COC(=O)N(CCC#CC1=CC=C(C=C1)OCCCCN2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)O,COC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
2904,CHEMBL3321791,QOECKZUXJGSVMP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,1207.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.91829272990265,C1CC2CC(CC1N2CCCSC3=CC=CC(=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCSc1cccc(F)c1
2905,CHEMBL1669425,QORUSIWOKHYRCP-SFHVURJKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.309803919971486,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=NC=C4,C[C@H](C1=C(CCN(C)Cc2ccncc2)Cc2ccccc21)c1cnccn1
2906,CHEMBL46516,QOYHHIBFXOOADH-UHFFFAOYSA-N,FLUSPIRILENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,12.0,NM,,,,,,,,,,,,,,,,,,,,7.920818753952375,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=C1NCN(c2ccccc2)C12CCN(CCCC(c1ccc(F)cc1)c1ccc(F)cc1)CC2
2907,CHEMBL96466,QPFYLKDZMPQIPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.89,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161780778092375,C1CN(CCC1C(=O)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)CCC5(CCN(C5)C(=O)C6=C(C=C(C=C6)Cl)Cl)C7=CC8=C(C=C7)OCO8,O=C(c1nc2ccccc2n1Cc1ccc(F)cc1)C1CCN(CCC2(c3ccc4c(c3)OCO4)CCN(C(=O)c3ccc(Cl)cc3Cl)C2)CC1
2909,CHEMBL438,QPPBRPIAZZHUNT-UHFFFAOYSA-N,SULFAMERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1
2910,CHEMBL438,QPPBRPIAZZHUNT-UHFFFAOYSA-N,SULFAMERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=NC=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1
2912,CHEMBL1767163,QQERDUJEEYWVED-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.400007822415903,CN(CCCCC1=CC=C(C=C1)OCCCN2CCCCCC2)CCN3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)Cl,CN(CCCCc1ccc(OCCCN2CCCCCC2)cc1)CCn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
2913,CHEMBL318320,QQJIHDLIMPSIHG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,81.28,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.090016305060157,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)[N+](=O)[O-],CCOC(=O)N1CCN(CCCOc2ccc(-c3ccc([N+](=O)[O-])cc3)cc2)CC1
2914,CHEMBL515914,QQOBRRFOVWGIMD-OJAKKHQRSA-N,AZARIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
2915,CHEMBL515914,QQOBRRFOVWGIMD-OJAKKHQRSA-N,AZARIBINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C(=O)NC(=O)C=N2)OC(=O)C)OC(=O)C,CC(=O)OC[C@H]1O[C@@H](n2ncc(=O)[nH]c2=O)[C@H](OC(C)=O)[C@@H]1OC(C)=O
2916,CHEMBL2207655,QQODNMGQNZBOAF-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CC1(CN(C1)S(=O)(=O)C2=CC3=C(C=C2)C(=CNC3=O)C(=O)NC[C@H](CN4CCC(CC4)OC5=CC(=C(C=C5)Cl)Cl)O)O,CC1(O)CN(S(=O)(=O)c2ccc3c(C(=O)NC[C@@H](O)CN4CCC(Oc5ccc(Cl)c(Cl)c5)CC4)c[nH]c(=O)c3c2)C1
2918,CHEMBL331077,QQWLSTBNUSPPGV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,<,1000.0,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=NC=C4,CN(C)CC1CC2c3ccccc3Cc3ccncc3N2O1
2919,CHEMBL1774497,QQXGHFOKGJXCOQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,70.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.154901959985742,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4CCC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4CCc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2920,CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
2921,CHEMBL1262,QRJJEGAJXVEBNE-HKOYGPOVSA-N,OXICONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1Cl)Cl)CO/N=C(\CN2C=CN=C2)/C3=C(C=C(C=C3)Cl)Cl,Clc1ccc(CO/N=C(\Cn2ccnc2)c2ccc(Cl)cc2Cl)c(Cl)c1
2922,CHEMBL28833,QRQZDZPCRVUFNL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCCC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4,CCCc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
2923,CHEMBL271096,QRWDBCPLADXSGV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC=C(C=C5)C(F)(F)F,CCc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2ccc(C(F)(F)F)cc2)n1C)CC3
2924,CHEMBL64,QRXWMOHMRWLFEY-UHFFFAOYSA-N,ISONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C(=O)NN,NNC(=O)c1ccncc1
2925,CHEMBL64,QRXWMOHMRWLFEY-UHFFFAOYSA-N,ISONIAZID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C(=O)NN,NNC(=O)c1ccncc1
2927,CHEMBL413965,QRZAKQDHEVVFRX-UHFFFAOYSA-N,FELBINAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O,O=C(O)Cc1ccc(-c2ccccc2)cc1
2928,CHEMBL413965,QRZAKQDHEVVFRX-UHFFFAOYSA-N,FELBINAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC=C(C=C2)CC(=O)O,O=C(O)Cc1ccc(-c2ccccc2)cc1
2929,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.79,NM,,,,,,,,,,,,,,,,,,,,9.102372908709556,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
2930,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,1.67,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.777283528852417,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
2931,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,8.79,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.056011124926227,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
2932,CHEMBL21731,QSLMDECMDJKHMQ-UHFFFAOYSA-N,MAPROTILINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.02,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.991399828238082,CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24,CNCCCC12CCC(c3ccccc31)c1ccccc12
2933,CHEMBL30713,QSQQQURBVYWZKJ-UHFFFAOYSA-N,ALPHA-METHYLTRYPTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23602445.0,Ki,>,10000.0,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting analysis,An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(CC1=CNC2=CC=CC=C21)N,CC(N)Cc1c[nH]c2ccccc12
2934,CHEMBL1200748,QTAOMKOIBXZKND-PPHPATTJSA-N,CARBIDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
2935,CHEMBL1200748,QTAOMKOIBXZKND-PPHPATTJSA-N,CARBIDOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN.O,C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O
2936,CHEMBL3099716,QTAONPFQLNZKSD-XJABCFGWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,48500.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,4.314258261397736,CC1([C@@H](N(C(=O)O1)C2CCC(CC2)C3=CC(=C(N=C3)N)C4=NC=CC=N4)C5=CC=CC=C5)C,CC1(C)OC(=O)N(C2CCC(c3cnc(N)c(-c4ncccn4)c3)CC2)[C@H]1c1ccccc1
2937,CHEMBL434063,QTQMRBZOBKYXCG-MHZLTWQESA-N,GW1929,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1
2938,CHEMBL434063,QTQMRBZOBKYXCG-MHZLTWQESA-N,GW1929,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)C[C@@H](C(=O)O)NC2=CC=CC=C2C(=O)C3=CC=CC=C3)C4=CC=CC=N4,CN(CCOc1ccc(C[C@H](Nc2ccccc2C(=O)c2ccccc2)C(=O)O)cc1)c1ccccn1
2941,CHEMBL2205828,QUMVESOWCHBEEV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=CC(=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC,COc1cc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)cc(OC)c1
2942,CHEMBL1774506,QUPFMAXRMLKPQC-WMDMUMDLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,135.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.8696662315049934,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4CCC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCCN(CC/C=C3/c4ccccc4CCc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
2943,,QUROTGLADLKIIK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,1778.28,NM,,,,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.7499998559187055,C1CCN(CC1)CCN2C(=CC3=C2N=CC=C3)C4CCCO4,c1cnc2c(c1)cc(C1CCCO1)n2CCN1CCCCC1
2946,CHEMBL238504,QUXZAXNZEZALDL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,3162.28,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.4999996786570655,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C5N=CC=CN5N=C4.C(=O)O,O=C(c1cnn2cccnc12)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
2948,CHEMBL2158814,QVLZVRFIGXNZMN-UHFFFAOYSA-N,AZD-3778,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22931505.0,IC50,=,40.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Chemokine receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.397940008672037,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
2949,CHEMBL2158814,QVLZVRFIGXNZMN-UHFFFAOYSA-N,AZD-3778,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
2950,CHEMBL2158814,QVLZVRFIGXNZMN-UHFFFAOYSA-N,AZD-3778,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
2951,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,97723.72,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,4.010000009312982,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Cc1ccccc1C(OCCN(C)C)c1ccccc1
2952,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1241.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.90622821850127,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Cc1ccccc1C(OCCN(C)C)c1ccccc1
2953,CHEMBL900,QVYRGXJJSLMXQH-UHFFFAOYSA-N,ORPHENADRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,144.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.841637507904752,CC1=CC=CC=C1C(C2=CC=CC=C2)OCCN(C)C,Cc1ccccc1C(OCCN(C)C)c1ccccc1
2956,CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
2957,CHEMBL114,QWAXKHKRTORLEM-UGJKXSETSA-N,SAQUINAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@H]([C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)N)NC(=O)C4=NC5=CC=CC=C5C=C4)O,CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1
2958,CHEMBL1109,QWCJHSGMANYXCW-UHFFFAOYSA-N,SULFAPHENAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1
2959,CHEMBL1109,QWCJHSGMANYXCW-UHFFFAOYSA-N,SULFAPHENAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)N2C(=CC=N2)NS(=O)(=O)C3=CC=C(C=C3)N,Nc1ccc(S(=O)(=O)Nc2ccnn2-c2ccccc2)cc1
2960,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
2961,CHEMBL49,QWCRAEMEVRGPNT-UHFFFAOYSA-N,BUSPIRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1
2963,CHEMBL1113,QWGDMFLQWFTERH-UHFFFAOYSA-N,AMOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,99.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.00436480540245,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
2964,CHEMBL1113,QWGDMFLQWFTERH-UHFFFAOYSA-N,AMOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,11.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.9586073148417755,C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,Clc1ccc2c(c1)C(N1CCNCC1)=Nc1ccccc1O2
2966,CHEMBL105268,QWIRSRRDSYVSEG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,380.19,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.41999931041096,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=CC(=C3)C#N,CCOC(=O)N1CCN(CCCOc2ccc(-c3cccc(C#N)c3)cc2)CC1
2967,CHEMBL411293,QWMBVXDLQBRGEQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=CC(=CC6=N5)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5nc6cc(C(F)(F)F)ccn6c5CC4)n3C)cccc2n1
2968,CHEMBL255826,QWRZAQFQULNINP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)N7CCCCC7,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(N7CCCCC7)oc6cc5CC4)n3C)cccc2n1
2969,CHEMBL551340,QWTQKWHOWDAFRM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,75.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,7.1249387366083,CN(C)CCC1=C(C2=CC=CC=C2S1)CC3=NC=CN=C3,CN(C)CCc1sc2ccccc2c1Cc1cnccn1
2970,CHEMBL1365675,QXAITBQSYVNQDR-ZIOPAAQOSA-N,AMITRAZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Cc1ccc(N=CN(C)C=Nc2ccc(C)cc2C)c(C)c1
2971,CHEMBL1365675,QXAITBQSYVNQDR-ZIOPAAQOSA-N,AMITRAZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C=C1)N=CN(C)C=NC2=C(C=C(C=C2)C)C)C,Cc1ccc(N=CN(C)C=Nc2ccc(C)cc2C)c(C)c1
2972,CHEMBL416,QXKHYNVANLEOEG-UHFFFAOYSA-N,METHOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,COc1c2occc2cc2ccc(=O)oc12
2973,CHEMBL416,QXKHYNVANLEOEG-UHFFFAOYSA-N,METHOXSALEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2,COc1c2occc2cc2ccc(=O)oc12
2974,CHEMBL1767159,QYAXGGUCDQSHIT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C1CCCN(Cc2ccc(OCCCN3CCCCCC3)cc2)CC1
2978,CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
2979,CHEMBL527,QYSPLQLAKJAUJT-UHFFFAOYSA-N,PIROXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O
2980,CHEMBL1042,QYSXJUFSXHHAJI-YRZJJWOYSA-N,CHOLECALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C
2981,CHEMBL1042,QYSXJUFSXHHAJI-YRZJJWOYSA-N,CHOLECALCIFEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H](CCCC(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C,C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C
2982,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,EC50,=,0.4,NM,,inverse_agonist,,binding,,,,,,,,,,,,,,,,9.397940008672037,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2983,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,2.77,NM,,,,,,,,,,,,,,,,,,,,8.557520230935554,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2984,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,,,,,,8.920818753952375,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2985,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,2.8,NM,,,,,,,,,,,,,,,,,,,,8.55284196865778,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2986,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.23,NM,,,,,,,,,,,,,,,,,,,,9.638272163982409,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2987,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,3.1,NM,,,,,,,,,,,,,,,,,,,,8.508638306165727,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2988,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,17.0,NM,,,,,,,,,,,,,,,Binding affinity against histamine H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,7.769551078621726,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2989,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.54,NM,,,,,,,,,,,,,,,,,,,,8.812479279163536,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2990,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.63,NM,,,,,,,,,,,,,,,,,,,,8.787812395596044,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2991,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,,,,,,8.920818753952375,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2992,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,2.1,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.67778070526608,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2993,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.1,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.958607314841776,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2994,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,1.8,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,8.744727494896694,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2995,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,2.38,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.623423042943488,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2997,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,1.8,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,8.744727494896694,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2998,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,9.0,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
2999,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.91,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.308918507877031,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
3000,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.5710000000000001,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.243363891754154,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
3001,CHEMBL42,QZUDBNBUXVUHMW-UHFFFAOYSA-N,CLOZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.0,CN1CCN(CC1)C2=NC3=C(C=CC(=C3)Cl)NC4=CC=CC=C42,CN1CCN(C2=Nc3cc(Cl)ccc3Nc3ccccc32)CC1
3003,CHEMBL153994,QZYRMAITXZSSGA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,316227766016838.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.5,CC1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=CC=C3,Cc1ccc(C(CCc2ncc(CCN)[nH]2)c2ccccc2)cc1
3005,CHEMBL240185,RAGNKICHAZGMOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.C(=O)O,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
3006,CHEMBL105385,RAHWSYMHXYDXJB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4500041484693496,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)Cl,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccc(Cl)cc3)cc2)CC1
3007,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27639363.0,Ki,=,42.6,NM,,,,,,,,,,,,,,,,,,,,7.370590400897282,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3008,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,27.0,NM,,,,,,,,,,,,,,,,,,,,7.568636235841013,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3009,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,5.2,NM,,,,,,,,,,,,,,,,,,,,8.2839966563652,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3010,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,88.0,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,7.055517327849832,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3011,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,,,,,,7.823908740944319,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3012,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,2.6,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,8.585026652029184,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3013,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,33.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.481486060122112,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3014,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,7.721246399047171,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3015,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,868.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.061480274823508,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3016,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,25.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.602059991327962,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3017,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2.87,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.542118103266008,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3018,CHEMBL85,RAPZEAPATHNIPO-UHFFFAOYSA-N,RISPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,7.0,CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F,Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2
3019,CHEMBL1909048,RBCUCXILXJXLTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl,O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1
3020,CHEMBL1909048,RBCUCXILXJXLTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCC1CC2=CC=CC=C2)C(=O)C3=CC=CC=C3Cl,O=C(c1ccccc1Cl)N1CCC(Cc2ccccc2)CC1
3021,CHEMBL95243,RBJZEZVXAVEQFQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.02,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.220403508742175,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)C(=O)OC)OC,COC(=O)c1ccc(Cn2c(C(=O)C3CCN(CCC4(c5ccc(OC)c(OC)c5)CCN(C(=O)c5cc(OC)c(OC)c(OC)c5)C4)CC3)nc3ccccc32)cc1
3022,CHEMBL1630578,RBKASMJPSJDQKY-RBFSKHHSSA-N,TIRILIZAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@H]1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1
3023,CHEMBL1630578,RBKASMJPSJDQKY-RBFSKHHSSA-N,TIRILIZAD,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4(C3=CC[C@@]2([C@H]1C(=O)CN5CCN(CC5)C6=NC(=NC(=C6)N7CCCC7)N8CCCC8)C)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)C3=CC[C@]2(C)[C@H]1C(=O)CN1CCN(c2cc(N3CCCC3)nc(N3CCCC3)n2)CC1
3024,CHEMBL270209,RBZIHZIBFQXVQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5CCOCC5,Cc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(C2CCOCC2)n1C)CC3
3025,CHEMBL311350,RCIMBBZXSXFZBV-UHFFFAOYSA-N,PIROMIDIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCCC3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCCC3)nc21
3026,CHEMBL311350,RCIMBBZXSXFZBV-UHFFFAOYSA-N,PIROMIDIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CN=C(N=C21)N3CCCC3)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cnc(N3CCCC3)nc21
3027,CHEMBL428647,RCINICONZNJXQF-MZXODVADSA-N,PACLITAXEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
3028,CHEMBL428647,RCINICONZNJXQF-MZXODVADSA-N,PACLITAXEL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
3030,CHEMBL102331,RDGBZPAYYHGGML-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,7400.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.130768280269023,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=CN=CC=C3,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)c3cccnc3)C2)cc1
3032,CHEMBL1297,RDJGLLICXDHJDY-UHFFFAOYSA-N,FENOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
3033,CHEMBL1297,RDJGLLICXDHJDY-UHFFFAOYSA-N,FENOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O,CC(C(=O)O)c1cccc(Oc2ccccc2)c1
3034,CHEMBL841,RDOIQAHITMMDAJ-UHFFFAOYSA-N,LOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
3035,CHEMBL841,RDOIQAHITMMDAJ-UHFFFAOYSA-N,LOPERAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
3036,CHEMBL1200993,REEUVFCVXKWOFE-UHFFFAOYSA-K,GALLAMINE TRIETHIODIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC
3037,CHEMBL1200993,REEUVFCVXKWOFE-UHFFFAOYSA-K,GALLAMINE TRIETHIODIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+](CC)(CC)CCOC1=C(C(=CC=C1)OCC[N+](CC)(CC)CC)OCC[N+](CC)(CC)CC.[I-].[I-].[I-],CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC
3039,CHEMBL2158833,REJVZJBLJWRHQL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)CC4=CC=C(C=C4)C(=O)O,O=C(O)c1ccc(CN2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
3040,CHEMBL640,REQCZEXYDRLIBE-UHFFFAOYSA-N,PROCAINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CCN(CC)CCNC(=O)c1ccc(N)cc1
3041,CHEMBL640,REQCZEXYDRLIBE-UHFFFAOYSA-N,PROCAINAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC=C(C=C1)N,CCN(CC)CCNC(=O)c1ccc(N)cc1
3043,CHEMBL2146801,REXDQAIKTDDWAC-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.251,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.600326278518963,COCCN1CCC[C@@H]1CN2C(=O)C3=C(C=NC=C3)C(=N2)CC4=CC=C(C=C4)Cl,COCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2cnccc2c1=O
3044,CHEMBL1767160,REXVRCXDIWIKGL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.799970733446231,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCN3CCCC(CC3)N4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C1CCCN(CCCc2ccc(OCCCN3CCCCCC3)cc2)CC1
3045,CHEMBL28079,REZGGXNDEMKIQB-UHFFFAOYSA-N,ZAPRINAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,CCCOc1ccccc1-c1nc2n[nH]nc2c(=O)[nH]1
3046,CHEMBL28079,REZGGXNDEMKIQB-UHFFFAOYSA-N,ZAPRINAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCOC1=CC=CC=C1C2=NC3=NNN=C3C(=O)N2,CCCOc1ccccc1-c1nc2n[nH]nc2c(=O)[nH]1
3047,CHEMBL179234,REZSROOERNUDJU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15634025.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human H1 histamine receptor,2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC3=C(C=C2)N=C(C=C3)N4CCN(CC4)C5CC5,O=C(c1ccc2nc(N3CCN(C4CC4)CC3)ccc2c1)C1CC1
3048,CHEMBL320178,RFDSGHNJJQPTLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.799998134593397,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccc(C#N)cc3)cc2)CC1
3049,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
3050,CHEMBL106,RFHAOTPXVQNOHP-UHFFFAOYSA-N,FLUCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F
3052,CHEMBL1201216,RFWZESUMWJKKRN-UHFFFAOYSA-N,DAPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
3053,CHEMBL1201216,RFWZESUMWJKKRN-UHFFFAOYSA-N,DAPIPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1N2CCN(CC2)CCC3=NN=C4N3CCCC4,Cc1ccccc1N1CCN(CCc2nnc3n2CCCC3)CC1
3054,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,8.33,NM,,,,,,,,,,,,,,,,,,,,8.079354998593212,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3055,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,8.0,NM,,,,,,,,,,,,,,,,,,,,8.096910013008056,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3056,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,8.0,NM,,,,,,,,,,,,,,,,,,,,8.096910013008056,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3057,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3058,CHEMBL567,RGCVKNLCSQQDEP-UHFFFAOYSA-N,PERPHENAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl)CCO,OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3059,CHEMBL1923525,RGFBLHAWTZMUAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,707.95,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.149997413907538,CN(C)CCSC1=NC2=CC=CC=C2C3=NN=NN31,CN(C)CCSc1nc2ccccc2c2nnnn12
3060,CHEMBL572034,RGGWURWNJUDTIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,121.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.917214629683549,CC1=CC=C(C=C1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)O,Cc1ccc(CCCCN2CCC(C(O)c3ccccc3)CC2)cc1
3061,CHEMBL411,RGLYKWWBQGJZGM-ISLYRVAYSA-N,DIETHYLSTILBESTROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
3062,CHEMBL411,RGLYKWWBQGJZGM-ISLYRVAYSA-N,DIETHYLSTILBESTROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC/C(=C(/CC)\C1=CC=C(C=C1)O)/C2=CC=C(C=C2)O,CC/C(=C(/CC)c1ccc(O)cc1)c1ccc(O)cc1
3064,CHEMBL2208429,RGQXJYRGDMABLT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=NNC4=CC=CC=C43)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1n[nH]c2ccccc12
3065,CHEMBL105515,RGULNTQENHHTRC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1CCCC(N1CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)C,CC1CCCC(C)N1CCCOc1ccc(-c2ccc(C#N)cc2)cc1
3067,CHEMBL2208422,RHDOFWFMSRHNFN-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNS(=O)(=O)C3=CC=CC(=C3)C#N)O,N#Cc1cccc(S(=O)(=O)NC[C@@H](O)CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)c1
3068,CHEMBL65518,RHEMXJFXAARMOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,4168.69,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.380000399499542,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)N3CCOCC3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)N3CCOCC3)CC2)cc1
3071,CHEMBL435301,RHPCETHLGGFAQB-MQSINFNDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,4.3,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.366531544420411,CN(C)C[C@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,CN(C)C[C@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1
3072,CHEMBL364270,RHPCETHLGGFAQB-SHZHJNINSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,14.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,7.853871964321763,CN(C)C[C@@H]1CC2[C@H](O1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,CN(C)C[C@@H]1CC2c3ccccc3Oc3ccc(Cl)cc3[C@H]2O1
3073,CHEMBL2171023,RIEFZSRXHBEIFW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=CC=C4C(=O)O,O=C(O)c1ccccc1C(=O)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3074,CHEMBL1308,RIKMMFOAQPJVMX-UHFFFAOYSA-N,FOMEPIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CNN=C1,Cc1cn[nH]c1
3075,CHEMBL1308,RIKMMFOAQPJVMX-UHFFFAOYSA-N,FOMEPIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CNN=C1,Cc1cn[nH]c1
3076,CHEMBL560917,RIUIDVINUPJOQH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,105.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.978810700930063,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CCC(=O)O,Cn1c(N2CCN(CCCN3c4ccccc4Sc4ccc(CCC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3078,CHEMBL154068,RIXQVRQUELEXES-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,50118.72,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,4.300000029139089,C1=CC(=C(C=C1C2=NC=C(N2)CCN)Cl)Cl,NCCc1cnc(-c2ccc(Cl)c(Cl)c2)[nH]1
3079,CHEMBL154068,RIXQVRQUELEXES-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,50118723362727.1,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.699999999999998,C1=CC(=C(C=C1C2=NC=C(N2)CCN)Cl)Cl,NCCc1cnc(-c2ccc(Cl)c(Cl)c2)[nH]1
3080,CHEMBL1092652,RJAXVZUSTIFVGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.1,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.67778070526608,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NN=CC=C3,CN(C)CCC1=C(Cc2cccnn2)c2ccc(Cl)cc2C1
3081,CHEMBL103,RJKFOVLPORLFTN-LEKSSAKUSA-N,PROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
3082,CHEMBL103,RJKFOVLPORLFTN-LEKSSAKUSA-N,PROGESTERONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C
3083,CHEMBL1554,RJURFGZVJUQBHK-IIXSONLDSA-N,DACTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O
3084,CHEMBL1554,RJURFGZVJUQBHK-IIXSONLDSA-N,DACTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@@H](C(=O)N[C@@H](C(=O)N2CCC[C@H]2C(=O)N(CC(=O)N([C@H](C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)N[C@H]6[C@H](OC(=O)[C@@H](N(C(=O)CN(C(=O)[C@@H]7CCCN7C(=O)[C@H](NC6=O)C(C)C)C)C)C(C)C)C)N)C,Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O
3085,CHEMBL83777,RJYJDEQXOIQEGZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC=C3F,CN(C)CC1CC2c3c(F)cccc3Cc3ccccc3N2O1
3086,CHEMBL271097,RKDBVDKLNHXCIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCCN4CCc5cc6nc(C(F)(F)F)oc6c(C)c5CC4)n3C)cccc2n1
3087,CHEMBL185825,RKEGNNLTPLWIIC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,109.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.962573502059376,C1CN(CCN1CCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,NC(=O)N(O)CCC#Cc1ccc(OCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
3089,CHEMBL517712,RKUNBYITZUJHSG-SPUOUPEWSA-N,ATROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(CO)c1ccccc1)C2
3090,CHEMBL517712,RKUNBYITZUJHSG-SPUOUPEWSA-N,ATROPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1[C@H]2CC[C@@H]1CC(OC(=O)C(CO)c1ccccc1)C2
3091,CHEMBL9751,RKUNBYITZUJHSG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1600.0,NM,,,,,,,,,,,,,,,,,,,,5.795880017344076,CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3,CN1C2CCC1CC(OC(=O)C(CO)c1ccccc1)C2
3092,CHEMBL498,RKWGIWYCVPQPMF-UHFFFAOYSA-N,CHLORPROPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
3093,CHEMBL498,RKWGIWYCVPQPMF-UHFFFAOYSA-N,CHLORPROPAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1
3094,CHEMBL1237,RLAWWYSOJDYHDC-BZSNNMDCSA-N,LISINOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
3095,CHEMBL1237,RLAWWYSOJDYHDC-BZSNNMDCSA-N,LISINOPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O,NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O
3096,CHEMBL295001,RLMGUPUESXPDFJ-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,108.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.966576244513051,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)F,CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1
3097,CHEMBL62803,RLVMZEQCHVFJEJ-UHFFFAOYSA-N,A-923,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.5600045260461926,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)OCC)CC2)cc1
3098,CHEMBL272478,RLYPJRVMOKDHBV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C(C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6c(cc5CC4)C(=O)N(C(C)C)C6)n3C)cccc2n1
3099,CHEMBL273199,RLZDEABBOHACIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=CC2=C(C=CC=C2C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C=C(C=C5)C6=CC(=NN6C)C)C=N1,Cc1cc2c(-c3nnc(SCCCN4CCc5ccc(-c6cc(C)nn6C)cc5CC4)n3C)cccc2cn1
3101,CHEMBL2207639,RMDQSWIVOHIFNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,6500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.187086643357143,COC1=CC=CC=C1N2CCN(CC2)CC3=CC(=C4C3=CC=CC=C4)CN5CCOCC5,COc1ccccc1N1CCN(Cc2cc(CN3CCOCC3)c3cccccc2-3)CC1
3102,CHEMBL1108,RMEDXOLNCUSCGS-UHFFFAOYSA-N,DROPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4519.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.344957658668799,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
3103,CHEMBL1108,RMEDXOLNCUSCGS-UHFFFAOYSA-N,DROPERIDOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,525.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.279840696594043,C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F,O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
3104,CHEMBL2207280,RMQXJQUUIKBXMM-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=C(C=C4)F)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2ccc(F)cc12
3105,CHEMBL2158776,RMSWKUOSOVPFPF-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,COC1=CC=C(C=C1)C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,COc1ccc(C[C@@H](C(=O)O)N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
3106,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCNN,NNCCc1ccccc1
3107,CHEMBL1089,RMUCZJUITONUFY-UHFFFAOYSA-N,PHENELZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCNN,NNCCc1ccccc1
3108,CHEMBL1923526,RMZULTRHWHVHDS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,707.95,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.149997413907538,C1CN(CCN1CCO)C2=C3C=CSC3=NC=N2,OCCN1CCN(c2ncnc3sccc23)CC1
3109,CHEMBL12856,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,INAMRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,Nc1cc(-c2ccncc2)c[nH]c1=O
3110,CHEMBL12856,RNLQIBCLLYYYFJ-UHFFFAOYSA-N,INAMRINONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=CC=C1C2=CNC(=O)C(=C2)N,Nc1cc(-c2ccncc2)c[nH]c1=O
3112,CHEMBL1632158,RNXYMZNGMNWKMC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21075638.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,Binding affinity to Histamine receptor H1,Synthesis and pharmacological properties of novel hydrophilic 5-HT4 receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,5.899998417198647,COC(=O)CCCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42,COC(=O)CCCCCN1CCC(CNC(=O)c2c3n(c4ccccc24)CCCO3)CC1
3113,CHEMBL488,ROBVIMPUHSLWNV-UHFFFAOYSA-N,AMINOGLUTETHIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O
3114,CHEMBL488,ROBVIMPUHSLWNV-UHFFFAOYSA-N,AMINOGLUTETHIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(CCC(=O)NC1=O)C2=CC=C(C=C2)N,CCC1(c2ccc(N)cc2)CCC(=O)NC1=O
3115,CHEMBL184238,ROFVXGGUISEHAM-UHFFFAOYSA-N,URB597,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16352709.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1CCC(CC1)NC(=O)OC2=CC=CC(=C2)C3=CC(=CC=C3)C(=O)N,NC(=O)c1cccc(-c2cccc(OC(=O)NC3CCCCC3)c2)c1
3116,CHEMBL476935,ROKAKGMAWJNFEN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,157.6,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.802443786846464,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=CC=C(C=C3)Cl,O=C(CCCN1CCN(c2ccc(Cl)cc2)CC1)c1ccc(F)cc1
3117,CHEMBL654,RONZAEMNMFQXRA-UHFFFAOYSA-N,MIRTAZAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.6,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.795880017344075,CN1CCN2C(C1)C3=CC=CC=C3CC4=C2N=CC=C4,CN1CCN2c3ncccc3Cc3ccccc3C2C1
3118,CHEMBL2158834,ROQGCKBWSKAVEH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=C(C=CC=N4)C(=O)O,O=C(O)c1cccnc1N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3119,CHEMBL276832,RPTUSVTUFVMDQK-UHFFFAOYSA-N,HYDRALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=NN=C2NN,NNc1nncc2ccccc12
3120,CHEMBL276832,RPTUSVTUFVMDQK-UHFFFAOYSA-N,HYDRALAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=NN=C2NN,NNc1nncc2ccccc12
3121,CHEMBL167223,RPUXCIYWJSVFFV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,0.813,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,9.089909454405932,CC(C1=CC=CC=N1)C2=C(CC3=C2C=CC(=C3)Cl)CCN(C)C,CC(C1=C(CCN(C)C)Cc2cc(Cl)ccc21)c1ccccn1
3122,CHEMBL1794855,RPZYOWNZYQHSLJ-SPIKMXEPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15203136.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards histamine H1 receptor,"(+/-)8-Amino-5,6,7,8-tetrahydroisoquinolines as novel antinociceptive agents.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CCN(C1C2=C(C=CN=C2)CCC1)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O,CCN(C)C1CCCc2ccncc21
3123,CHEMBL3104092,RQBRUGMHSQYCNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,47.86,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.320027305722581,CN1CCC2=C(C1)C3=CC=CC4=C3N2CC5=CC=CC=C5C4,CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1
3124,CHEMBL3104092,RQBRUGMHSQYCNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,48.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.3187587626244115,CN1CCC2=C(C1)C3=CC=CC4=C3N2CC5=CC=CC=C5C4,CN1CCc2c(c3cccc4c3n2Cc2ccccc2C4)C1
3126,CHEMBL43491,RQTZTSPFFYDZKA-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,58.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.236572006437062,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)C4=C(C=C(C=C4)F)C#N,CC1=C(C(=O)NCCCN2CCC(c3ccc(F)cc3C#N)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1
3127,CHEMBL1201139,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,MEGESTROL ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
3128,CHEMBL1201139,RQZAXGRLVPAYTJ-GQFGMJRRSA-N,MEGESTROL ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
3129,CHEMBL42710,RRAFCDWBNXTKKO-UHFFFAOYSA-N,EUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)CC=C)O,C=CCc1ccc(O)c(OC)c1
3130,CHEMBL42710,RRAFCDWBNXTKKO-UHFFFAOYSA-N,EUGENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=CC(=C1)CC=C)O,C=CCc1ccc(O)c(OC)c1
3132,CHEMBL2205831,RRBNCHNWWUXYEM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCC(CC1)CN2C3C4C5CC6C4C2(C7C6C5C73)O,OC12C3C4CC5C6C4C1C6C(C53)N2CC1CCCCC1
3133,CHEMBL2205831,RRBNCHNWWUXYEM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1CCC(CC1)CN2C3C4C5CC6C4C2(C7C6C5C73)O,OC12C3C4CC5C6C4C1C6C(C53)N2CC1CCCCC1
3134,CHEMBL105267,RRBSCZCNYAJFEJ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,13803.84,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.860000083248981,C1CN(C[C@@H]1N)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CC[C@@H](N)C3)cc2)cc1
3135,CHEMBL799,RRGUKTPIGVIEKM-UHFFFAOYSA-N,CILOSTAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1
3136,CHEMBL799,RRGUKTPIGVIEKM-UHFFFAOYSA-N,CILOSTAZOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4,O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1
3138,CHEMBL2207634,RSTJJQONPRJAIE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,,,,Not Determined,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CCCC#CC1=C2C=CC=CC=C2C(=C1)CN3CCN(CC3)C4=CC=CC=C4OC,CCCC#Cc1cc(CN2CCN(c3ccccc3OC)CC2)c2cccccc1-2
3139,CHEMBL1909076,RSTSYGXUDMJEFP-SECBINFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CNC(=S)SC[C@H](C(=O)O)N,N[C@H](CSC(=S)NCc1ccccc1)C(=O)O
3140,CHEMBL1909076,RSTSYGXUDMJEFP-SECBINFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CNC(=S)SC[C@H](C(=O)O)N,N[C@H](CSC(=S)NCc1ccccc1)C(=O)O
3142,CHEMBL315044,RTEBNFQOFLORPE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,14.45,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.840132152907432,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)OC,COc1ccc2c(c1)C1CC(CN(C)C)ON1c1ccccc1C2
3143,CHEMBL1456,RTGDFNSFWBGLEC-SYZQJQIISA-N,MYCOPHENOLATE MOFETIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2
3144,CHEMBL1456,RTGDFNSFWBGLEC-SYZQJQIISA-N,MYCOPHENOLATE MOFETIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2COC(=O)C2=C(C(=C1OC)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)O,COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2
3145,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1100.0,NM,,,,,,,,,,,,,,,,,,,,5.9586073148417755,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
3146,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,5400.0,NM,,,,,,,,,,,,,,,,,,,,5.267606240177033,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
3148,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
3149,CHEMBL41,RTHCYVBBDHJXIQ-UHFFFAOYSA-N,FLUOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F,CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1
3150,CHEMBL403181,RTMHXVRCXRAHLV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,CCC1=NOC2=C1C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C,CCc1noc2cc3c(cc12)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
3151,CHEMBL2391167,RTNOWHVTNCEMDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23591112.0,Ki,>,9300.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (part II).,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.031517051446065,CC1CCCN1C2CCN(C2)C3=CC(=C(C=C3)NC(=O)C4=C(C=CC(=C4)F)C)C,Cc1cc(N2CCC(N3CCCC3C)C2)ccc1NC(=O)c1cc(F)ccc1C
3152,CHEMBL361355,RTRADBQSZJIRMT-GOSISDBHSA-N,A-317920,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,,,,,,5.40000018605658,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(=O)C4=CC=CO4,C[C@@H](NC(=O)c1ccco1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3153,CHEMBL430471,RTZKLQYXUHBGFX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.04,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.297569463554474,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCCOC6=CC=CC=C6C(=O)O)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4CCCCOc4ccccc4C(=O)O)CC3)(c3ccccc3)C2)cc(OC)c1OC
3154,CHEMBL329685,RUKTXHCGSFMYLO-JCNKGUCWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,9.3,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.031517051446064,CNCC1C[C@H]2[C@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CNCC1C[C@@H]2c3ccccc3Cc3ccccc3[C@H]2O1
3155,CHEMBL2112371,RUKTXHCGSFMYLO-SNRMKQJTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.5,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.455931955649724,CNC[C@@H]1C[C@@H]2[C@@H](O1)C3=CC=CC=C3CC4=CC=CC=C24,CNC[C@@H]1C[C@H]2c3ccccc3Cc3ccccc3[C@@H]2O1
3156,CHEMBL2171049,RUMOWLXMMCFECC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC=C(C=C4)Cl,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)cc4)CC3)CC2)cc1
3157,CHEMBL79568,RUNAWWHMBJYHQQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CCCCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CCCCC1CC2c3ccccc3Cc3ccccc3N2O1
3159,CHEMBL60360,RURVOBDSGULLAW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,60.26,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.219970872662662,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CC3=NC=CS3,CCCCCC(=O)c1ccc(OCCCN2CCN(Cc3nccs3)CC2)cc1
3161,CHEMBL315308,RUWZQSJWDUNAEU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,7.94,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,CN(C)CC1CC2C3=CC=CC=C3CC4=C(N2O1)C=C(C=C4)C5=CC=CC=C5,CN(C)CC1CC2c3ccccc3Cc3ccc(-c4ccccc4)cc3N2O1
3162,CHEMBL707,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,DOXAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
3163,CHEMBL707,RUZYUOTYCVRMRZ-UHFFFAOYSA-N,DOXAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC,COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC
3164,CHEMBL189118,RVSLLQIPFFIMSB-KPKJPENVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16134937.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against Histamine H1 receptor,"6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode.",J. Med. Chem.,PUBLICATION,,5.0,CC1=CC(=NC2=C1C=C(C=C2)NC(=O)/C=C/C3=CC=C(C=C3)OC(F)(F)F)N(C)CCN(C)C,Cc1cc(N(C)CCN(C)C)nc2ccc(NC(=O)/C=C/c3ccc(OC(F)(F)F)cc3)cc12
3165,CHEMBL1946258,RWCQKGYXYLNOEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCC(=O)C3=NC4=CC=CC=C4S3,O=C(CCCN1CCCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1
3166,CHEMBL1256017,RWTGFMPOODRXIM-UHFFFAOYSA-N,ARCAINE SULFATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCN=C(N)N)CN=C(N)N.OS(=O)(=O)O,NC(N)=NCCCCN=C(N)N
3167,CHEMBL1256017,RWTGFMPOODRXIM-UHFFFAOYSA-N,ARCAINE SULFATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCN=C(N)N)CN=C(N)N.OS(=O)(=O)O,NC(N)=NCCCCN=C(N)N
3168,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,,,,,,8.0,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3169,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,78.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.107905397309519,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3170,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,78.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.107905397309519,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3171,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,27.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.568636235841013,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3172,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,78.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,7.107905397309519,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3173,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25494650.0,IC50,=,15.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),CNS drug design: balancing physicochemical properties for optimal brain exposure.,J. Med. Chem.,PUBLICATION,,7.823908740944319,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3174,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3175,CHEMBL914,RWTNPBWLLIMQHL-UHFFFAOYSA-N,FEXOFENADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O,CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3176,CHEMBL1909065,RWVUEZAROXKXRT-VQLSFVLHSA-N,LYSERGOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
3177,CHEMBL1909065,RWVUEZAROXKXRT-VQLSFVLHSA-N,LYSERGOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
3180,CHEMBL10780,RXMTUVIKZRXSSM-UHFFFAOYSA-N,"2,2-DIPHENYLETHYLAMINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1=CC=C(C=C1)C(CN)C2=CC=CC=C2,NCC(c1ccccc1)c1ccccc1
3181,CHEMBL469912,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,PUROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@@H](n3cnc4c(N(C)C)ncnc43)[C@@H]2O)cc1
3182,CHEMBL469912,RXWNCPJZOCPEPQ-NVWDDTSBSA-N,PUROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC=NC2=C1N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)NC(=O)[C@H](CC4=CC=C(C=C4)OC)N)O,COc1ccc(C[C@H](N)C(=O)N[C@@H]2[C@@H](CO)O[C@@H](n3cnc4c(N(C)C)ncnc43)[C@@H]2O)cc1
3183,CHEMBL1214185,RXZBMPWDPOLZGW-XMRMVWPWSA-N,ROXITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
3184,CHEMBL1214185,RXZBMPWDPOLZGW-XMRMVWPWSA-N,ROXITHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](/C(=N/OCOCCOC)/[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O
3187,CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
3188,CHEMBL1064,RYMZZMVNJRMUDD-HGQWONQESA-N,SIMVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21
3189,CHEMBL113,RYYVLZVUVIJVGH-UHFFFAOYSA-N,CAFFEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Cn1c(=O)c2c(ncn2C)n(C)c1=O
3190,CHEMBL113,RYYVLZVUVIJVGH-UHFFFAOYSA-N,CAFFEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C=NC2=C1C(=O)N(C(=O)N2C)C,Cn1c(=O)c2c(ncn2C)n(C)c1=O
3192,CHEMBL2146804,RZBPSXCZVILRNE-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.6920000000000001,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.159893905543242,CN1CCC[C@@H]1CN2C(=O)C3=C(C=CN=C3)C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccncc2c1=O
3193,CHEMBL118,RZEKVGVHFLEQIL-UHFFFAOYSA-N,CELECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
3194,CHEMBL118,RZEKVGVHFLEQIL-UHFFFAOYSA-N,CELECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F,Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1
3195,CHEMBL45245,RZFVLEJOHSLEFR-UHFFFAOYSA-N,PHENANTHRIDIN-6(5H)-ONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O,O=c1[nH]c2ccccc2c2ccccc12
3196,CHEMBL45245,RZFVLEJOHSLEFR-UHFFFAOYSA-N,PHENANTHRIDIN-6(5H)-ONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC=C3NC2=O,O=c1[nH]c2ccccc2c2ccccc12
3197,CHEMBL122,RZJQGNCSTQAWON-UHFFFAOYSA-N,ROFECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
3198,CHEMBL122,RZJQGNCSTQAWON-UHFFFAOYSA-N,ROFECOXIB,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3,CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1
3199,CHEMBL1480,RZTAMFZIAATZDJ-UHFFFAOYSA-N,FELODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
3200,CHEMBL1480,RZTAMFZIAATZDJ-UHFFFAOYSA-N,FELODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl
3201,CHEMBL112,RZVAJINKPMORJF-UHFFFAOYSA-N,ACETAMINOPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC=C(C=C1)O,CC(=O)Nc1ccc(O)cc1
3202,CHEMBL112,RZVAJINKPMORJF-UHFFFAOYSA-N,ACETAMINOPHEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=CC=C(C=C1)O,CC(=O)Nc1ccc(O)cc1
3203,CHEMBL138809,RZZAEVQHACUOGI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11784148.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of mepyramine binding to Histamine H1 receptor,Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1.,J. Med. Chem.,PUBLICATION,,5.0,COC1C2=CC=CC=C2C3(O1)CCN(CC3)CC4=CC=CC=C4,COC1OC2(CCN(Cc3ccccc3)CC2)c2ccccc21
3204,CHEMBL1767135,SAKVKDBLCRHLAV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.0,CN(C)CCCN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl,CN(C)CCCn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
3205,CHEMBL2146811,SAMYTBZVLLYSKN-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.537,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.270025714300443,COCCN1CCC[C@@H]1CN2C(=O)C3=C(C(=N2)CC4=CC=C(C=C4)Cl)N=CC=C3,COCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ncccc2c1=O
3206,CHEMBL87708,SAPNXPWPAUFAJU-UHFFFAOYSA-N,LOFEPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,360.0,NM,,,,,,,,,,,,,,,,,,,,6.443697499232713,CN(CCCN1C2=CC=CC=C2CCC3=CC=CC=C31)CC(=O)C4=CC=C(C=C4)Cl,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1
3211,CHEMBL509,SBDNJUWAMKYJOX-UHFFFAOYSA-N,MECLOFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
3212,CHEMBL509,SBDNJUWAMKYJOX-UHFFFAOYSA-N,MECLOFENAMIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=C(C=C1)Cl)NC2=CC=CC=C2C(=O)O)Cl,Cc1ccc(Cl)c(Nc2ccccc2C(=O)O)c1Cl
3213,CHEMBL95127,SBMCXVUSNRZQAG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.53,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.185086818724926,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CO6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccco4)CC3)(c3ccccc3)C2)cc(OC)c1OC
3214,CHEMBL95127,SBMCXVUSNRZQAG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,293.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.533132379645891,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CO6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccco4)CC3)(c3ccccc3)C2)cc(OC)c1OC
3215,CHEMBL31354,SBPRIAGPYFYCRT-UHFFFAOYSA-N,"WAY-100,635",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16915381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,COC1=CC=CC=C1N2CCN(CC2)CCN(C3=CC=CC=N3)C(=O)C4CCCCC4,COc1ccccc1N1CCN(CCN(C(=O)C2CCCCC2)c2ccccn2)CC1
3216,CHEMBL1384,SBUJHOSQTJFQJX-NOAMYHISSA-N,KANAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
3217,CHEMBL1384,SBUJHOSQTJFQJX-NOAMYHISSA-N,KANAMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O
3218,CHEMBL104700,SCDKHPSUXHBJDJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CC3=CN=CC=C3,c1cncc(CN2C3CCC2CC3)c1
3219,CHEMBL1413,SCKYRAXSEDYPSA-UHFFFAOYSA-N,CICLOPIROX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(C(=C1)C2CCCCC2)O,Cc1cc(C2CCCCC2)n(O)c(=O)c1
3220,CHEMBL1413,SCKYRAXSEDYPSA-UHFFFAOYSA-N,CICLOPIROX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(C(=C1)C2CCCCC2)O,Cc1cc(C2CCCCC2)n(O)c(=O)c1
3221,CHEMBL551347,SDEZSIUXMXPOCO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,18.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.73754891026957,C1CN(CCC1N2C=CC=N2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(n4cccn4)CC3)nc3ccccc32)cc1
3222,CHEMBL2171015,SDPQHMHFTWVGGO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,100.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)S(=O)(=O)NC(=O)C4=CC=CC=C4,O=C(NS(=O)(=O)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1)c1ccccc1
3223,CHEMBL888,SDUQYLNIPVEERB-QPPQHZFASA-N,GEMCITABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
3224,CHEMBL888,SDUQYLNIPVEERB-QPPQHZFASA-N,GEMCITABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
3225,CHEMBL1923530,SDYJUASJEOPULH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,3235.94,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.489999539566098,C1CCC(C1)N2CCN(CC2)C3=NC=NC4=CC=CC=C43,c1ccc2c(N3CCN(C4CCCC4)CC3)ncnc2c1
3226,CHEMBL1277034,SECVFAJWTWEYDD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,316.23,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.499996931948306,C1CC2(CC1N3CC(C3)CC(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)CC1CN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)C1
3227,CHEMBL439,SEEPANYCNGTZFQ-UHFFFAOYSA-N,SULFADIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
3228,CHEMBL439,SEEPANYCNGTZFQ-UHFFFAOYSA-N,SULFADIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1
3229,CHEMBL1477,SEERZIQQUAZTOL-ANMDKAQQSA-N,CERIVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
3230,CHEMBL1477,SEERZIQQUAZTOL-ANMDKAQQSA-N,CERIVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(C(=N1)C(C)C)COC)C2=CC=C(C=C2)F)/C=C/[C@H](C[C@H](CC(=O)O)O)O,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1
3231,CHEMBL2158783,SEIOTCVWLCUESB-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,39.81,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O)Cl,Cc1c(Cl)ccc(OC2CCN(CC3CCN([C@@H](Cc4ccc(F)cc4)C(=O)O)CC3)CC2)c1Cl
3233,CHEMBL165790,SFBODOKJTYAUCM-UHFFFAOYSA-N,IPRIFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1
3234,CHEMBL165790,SFBODOKJTYAUCM-UHFFFAOYSA-N,IPRIFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC1=CC2=C(C=C1)C(=O)C(=CO2)C3=CC=CC=C3,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1
3235,CHEMBL1946123,SFPSQBFPUCFLEZ-AIZNXBIQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,1719.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,5.764724123312948,C1C[C@H]2CC(C[C@@H]1N2CCCCC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2CCCCc1ccc(F)cc1
3236,CHEMBL3321788,SFPSQBFPUCFLEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,1719.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.764724123312948,C1CC2CC(CC1N2CCCCC3=CC=C(C=C3)F)(C4=CC=C(C=C4)Cl)O,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1ccc(F)cc1
3240,CHEMBL852,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,MELPHALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
3241,CHEMBL852,SGDBTWWWUNNDEQ-LBPRGKRZSA-N,MELPHALAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)N(CCCl)CCCl,N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
3242,CHEMBL360953,SGFIBQBVOOVDSS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771458.0,Ki,=,22.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for H1 histamine receptor expressed in CHO cells,"Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.",J. Med. Chem.,PUBLICATION,,7.657577319177793,CN1C=CC2=C1CCN3C=CN=C3C2=C4CCNCC4,Cn1ccc2c1CCn1ccnc1C2=C1CCNCC1
3243,CHEMBL2432052,SGFPDDMJMPKKTB-RAOGCBAWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CN(CCC1=CC(=CC=C1)F)[C@H]2C3C4CC5C3C(=O)C6C2C4C56,CN(CCc1cccc(F)c1)[C@H]1C2C3CC4C2C(=O)C2C4C3C21
3244,CHEMBL1946744,SGGMEYGWAJEGIP-WPUZRXDDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1C[C@H]2CC(C[C@@H]1N2CCCCC(=O)C3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O,O=C(CCCCN1[C@H]2CC[C@@H]1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1
3247,CHEMBL282468,SGMZJAMFUVOLNK-UHFFFAOYSA-M,CHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCO.[Cl-],C[N+](C)(C)CCO
3248,CHEMBL282468,SGMZJAMFUVOLNK-UHFFFAOYSA-M,CHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCO.[Cl-],C[N+](C)(C)CCO
3252,CHEMBL273915,SGSDMASCYPMWHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.56,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.341035157335565,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=C(C=C7)C(=O)O)OC,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(C(=O)O)cc4)CC3)CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)C2)cc1OC
3253,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
3254,CHEMBL6966,SGTNSNPWRIOYBX-UHFFFAOYSA-N,VERAPAMIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC,COc1ccc(CCN(C)CCCC(C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC
3255,CHEMBL429,SGUAFYQXFOLMHL-UHFFFAOYSA-N,LABETALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
3256,CHEMBL429,SGUAFYQXFOLMHL-UHFFFAOYSA-N,LABETALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O,CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
3259,CHEMBL653,SGXXNSQHWDMGGP-IZZDOVSWSA-N,NIZATIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C,CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
3260,CHEMBL653,SGXXNSQHWDMGGP-IZZDOVSWSA-N,NIZATIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C,CN/C(=C\[N+](=O)[O-])NCCSCc1csc(CN(C)C)n1
3261,CHEMBL547,SHGAZHPCJJPHSC-XFYACQKRSA-N,ISOTRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
3262,CHEMBL547,SHGAZHPCJJPHSC-XFYACQKRSA-N,ISOTRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C\C(=O)O)C(C)(C)CCC1
3263,CHEMBL38,SHGAZHPCJJPHSC-YCNIQYBTSA-N,TRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
3264,CHEMBL38,SHGAZHPCJJPHSC-YCNIQYBTSA-N,TRETINOIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1
3265,CHEMBL316438,SHNQYDFOONPSKV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,3.02,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.51999305704285,C1CCN(C1)CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2,c1ccc2c(c1)Cc1ccccc1N1OC(CN3CCCC3)CC21
3267,CHEMBL2171215,SHRVEEBUQYOBLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)CC4=CC=CC=C4,O=C(NS(=O)(=O)Cc1ccccc1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3268,CHEMBL1259190,SHVCHMGRIYXVAY-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,5.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.301029995663981,CC(C)C(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@@H]2N4CCN(CC4)C,CC(C)C(=O)NCc1ccc2c(c1)[C@@H](N1CCN(C)CC1)Cc1ccccc1S2
3269,CHEMBL1259189,SHVCHMGRIYXVAY-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,4.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.346787486224656,CC(C)C(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@H]2N4CCN(CC4)C,CC(C)C(=O)NCc1ccc2c(c1)[C@H](N1CCN(C)CC1)Cc1ccccc1S2
3270,CHEMBL1259145,SHVCHMGRIYXVAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Non-toxic,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CC(C)C(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C,CC(C)C(=O)NCc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2
3271,CHEMBL1767143,SHXAAVWRLZPGKQ-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,630.96,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,6.19999817218203,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)C(=O)OC,COC(=O)c1ccc(Cc2nn(C[C@H]3CCCN3C)c(=O)c3ccccc23)cc1
3272,CHEMBL43048,SHXWCVYOXRDMCX-UHFFFAOYSA-N,METHYLENEDIOXYMETHAMPHETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12761331.0,Ki,=,2138.0,NM,,,,,,,,,,,,,,,,,,,,5.669992299127242,CC(CC1=CC2=C(C=C1)OCO2)NC,CNC(C)Cc1ccc2c(c1)OCO2
3273,CHEMBL1200396,SIEYLFHKZGLBNX-UHFFFAOYSA-N,BUPIVACAINE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
3274,CHEMBL1200396,SIEYLFHKZGLBNX-UHFFFAOYSA-N,BUPIVACAINE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl,CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
3275,CHEMBL303737,SIFNBTNSQZZNNX-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,14454.4,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.8399999311187,C1CCC(CC1)C[C@H](C(=O)N2CCN(CC2)CCCOC3=CC=C(C=C3)C(=O)C4CC4)N,N[C@H](CC1CCCCC1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3276,CHEMBL102384,SJDGVHQTEPPTSY-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,4500.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.346787486224656,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2Cl)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3ccccc3Cl)C2)cc1)C1CC1
3277,CHEMBL1946745,SJEXSMOVRPPLBZ-VXMMSVGHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,187.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,6.7281583934635005,C1C[C@H]2CC(C[C@@H]1N2CCCCC3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O,OC1(c2ccc(Cl)cc2)C[C@@H]2CC[C@H](C1)N2CCCCc1nc2ccccc2s1
3278,CHEMBL291338,SJQBHPJLLIJASD-UHFFFAOYSA-N,"3,3',4',5-TETRACHLOROSALICYLANILIDE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl,O=C(Nc1ccc(Cl)c(Cl)c1)c1cc(Cl)cc(Cl)c1O
3279,CHEMBL291338,SJQBHPJLLIJASD-UHFFFAOYSA-N,"3,3',4',5-TETRACHLOROSALICYLANILIDE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1NC(=O)C2=C(C(=CC(=C2)Cl)Cl)O)Cl)Cl,O=C(Nc1ccc(Cl)c(Cl)c1)c1cc(Cl)cc(Cl)c1O
3280,CHEMBL60401,SJQFNVCRPKMBTI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,100000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.0,CNCC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3,CNCC(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3283,CHEMBL2432050,SJWCMFMHVZULSJ-DKSPCFMDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,,C1C2C3CC4C2[C@@H](C5C1C3C45)NCCCC6=CC(=CC=C6)F,Fc1cccc(CCCN[C@H]2C3C4CC5C6C4CC3C6C52)c1
3284,CHEMBL62741,SKDLGPGMOATMSN-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,14454.4,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.8399999311187,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC(C)C)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@H](N)CC(C)C)CC2)cc1
3285,CHEMBL291847,SKDLGPGMOATMSN-QHCPKHFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9772.37,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.010000098195094,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC(C)C)N,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](N)CC(C)C)CC2)cc1
3286,CHEMBL1278021,SKOALCKWENTDHG-NRWPOFLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,158.49,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.799998134593397,C1CN(CC(=C1)C(=O)O)C2CC[C@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35,O=C(O)C1=CCCN(C2CC[C@@]3(Cc4ccccc4Cc4ccccc43)C2)C1
3287,CHEMBL1277935,SKOALCKWENTDHG-TUXUZCGSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.700057099977232,C1CN(CC(=C1)C(=O)O)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35,O=C(O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
3288,CHEMBL1277935,SKOALCKWENTDHG-TUXUZCGSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.599980364934843,C1CN(CC(=C1)C(=O)O)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35,O=C(O)C1=CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
3289,CHEMBL115280,SKVXOYIMICHFPV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,496.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.304518323509803,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CC4=CC(=CC=C4)OC5=CC=CC=C5,O=C1NCN(c2ccccc2)C12CCN(Cc1cccc(Oc3ccccc3)c1)CC2
3290,CHEMBL2207662,SKXJKSJHHFLVAP-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C=C3C(F)(F)F)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)cc1C(F)(F)F
3291,CHEMBL27577,SKZKKFZAGNVIMN-UHFFFAOYSA-N,SALICYLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)N)O,NC(=O)c1ccccc1O
3292,CHEMBL27577,SKZKKFZAGNVIMN-UHFFFAOYSA-N,SALICYLAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)N)O,NC(=O)c1ccccc1O
3293,CHEMBL412873,SLRCCWJSBJZJBV-TUVASFSCSA-N,SPARTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1
3294,CHEMBL412873,SLRCCWJSBJZJBV-TUVASFSCSA-N,SPARTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN2C[C@H]3C[C@@H]([C@H]2C1)CN4[C@H]3CCCC4,C1CCN2C[C@H]3C[C@H](CN4CCCC[C@H]34)[C@@H]2C1
3295,CHEMBL1088,SLVMESMUVMCQIY-UHFFFAOYSA-N,MESORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,1.81,NM,,,,,,,,,,,,,,,,,,,,8.742321425130816,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21
3296,CHEMBL1088,SLVMESMUVMCQIY-UHFFFAOYSA-N,MESORIDAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,1.8,NM,,,,,,,,,,,,,,,,,,,,8.744727494896694,CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)S(=O)C,CN1CCCCC1CCN1c2ccccc2Sc2ccc([S+](C)[O-])cc21
3297,CHEMBL1046,SLXKOJJOQWFEFD-UHFFFAOYSA-N,AMINOCAPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCC(=O)O)CCN,NCCCCCC(=O)O
3298,CHEMBL1046,SLXKOJJOQWFEFD-UHFFFAOYSA-N,AMINOCAPROIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CCC(=O)O)CCN,NCCCCCC(=O)O
3299,CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,158.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.801342913045577,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
3300,CHEMBL30008,SMANXXCATUTDDT-QPJJXVBHSA-N,FLUNARIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,18.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.744727494896693,C1CN(CCN1C/C=C/C2=CC=CC=C2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,Fc1ccc(C(c2ccc(F)cc2)N2CCN(C/C=C/c3ccccc3)CC2)cc1
3302,CHEMBL1201195,SNBUBQHDYVFSQF-HIFRSBDPSA-N,CEFMETAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
3303,CHEMBL1201195,SNBUBQHDYVFSQF-HIFRSBDPSA-N,CEFMETAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O,CO[C@@]1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
3304,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2,CN1CCC[C@H]1c1cccnc1
3305,CHEMBL3,SNICXCGAKADSCV-JTQLQIEISA-N,NICOTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCC[C@H]1C2=CN=CC=C2,CN1CCC[C@H]1c1cccnc1
3306,CHEMBL1090198,SNPICWUEPVAZAM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.823908740944319,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CC=N3,CN(C)CCC1=C(Cc2ncccn2)c2ccccc2C1
3307,CHEMBL1371937,SNPLKNRPJHDVJA-UHFFFAOYSA-N,PANTHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CO)C(C(=O)NCCCO)O,CC(C)(CO)C(O)C(=O)NCCCO
3308,CHEMBL1371937,SNPLKNRPJHDVJA-UHFFFAOYSA-N,PANTHENOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(CO)C(C(=O)NCCCO)O,CC(C)(CO)C(O)C(=O)NCCCO
3309,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
3310,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
3311,CHEMBL894,SNPPWIUOZRMYNY-UHFFFAOYSA-N,BUPROPION,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C,CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1
3312,CHEMBL1774493,SNSVDJAVYWDAAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,128.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.892790030352131,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4COC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4COc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3314,CHEMBL1222693,SOXIOTAVNTWQJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,CC1=C(N2CC3=CC=CC=C3C=C(C2=N1)N4CCN(CC4)CC(C)(C)C(=O)O)C,Cc1nc2n(c1C)Cc1ccccc1C=C2N1CCN(CC(C)(C)C(=O)O)CC1
3316,CHEMBL1201353,SOYKEARSMXGVTM-HNNXBMFYSA-N,DEXCHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.29,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.201349354554733,CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1
3317,CHEMBL1201353,SOYKEARSMXGVTM-HNNXBMFYSA-N,DEXCHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.73,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.136677139879543,CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1
3318,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,30.0,NM,,,,,,,,,,,,,,,,,,,,7.522878745280337,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3319,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,15.0,NM,,,,,,,,,,,,,,,,,,,,7.823908740944319,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3320,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,2.51,NM,,,,,,,,,,,,,,,,,,,,8.600326278518963,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3321,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,2.51,NM,,,,,,,,,,,,,,,,,,,,8.600326278518963,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3322,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,2.67,NM,,,,,,,,,,,,,,,,,,,,8.573488738635424,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3323,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,4.81,NM,,,,,,,,,,,,,,,,,,,,8.317854923626168,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3324,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17846138.0,IC50,=,66.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine receptor subtype 1 expressed in CHO cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,7.180456064458133,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3325,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.154901959985743,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3326,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,0.92,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,9.036212172654443,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3327,CHEMBL505,SOYKEARSMXGVTM-UHFFFAOYSA-N,CHLORPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,=,4.47,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.349692476868062,CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2,CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1
3329,CHEMBL157842,SOZBJQHYMWHOEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,2511.89,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1=CC(=CN=C1)CCCCCCCCCCN,NCCCCCCCCCCc1cccnc1
3330,CHEMBL157842,SOZBJQHYMWHOEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,125892541179417.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.100000000000001,C1=CC(=CN=C1)CCCCCCCCCCN,NCCCCCCCCCCc1cccnc1
3331,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
3332,CHEMBL1200633,SPBDXSGPUHCETR-JFUDTMANSA-N,IVERMECTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)O[C@@H]1C(C)C,CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2
3333,CHEMBL15511,SPFYMRJSYKOXGV-UHFFFAOYSA-N,ENROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1
3334,CHEMBL15511,SPFYMRJSYKOXGV-UHFFFAOYSA-N,ENROFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CCN(CC1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4CC4)F,CCN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3C2CC2)CC1
3335,CHEMBL1493,SPIUTQOUKAMGCX-UHFFFAOYSA-N,FLAVOXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
3336,CHEMBL1493,SPIUTQOUKAMGCX-UHFFFAOYSA-N,FLAVOXATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4,Cc1c(-c2ccccc2)oc2c(C(=O)OCCN3CCCCC3)cccc2c1=O
3337,CHEMBL2031885,SPKOQCHHYOCMGR-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,8750.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.057991946977686,C[C@@H]1CCCN1CCN2CCC3=C(C2=O)C=CC(=C3)C4=CC=C(C=C4)C(=O)N5CCCC5,C[C@@H]1CCCN1CCN1CCc2cc(-c3ccc(C(=O)N4CCCC4)cc3)ccc2C1=O
3338,CHEMBL294519,SPQNXJVWMXXMNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,288.4,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.540004743952608,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CC=C3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3ccccc3)CC2)cc1
3339,CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O
3340,CHEMBL1255837,SPXACGZWWVIDGR-SPZWACKZSA-N,DIHYDROERGOCRISTINE MESYLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C.CS(=O)(=O)O,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@@H]3c4cccc5[nH]cc(c45)C[C@H]3N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O
3341,CHEMBL1774507,SPYSLLTXIWIQNL-MWYAZZEHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,153.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.815308569182402,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CC/C=C\3/C4=CC=CC=C4CCC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCCN(CC/C=C3/c4ccccc4CCc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3342,CHEMBL1092599,SQDIKQKCDLMHCF-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,3.1,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.508638306165727,CC1=CSC(=N1)[C@H](C)C2=C(CC3=CC=CC=C32)CCN(C)C,Cc1csc([C@H](C)C2=C(CCN(C)C)Cc3ccccc32)n1
3343,CHEMBL1669411,SQGLQUFJVYRVPS-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,91.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.040958607678906,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CCC(F)(F)F,C[C@H](C1=C(CCN(C)CCC(F)(F)F)Cc2ccccc21)c1cnccn1
3345,CHEMBL1902981,SQUNAWUMZGQQJD-UHFFFAOYSA-N,EPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1
3346,CHEMBL1902981,SQUNAWUMZGQQJD-UHFFFAOYSA-N,EPERISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2,CCc1ccc(C(=O)C(C)CN2CCCCC2)cc1
3348,CHEMBL1091069,SROGIGROUAOOFN-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,5.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.301029995663981,C[C@H](C1=C(SC2=CC=CC=C21)CCN(C)C)C3=C(C=CC=N3)OC,COc1cccnc1[C@H](C)c1c(CCN(C)C)sc2ccccc12
3349,CHEMBL40733,SRPXSILJHWNFMK-ZBEGNZNMSA-N,DESMETHYLSERTRALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,9000.0,NM,,,,,,,,,,,,,,,,,,,,5.045757490560675,C1C[C@@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N,N[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3350,CHEMBL2030629,SRRZEMVAQOSBLB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCC3=CC=CC=N3,c1ccc(CCN2C3CCC2CC3)nc1
3351,CHEMBL551394,SSIZXVUYAOUIQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,41.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.387216143280264,CN1C(=CC(=O)N(C1=O)C)C2=CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O,Cn1c(C2=CCN(CCCN3c4ccccc4Sc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3352,CHEMBL338790,SSMIFVHARFVINF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N,Nc1ccc2c3c(cccc13)C(=O)NC2=O
3353,CHEMBL338790,SSMIFVHARFVINF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=CC3=C2C(=C1)C(=O)NC3=O)N,Nc1ccc2c3c(cccc13)C(=O)NC2=O
3354,CHEMBL1902627,SSMSBSWKLKKXGG-UHFFFAOYSA-N,CLORPRENALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=CC=C1Cl)O,CC(C)NCC(O)c1ccccc1Cl
3355,CHEMBL1902627,SSMSBSWKLKKXGG-UHFFFAOYSA-N,CLORPRENALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=CC=C1Cl)O,CC(C)NCC(O)c1ccccc1Cl
3356,CHEMBL537027,SSNHYUGXRZNUCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3420.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.465973893943866,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)O)C7=CC=CC=C7.Cl,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(C(=O)O)cc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
3358,CHEMBL49080,STJMRWALKKWQGH-UHFFFAOYSA-N,CLENBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1
3359,CHEMBL49080,STJMRWALKKWQGH-UHFFFAOYSA-N,CLENBUTEROL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=C(C(=C1)Cl)N)Cl)O,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1
3360,CHEMBL178,STQGQHZAVUOBTE-VGBVRHCVSA-N,DAUNORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
3361,CHEMBL178,STQGQHZAVUOBTE-VGBVRHCVSA-N,DAUNORUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1
3362,CHEMBL2171046,STXMJDYUJFBELE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,CC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=C(C=C(C=C4)Cl)Cl,Cc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)cc4Cl)CC3)CC2)cc1
3363,CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1
3364,CHEMBL1503,SUBDBMMJDZJVOS-UHFFFAOYSA-N,OMEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC,COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)[nH]c2c1
3365,CHEMBL134423,SUBRNIMHHUWIJU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Binding affinity towards histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1C[Si](CC1N2CCN(CC2)C3=CC=CC=C3)(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,Fc1ccc([Si]2(c3ccc(F)cc3)CCC(N3CCN(c4ccccc4)CC3)C2)cc1
3366,,SUGVYNSRNKFXQM-ACSDJOOWSA-N,SR144528,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,9454810.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1=CC=C(C=C1)CN2C(=CC(=N2)C(=O)NC3[C@]4(CCC(C4)C3(C)C)C)C5=CC(=C(C=C5)Cl)C,Cc1ccc(Cn2nc(C(=O)NC3C(C)(C)C4CC[C@@]3(C)C4)cc2-c2ccc(Cl)c(C)c2)cc1
3367,CHEMBL2158823,SUHCNXHLKUQVER-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC(=C4)C(=O)O,O=C(O)c1cccc(N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
3368,CHEMBL1567463,SUHOQUVVVLNYQR-MRVPVSSYSA-N,CHOLINE ALFOSCERATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O,C[N+](C)(C)CCOP(=O)([O-])OC[C@H](O)CO
3369,CHEMBL1567463,SUHOQUVVVLNYQR-MRVPVSSYSA-N,CHOLINE ALFOSCERATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOP(=O)([O-])OC[C@@H](CO)O,C[N+](C)(C)CCOP(=O)([O-])OC[C@H](O)CO
3370,CHEMBL559061,SULKMHQPINMVTR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.537602002101043,CN(C)CCN(C)C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(C)CCN(C)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
3372,CHEMBL346574,SUOANLAYTVIAIR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=CC=C(C=C1)CCCCCC2=NC=C(N2)CCN,NCCc1cnc(CCCCCc2ccccc2)[nH]1
3374,CHEMBL272150,SUTBGEJWOOOUFT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc6oc(C(F)(F)F)nc6c5CC4)n3C)cccc2n1
3375,CHEMBL2207656,SUYKBMCECCINPJ-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,2.51,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.600326278518963,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC=C4F)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2c(F)cccc12
3376,CHEMBL401752,SVBOCVYSHIJYID-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C,CCc1nc2cc3c(c(C)c2o1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
3378,CHEMBL1935447,SWDWBOARDFBZAD-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2[C@H]4CNCCS4,COc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
3379,CHEMBL1935448,SWDWBOARDFBZAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,92.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.036212172654443,COC1=CC=C(C=C1)CN2C3=CC=CC=C3N=C2C4CNCCS4,COc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
3380,CHEMBL2431120,SWEOAXMICIJCQC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1420.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,5.847711655616942,COC1=CC=CC=C1N2CCN(CC2)C3=NC(=NC4=CC(=C(C=C43)OC)OC)C5CC5,COc1cc2nc(C3CC3)nc(N3CCN(c4ccccc4OC)CC3)c2cc1OC
3381,CHEMBL1935446,SWFSQSZMVIJILA-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.3,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,C1CS[C@H](CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c([C@H]3CNCCS3)nc3ccccc32)cc1
3382,CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
3383,CHEMBL1935445,SWFSQSZMVIJILA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,95.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.022276394711152,C1CSC(CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c(C3CNCCS3)nc3ccccc32)cc1
3384,CHEMBL313189,SWGWJQBPCJEQJC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,83.18,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.079981083971085,CN(C)CCC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CN(C)CCC1CC2c3ccccc3Cc3ccccc3N2O1
3385,CHEMBL319244,SWUARLUWKZWEBQ-VQHVLOKHSA-N,CAFFEIC ACID PHENETHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O,O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1
3386,CHEMBL319244,SWUARLUWKZWEBQ-VQHVLOKHSA-N,CAFFEIC ACID PHENETHYL ESTER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CCOC(=O)/C=C/C2=CC(=C(C=C2)O)O,O=C(/C=C/c1ccc(O)c(O)c1)OCCc1ccccc1
3387,CHEMBL2413153,SXCVVYUSUGUSMW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23816046.0,Ki,=,512.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),"Synthesis and in vivo evaluation of [(18)F]2-(4-(4-(2-(2-fluoroethoxy)phenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)-dione ([(18)F]FECUMI-101) as an imaging probe for 5-HT1A receptor agonist in nonhuman primates.",Bioorg. Med. Chem.,PUBLICATION,,6.29073003902417,CN1C(=O)C=NN(C1=O)CCCCN2CCN(CC2)C3=CC=CC=C3OCCF,Cn1c(=O)cnn(CCCCN2CCN(c3ccccc3OCCF)CC2)c1=O
3389,CHEMBL2146484,SXNOWQCFHNZUIX-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.355,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.449771646944908,CN1CCC[C@@H]1CN2C(=O)C3=C(C=CC=N3)C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2cccnc2c1=O
3391,CHEMBL566534,SXYIRMFQILZOAM-HVNFFKDJSA-N,ARTEMETHER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3
3392,CHEMBL566534,SXYIRMFQILZOAM-HVNFFKDJSA-N,ARTEMETHER,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C,CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3
3393,CHEMBL1935433,SYDJFDHCVPRQIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.309803919971486,C1CCN(CC1)C(=O)CN2CCCC(C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,O=C(CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1)N1CCCCC1
3394,CHEMBL195927,SYERHDJULLPKRY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)C3CCN(CC3)C4=CC=CC=C4OC)OC,COc1ccccc1N1CCC(C(=O)Nc2ccc(OC)c(N3CCN(C)CC3)c2)CC1
3395,CHEMBL393718,SYNXMLXHBZIEOT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,520.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2839966563652006,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)S(=O)(=O)N)OC,CCOc1cc(CN2CCC(Nc3nc4cc(S(N)(=O)=O)ccc4o3)CC2)ccc1OC
3396,CHEMBL62716,SYSBZXCPPMQIMC-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,21877.62,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6599999253499025,CC(C)(C)[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,CC(C)(C)[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3397,CHEMBL563,SYTBZMRGLBWNTM-UHFFFAOYSA-N,FLURBIPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
3398,CHEMBL563,SYTBZMRGLBWNTM-UHFFFAOYSA-N,FLURBIPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O,CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
3399,CHEMBL1201010,SYWHXTATXSMDSB-GSLJADNHSA-N,FLUDROCORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
3400,CHEMBL1201010,SYWHXTATXSMDSB-GSLJADNHSA-N,FLUDROCORTISONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)CC[C@@]43C)F)O)C)O,CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C
3401,CHEMBL61120,SZCLNIBNFBNHIY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,28183.83,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.5499999894083,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)CCN,NCCC(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3402,CHEMBL1669405,SZKXEXNSYILRKM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,7.2,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.142667503568731,CCN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CCN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
3403,CHEMBL295416,SZRPDCCEHVWOJX-UHFFFAOYSA-N,PIRINIXIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C
3404,CHEMBL295416,SZRPDCCEHVWOJX-UHFFFAOYSA-N,PIRINIXIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)NC2=CC(=NC(=N2)SCC(=O)O)Cl)C,Cc1cccc(Nc2cc(Cl)nc(SCC(=O)O)n2)c1C
3405,CHEMBL86,TTWJBBZEZQICBI-UHFFFAOYSA-N,METOCLOPRAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC
3406,CHEMBL86,TTWJBBZEZQICBI-UHFFFAOYSA-N,METOCLOPRAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl,CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC
3408,CHEMBL1946124,TUSPVTWVRDALHT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCC3CC4=C(C3=O)C=CC(=C4)F,O=C1c2ccc(F)cc2CC1CCN1CCCN(c2ccc(Cl)cc2)CC1
3409,CHEMBL271449,TUZSKSVCURDDOD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3ccc4oc(C(F)(F)F)nc4c3CC2)n1C
3410,CHEMBL1144,TUZYXOIXSAXUGO-PZAWKZKUSA-N,PRAVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
3411,CHEMBL1144,TUZYXOIXSAXUGO-PZAWKZKUSA-N,PRAVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21
3412,CHEMBL63125,TVAKGPNWRYKDTE-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,6760.83,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.169999984192581,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](C)NC(=O)OC(C)(C)C)CC2)cc1
3413,CHEMBL1222762,TVBIHDSWRDFHAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4Cl)C(=O)O,CC(C)(CN1CCN(C2=Cc3ccccc3Cn3c(Cl)cnc32)CC1)C(=O)O
3414,CHEMBL2205826,TVDFWGUKMIRJAD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC(=C(C=C1)CN2C3C4C5CC6C4C2(C7C6C5C73)O)OC,COc1ccc(CN2C3C4C5CC6C7C5C3C7C2(O)C64)c(OC)c1
3415,CHEMBL558663,TVKCCIBAUDHHBL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,14.1,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.85078088734462,CN(CC1CCOCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)OC,COc1ccc(Cn2c(N3CCC(N(C)CC4CCOCC4)CC3)nc3ccccc32)cc1
3417,CHEMBL1237044,TVYLLZQTGLZFBW-UHFFFAOYSA-N,TRAMADOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,COc1cccc(C2(O)CCCCC2CN(C)C)c1
3418,CHEMBL1237044,TVYLLZQTGLZFBW-UHFFFAOYSA-N,TRAMADOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)CC1CCCCC1(C2=CC(=CC=C2)OC)O,COc1cccc(C2(O)CCCCC2CN(C)C)c1
3419,CHEMBL376180,TVZGACDUOSZQKY-LBPRGKRZSA-N,AMINOPTERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1
3420,CHEMBL376180,TVZGACDUOSZQKY-LBPRGKRZSA-N,AMINOPTERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCC2=CN=C3C(=N2)C(=NC(=N3)N)N,Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2n1
3421,CHEMBL60620,TWDZILVPGOSJTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)NCC,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)NCC)CC2)cc1
3422,CHEMBL2205812,TWMXGXSGGIIQDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,3839.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.415781887882595,COC1=CC=C(C=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)cc1
3424,CHEMBL683,TXCGAZHTZHNUAI-UHFFFAOYSA-N,CLOFIBRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl,CC(C)(Oc1ccc(Cl)cc1)C(=O)O
3425,CHEMBL683,TXCGAZHTZHNUAI-UHFFFAOYSA-N,CLOFIBRIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)Cl,CC(C)(Oc1ccc(Cl)cc1)C(=O)O
3426,CHEMBL1371125,TXVHTIQJNYSSKO-UHFFFAOYSA-N,BENZO[E]PYRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4,c1ccc2c(c1)c1cccc3ccc4cccc2c4c31
3427,CHEMBL1371125,TXVHTIQJNYSSKO-UHFFFAOYSA-N,BENZO[E]PYRENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C3=CC=CC4=C3C5=C(C=CC=C25)C=C4,c1ccc2c(c1)c1cccc3ccc4cccc2c4c31
3431,CHEMBL28651,TYDSNTMUQPPTLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11378358.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to cloned Histamine H1 receptor,Synthesis of potent and selective dopamine D(4) antagonists as candidate radioligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CSC1=CC=C(C=C1)N2CCN(CC2)CC3=CNC4=C3C=CC=N4,CSc1ccc(N2CCN(Cc3c[nH]c4ncccc34)CC2)cc1
3432,CHEMBL2158789,TYDWSEQLTIBAPO-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,199.53,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@](C)(CC4=CC=CC=C4)C(=O)O,Cc1c(OC2CCN(CC3CCN([C@@](C)(Cc4ccccc4)C(=O)O)CC3)CC2)ccc(Cl)c1Cl
3433,CHEMBL2220427,TYQXKHPOXXXCTP-CSLYCKPJSA-N,ERYTHROMYCIN ESTOLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
3434,CHEMBL2220427,TYQXKHPOXXXCTP-CSLYCKPJSA-N,ERYTHROMYCIN ESTOLATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CC)(C)O)C)C)O)(C)O,CCC(=O)O[C@H]1[C@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]3C[C@@](C)(OC)[C@@H](O)[C@H](C)O3)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)O[C@H](C)C[C@@H]1N(C)C
3435,CHEMBL1783972,TZBFBARTOUGERH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,7160.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.145086977692143,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C5=CN=CC=C5,CN1CCc2c(c3cc(-c4cccnc4)ccc3n2CCc2ccccn2)C1
3436,CHEMBL1783972,TZBFBARTOUGERH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C5=CN=CC=C5,CN1CCc2c(c3cc(-c4cccnc4)ccc3n2CCc2ccccn2)C1
3437,CHEMBL44,TZBJGXHYKVUXJN-UHFFFAOYSA-N,GENISTEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
3438,CHEMBL44,TZBJGXHYKVUXJN-UHFFFAOYSA-N,GENISTEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12
3439,CHEMBL1371,TZFWDZFKRBELIQ-UHFFFAOYSA-N,CHLORZOXAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1Cl)NC(=O)O2,O=c1[nH]c2cc(Cl)ccc2o1
3440,CHEMBL1371,TZFWDZFKRBELIQ-UHFFFAOYSA-N,CHLORZOXAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C=C1Cl)NC(=O)O2,O=c1[nH]c2cc(Cl)ccc2o1
3443,CHEMBL256472,TZVRVTZSSPWUGF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)COC,COCc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
3444,CHEMBL70927,TZXKOCQBRNJULO-UHFFFAOYSA-N,DEFERIPRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C=CN1C)O,Cc1c(O)c(=O)ccn1C
3445,CHEMBL70927,TZXKOCQBRNJULO-UHFFFAOYSA-N,DEFERIPRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)C=CN1C)O,Cc1c(O)c(=O)ccn1C
3448,CHEMBL459350,TZZKWSLLNPOOCC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,79.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.102372908709557,CN(CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31)CC4=CC=C(C=C4)OCCCN5CCCCC5,CN(CCC=C1c2ccccc2CCc2ccccc21)Cc1ccc(OCCCN2CCCCC2)cc1
3449,CHEMBL302886,UAFWEWMUOVIYPG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1778.28,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7499998559187055,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3CC3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)C3CC3)CC2)cc1
3450,CHEMBL272546,UALAMQRWRIVLLQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C(N=CO5)C,CCc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
3451,CHEMBL10602,UAUJDKBNVRSJBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,5172.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.286341483791643,CN(C)CC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CC(c1ccccc1)c1ccccc1
3452,CHEMBL959,UBCHPRBFMUDMNC-UHFFFAOYSA-N,RIMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C12CC3CC(C1)CC(C3)C2)N,CC(N)C12CC3CC(CC(C3)C1)C2
3453,CHEMBL959,UBCHPRBFMUDMNC-UHFFFAOYSA-N,RIMANTADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C12CC3CC(C1)CC(C3)C2)N,CC(N)C12CC3CC(CC(C3)C1)C2
3454,CHEMBL322695,UBCZIICPWSGHLS-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC(=O)C1=CC=C(C=C1)OCCCN2CC[C@@H](C2)NC(=O)C3=NC=CN=C3,CC(=O)c1ccc(OCCCN2CC[C@H](NC(=O)c3cnccn3)C2)cc1
3455,CHEMBL1935574,UBEJREHBDACTGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,10500.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.978810700930062,C1CN(CCN1)C2=NC(=NC3=C2C=CC(=C3)C4=CC=CO4)N,Nc1nc(N2CCNCC2)c2ccc(-c3ccco3)cc2n1
3456,CHEMBL43882,UBOXGVDOUJQMTN-UHFFFAOYSA-N,TRICHLOROETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(Cl)Cl)Cl,ClCC(Cl)Cl
3457,CHEMBL43882,UBOXGVDOUJQMTN-UHFFFAOYSA-N,TRICHLOROETHANE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(Cl)Cl)Cl,ClCC(Cl)Cl
3459,CHEMBL14690,UCAIEVHKDLMIFL-UHFFFAOYSA-N,CLOBENPROPIT,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12606603.0,Ki,=,2754.23,NM,,,,,,,,,,,,,,,,,,,,5.559999795538785,C1=CC(=CC=C1CN=C(N)SCCCC2=CN=CN2)Cl,NC(=NCc1ccc(Cl)cc1)SCCCc1cnc[nH]1
3460,CHEMBL102929,UCAOEOZGCIGAIW-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,16000.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.795880017344076,CC1=CC=CC=C1S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,Cc1ccccc1S(=O)(=O)N[C@H]1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)C1
3461,CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
3462,CHEMBL84,UCFGDBYHRUNTLO-QHCPKHFHSA-N,TOPOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC(=C5CN(C)C)O)N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1
3463,CHEMBL787,UCHDWCPVSPXUMX-TZIWLTJVSA-N,MONTELUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
3464,CHEMBL787,UCHDWCPVSPXUMX-TZIWLTJVSA-N,MONTELUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)O)O,CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1
3466,CHEMBL318235,UCNOTTVNPRSTFW-XSFNXXSESA-N,R-226161,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17407815.0,Ki,=,74.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human cloned histamine H1 receptor,Tricyclic isoxazolines: identification of R226161 as a potential new antidepressant that combines potent serotonin reuptake inhibition and alpha2-adrenoceptor antagonism.,Bioorg. Med. Chem.,PUBLICATION,,7.130768280269023,C/C(=C\C1=CC=C(C=C1)F)/CN2CCN(CC2)C[C@H]3[C@@H]4COC5=CC(=C(C=C5C4=NO3)OC)OC,COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C(C)=C/c4ccc(F)cc4)CC3)[C@@H]1CO2
3467,CHEMBL459373,UCQNMJXTWOYVNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,205.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.688246138944246,CN(CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl)CC4=CC=C(C=C4)OCCCN5CCCCC5,CN(CCCN1c2ccccc2Sc2ccc(Cl)cc21)Cc1ccc(OCCCN2CCCCC2)cc1
3468,CHEMBL372795,UCSJYZPVAKXKNQ-HZYVHMACSA-N,STREPTOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
3469,CHEMBL372795,UCSJYZPVAKXKNQ-HZYVHMACSA-N,STREPTOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O,CN[C@@H]1[C@H](O[C@H]2[C@H](O[C@@H]3[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]3O)O[C@@H](C)[C@]2(O)C=O)O[C@@H](CO)[C@H](O)[C@H]1O
3471,CHEMBL679,UCTWMZQNUQWSLP-VIFPVBQESA-N,EPINEPHRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC[C@@H](C1=CC(=C(C=C1)O)O)O,CNC[C@H](O)c1ccc(O)c(O)c1
3472,CHEMBL679,UCTWMZQNUQWSLP-VIFPVBQESA-N,EPINEPHRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC[C@@H](C1=CC(=C(C=C1)O)O)O,CNC[C@H](O)c1ccc(O)c(O)c1
3473,CHEMBL564370,UDCCWKBPMHTQIP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,23.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.638272163982407,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3476,CHEMBL537218,UDGQQGZVMXRRQI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,CC(C)(C)C(=O)N1CCN(C(=O)C1)C2=CC=C(C=C2)OCCCN3CCCCC3.Cl,CC(C)(C)C(=O)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
3478,CHEMBL558551,UEJJHQNACJXSKW-SECBINFHSA-N,(R)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
3479,CHEMBL558551,UEJJHQNACJXSKW-SECBINFHSA-N,(R)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
3480,CHEMBL468,UEJJHQNACJXSKW-UHFFFAOYSA-N,THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
3481,CHEMBL468,UEJJHQNACJXSKW-UHFFFAOYSA-N,THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1
3482,CHEMBL426123,UEJJHQNACJXSKW-VIFPVBQESA-N,(-)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
3483,CHEMBL426123,UEJJHQNACJXSKW-VIFPVBQESA-N,(-)-THALIDOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(=O)NC(=O)[C@H]1N2C(=O)C3=CC=CC=C3C2=O,O=C1CC[C@H](N2C(=O)c3ccccc3C2=O)C(=O)N1
3484,CHEMBL2171019,UEMKNKCKJCNUSX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,CS(=O)(=O)C1=CC=CC(=C1)C(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,CS(=O)(=O)c1cccc(C(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
3485,CHEMBL252719,UEQUQVLFIPOEMF-GOSISDBHSA-N,(S)-MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.36,NM,,,,,,,,,,,,,,,,,,,,9.443697499232712,CN1CCN2[C@H](C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3[C@H]2C1
3486,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,3.39,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.469800301796917,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
3487,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771415.0,Ki,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to human Histamine H1 receptor ,Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents.,J. Med. Chem.,PUBLICATION,,8.769551078621726,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
3488,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1.51,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.821023052706831,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
3489,CHEMBL6437,UEQUQVLFIPOEMF-UHFFFAOYSA-N,MIANSERIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.175,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.756961951313707,CN1CCN2C(C1)C3=CC=CC=C3CC4=CC=CC=C42,CN1CCN2c3ccccc3Cc3ccccc3C2C1
3490,CHEMBL60837,UFCWZCWTDINVOS-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16982.44,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769999911123512,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CO)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](CO)NC(=O)OC(C)(C)C)CC2)cc1
3491,CHEMBL1277216,UFCXUUIZIMGORH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.100015437450608,C1CC2(CC1N3CCC(CC3)C(=O)O)CC4=CC=CC=C4OC5=CC=CC=C25,O=C(O)C1CCN(C2CCC3(Cc4ccccc4Oc4ccccc43)C2)CC1
3493,CHEMBL1241,UFLGIAIHIAPJJC-UHFFFAOYSA-N,TRIPELENNAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,39.81,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.400007822415903,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2,CN(C)CCN(Cc1ccccc1)c1ccccn1
3494,CHEMBL1241,UFLGIAIHIAPJJC-UHFFFAOYSA-N,TRIPELENNAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,1e+17,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-8.0,CN(C)CCN(CC1=CC=CC=C1)C2=CC=CC=N2,CN(C)CCN(Cc1ccccc1)c1ccccn1
3495,CHEMBL940,UGJMXCAKCUNAIE-UHFFFAOYSA-N,GABAPENTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)(CC(=O)O)CN,NCC1(CC(=O)O)CCCCC1
3496,CHEMBL940,UGJMXCAKCUNAIE-UHFFFAOYSA-N,GABAPENTIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC(CC1)(CC(=O)O)CN,NCC1(CC(=O)O)CCCCC1
3497,CHEMBL275443,UGYXPZQILZRKJJ-UHFFFAOYSA-N,4-METHYLHISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19791743.0,EC50,=,15848.93,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase assay,Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.,J. Med. Chem.,PUBLICATION,,4.800000052738446,CC1=C(N=CN1)CCN,Cc1[nH]cnc1CCN
3500,CHEMBL803,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,CYTARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
3501,CHEMBL803,UHDGCWIWMRVCDJ-CCXZUQQUSA-N,CYTARABINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O,Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1
3502,CHEMBL1092649,UHPLDFSEISHDBD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccc(F)cc2C1
3504,CHEMBL203266,UHWVSEOVJBQKBE-UHFFFAOYSA-N,TRIMETAZIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,COc1ccc(CN2CCNCC2)c(OC)c1OC
3505,CHEMBL203266,UHWVSEOVJBQKBE-UHFFFAOYSA-N,TRIMETAZIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C(=C(C=C1)CN2CCNCC2)OC)OC,COc1ccc(CN2CCNCC2)c(OC)c1OC
3506,CHEMBL255806,UHZJBSJVGFOSSA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C)oc6c(Br)c5CC4)n3C)cccc2n1
3507,CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
3508,CHEMBL1428,UIAGMCDKSXEBJQ-UHFFFAOYSA-N,NIMODIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1c1cccc([N+](=O)[O-])c1
3509,CHEMBL34431,UIAYVIIHMORPSJ-UHFFFAOYSA-N,CILOSTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3,CN(C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1)C1CCCCC1
3510,CHEMBL34431,UIAYVIIHMORPSJ-UHFFFAOYSA-N,CILOSTAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C1CCCCC1)C(=O)CCCOC2=CC3=C(C=C2)NC(=O)C=C3,CN(C(=O)CCCOc1ccc2[nH]c(=O)ccc2c1)C1CCCCC1
3511,CHEMBL564446,UIDVVYFYTIPHHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,IC50,=,3.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.481486060122112,CN(C1CCN(CC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F)C5CCOCC5,CN(C1CCOCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
3512,CHEMBL211501,UIFFUZWRFRDZJC-SBOOETFBSA-N,ANTIMYCIN A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,CCCCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C
3513,CHEMBL211501,UIFFUZWRFRDZJC-SBOOETFBSA-N,ANTIMYCIN A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCCC[C@@H]1[C@H]([C@@H](OC(=O)[C@H]([C@H](OC1=O)C)NC(=O)C2=C(C(=CC=C2)NC=O)O)C)OC(=O)CC(C)C,CCCCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C
3514,CHEMBL2158841,UJDYUOWUTALBPP-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)F)C(=O)O,O=C(O)[C@H](Cc1ccc(F)cc1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3515,CHEMBL1767138,UJMUXUJLIHKBEA-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.158,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.801342913045575,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)O,CN1CCC[C@@H]1Cn1nc(Cc2ccc(O)cc2)c2ccccc2c1=O
3517,CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
3518,CHEMBL1385840,UJYGDMFEEDNVBF-OGGGUQDZSA-N,ERGOCORNINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
3519,CHEMBL402826,UKHPZHQUPSAUMR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C,CCCc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
3520,CHEMBL64406,UKHVQZVXQRGRSL-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,8128.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.089999741487069,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(=O)OC(C)(C)C,C[C@@H](NC(=O)OC(C)(C)C)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3524,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
3525,CHEMBL532,ULGZDMOVFRHVEP-RWJQBGPGSA-N,ERYTHROMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O
3528,CHEMBL2158822,UMSPPMMERAOIRT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,6.31,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC=C4C(=O)O,O=C(O)c1ccccc1N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3529,CHEMBL1419,UNAANXDKBXWMLN-UHFFFAOYSA-N,SIBUTRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
3530,CHEMBL1419,UNAANXDKBXWMLN-UHFFFAOYSA-N,SIBUTRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C,CC(C)CC(N(C)C)C1(c2ccc(Cl)cc2)CCC1
3531,CHEMBL1201356,UNBRKDKAWYKMIV-QWQRMKEZSA-N,METHYLERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
3532,CHEMBL1201356,UNBRKDKAWYKMIV-QWQRMKEZSA-N,METHYLERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CC[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
3533,CHEMBL1167,UNFWWIHTNXNPBV-WXKVUWSESA-N,SPECTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O,CN[C@H]1[C@@H](O)[C@@H](NC)[C@H](O)[C@H]2O[C@@H]3O[C@H](C)CC(=O)[C@]3(O)O[C@H]12
3534,CHEMBL1167,UNFWWIHTNXNPBV-WXKVUWSESA-N,SPECTINOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC(=O)[C@]2([C@@H](O1)O[C@@H]3[C@H]([C@@H]([C@@H]([C@@H]([C@H]3O2)NC)O)NC)O)O,CN[C@H]1[C@@H](O)[C@@H](NC)[C@H](O)[C@H]2O[C@@H]3O[C@H](C)CC(=O)[C@]3(O)O[C@H]12
3535,CHEMBL59870,UNKGZIGUDPASTI-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,4677.35,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.330000131185909,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC(C)C)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](CC(C)C)NC(=O)OC(C)(C)C)CC2)cc1
3536,CHEMBL63112,UNKGZIGUDPASTI-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,8128.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.089999741487069,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)CC2)cc1
3537,CHEMBL1243335,UNQMLUWBMWGIRY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)SCC(C2=CC=CC=N2)C3=CN=CN3,CC(C)(C)c1ccc(SCC(c2ccccn2)c2cnc[nH]2)cc1
3538,CHEMBL1946254,UNTNFKPMHAXOEK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22336245.0,Ki,=,61.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-Pyrilamine from human histamine H1 receptor by liquid scintillation counter,"Structure-activity relationship studies of SYA 013, a homopiperazine analog of haloperidol.",Bioorg. Med. Chem.,PUBLICATION,,7.214670164989233,C1CN(CCN(C1)C2=CC=C(C=C2)Cl)CCCCC3=NC4=CC=CC=C4S3,Clc1ccc(N2CCCN(CCCCc3nc4ccccc4s3)CC2)cc1
3541,CHEMBL84293,UOSUONQDJGNZCQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,13.49,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.869988050328097,CCN(CC)CC1CC2C3=CC=CC=C3CC4=CC=CC=C4N2O1,CCN(CC)CC1CC2c3ccccc3Cc3ccccc3N2O1
3542,CHEMBL1278019,UOSUQZZICNGJPM-QNVARPAVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,794.33,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,6.0999990348465305,C1CC(CN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)(C(=O)O)F,O=C(O)C1(F)CCCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
3543,CHEMBL2171040,UOWPMQNCLJZBEA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,COC1=CC=CC=C1S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,COc1ccccc1S(=O)(=O)NC(=O)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3544,CHEMBL1020,UPSPUYADGBWSHF-UHFFFAOYSA-N,TOLMETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
3545,CHEMBL1020,UPSPUYADGBWSHF-UHFFFAOYSA-N,TOLMETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=C(C=C1)C(=O)C2=CC=C(N2C)CC(=O)O,Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1
3551,CHEMBL552057,UQAJLTTZWHXNJH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,35.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.455931955649724,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CCCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCN(CCCCN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3552,CHEMBL325258,UQMFUNLNAONENR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,280.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,6.552841968657781,C1CN(CCN1CCCC2=CC=CC=C2)C(=O)OCCC3=CC=C(C=C3)C#N,N#Cc1ccc(CCOC(=O)N2CCN(CCCc3ccccc3)CC2)cc1
3553,CHEMBL1489254,URAYPUMNDPQOKB-UHFFFAOYSA-N,TRIACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(COC(=O)C)OC(=O)C,CC(=O)OCC(COC(C)=O)OC(C)=O
3554,CHEMBL1489254,URAYPUMNDPQOKB-UHFFFAOYSA-N,TRIACETIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(COC(=O)C)OC(=O)C,CC(=O)OCC(COC(C)=O)OC(C)=O
3555,CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
3556,CHEMBL384467,UREBDLICKHMUKA-CXSFZGCWSA-N,DEXAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
3557,CHEMBL632,UREBDLICKHMUKA-DVTGEIKXSA-N,BETAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
3558,CHEMBL632,UREBDLICKHMUKA-DVTGEIKXSA-N,BETAMETHASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO
3559,CHEMBL221753,UREZNYTWGJKWBI-UHFFFAOYSA-M,BENZETHONIUM CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1
3560,CHEMBL221753,UREZNYTWGJKWBI-UHFFFAOYSA-M,BENZETHONIUM CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)CC(C)(C)C1=CC=C(C=C1)OCCOCC[N+](C)(C)CC2=CC=CC=C2.[Cl-],CC(C)(C)CC(C)(C)c1ccc(OCCOCC[N+](C)(C)Cc2ccccc2)cc1
3561,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,,,,,,8.657577319177793,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3562,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,,,,,,7.721246399047171,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3563,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11170639.0,Ki,=,21.0,NM,,,,,,,,,,,,,,,Binding affinity towards human H1 receptor,Current and novel approaches to the drug treatment of schizophrenia.,J. Med. Chem.,PUBLICATION,,7.67778070526608,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3564,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,11.0,NM,,,,,,,,,,,,,,,,,,,,7.9586073148417755,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3565,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14998318.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,Binding affinity towards human histamine H1 receptor,Selective optimization of side activities: another way for drug discovery.,J. Med. Chem.,PUBLICATION,,7.721246399047171,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3566,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,8.7,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,8.060480747381384,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3567,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,39.6,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.402304814074488,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3568,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,4.6,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.337242168318426,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3569,CHEMBL716,URKOMYMAXPYINW-UHFFFAOYSA-N,QUETIAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,10.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.0,C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42,OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
3570,CHEMBL2030628,URNOPSHFIGOPOJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CC2CCC1N2CCC3=CC(=CC=C3)F,Fc1cccc(CCN2C3CCC2CC3)c1
3571,CHEMBL1767139,URSKGEZFWCRYMD-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,5.01,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.300162274132754,CCOC1=CC=C(C=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C,CCOc1ccc(Cc2nn(C[C@H]3CCCN3C)c(=O)c3ccccc23)cc1
3572,CHEMBL221886,URWAJWIAIPFPJE-YFMIWBNJSA-N,SISOMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O
3573,CHEMBL221886,URWAJWIAIPFPJE-YFMIWBNJSA-N,SISOMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(CO[C@@H]([C@@H]([C@H]1NC)O)O[C@H]2[C@@H](C[C@@H]([C@H]([C@@H]2O)O[C@@H]3[C@@H](CC=C(O3)CN)N)N)N)O,CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3OC(CN)=CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O
3574,CHEMBL1923534,URWAMRSFMYPXOS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,8128.31,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.089999741487069,C1CCC(CC1)C2=NC(=NN2C3=CC=CC=C3)SCCN,NCCSc1nc(C2CCCCC2)n(-c2ccccc2)n1
3575,CHEMBL429914,URXBXRUUVSTMJM-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18077160.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by [35S]GTP-gamma-S binding assay,In vitro SAR of pyrrolidine-containing histamine H3 receptor antagonists: trends across multiple chemical series.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C[C@@H]1CCCN1CCC2=CC=C(C=C2)OCC3=CC=CC=C3,C[C@@H]1CCCN1CCc1ccc(OCc2ccccc2)cc1
3576,CHEMBL318659,URZPDWAADSKBHJ-QENMJEOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.522878745280337,CN1CCN(CC1)CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35,CN1CCN(CC2C[C@@H]3c4ccccc4Cc4ccccc4[C@H]3O2)CC1
3577,CHEMBL319352,USCDVFNXTCISHV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,500.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,6.301029995663981,CN1N=C(N=N1)C2=CC3=C(C=C2)N(C=C3C4CCN(CC4)CCN5CCNC5=O)C6=CC=C(C=C6)F,Cn1nnc(-c2ccc3c(c2)c(C2CCN(CCN4CCNC4=O)CC2)cn3-c2ccc(F)cc2)n1
3578,CHEMBL2037528,USGLWFZAXHASGB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22520153.0,Ki,=,46.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 histamine receptor by liquid scintillation assay,Benzothiazoles as probes for the 5HT(1A) receptor and the serotonin transporter (SERT): A search for new dual-acting agents as potential antidepressants.,Eur. J. Med. Chem.,PUBLICATION,,7.337242168318426,C1CN(CCN1CCCCC(=O)C2=NC3=CC=CC=C3S2)C4=CC=C(C=C4)Cl,O=C(CCCCN1CCN(c2ccc(Cl)cc2)CC1)c1nc2ccccc2s1
3579,CHEMBL402015,USKZVJAZXRLUHK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCN4CCc5cc6nc(C)oc6c(Br)c5CC4)n3C)cccc2n1
3580,CHEMBL320002,USQNYIPSWUNBEC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.69,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.174573882232178,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC8=C(C=C7)OCO8,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc4c(c3)OCO4)C2)cc(OC)c1OC
3582,CHEMBL502896,USROQQUKEBHOFF-SKKCDYJJSA-N,CETRAXATE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O.Cl,NCC1CCC(C(=O)Oc2ccc(CCC(=O)O)cc2)CC1
3583,CHEMBL502896,USROQQUKEBHOFF-SKKCDYJJSA-N,CETRAXATE HYDROCHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(CCC1CN)C(=O)OC2=CC=C(C=C2)CCC(=O)O.Cl,NCC1CCC(C(=O)Oc2ccc(CCC(=O)O)cc2)CC1
3584,CHEMBL305371,USVPOSBOAJRHOO-XMMPIXPASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9772.37,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.010000098195094,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CC=C(C=C4)O)N,N[C@H](Cc1ccc(O)cc1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3585,CHEMBL502620,USZYSDMBJDPRIF-SVEJIMAYSA-N,ACLARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O,CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC
3586,CHEMBL502620,USZYSDMBJDPRIF-SVEJIMAYSA-N,ACLARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]1(C[C@@H](C2=C(C3=C(C=C2[C@H]1C(=O)OC)C(=O)C4=C(C3=O)C(=CC=C4)O)O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O[C@H]7CCC(=O)[C@@H](O7)C)O)N(C)C)O,CC[C@@]1(O)C[C@H](O[C@H]2C[C@H](N(C)C)[C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)c2c(cc3c(c2O)C(=O)c2c(O)cccc2C3=O)[C@H]1C(=O)OC
3587,CHEMBL1333512,UTGQNNCQYDRXCH-UHFFFAOYSA-N,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3,c1ccc(Nc2ccc(Nc3ccccc3)cc2)cc1
3588,CHEMBL1333512,UTGQNNCQYDRXCH-UHFFFAOYSA-N,"N,N'-DIPHENYL-P-PHENYLENEDIAMINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)NC2=CC=C(C=C2)NC3=CC=CC=C3,c1ccc(Nc2ccc(Nc3ccccc3)cc2)cc1
3593,CHEMBL569270,UTPGRZGMQVAYAA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24147864.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by PDSP assay,Synthesis and evaluation in monkey of [(18)F]4-fluoro-N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([(18)F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1).,J. Med. Chem.,PUBLICATION,,5.0,CNC1=NC=NC(=C1)C2=CSC(=N2)N(C)C(=O)C3=CC=C(C=C3)F,CNc1cc(-c2csc(N(C)C(=O)c3ccc(F)cc3)n2)ncn1
3594,CHEMBL2171031,UTVOOLLPUMDSJS-IRLDBZIGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,>,5011.87,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.3000002024454185,CC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3CC[C@H](C[C@H]3C(=O)O)OC4=C(C(=C(C=C4)Cl)C)Cl,Cc1ccc(C(=O)N2CCC(N3CC[C@@H](Oc4ccc(Cl)c(C)c4Cl)C[C@H]3C(=O)O)CC2)cc1
3595,CHEMBL2171030,UTVOOLLPUMDSJS-RBBKRZOGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,>,6309.57,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200000237109354,CC1=CC=C(C=C1)C(=O)N2CCC(CC2)N3CC[C@@H](C[C@@H]3C(=O)O)OC4=C(C(=C(C=C4)Cl)C)Cl,Cc1ccc(C(=O)N2CCC(N3CC[C@H](Oc4ccc(Cl)c(C)c4Cl)C[C@@H]3C(=O)O)CC2)cc1
3596,CHEMBL609328,UTYFBWKQSXSRBL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,=,725.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.139661993429006,C1C2=CC=CC=C2C(C3=CC=CC=C31)CNCCCC4=CC=CC=C4,c1ccc(CCCNCC2c3ccccc3Cc3ccccc32)cc1
3597,CHEMBL13378,UUDAMDVQRQNNHZ-UHFFFAOYSA-N,"(R,S)-AMPA",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)NO1)CC(C(=O)O)N,Cc1o[nH]c(=O)c1CC(N)C(=O)O
3598,CHEMBL13378,UUDAMDVQRQNNHZ-UHFFFAOYSA-N,"(R,S)-AMPA",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=O)NO1)CC(C(=O)O)N,Cc1o[nH]c(=O)c1CC(N)C(=O)O
3599,CHEMBL1092259,UUEDQZRCAVWNIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.853871964321762,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)Cl)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccc(Cl)cc2C1
3600,CHEMBL357995,UUOJIACWOAYWEZ-UHFFFAOYSA-N,BOPINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1
3601,CHEMBL357995,UUOJIACWOAYWEZ-UHFFFAOYSA-N,BOPINDOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC2=C(N1)C=CC=C2OCC(CNC(C)(C)C)OC(=O)C3=CC=CC=C3,Cc1cc2c(OCC(CNC(C)(C)C)OC(=O)c3ccccc3)cccc2[nH]1
3602,CHEMBL24441,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,BETAHISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC1=CC=CC=N1,CNCCc1ccccn1
3603,CHEMBL24441,UUQMNUMQCIQDMZ-UHFFFAOYSA-N,BETAHISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNCCC1=CC=CC=N1,CNCCc1ccccn1
3604,CHEMBL570033,UURQFLKKSYYPEF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,203.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.692503962086787,C1CN(CCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O)CCCCC4=CC=C(C=C4)C(=O)O,O=C(O)c1ccc(CCCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3605,CHEMBL1172754,UUTLATQGKXUVDD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20541426.0,Ki,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]rilamine from human histamine H1 receptor expressed in CHO cells after 1 hr by liquid scintillation counting,Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.,Bioorg. Med. Chem.,PUBLICATION,,6.0,C1CN(CCC1CC2=CN=CN2)C3=CC=C(C=C3)C(F)(F)F,FC(F)(F)c1ccc(N2CCC(Cc3cnc[nH]3)CC2)cc1
3606,CHEMBL535631,UUVMYIPSOIHEGH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,CC(C)N1CCC(CC1)OC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)F.Cl,CC(C)N1CCC(Oc2ccc(N3CCN(C(=O)c4ccc(F)cc4)CC3=O)cc2)CC1
3607,CHEMBL1455,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,ALTRETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,CN(C)c1nc(N(C)C)nc(N(C)C)n1
3608,CHEMBL1455,UUVWYPNAQBNQJQ-UHFFFAOYSA-N,ALTRETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C,CN(C)c1nc(N(C)C)nc(N(C)C)n1
3609,CHEMBL1767162,UUYDLXMNWLLYQV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.400007822415903,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCNCCN3C(=O)C4=CC=CC=C4C(=N3)CC5=CC=C(C=C5)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1CCNCCCCc1ccc(OCCCN2CCCCCC2)cc1
3610,CHEMBL62527,UVFIYINSVIEJKT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,3981.07,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)C(C)C)CC2)cc1
3611,CHEMBL648,UVKZSORBKUEBAZ-UHFFFAOYSA-N,CYCLIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,38.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.420216403383191,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,CN1CCN(C(c2ccccc2)c2ccccc2)CC1
3612,CHEMBL648,UVKZSORBKUEBAZ-UHFFFAOYSA-N,CYCLIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,4.44,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.35261702988538,CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=CC=C3,CN1CCN(C(c2ccccc2)c2ccccc2)CC1
3613,CHEMBL404811,UVYVLBIGDKGWPX-YCCXZQINSA-N,DIGITONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1,C[C@H]1[C@H]2[C@@H](O[C@]13CC[C@@H](C)CO3)[C@@H](O)[C@H]1[C@@H]3CC[C@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@H](O[C@@H]6O[C@H](CO)C(O)[C@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)C[C@]4(C)[C@H]3CC[C@@]12C
3614,CHEMBL404811,UVYVLBIGDKGWPX-YCCXZQINSA-N,DIGITONIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)[C@H]([C@@H]4[C@@]3(CC[C@H]5[C@H]4CC[C@@H]6[C@@]5(C[C@H]([C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@H](C([C@H](O8)CO)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O)O)O[C@H]2[C@@H]([C@H]([C@H]([C@H](O2)CO)O)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O)O)C)C)O)C)OC1,C[C@H]1[C@H]2[C@@H](O[C@]13CC[C@@H](C)CO3)[C@@H](O)[C@H]1[C@@H]3CC[C@H]4C[C@@H](O[C@@H]5O[C@H](CO)[C@H](O[C@@H]6O[C@H](CO)C(O)[C@H](O[C@@H]7OC[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)C[C@]4(C)[C@H]3CC[C@@]12C
3615,CHEMBL139835,UWFYSQMTEOIJJG-FDTZYFLXSA-N,CYPROTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
3616,CHEMBL139835,UWFYSQMTEOIJJG-FDTZYFLXSA-N,CYPROTERONE ACETATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C=C(C4=CC(=O)[C@@H]5C[C@@H]5[C@]34C)Cl)C)OC(=O)C,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C
3617,CHEMBL481,UWKQSNNFCGGAFS-XIFFEERXSA-N,IRINOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
3618,CHEMBL481,UWKQSNNFCGGAFS-XIFFEERXSA-N,IRINOTECAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7,CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
3620,CHEMBL2146807,UXQVMDVKHFQOEU-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.631,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.199970640755863,CCCCN1CCC[C@@H]1CN2C(=O)C3=C(C=CC=N3)C(=N2)CC4=CC=C(C=C4)Cl,CCCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2cccnc2c1=O
3621,CHEMBL86754,UXZFQZANDVDGMM-UHFFFAOYSA-N,IODOQUINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C(C=C2I)I)O)N=C1,Oc1c(I)cc(I)c2cccnc12
3622,CHEMBL86754,UXZFQZANDVDGMM-UHFFFAOYSA-N,IODOQUINOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC2=C(C(=C(C=C2I)I)O)N=C1,Oc1c(I)cc(I)c2cccnc12
3623,CHEMBL282575,UYIFTLBWAOGQBI-BZDYCCQFSA-N,ESTRADIOL BENZOATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
3624,CHEMBL282575,UYIFTLBWAOGQBI-BZDYCCQFSA-N,ESTRADIOL BENZOATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)OC(=O)C5=CC=CC=C5,C[C@]12CC[C@@H]3c4ccc(OC(=O)c5ccccc5)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
3625,CHEMBL305187,UYNVMODNBIQBMV-UHFFFAOYSA-N,IFENPRODIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,1681106.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Compound was tested for the binding affinity against histamine H1 receptor by using [3H]mepyramine as radioligand,Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds.,J. Med. Chem.,PUBLICATION,,6.0,CC(C(C1=CC=C(C=C1)O)O)N2CCC(CC2)CC3=CC=CC=C3,CC(C(O)c1ccc(O)cc1)N1CCC(Cc2ccccc2)CC1
3627,CHEMBL152126,UYZUQDLFLZXDNQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,630.96,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.19999817218203,C1CCN(C1)CCCCCCCCC2=CN=CN2,c1ncc(CCCCCCCCN2CCCC2)[nH]1
3628,CHEMBL152126,UYZUQDLFLZXDNQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1CCN(C1)CCCCCCCCC2=CN=CN2,c1ncc(CCCCCCCCN2CCCC2)[nH]1
3629,CHEMBL2151156,UZFUMFWJEGINFP-UHFFFAOYSA-N,GSK541636,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,12.59,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,7.899974269892138,CC1(CCCN(C1)CCCOC2=CC=C(C=C2)C3CCN(CC3)C(=O)C4=CC=C(C5=CC=CC=C54)CCC(=O)O)C,CC1(C)CCCN(CCCOc2ccc(C3CCN(C(=O)c4ccc(CCC(=O)O)c5ccccc45)CC3)cc2)C1
3632,CHEMBL80,UZHSEJADLWPNLE-GRGSLBFTSA-N,NALOXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
3633,CHEMBL80,UZHSEJADLWPNLE-GRGSLBFTSA-N,NALOXONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O,C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5
3635,CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
3636,CHEMBL1191,VACCAVUAMIDAGB-UHFFFAOYSA-N,SULFAMETHIZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C(S1)NS(=O)(=O)C2=CC=C(C=C2)N,Cc1nnc(NS(=O)(=O)c2ccc(N)cc2)s1
3637,CHEMBL137,VAOCPAMSLUNLGC-UHFFFAOYSA-N,METRONIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CCO)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CCO
3638,CHEMBL137,VAOCPAMSLUNLGC-UHFFFAOYSA-N,METRONIDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC=C(N1CCO)[N+](=O)[O-],Cc1ncc([N+](=O)[O-])n1CCO
3640,CHEMBL94249,VAPDJJGAJMZUCA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,501.19,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.299997602857746,C1=C(NC=N1)CCCCCCCCCCN,NCCCCCCCCCCc1cnc[nH]1
3641,CHEMBL94249,VAPDJJGAJMZUCA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,199526231496888.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.3,C1=C(NC=N1)CCCCCCCCCCN,NCCCCCCCCCCc1cnc[nH]1
3643,CHEMBL263881,VAYOSLLFUXYJDT-RDTXWAMCSA-N,LYSERGIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12213075.0,Ki,=,1540.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor,"Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD).",J. Med. Chem.,PUBLICATION,,5.8124792791635365,CCN(CC)C(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,CCN(CC)C(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
3645,CHEMBL2030637,VBKWQJLSFFFYLC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CCCC2=CC(=CC=C2)F,Fc1cccc(CCCN2CCCC2)c1
3646,CHEMBL95125,VBMKWPABKWXAOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.36,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.196542884351587,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=CC=N6)C7=CC(=C(C=C7)Cl)Cl,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccccn4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
3647,,VBOQYPQEPHKASR-GSVOUGTGSA-N,D-HOMOCYSTEIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)(=O)O)[C@H](C(=O)O)N,N[C@H](CCS(=O)(=O)O)C(=O)O
3648,CHEMBL230951,VBOQYPQEPHKASR-VKHMYHEASA-N,L-HOMOCYSTEATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(CS(=O)(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCS(=O)(=O)O)C(=O)O
3650,CHEMBL454890,VCADIWSEVTZZOR-UHFFFAOYSA-N,VUF-10499,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19053770.0,Ki,=,97.72,NM,,,cell_based,,,,,NIH3T3,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in NIH3T3 cells,Discovery of quinazolines as histamine H4 receptor inverse agonists using a scaffold hopping approach.,J. Med. Chem.,PUBLICATION,,7.010016541698601,CN1CCN(CC1)C2=NC3=C(C=C(C=C3)Cl)C(=N2)NCC4=COC=C4,CN1CCN(c2nc(NCc3ccoc3)c3cc(Cl)ccc3n2)CC1
3654,CHEMBL402215,VCJRZGBNXMAJCB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(C(F)(F)F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3ccc4oc(C(F)(F)C(F)(F)F)nc4c3CC2)n1C
3658,CHEMBL611,VCKUSRYTPJJLNI-UHFFFAOYSA-N,TERAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
3659,CHEMBL611,VCKUSRYTPJJLNI-UHFFFAOYSA-N,TERAZOSIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC,COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC
3660,CHEMBL1277678,VCLTUEPMXZBALZ-FHZUCYEKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415903,C1C[C@@]2(CC1N3CCC(CC3)(C(=O)O)F)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1(F)CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1
3661,CHEMBL403804,VCXXQIVAVCLUOT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(S1)C3=C(CCN(CC3)CCCSC4=NN=C(N4C)C5=C(N=CO5)C)C=C2,CCc1nc2ccc3c(c2s1)CCN(CCCSc1nnc(-c2ocnc2C)n1C)CC3
3662,CHEMBL64059,VCYFASOCVKPRSB-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CCC4=CC=CC=C4)N,N[C@H](CCc1ccccc1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3663,CHEMBL98079,VDAMCZUHIJCJPK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.63,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.178486471595226,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
3664,CHEMBL2207642,VDCBDIRJDJYCIZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23099096.0,Ki,=,490.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in insect Sf9 cell membrane preparation after 60 mins by scintillation counting analysis,Novel azulene derivatives for the treatment of erectile dysfunction.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.309803919971486,COC1=CC=CC=C1N2CCN(CC2)CC3=C4C=CC=CC=C4C(=C3)CN5CCN(CC5)C6=CC=C(C=C6)Cl,COc1ccccc1N1CCN(Cc2cc(CN3CCN(c4ccc(Cl)cc4)CC3)c3cccccc2-3)CC1
3666,CHEMBL2208421,VDFDTTRCUDMUDX-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,COC1=CC(=CC=C1)SC[C@H](CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)O,COc1cccc(SC[C@@H](O)CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)c1
3667,CHEMBL2171028,VDNHGXHYXNDCOW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,15.85,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)C4=CC=CC=C4NCCC(=O)O,O=C(O)CCNc1ccccc1C(=O)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3671,CHEMBL1093294,VDXIBLBHDRKGBK-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,2.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.537602002101043,C[C@H](C1=C(N=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,COc1ncccc1[C@@H](C)c1c(CCN(C)C)sc2ccccc12
3672,CHEMBL239321,VDZPNNUVDOABNY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=C(C=C(C=C5)F)F.C(=O)O,O=C(c1ccc(F)cc1F)N1CCN(c2ccc(OC3CCN(C4CCC4)CC3)cc2)C(=O)C1
3673,CHEMBL419912,VECOVVSVBRZIJA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3715.35,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4300002677960535,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=NC=C3,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccncc3)cc2)CC1
3674,CHEMBL2031874,VEGKMRUZYWQMBZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.0,CN(C)C(=O)C1=CC=C(C=C1)C2=CC3=C(C=C2)C(=O)N(CC3)CCN4CCCC4,CN(C)C(=O)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
3675,CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
3676,CHEMBL119385,VEPKQEUBKLEPRA-UHFFFAOYSA-N,VX-745,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)C2=C3C=CC(=NN3C=NC2=O)SC4=C(C=C(C=C4)F)F)Cl,O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl
3677,CHEMBL1200629,VEPSYABRBFXYIB-PWXDFCLTSA-M,VECURONIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-],CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
3678,CHEMBL1200629,VEPSYABRBFXYIB-PWXDFCLTSA-M,VECURONIUM BROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-],CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1
3679,CHEMBL277474,VEQOALNAAJBPNY-UHFFFAOYSA-N,ANTIPYRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(N1C)C2=CC=CC=C2,Cc1cc(=O)n(-c2ccccc2)n1C
3680,CHEMBL277474,VEQOALNAAJBPNY-UHFFFAOYSA-N,ANTIPYRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=O)N(N1C)C2=CC=CC=C2,Cc1cc(=O)n(-c2ccccc2)n1C
3681,CHEMBL571389,VFCNPRIWDSWJIG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,39.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.4089353929735005,CC1=CC=C(C=C1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,Cc1ccc(CCCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3683,CHEMBL2146806,VFIDGXZRONKQBZ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.398,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.400116927926312,CCCCN1CCC[C@@H]1CN2C(=O)C3=C(C=NC=C3)C(=N2)CC4=CC=C(C=C4)Cl,CCCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2cnccc2c1=O
3684,CHEMBL1277854,VFKIKYZNUCGJGD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.400007822415903,C1CC2(CC1N3CCC(=CC3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1=CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1
3685,CHEMBL283196,VFMMPHCGEFXGIP-UHFFFAOYSA-N,ALPHA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12
3686,CHEMBL283196,VFMMPHCGEFXGIP-UHFFFAOYSA-N,ALPHA-NAPHTHOFLAVONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C4=CC=CC=C4C=C3,O=c1cc(-c2ccccc2)oc2c1ccc1ccccc12
3687,CHEMBL117537,VGBOISIRCIDEGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11585444.0,IC50,=,1930.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,From hit to lead. Analyzing structure-profile relationships.,J. Med. Chem.,PUBLICATION,,5.714442690992227,C1CN(CCN1CCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)CCCC4=CC=CC=C4,O=C(CCCc1ccccc1)N1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
3688,,VGFZCFWVSYIXEK-UHFFFAOYSA-N,K604,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15798001.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CC1CC(C2=CC=CC=C2N1C(=O)C3=CC=CC=C3)N(C4=CC=CC=C4)C(=O)C5CC5,CC1CC(N(C(=O)C2CC2)c2ccccc2)c2ccccc2N1C(=O)c1ccccc1
3689,CHEMBL29292,VGGGPCQERPFHOB-RDBSUJKOSA-N,UBENIMEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O
3690,CHEMBL29292,VGGGPCQERPFHOB-RDBSUJKOSA-N,UBENIMEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](CC1=CC=CC=C1)N)O,CC(C)C[C@H](NC(=O)[C@@H](O)[C@H](N)Cc1ccccc1)C(=O)O
3691,CHEMBL589388,VGJCKVYMMJXTIH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,68.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.167491087293763,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=C4)C=CC(=C3)C(F)(F)F,CN1CCc2c(c3cc(C(F)(F)F)ccc3n2CCc2ccccc2)C1
3692,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3693,CHEMBL809,VGKDLMBJGBXTGI-SJCJKPOMSA-N,SERTRALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3694,CHEMBL284994,VGKDLMBJGBXTGI-YVEFUNNKSA-N,"(1R,4S)-TRANS-SERTRALINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN[C@@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl,CN[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21
3695,CHEMBL555146,VGSYEFOBFMUWGO-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313227.0,Ki,=,5440.0,NM,,,,,,,,,,,,,,,Binding affinity to human recombinant H1 receptor,Radiosynthesis and evaluation of an (18)F-labeled positron emission tomography (PET) radioligand for brain histamine subtype-3 receptors based on a nonimidazole 2-aminoethylbenzofuran chemotype.,J. Med. Chem.,PUBLICATION,,5.2644011003018205,C[C@@H]1CCCN1CCC2=CC3=C(O2)C=CC(=C3)C(=O)C4=CC=C(C=C4)F,C[C@@H]1CCCN1CCc1cc2cc(C(=O)c3ccc(F)cc3)ccc2o1
3698,CHEMBL2429890,VGYQUDBPYFLBLJ-PTCVETCVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,=,4178.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.379031564355709,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC7=C(C=C6)OCO7,c1cc2c(cc1CN[C@H]1C3C4CC5C6C4CC3C6C51)OCO2
3700,CHEMBL299052,VHGCDTVCOLNTBX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,5500.0,NM,,,,,,,,,,,,,,,,,,,,5.259637310505756,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CNCCC(Oc1ccccc1C)c1ccccc1
3701,CHEMBL299052,VHGCDTVCOLNTBX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12431845.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,,,,,,6.0,CC1=CC=CC=C1OC(CCNC)C2=CC=CC=C2,CNCCC(Oc1ccccc1C)c1ccccc1
3702,CHEMBL1767152,VHHWNRROUCRXSK-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,31.62,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.500038134403809,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CCC4=CC=CC=C4,CN1CCC[C@@H]1Cn1nc(CCc2ccccc2)c2ccccc2c1=O
3703,CHEMBL250699,VHKBTPQDHDSBSP-UHFFFAOYSA-N,A-803467,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17483457.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from histamine H1 receptor,"A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.",Proc. Natl. Acad. Sci. U.S.A.,PUBLICATION,,5.0,COC1=CC(=CC(=C1)NC(=O)C2=CC=C(O2)C3=CC=C(C=C3)Cl)OC,COc1cc(NC(=O)c2ccc(-c3ccc(Cl)cc3)o2)cc(OC)c1
3704,CHEMBL270299,VHKZGNPOHPFPER-ONNFQVAWSA-N,BAY-11-7085,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N,CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1
3705,CHEMBL270299,VHKZGNPOHPFPER-ONNFQVAWSA-N,BAY-11-7085,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)/C=C/C#N,CC(C)(C)c1ccc(S(=O)(=O)/C=C/C#N)cc1
3706,CHEMBL960,VHOGYURTWQBHIL-UHFFFAOYSA-N,LEFLUNOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
3707,CHEMBL960,VHOGYURTWQBHIL-UHFFFAOYSA-N,LEFLUNOMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F,Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1
3708,CHEMBL650,VHRSUDSXCMQTMA-PJHHCJLFSA-N,METHYLPREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
3709,CHEMBL650,VHRSUDSXCMQTMA-PJHHCJLFSA-N,METHYLPREDNISOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12
3710,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
3711,CHEMBL22587,VHVPQPYKVGDNFY-ZPGVKDDISA-N,ITRACONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl,CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O
3712,CHEMBL1935437,VIEHHRQCEMIKCL-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.2,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.920818753952375,C1C[C@H](CNC1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c([C@@H]3CCCNC3)nc3ccccc32)cc1
3713,CHEMBL1162,VIKNJXKGJWUCNN-XGXHKTLJSA-N,NORETHINDRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
3714,CHEMBL1162,VIKNJXKGJWUCNN-XGXHKTLJSA-N,NORETHINDRONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C
3715,CHEMBL1087493,VILNAIPEYFWQQH-AWEZNQCLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,4.8,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.318758762624412,CCOCCN1C2=CC=CC=C2N=C1N3CC[C@@H](C3)N(C)C,CCOCCn1c(N2CC[C@H](N(C)C)C2)nc2ccccc21
3716,CHEMBL267894,VIROVYVQCGLCII-UHFFFAOYSA-N,AMOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
3717,CHEMBL267894,VIROVYVQCGLCII-UHFFFAOYSA-N,AMOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1(C(=O)NC(=O)NC1=O)CCC(C)C,CCC1(CCC(C)C)C(=O)NC(=O)NC1=O
3718,CHEMBL60383,VJAQRKGFVIGFJD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,97.72,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.010016541698601,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=C(S3)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3ccc(C)s3)CC2)cc1
3719,CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
3720,CHEMBL44657,VJJPUSNTGOMMGY-MRVIYFEKSA-N,ETOPOSIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O
3721,CHEMBL565083,VKAAMGNCPQOWFB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,72.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.142667503568733,CC(C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O,CC(C(=O)O)c1ccc2c(c1)N(CCCN1CCCN(c3cc(=O)n(C)c(=O)n3C)CC1)c1ccccc1S2
3722,CHEMBL1276308,VKHAHZOOUSRJNA-GCNJZUOMSA-N,MIFEPRISTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
3723,CHEMBL1276308,VKHAHZOOUSRJNA-GCNJZUOMSA-N,MIFEPRISTONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C
3724,CHEMBL12089,VKJGBAJNNALVAV-UHFFFAOYSA-M,BERBERINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-],COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
3725,CHEMBL12089,VKJGBAJNNALVAV-UHFFFAOYSA-M,BERBERINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC.[Cl-],COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2
3728,CHEMBL1726,VKQFCGNPDRICFG-UHFFFAOYSA-N,NISOLDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]
3729,CHEMBL1726,VKQFCGNPDRICFG-UHFFFAOYSA-N,NISOLDIPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-]
3730,CHEMBL559557,VKVAJQSZVWNRMB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.619788758288394,CN(CCC1=CC=CC=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(CCc1ccccc1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
3731,CHEMBL558,VLPIATFUUWWMKC-UHFFFAOYSA-N,MEXILETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)OCC(C)N,Cc1cccc(C)c1OCC(C)N
3732,CHEMBL558,VLPIATFUUWWMKC-UHFFFAOYSA-N,MEXILETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C(=CC=C1)C)OCC(C)N,Cc1cccc(C)c1OCC(C)N
3733,CHEMBL2158829,VLUYCVQWTQUWPI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC(=CC=C4)OCC(=O)O,O=C(O)COc1cccc(N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
3735,CHEMBL310183,VMLLHZVDHFWOOM-UHFFFAOYSA-N,R-95292,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,102.33,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.989997025872941,CN(C)CC1CC2C3=CC=CC=C3OC4=C(N2O1)C=C(C=C4)Cl,CN(C)CC1CC2c3ccccc3Oc3ccc(Cl)cc3N2O1
3736,CHEMBL1612004,VMPITZXILSNTON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1N,COc1ccccc1N
3737,CHEMBL1612004,VMPITZXILSNTON-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=CC=C1N,COc1ccccc1N
3738,CHEMBL1222763,VMTWXOTZXVFSPH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,39.81,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.400007822415903,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC(=C4)F)C(=O)O,CC(C)(CN1CCN(C2=Cc3ccccc3Cn3cc(F)nc32)CC1)C(=O)O
3739,CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
3740,CHEMBL1790041,VMXUWOKSQNHOCA-UHFFFAOYSA-N,RANITIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC(=C[N+](=O)[O-])NCCSCC1=CC=C(O1)CN(C)C,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
3741,CHEMBL512,VMXUWOKSQNHOCA-UKTHLTGXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
3742,CHEMBL512,VMXUWOKSQNHOCA-UKTHLTGXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C,CN/C(=C\[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1
3743,CHEMBL1093044,VMZBJCIUNPGQKF-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,32000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.494850021680094,C[C@@H](C1=CC=CC=N1)C2=C(SC3=CC=CC=C32)CCNC,CNCCc1sc2ccccc2c1[C@@H](C)c1ccccn1
3744,CHEMBL64247,VMZMMCADYHQFBW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,562.34,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2500010234416505,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)C(C)(C)C,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)c3ccc(C(C)(C)C)cc3)cc2)CC1
3745,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,29406.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,4.531564047103727,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
3746,CHEMBL104,VNFPBHJOKIVQEB-UHFFFAOYSA-N,CLOTRIMAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3416.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.466482137983032,C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1
3749,CHEMBL156071,VNMMBNWUESETSJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198647,C1=C(NC=N1)CCCCCCCCCCCCCN,NCCCCCCCCCCCCCc1cnc[nH]1
3750,CHEMBL156071,VNMMBNWUESETSJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,2511886431509580.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-6.4,C1=C(NC=N1)CCCCCCCCCCCCCN,NCCCCCCCCCCCCCc1cnc[nH]1
3751,CHEMBL1092597,VNNFGZRIODMCIW-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,C[C@H](C1=C(CC2=CC=CC=C21)CCN(C)C)C3=NC=CN=C3OC,COc1nccnc1[C@H](C)C1=C(CCN(C)C)Cc2ccccc21
3754,CHEMBL155328,VNRWRBJKPUBFDY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,<,10000000000000.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.0,C1=C(N=CS1)CCN,NCCc1cscn1
3756,CHEMBL257524,VNUWHBRXYDCOFA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)C(C)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C,CCc1nc2cc3c(c(C)c2o1)CCN(C(C)CCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
3758,CHEMBL2158771,VNYAKKUPVDUAEG-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=C(C=C4)C#N)C(=O)O,N#Cc1ccc(C[C@@H](C(=O)O)N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
3761,CHEMBL1632412,VOIJIMTXMUBFDD-VLGSPTGOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)NC(=C2)/C(=N\O)/C3CCN(CC3)C,Cc1ccc2[nH]c(/C(=N\O)C3CCN(C)CC3)cc2c1
3762,CHEMBL2158775,VOPUEJLKUSXAOZ-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,COC1=CC=CC=C1C[C@@H](C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,COc1ccccc1C[C@@H](C(=O)O)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3763,CHEMBL1082296,VORZMLWIEYTBEN-JPYJTQIMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20452213.0,EC50,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in human SK-N-MC cells,Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)OCCCN2C[C@H]3CCCN[C@H]3C2)C4=NC5=C(N4)C=CC(=C5C)F,Cc1cc(OCCCN2C[C@H]3CCCN[C@H]3C2)ccc1-c1nc2c(C)c(F)ccc2[nH]1
3764,CHEMBL2112461,VOSJYQCPCAXSLK-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,3890.45,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.410000161858409,C[C@]1(CCN(C1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N)O,C[C@@]1(O)CCN(CCCOc2ccc(-c3ccc(C#N)cc3)cc2)C1
3765,CHEMBL1370,VOVIALXJUBGFJZ-KWVAZRHASA-N,BUDESONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
3766,CHEMBL1370,VOVIALXJUBGFJZ-KWVAZRHASA-N,BUDESONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C,CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
3767,CHEMBL135,VOXZDWNPVJITMN-ZBRFXRBCSA-N,ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
3768,CHEMBL135,VOXZDWNPVJITMN-ZBRFXRBCSA-N,ESTRADIOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O
3769,CHEMBL239724,VPAXWNMEGKLSOJ-FERBBOLQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C[C@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,C[C@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
3770,CHEMBL239299,VPAXWNMEGKLSOJ-GMUIIQOCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=C(C=C(C=C4)F)F.C(=O)O,C[C@@H]1CCCN1CCCOc1ccc(N2CCN(C(=O)c3ccc(F)cc3F)CC2=O)cc1
3772,CHEMBL1909073,VPUGSHLBERYQGC-UHFFFAOYSA-M,PIPERILATE ETHOBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+]1(CCCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-],CC[N+]1(CCOC(=O)C(O)(c2ccccc2)c2ccccc2)CCCCC1
3773,CHEMBL1909073,VPUGSHLBERYQGC-UHFFFAOYSA-M,PIPERILATE ETHOBROMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[N+]1(CCCCC1)CCOC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O.[Br-],CC[N+]1(CCOC(=O)C(O)(c2ccccc2)c2ccccc2)CCCCC1
3774,CHEMBL331188,VPZDYZMLWKUTOB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12443779.0,IC50,=,16.6,NM,,,,,,,,,,,,,,,Binding affinity against Histamine H1 receptor,2-(Dimethylaminomethyl)-tetrahydroisoxazolopyridobenzazepine derivatives. Synthesis of a new 5-HT(2C) antagonist with potential anxiolytic properties.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.779891911959945,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)N=CC=C3,CN(C)CC1CC2c3cccnc3Cc3ccccc3N2O1
3775,CHEMBL92333,VQILFXAHDTXCBG-KUOLHFIUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,471.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3269790928711025,C1CN(CCN1CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35)C6=CC(=CC=C6)Cl,Clc1cccc(N2CCN(CC3C[C@@H]4c5ccccc5Cc5ccccc5[C@H]4O3)CC2)c1
3776,CHEMBL1201207,VQODGRNSFPNSQE-DVTGEIKXSA-N,BETAMETHASONE PHOSPHORIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,10060.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,4.9974020192800905,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
3777,CHEMBL1201207,VQODGRNSFPNSQE-DVTGEIKXSA-N,BETAMETHASONE PHOSPHORIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1169.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.93218548883816,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COP(=O)(O)O)O)C)O)F)C,C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)COP(=O)(O)O
3778,CHEMBL229383,VQOXZBDYSJBXMA-VHFLTRTASA-N,NYSTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H]([C@@H](CC[C@H](C[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)C)O)N)O,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@H]3O[C@@H](C)[C@H](O)[C@@H](N)[C@H]3O)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2
3779,CHEMBL229383,VQOXZBDYSJBXMA-VHFLTRTASA-N,NYSTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C/CC/C=C/C=C/C=C/C=C/[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H]([C@@H](CC[C@H](C[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@@H]3[C@@H]([C@@H]([C@H]([C@@H](O3)C)O)N)O,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@H]3O[C@@H](C)[C@H](O)[C@@H](N)[C@H]3O)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2
3781,CHEMBL623,VRBKIVRKKCLPHA-UHFFFAOYSA-N,NEFAZODONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl,CCc1nn(CCCN2CCN(c3cccc(Cl)c3)CC2)c(=O)n1CCOc1ccccc1
3782,CHEMBL661,VREFGVBLTWBCJP-UHFFFAOYSA-N,ALPRAZOLAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
3783,CHEMBL661,VREFGVBLTWBCJP-UHFFFAOYSA-N,ALPRAZOLAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4,Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2
3784,CHEMBL1923533,VRGIOLYGCLOIJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,6309.57,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.200000237109354,C1CC1NCC(CN2C3=CC=CC=C3C4=CC=CC=C42)O,OC(CNC1CC1)Cn1c2ccccc2c2ccccc21
3785,CHEMBL1323355,VRQVVMDWGGWHTJ-AWEZNQCLSA-N,DEXTROMEPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,0.58,NM,,,,,,,,,,,,,,,,,,,,9.236572006437065,C[C@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C,COc1ccc2c(c1)N(C[C@@H](C)CN(C)C)c1ccccc1S2
3786,CHEMBL1400945,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,PREGNENOLONE CARBONITRILE ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N,CC(=O)[C@H]1[C@H](C#N)C[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C
3787,CHEMBL1400945,VSBHRRMYCDQLJF-ZDNYCOCVSA-N,PREGNENOLONE CARBONITRILE ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)[C@H]1[C@@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C#N,CC(=O)[C@H]1[C@H](C#N)C[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C
3788,CHEMBL3094217,VSGRIQNOEXFJLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,1995.26,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCOC2=CC3=C(CCN(CC3)CC4CC4)C=C2,c1cc2c(cc1OCCN1CCCCC1)CCN(CC1CC1)CC2
3789,CHEMBL65,VSJKWCGYPAHWDS-FQEVSTJZSA-N,CAMPTOTHECIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
3790,CHEMBL65,VSJKWCGYPAHWDS-FQEVSTJZSA-N,CAMPTOTHECIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O,CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1
3791,CHEMBL26116,VSKJPAMQPJDPLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,2220.0,NM,,,,,,,,,,,,,,,,,,,,5.653647025549362,C1=CC(=CC(=C1)Br)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(Br)c2)[nH]1
3792,CHEMBL26116,VSKJPAMQPJDPLL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,199.53,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,C1=CC(=CC(=C1)Br)C2=NC=C(N2)CCN,NCCc1cnc(-c2cccc(Br)c2)[nH]1
3794,CHEMBL467,VSNHCAURESNICA-UHFFFAOYSA-N,HYDROXYUREA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(N)NO,NC(=O)NO
3795,CHEMBL467,VSNHCAURESNICA-UHFFFAOYSA-N,HYDROXYUREA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(N)NO,NC(=O)NO
3797,CHEMBL3187365,VSWBSWWIRNCQIJ-UHFFFAOYSA-N,ASENAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8935801.0,Ki,=,0.16,NM,,,,,,,,,,,,,,,,,,,,9.795880017344077,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1
3798,CHEMBL3187365,VSWBSWWIRNCQIJ-UHFFFAOYSA-N,ASENAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,9.3,NM,,,,,,,,,,,,,,,,,,,,8.031517051446064,CN1CC2C(C1)C3=C(C=CC(=C3)Cl)OC4=CC=CC=C24,CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1
3799,CHEMBL570915,VTDHRHRPPVJGSU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=C(C=C1)CCCCN2CCC(CC2)CO,Cc1ccc(CCCCN2CCC(CO)CC2)cc1
3800,CHEMBL2158826,VTIFNIOOCLEWLJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,5.01,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.300162274132754,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C4=CC=CC(=C4)CC(=O)O,O=C(O)Cc1cccc(N2CCC(CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)c1
3801,CHEMBL76904,VTJXFTPMFYAJJU-UHFFFAOYSA-N,TYRPHOSTIN 23,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C=C(C#N)C#N)O)O,N#CC(C#N)=Cc1ccc(O)c(O)c1
3802,CHEMBL76904,VTJXFTPMFYAJJU-UHFFFAOYSA-N,TYRPHOSTIN 23,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C=C(C#N)C#N)O)O,N#CC(C#N)=Cc1ccc(O)c(O)c1
3803,CHEMBL2205818,VTLZIWJSKWWYHL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1C2C3C4C1C5C2C6C3C4C5(N6CCC7=CC=NC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2CCc1ccncc1
3804,CHEMBL257369,VTSMNPQRBXHIOD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCCN4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCCN4CCc5cc6nc(C(F)(F)F)oc6c(Br)c5CC4)n3C)cccc2n1
3805,CHEMBL62903,VTWBFMFJUOTCOL-MUUNZHRXSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,16982.44,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.769999911123512,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](CC3=CC=NC=C3)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](Cc3ccncc3)NC(=O)OC(C)(C)C)CC2)cc1
3806,CHEMBL62266,VTWBFMFJUOTCOL-NDEPHWFRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,9332.54,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.030000139977383,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](CC3=CC=NC=C3)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@H](Cc3ccncc3)NC(=O)OC(C)(C)C)CC2)cc1
3807,CHEMBL104947,VUNCADMBSQOCKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,1479.11,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.829999526735648,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CN=CN3,CCOC(=O)N1CCN(CCCOc2ccc(-c3cnc[nH]3)cc2)CC1
3810,CHEMBL272545,VURVNYUMSCKMDC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1258.93,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.899998417198647,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C,CCc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
3813,CHEMBL1669419,VVGNEGYIOFKVTA-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,6.7,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.173925197299173,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=CC=CS4,C[C@H](C1=C(CCN(C)Cc2cccs2)Cc2ccccc21)c1cnccn1
3814,CHEMBL1222554,VVGXLRREHSRFOF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.599980364934843,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4)C(=O)O,CC(C)(CN1CCN(C2=Cc3ccccc3Cn3ccnc32)CC1)C(=O)O
3815,CHEMBL1679,VVIAGPKUTFNRDU-ABLWVSNPSA-N,LEUCOVORIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2
3816,CHEMBL1679,VVIAGPKUTFNRDU-ABLWVSNPSA-N,LEUCOVORIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1C(N(C2=C(N1)N=C(NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O,Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2
3817,CHEMBL1091792,VVIWSBGDDVESJJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,59.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.229147988357856,CC(C1=NC(=CC=C1)OC)C2=C(SC3=CC=CC=C32)CCN(C)C,COc1cccc(C(C)c2c(CCN(C)C)sc3ccccc23)n1
3818,CHEMBL1430,VVNCNSJFMMFHPL-VKHMYHEASA-N,PENICILLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)([C@H](C(=O)O)N)S,CC(C)(S)[C@@H](N)C(=O)O
3819,CHEMBL1430,VVNCNSJFMMFHPL-VKHMYHEASA-N,PENICILLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)([C@H](C(=O)O)N)S,CC(C)(S)[C@@H](N)C(=O)O
3820,CHEMBL1092258,VWGHJDXVTAUEQY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,8.9,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.050609993355089,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)OC)CC3=NC=CN=C3,COc1ccc2c(c1)CC(CCN(C)C)=C2Cc1cnccn1
3822,CHEMBL154566,VWLKACVZBHNAND-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,7943.28,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.100000128334196,C1=CC=NC(=C1)CCCCCCCCCN,NCCCCCCCCCc1ccccn1
3823,CHEMBL154566,VWLKACVZBHNAND-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,31622776601683.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.5,C1=CC=NC(=C1)CCCCCCCCCN,NCCCCCCCCCc1ccccn1
3824,CHEMBL649,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,NADOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
3825,CHEMBL649,VWPOSFSPZNDTMJ-UCWKZMIHSA-N,NADOLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(COC1=CC=CC2=C1C[C@@H]([C@@H](C2)O)O)O,CC(C)(C)NCC(O)COc1cccc2c1C[C@H](O)[C@H](O)C2
3826,CHEMBL1766,VWVSBHGCDBMOOT-IIEHVVJPSA-N,DESOXIMETASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
3827,CHEMBL1766,VWVSBHGCDBMOOT-IIEHVVJPSA-N,DESOXIMETASONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@H]1C(=O)CO)C)O)F)C,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO
3828,CHEMBL1222553,VXQLVBTWUUQZBI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCN1CCC(=O)O)C2=CC3=CC=CC=C3CN4C2=NC=C4,O=C(O)CCN1CCN(C2=Cc3ccccc3Cn3ccnc32)CC1
3830,CHEMBL153919,VXSXTQRWBIOLHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,31622776601683.8,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-4.5,C1=CC(=CC(=C1)Cl)CC2=NC(=CS2)CCN,NCCc1csc(Cc2cccc(Cl)c2)n1
3832,CHEMBL272086,VYGLNPIKDOAMBL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C=C5CC4)C(=O)N(C6)C(C)C,Cc1ccc2c(-c3nnc(SCCC(C)N4CCc5cc6c(cc5CC4)C(=O)N(C(C)C)C6)n3C)cccc2n1
3833,CHEMBL101,VYMDGNCVAMGZFE-UHFFFAOYSA-N,PHENYLBUTAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
3834,CHEMBL101,VYMDGNCVAMGZFE-UHFFFAOYSA-N,PHENYLBUTAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3,CCCCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O
3835,CHEMBL1388,VYQNWZOUAUKGHI-UHFFFAOYSA-N,MONOBENZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)COC2=CC=C(C=C2)O,Oc1ccc(OCc2ccccc2)cc1
3836,CHEMBL1388,VYQNWZOUAUKGHI-UHFFFAOYSA-N,MONOBENZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)COC2=CC=C(C=C2)O,Oc1ccc(OCc2ccccc2)cc1
3837,CHEMBL1230333,VYTXLSQVYGNWLV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)CCCC(=O)O,O=C(O)CCCc1cccs1
3838,CHEMBL1230333,VYTXLSQVYGNWLV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CSC(=C1)CCCC(=O)O,O=C(O)CCCc1cccs1
3839,CHEMBL255778,VYZFKCYKUBTWCJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br,CCc1nc2cc3c(c(Br)c2o1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
3840,CHEMBL431458,VZFRWFDQRYRONC-WLHGVMLRSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,233.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.632644078973981,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC=CC=C7.C(=C/C(=O)O)\C(=O)O,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
3841,CHEMBL44814,VZGDMQKNWNREIO-UHFFFAOYSA-N,CARBON TETRACHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)(Cl)Cl,ClC(Cl)(Cl)Cl
3842,CHEMBL44814,VZGDMQKNWNREIO-UHFFFAOYSA-N,CARBON TETRACHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(Cl)(Cl)(Cl)Cl,ClC(Cl)(Cl)Cl
3843,CHEMBL241330,WAQMOZNGKRFENV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18020391.0,Ki,>,5000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling.,J. Med. Chem.,PUBLICATION,,5.301029995663981,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC(=O)C3=CC(=CC=C3)S(=O)(=O)C)Cl,CCOc1cc(CN2CCC(NC(=O)c3cccc(S(C)(=O)=O)c3)CC2)ccc1Cl
3844,CHEMBL1259203,WAWSGWZTHJAPIA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Not Determined,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CN1CCC(CC1)C2=CN(C3=C2C=C(C=C3)C4=CN=CN=C4)C5=CC=C(C=C5)F,CN1CCC(c2cn(-c3ccc(F)cc3)c3ccc(-c4cncnc4)cc23)CC1
3845,CHEMBL257900,WAWZDKTUQQRILI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCN4CCC5=CC6=C(C(=C5CC4)C)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCN4CCc5cc6nc(C(F)(F)F)oc6c(C)c5CC4)n3C)cccc2n1
3847,CHEMBL2208433,WBCSOAILRDZMDJ-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,CN(C[C@H](CN1CCC(CC1)OC2=CC(=C(C=C2)Cl)Cl)O)C(=O)C3=CNC(=O)C4=CC=CC=C43,CN(C[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)C(=O)c1c[nH]c(=O)c2ccccc12
3848,CHEMBL164290,WBNQDOYYEUMPFS-UHFFFAOYSA-N,N-NITROSODIETHYLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)N=O,CCN(CC)N=O
3849,CHEMBL164290,WBNQDOYYEUMPFS-UHFFFAOYSA-N,N-NITROSODIETHYLAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)N=O,CCN(CC)N=O
3850,CHEMBL1079180,WCUAFHYQNZBNRN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,1374.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.862013267276469,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC(=C(C=C4O3)S(=O)(=O)N)Cl)F,CCOc1cc(CN2CCC(Nc3nc4cc(Cl)c(S(N)(=O)=O)cc4o3)CC2)ccc1F
3851,CHEMBL2158769,WCXUWQZNCRRRDD-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.799970733446231,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4C#N)C(=O)O,N#Cc1ccccc1C[C@@H](C(=O)O)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
3852,CHEMBL107162,WCZJQEWLLYRYTJ-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,4400.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.356547323513811,COC1=CC=C(C=C1)S(=O)(=O)N[C@H]2CCN(C2)CCCOC3=CC=C(C=C3)C(=O)C4CC4,COc1ccc(S(=O)(=O)N[C@H]2CCN(CCCOc3ccc(C(=O)C4CC4)cc3)C2)cc1
3853,CHEMBL254219,WDJUZGPOPHTGOT-XUDUSOBPSA-N,DIGITOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
3854,CHEMBL254219,WDJUZGPOPHTGOT-XUDUSOBPSA-N,DIGITOXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5CC[C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)C)C)C)O)O,C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@]5(C)[C@H]6CC[C@]7(C)[C@@H](C8=CC(=O)OC8)CC[C@]7(O)[C@@H]6CC[C@@H]5C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
3855,CHEMBL571174,WDNSSDFBUPTPTP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,61.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.214670164989233,CC1CCC(CC1)CCCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,CC1CCC(CCCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)CC1
3856,CHEMBL1660,WDZCUPBHRAEYDL-GZAUEHORSA-N,RIFAPENTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
3857,CHEMBL1660,WDZCUPBHRAEYDL-GZAUEHORSA-N,RIFAPENTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C6CCCC6)/C,CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C
3858,CHEMBL420,WDZVGELJXXEGPV-YIXHJXPBSA-N,GUANABENZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl,NC(N)=N/N=C/c1c(Cl)cccc1Cl
3859,CHEMBL420,WDZVGELJXXEGPV-YIXHJXPBSA-N,GUANABENZ,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)Cl)/C=N/N=C(N)N)Cl,NC(N)=N/N=C/c1c(Cl)cccc1Cl
3860,CHEMBL485259,WEEGYLXZBRQIMU-UHFFFAOYSA-N,EUCALYPTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C2CCC(O1)(CC2)C)C,CC12CCC(CC1)C(C)(C)O2
3861,CHEMBL485259,WEEGYLXZBRQIMU-UHFFFAOYSA-N,EUCALYPTOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(C2CCC(O1)(CC2)C)C,CC12CCC(CC1)C(C)(C)O2
3862,CHEMBL562676,WEFSNJOGTPXLGH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,123.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.910094888560603,CC(C)(C1=CC2=C(C=C1)SC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(C(C)(C)C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3863,CHEMBL140872,WEVJMQOBCRCIPF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,911.8,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,6.0401004121340565,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=NC=CC=N3,O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1
3864,CHEMBL140872,WEVJMQOBCRCIPF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,912.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,6.040005161671584,C1CN(CCN1CCCC(=O)C2=CC=C(C=C2)F)C3=NC=CC=N3,O=C(CCCN1CCN(c2ncccn2)CC1)c1ccc(F)cc1
3865,CHEMBL559206,WEVNWEYCEGALHH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,1258.93,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198647,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=CC=C4.Cl,O=C(c1ccccc1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
3866,CHEMBL448,WEXRUCMBJFQVBZ-UHFFFAOYSA-N,PENTOBARBITAL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CCCC(C)C1(C(=O)NC(=O)NC1=O)CC,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O
3869,CHEMBL1278088,WFQOETMVYMINSA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20931963.0,IC50,=,1000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor,"Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.",J. Med. Chem.,PUBLICATION,,6.0,C1CCC2=C(C1)C(=O)N(C(=N2)CCCCN3CCN(CC3)C4=NC5=CC=CC=C5C=C4)N,Nn1c(CCCCN2CCN(c3ccc4ccccc4n3)CC2)nc2c(c1=O)CCCC2
3870,CHEMBL106602,WFRROHNULMGADM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,446.68,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3500034925339595,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=CS3,CCOC(=O)N1CCN(CCCOc2ccc(-c3cccs3)cc2)CC1
3871,CHEMBL20883,WFWLQNSHRPWKFK-UHFFFAOYSA-N,TEGAFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(OC1)N2C=C(C(=O)NC2=O)F,O=c1[nH]c(=O)n(C2CCCO2)cc1F
3872,CHEMBL20883,WFWLQNSHRPWKFK-UHFFFAOYSA-N,TEGAFUR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CC(OC1)N2C=C(C(=O)NC2=O)F,O=c1[nH]c(=O)n(C2CCCO2)cc1F
3875,CHEMBL1278112,WGNYIJNJSDBPLE-JVPYDEADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.199970640755867,C1C[C@@]2(CC1N3CCOC(C3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1CN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CCO1
3876,CHEMBL415690,WHGYBXFWUBPSRW-FOUAGVGXSA-N,BETADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
3877,CHEMBL415690,WHGYBXFWUBPSRW-FOUAGVGXSA-N,BETADEX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C([C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)CO)CO)CO)CO)CO)CO)O)O)O,OC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CO)O[C@H](O[C@@H]4[C@@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@@H]6[C@@H](CO)O[C@H](O[C@@H]7[C@@H](CO)O[C@H](O[C@@H]8[C@@H](CO)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O
3878,CHEMBL402016,WHKXNUMKCCTWNI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C(F)(F)F)oc6cc5CC4)n3C)cccc2n1
3880,CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
3881,CHEMBL388590,WHQCHUCQKNIQEC-UHFFFAOYSA-N,BENZBROMARONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br,CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
3882,CHEMBL1481,WIGIZIANZCJQQY-RUCARUNLSA-N,GLIMEPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCC(C)CC3)cc2)C1=O
3883,CHEMBL1481,WIGIZIANZCJQQY-RUCARUNLSA-N,GLIMEPIRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCC(C)CC3)cc2)C1=O
3885,CHEMBL244946,WIHMMKGUBDZGEG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,794.33,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C=C(C=C5)C6=CC(=NN6C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc(-c6cc(C)nn6C)cc5CC4)n3C)cccc2n1
3886,CHEMBL130,WIIZWVCIJKGZOK-RKDXNWHRSA-N,CHLORAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl
3887,CHEMBL130,WIIZWVCIJKGZOK-RKDXNWHRSA-N,CHLORAMPHENICOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1[C@H]([C@@H](CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-],O=C(N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1)C(Cl)Cl
3888,CHEMBL1091793,WIKAXVDAJYMGCT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,38.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.420216403383191,CC(C1=NC(=CC=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,CC(c1cccc(F)n1)c1c(CCN(C)C)sc2ccccc12
3889,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,18.86,NM,,,,,,,,,,,,,,,,,,,,7.724458311598691,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3890,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,19.0,NM,,,,,,,,,,,,,,,,,,,,7.721246399047171,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3891,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,24.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.619788758288393,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3892,CHEMBL728,WIKYUJGCLQQFNW-UHFFFAOYSA-N,PROCHLORPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,2.79,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.554395796726402,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1
3893,CHEMBL465123,WIQRCHMSJFFONW-HNNXBMFYSA-N,SEPROXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C1=CC=C(C=C1)[C@H](CCN)OC2=CC=C(C=C2)C(F)(F)F,NCC[C@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1
3895,CHEMBL295395,WIVOLWKUZIBRAF-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,302.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.519993057042849,CC1=C([C@H](CC(=O)N1C)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=C(C=C(C=C4)F)F,CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3F)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1C
3896,CHEMBL2113738,WIVVHNDNAXIGIV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,446.68,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.3500034925339595,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3=CC=C(C=C3)SC,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)c3ccc(SC)cc3)cc2)CC1
3897,CHEMBL625,WJCNZQLZVWNLKY-UHFFFAOYSA-N,THIABENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,c1ccc2[nH]c(-c3cscn3)nc2c1
3898,CHEMBL625,WJCNZQLZVWNLKY-UHFFFAOYSA-N,THIABENDAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3,c1ccc2[nH]c(-c3cscn3)nc2c1
3899,CHEMBL97357,WJEAYMAHIVBPGF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.55,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.183758700008218,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)Cl)Cl,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
3900,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC3=CC=CC=C3S2,c1ccc2c(c1)Nc1ccccc1S2
3901,CHEMBL828,WJFKNYWRSNBZNX-UHFFFAOYSA-N,PHENOTHIAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)NC3=CC=CC=C3S2,c1ccc2c(c1)Nc1ccccc1S2
3903,CHEMBL1501,WJOHZNCJWYWUJD-IUGZLZTKSA-N,FLUOCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
3904,CHEMBL1501,WJOHZNCJWYWUJD-IUGZLZTKSA-N,FLUOCINONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C,CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C
3906,CHEMBL197408,WJYDVXOBGXFRGI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)C2=C(C=CC(=C2)NC(=O)N3CCN(CC3)C4=CC=C(C=C4)C5=CC=CC=C5)OC,COc1ccc(NC(=O)N2CCN(c3ccc(-c4ccccc4)cc3)CC2)cc1N1CCN(C)CC1
3907,CHEMBL271511,WKIHYCMRGGUMCH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)N5C=C(C=CC5=N4)C(F)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3nc4ccc(C(F)(F)F)cn4c3CC2)n1C
3908,CHEMBL2158784,WKNWCTUFTMDACE-DEOSSOPVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,31.62,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.500038134403809,CC1=C(C=CC(=C1Cl)Cl)OC2CCN(CC2)CC3CCN(CC3)[C@@H](CC4=CC=C(C=C4)F)C(=O)O,Cc1c(OC2CCN(CC3CCN([C@@H](Cc4ccc(F)cc4)C(=O)O)CC3)CC2)ccc(Cl)c1Cl
3909,CHEMBL486746,WKXIZVSDLMORMY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16554355.0,Ki,=,990.0,NM,,,,,,,,,,,,,,,,,,,,6.00436480540245,C1CCC(CC1)CCCC(=O)NC(=NCCCC2=CN=CN2)N,NC(=NCCCc1cnc[nH]1)NC(=O)CCCC1CCCCC1
3911,CHEMBL188021,WLCVFIFUKJWBRL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321763,C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CCCOC4=CC=C(C=C4)C#CCCN(C(=O)N)O)C5=C1C=CC=N5,NC(=O)N(O)CCC#Cc1ccc(OCCCN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)cc1
3912,CHEMBL288768,WLHRCQLHMHKOKG-JOCHJYFZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,10937710.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,Selectivity screen against human Histamine H1 receptor,"Selective alpha1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.200659450546419,CC1=C([C@H](CC(=O)N1)C2=CC(=C(C=C2)F)F)C(=O)NCCCN3CCC(CC3)(C#N)C4=CC=C(C=C4)F,CC1=C(C(=O)NCCCN2CCC(C#N)(c3ccc(F)cc3)CC2)[C@@H](c2ccc(F)c(F)c2)CC(=O)N1
3913,CHEMBL104809,WLLPQVLLLQINAX-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,5900.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.229147988357856,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC(=C2)F)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3cccc(F)c3)C2)cc1)C1CC1
3915,CHEMBL570961,WMENQMDKVSUACK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,,,,Not Active,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC=C(C=C1)CCCCC2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O,Cc1ccc(CCCCC2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1
3918,CHEMBL3238446,WMVDPHRVWOFAIP-HNNXBMFYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24650714.0,Ki,=,31622.78,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHO cell membrane after 120 mins by liquid scintillation counting analysis,Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties.,Eur. J. Med. Chem.,PUBLICATION,,4.499999953328897,C[C@@H](C(=O)N)NCC1=CC=C(C=C1)OCCCN2CCCCC2,C[C@H](NCc1ccc(OCCCN2CCCCC2)cc1)C(N)=O
3919,CHEMBL1774505,WNMOZKUIGRNEMN-JAHAZDFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,195.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.709965388637482,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C\3/C4=CC=CC=C4CCC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCN(CC/C=C3/c4ccccc4CCc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
3920,CHEMBL58922,WOFSEDMIUMNYEJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,255.0,NM,,,,,,,,,,,,,,,,,,,,6.5934598195660445,C1=CC=NC(=C1)C(CCNC(=NCCCC2=CN=CN2)N)C3=CC(=CC=C3)Cl,NC(=NCCCc1cnc[nH]1)NCCC(c1cccc(Cl)c1)c1ccccn1
3925,CHEMBL86091,WPLHYZJLPBROHU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC(=C3)C(F)(F)F,CN(C)CC1CC2c3cc(C(F)(F)F)ccc3Cc3ccccc3N2O1
3927,CHEMBL19236,WPNJAUFVNXKLIM-UHFFFAOYSA-N,MOXONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,COc1nc(C)nc(Cl)c1NC1=NCCN1
3928,CHEMBL19236,WPNJAUFVNXKLIM-UHFFFAOYSA-N,MOXONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=NC(=C(C(=N1)Cl)NC2=NCCN2)OC,COc1nc(C)nc(Cl)c1NC1=NCCN1
3929,CHEMBL1923532,WPPQAAJWSRLDOO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,4570.88,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.3400001801593495,CC(C)NCC1=CC=C(O1)C2=CC=CC=C2,CC(C)NCc1ccc(-c2ccccc2)o1
3931,CHEMBL274768,WPUIFWUHNWGBNW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,630957344480194.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.800000000000002,C1=CC=C(C=C1)C(CCCC2=NC=C(N2)CCN)C3=CC=CC=C3,NCCc1cnc(CCCC(c2ccccc2)c2ccccc2)[nH]1
3933,CHEMBL541,WPYMKLBDIGXBTP-UHFFFAOYSA-N,BENZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)O,O=C(O)c1ccccc1
3934,CHEMBL541,WPYMKLBDIGXBTP-UHFFFAOYSA-N,BENZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(=O)O,O=C(O)c1ccccc1
3935,CHEMBL2105807,WQGJEAMPBSZCIF-HKSLRPGUSA-N,MADURAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C.N,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
3936,CHEMBL2105807,WQGJEAMPBSZCIF-HKSLRPGUSA-N,MADURAMICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@H]([C@@](O[C@@H]1[C@H]2C[C@@H]([C@@H](O2)[C@@]3(CC[C@@H](O3)[C@@]4(CC[C@@]5(O4)C[C@@H]([C@H]([C@H](O5)[C@@H](C)[C@H]6[C@@H]([C@H]([C@@H]([C@](O6)(CC(=O)O)O)C)OC)OC)C)O)C)C)O[C@@H]7C[C@@H]([C@H]([C@@H](O7)C)OC)OC)(C)O)C.N,CO[C@H]1C[C@@H](O[C@H]2C[C@H]([C@H]3O[C@](C)(O)[C@H](C)C[C@@H]3C)O[C@H]2[C@]2(C)CC[C@H]([C@]3(C)CC[C@]4(C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H]5O[C@](O)(CC(=O)O)[C@@H](C)[C@H](OC)[C@H]5OC)O4)O3)O2)O[C@@H](C)[C@@H]1OC
3937,CHEMBL307145,WQGWDDDVZFFDIG-UHFFFAOYSA-N,PYROGALLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)O)O)O,Oc1cccc(O)c1O
3938,CHEMBL307145,WQGWDDDVZFFDIG-UHFFFAOYSA-N,PYROGALLOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)O)O)O,Oc1cccc(O)c1O
3939,CHEMBL105594,WQTAFNUFMGEGDM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,8912.51,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.049999969853415,C1CN(CCN1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CCNCC3)cc2)cc1
3940,CHEMBL1767134,WRGOSJVRKURGMQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.251,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.600326278518963,CN(C)CCN1C(=O)C2=CC=CC=C2C(=N1)CC3=CC=C(C=C3)Cl,CN(C)CCn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
3941,CHEMBL517140,WROHEWWOCPRMIA-UHFFFAOYSA-N,GSK189254,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24269482.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CNC(=O)C1=CN=C(C=C1)OC2=CC3=C(CCN(CC3)C4CCC4)C=C2,CNC(=O)c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1
3942,CHEMBL328356,WSAMXDVPPULVBH-KCDYIMILSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,6.0,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.221848749616356,CN1C2=CC=CC=C2[C@H]3CC(O[C@@H]3C4=CC=CC=C41)CN(C)C,CN(C)CC1C[C@@H]2c3ccccc3N(C)c3ccccc3[C@H]2O1
3943,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3194.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.495665088197536,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
3944,CHEMBL549,WSEQXVZVJXJVFP-UHFFFAOYSA-N,CITALOPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,371.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.430626090384954,CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F,CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
3945,CHEMBL908,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,CHLORPROTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,3.75,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.425968732272281,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21
3946,CHEMBL908,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,CHLORPROTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,1.0,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,9.0,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21
3947,CHEMBL908,WSPOMRSOLSGNFJ-AUWJEWJLSA-N,CHLORPROTHIXENE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,870.96,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,6.0600017900878385,CN(C)CC/C=C\1/C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CC/C=C1/c2ccccc2Sc2ccc(Cl)cc21
3948,CHEMBL272302,WSSKPYCMFWWDPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CN=CC=C5,CCc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2cccnc2)n1C)CC3
3949,CHEMBL467094,WSVWKHTVFGTTKJ-UHFFFAOYSA-N,NANTENINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19963380.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor,Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=CC(=C(C3=C2C1CC4=CC5=C(C=C43)OCO5)OC)OC,COc1cc2c3c(c1OC)-c1cc4c(cc1CC3N(C)CC2)OCO4
3950,CHEMBL239744,WSXMMXMXSWZQOD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.800000874803202,C1CCC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)Cl.C(=O)O,O=C(c1ccc(Cl)cc1)N1CCN(c2ccc(OC3CCN(C4CCCC4)CC3)cc2)C(=O)C1
3951,CHEMBL1009,WTDRDQBEARUVNC-LURJTMIESA-N,LEVODOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
3952,CHEMBL1009,WTDRDQBEARUVNC-LURJTMIESA-N,LEVODOPA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O,N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O
3953,CHEMBL229429,WTLBLIGPXACYET-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17571866.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography.,J. Med. Chem.,PUBLICATION,,5.0,C1=C(C=C(C=C1C#N)F)C#CC2=CSC(=N2)CF,N#Cc1cc(F)cc(C#Cc2csc(CF)n2)c1
3954,CHEMBL1783953,WTMKJZWIEBUUNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,930.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.031517051446066,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=CC=N4,CN1CCc2c(c3ccccc3n2CCc2ccccn2)C1
3955,CHEMBL1783953,WTMKJZWIEBUUNH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1820.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.739928612014924,CN1CCC2=C(C1)C3=CC=CC=C3N2CCC4=CC=CC=N4,CN1CCc2c(c3ccccc3n2CCc2ccccn2)C1
3956,CHEMBL307609,WTUOCEYWCJZOOS-HSZRJFAPSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,4.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,C1CN(CCN1CC2=CC=C(O2)CN(C(=O)N)O)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl,NC(=O)N(O)Cc1ccc(CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)o1
3957,CHEMBL304888,WUAKHYKTJKHZOM-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3300000383353785,C[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC(C)C,CC(C)N[C@H](C)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
3958,CHEMBL1169,WUBBRNOQWQTFEX-UHFFFAOYSA-N,AMINOSALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1N)O)C(=O)O,Nc1ccc(C(=O)O)c(O)c1
3959,CHEMBL1169,WUBBRNOQWQTFEX-UHFFFAOYSA-N,AMINOSALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1N)O)C(=O)O,Nc1ccc(C(=O)O)c(O)c1
3960,CHEMBL1598608,WUKZPHOXUVCQOR-UHFFFAOYSA-N,AZASETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,CN1C(=O)COc2c(C(=O)NC3CN4CCC3CC4)cc(Cl)cc21
3961,CHEMBL1598608,WUKZPHOXUVCQOR-UHFFFAOYSA-N,AZASETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C(=O)COC2=C(C=C(C=C21)Cl)C(=O)NC3CN4CCC3CC4,CN1C(=O)COc2c(C(=O)NC3CN4CCC3CC4)cc(Cl)cc21
3963,CHEMBL273348,WUWFMDMBOJLQIV-UHFFFAOYSA-N,TOSUFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F,NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1
3964,CHEMBL273348,WUWFMDMBOJLQIV-UHFFFAOYSA-N,TOSUFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CC1N)C2=C(C=C3C(=O)C(=CN(C3=N2)C4=C(C=C(C=C4)F)F)C(=O)O)F,NC1CCN(c2nc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2F)C1
3965,CHEMBL236587,WUXDFTYUVPKGCE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18020390.0,Ki,=,624.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach.",J. Med. Chem.,PUBLICATION,,6.204815410317576,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)OC,CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1OC
3966,CHEMBL236587,WUXDFTYUVPKGCE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,624.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.204815410317576,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=CC=CC=C4O3)OC,CCOc1cc(CN2CCC(Nc3nc4ccccc4o3)CC2)ccc1OC
3967,CHEMBL91397,WUZYKBABMWJHDL-UHFFFAOYSA-N,RUPATADINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,3.9,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,8.4089353929735,CC1=CC(=CN=C1)CN2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2,Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1
3968,CHEMBL558933,WVCNWPFTYDURBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,2.8,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.55284196865778,CN(C1CCCCC1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,CN(C1CCCCC1)C1CCN(c2nc3ccccc3n2Cc2ccc(F)cc2)CC1
3969,CHEMBL720,WVDDGKGOMKODPV-UHFFFAOYSA-N,BENZYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CO,OCc1ccccc1
3970,CHEMBL720,WVDDGKGOMKODPV-UHFFFAOYSA-N,BENZYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CO,OCc1ccccc1
3971,CHEMBL1278202,WVFQWSQTENHWCH-MTQWGCILSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,12.59,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.899974269892138,CC1(CCN(C1)C2CC[C@@]3(C2)CC4=CC=CC=C4CC5=CC=CC=C35)C(=O)O,CC1(C(=O)O)CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)C1
3973,CHEMBL1935432,WVNZODFRLMLDAL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,6.3,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.200659450546418,CCN(CC)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CCN(CC)C(=O)CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
3974,CHEMBL428,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,TROVAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F,NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12
3975,CHEMBL428,WVPSKSLAZQPAKQ-CDMJZVDBSA-N,TROVAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F,NC1[C@@H]2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)C[C@H]12
3976,CHEMBL119443,WVVSZNPYNCNODU-XTQGRXLLSA-N,ERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
3977,CHEMBL119443,WVVSZNPYNCNODU-XTQGRXLLSA-N,ERGONOVINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H](CO)NC(=O)[C@H]1CN([C@@H]2CC3=CNC4=CC=CC(=C34)C2=C1)C,C[C@@H](CO)NC(=O)[C@@H]1C=C2c3cccc4[nH]cc(c34)C[C@H]2N(C)C1
3978,CHEMBL154111,WVYADZUPLLSGPU-UHFFFAOYSA-N,SALSALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,O=C(Oc1ccccc1C(=O)O)c1ccccc1O
3979,CHEMBL154111,WVYADZUPLLSGPU-UHFFFAOYSA-N,SALSALATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)OC2=CC=CC=C2C(=O)O)O,O=C(Oc1ccccc1C(=O)O)c1ccccc1O
3980,CHEMBL1094452,WWEBJYNVUIMDCZ-GFCCVEGCSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@@H](C)C2CCCCC2,Cc1nc(N)sc1CCCN=C(N)NC(=O)C[C@@H](C)C1CCCCC1
3981,CHEMBL1094144,WWEBJYNVUIMDCZ-LBPRGKRZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)C[C@H](C)C2CCCCC2,Cc1nc(N)sc1CCCN=C(N)NC(=O)C[C@H](C)C1CCCCC1
3982,CHEMBL1094142,WWEBJYNVUIMDCZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20409707.0,EC50,>,10000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Chiral NG-acylated hetarylpropylguanidine-type histamine H2 receptor agonists do not show significant stereoselectivity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(SC(=N1)N)CCCN=C(N)NC(=O)CC(C)C2CCCCC2,Cc1nc(N)sc1CCCN=C(N)NC(=O)CC(C)C1CCCCC1
3984,CHEMBL2107797,WWYNJERNGUHSAO-CULCCENASA-N,NORGESTREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC
3985,CHEMBL2107797,WWYNJERNGUHSAO-CULCCENASA-N,NORGESTREL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC[C@]12CC[C@H]3[C@H]([C@@H]1CCC2(C#C)O)CCC4=CC(=O)CC[C@H]34,C#CC1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC
3987,CHEMBL10961,WXSURELOKDGQNF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,>,10000.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,5.0,CNCC(C1=CC=CC=C1)C2=CC=CC=C2,CNCC(c1ccccc1)c1ccccc1
3988,CHEMBL86715,WYDUSKDSKCASEF-UHFFFAOYSA-N,PROCYCLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,17782.79,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,4.7500001001404275,C1CCC(CC1)C(CCN2CCCC2)(C3=CC=CC=C3)O,OC(CCN1CCCC1)(c1ccccc1)C1CCCCC1
3989,CHEMBL250403,WYEGTIGJSHGEID-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17976986.0,Ki,>,2000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.698970004336019,CCCN1CCO[C@@H](C1)C2=CC(=CC=C2)O,CCCN1CCO[C@H](c2cccc(O)c2)C1
3990,CHEMBL328511,WYLMUYOKAITMJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.93,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.226945306635738,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)OC)C7=CC=CC=C7,COC(=O)c1ccc(Cn2c(C(=O)C3CCN(CCC4(c5ccccc5)CCN(C(=O)c5cc(OC)c(OC)c(OC)c5)C4)CC3)nc3ccccc32)cc1
3991,CHEMBL328511,WYLMUYOKAITMJI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1210.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.917214629683549,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)OC)C7=CC=CC=C7,COC(=O)c1ccc(Cn2c(C(=O)C3CCN(CCC4(c5ccccc5)CCN(C(=O)c5cc(OC)c(OC)c(OC)c5)C4)CC3)nc3ccccc32)cc1
3992,CHEMBL1767154,WYRUGBCTQBZIHO-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.316,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.500312917381596,CN1CCC[C@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC[C@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
3993,CHEMBL1767136,WYRUGBCTQBZIHO-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.158,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.801342913045575,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
3995,CHEMBL1767136,WYRUGBCTQBZIHO-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.162,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.790484985457367,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
3996,CHEMBL727,WYWHKKSPHMUBEB-UHFFFAOYSA-N,THIOGUANINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=C(N2)N,Nc1nc(=S)c2[nH]cnc2[nH]1
3997,CHEMBL727,WYWHKKSPHMUBEB-UHFFFAOYSA-N,THIOGUANINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC2=C(N1)C(=S)N=C(N2)N,Nc1nc(=S)c2[nH]cnc2[nH]1
3998,CHEMBL762,WYWIFABBXFUGLM-UHFFFAOYSA-N,OXYMETAZOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
3999,CHEMBL762,WYWIFABBXFUGLM-UHFFFAOYSA-N,OXYMETAZOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC(=C(C(=C1CC2=NCCN2)C)O)C(C)(C)C,Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1
4000,CHEMBL564201,WYXSYVWAUAUWLD-SHUUEZRQSA-N,6-AZAURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,O=c1cnn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1
4001,CHEMBL564201,WYXSYVWAUAUWLD-SHUUEZRQSA-N,6-AZAURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O,O=c1cnn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)[nH]1
4002,CHEMBL2103774,WZDGZWOAQTVYBX-XOINTXKNSA-N,TIBOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C
4003,CHEMBL2103774,WZDGZWOAQTVYBX-XOINTXKNSA-N,TIBOLONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1CC2=C(CCC(=O)C2)[C@@H]3[C@@H]1[C@@H]4CC[C@]([C@]4(CC3)C)(C#C)O,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C
4004,CHEMBL2031873,WZHAQWFZACLGKI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22313242.0,Ki,=,9620.0,NM,,,,,,,,,,,,,,,Binding affinity to H1 receptor,"2-(Pyrrolidin-1-yl)ethyl-3,4-dihydroisoquinolin-1(2H)-one derivatives as potent and selective histamine-3 receptor antagonists.",J. Med. Chem.,PUBLICATION,,5.016824927962186,C1CCC(C1)NC(=O)C2=CC=C(C=C2)C3=CC4=C(C=C3)C(=O)N(CC4)CCN5CCCC5,O=C(NC1CCCC1)c1ccc(-c2ccc3c(c2)CCN(CCN2CCCC2)C3=O)cc1
4005,CHEMBL1480987,WZHCOOQXZCIUNC-UHFFFAOYSA-N,CYCLANDELATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O,CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)C1
4006,CHEMBL1480987,WZHCOOQXZCIUNC-UHFFFAOYSA-N,CYCLANDELATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O,CC1CC(OC(=O)C(O)c2ccccc2)CC(C)(C)C1
4008,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4133.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,5.383734594718292,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
4009,CHEMBL19215,WZHJKEUHNJHDLS-QTGUNEKASA-N,METERGOLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,480.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.3187587626244115,CN1C[C@@H](C[C@H]2[C@H]1CC3=CN(C4=CC=CC2=C34)C)CNC(=O)OCC5=CC=CC=C5,CN1C[C@H](CNC(=O)OCc2ccccc2)C[C@@H]2c3cccc4c3c(cn4C)C[C@H]21
4010,CHEMBL330366,WZMVQZJKOVPVGZ-XIFFEERXSA-N,MDL-105212,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,IC50,=,3.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,8.522878745280337,COC1=CC(=CC(=C1OC)OC)C(=O)N2CC[C@](C2)(CCN3CCC(CC3)(C4=CC=CC=C4)C(=O)N)C5=CC(=C(C=C5)Cl)Cl,COc1cc(C(=O)N2CC[C@](CCN3CCC(C(N)=O)(c4ccccc4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
4011,CHEMBL330366,WZMVQZJKOVPVGZ-XIFFEERXSA-N,MDL-105212,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,10000.0,NM,,,,,,,,,,,,,,,Compound was evaluated for the antagonistic activity against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,COC1=CC(=CC(=C1OC)OC)C(=O)N2CC[C@](C2)(CCN3CCC(CC3)(C4=CC=CC=C4)C(=O)N)C5=CC(=C(C=C5)Cl)Cl,COc1cc(C(=O)N2CC[C@](CCN3CCC(C(N)=O)(c4ccccc4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
4012,CHEMBL245416,WZNJWVWKTVETCG-YFKPBYRVSA-N,L-MIMOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N,N[C@@H](Cn1ccc(=O)c(O)c1)C(=O)O
4013,CHEMBL245416,WZNJWVWKTVETCG-YFKPBYRVSA-N,L-MIMOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CN(C=C(C1=O)O)C[C@@H](C(=O)O)N,N[C@@H](Cn1ccc(=O)c(O)c1)C(=O)O
4014,CHEMBL328114,WZOMJNATDSYQHS-ZPWQMVEJSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,COC1=C(C=C2C(=C1)C3=NO[C@H]([C@@H]3CO2)CN4CCN(CC4)C/C=C/C5=CC=CC=C5)OC,COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C/c4ccccc4)CC3)[C@@H]1CO2
4015,CHEMBL158,WZPBZJONDBGPKJ-VEHQQRBSSA-N,AZTREONAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
4016,CHEMBL158,WZPBZJONDBGPKJ-VEHQQRBSSA-N,AZTREONAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@@H](C(=O)N1S(=O)(=O)O)NC(=O)/C(=N\OC(C)(C)C(=O)O)/C2=CSC(=N2)N,C[C@H]1[C@H](NC(=O)/C(=N\OC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O
4017,CHEMBL1923524,WZYLEAJVJMZIFE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,537.03,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.270001452716577,CC1=C2C(=CC=C1)C(=CN2CC3=CC=CC=C3)CCN,Cc1cccc2c(CCN)cn(Cc3ccccc3)c12
4018,CHEMBL540633,XAMKLIVWXRZDBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=CC=C5.Cl,O=C(c1ccccc1)N1CCN(c2ccc(OC3CCN(C4CCC4)CC3)cc2)C(=O)C1
4019,CHEMBL37858,XBHBWNFJWIASRO-UHFFFAOYSA-N,SARAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O
4020,CHEMBL37858,XBHBWNFJWIASRO-UHFFFAOYSA-N,SARAFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN(CCN1)C2=C(C=C3C(=C2)N(C=C(C3=O)C(=O)O)C4=CC=C(C=C4)F)F,O=C(O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O
4021,CHEMBL6273,XBJBPGROQZJDOJ-UHFFFAOYSA-N,FLEROXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F,CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1
4022,CHEMBL6273,XBJBPGROQZJDOJ-UHFFFAOYSA-N,FLEROXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)C2=C(C=C3C(=C2F)N(C=C(C3=O)C(=O)O)CCF)F,CN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(CCF)c3c2F)CC1
4024,CHEMBL2208431,XBJQRDCFABQBGT-CQSZACIVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,6.31,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.199970640755867,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=NNC(=O)C4=CC=CC=C43)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1n[nH]c(=O)c2ccccc12
4027,CHEMBL93519,XBURWGMHOIWDHZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.3,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.200659450546418,COC1=CC=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5CC7=CC=CC=N7,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccccn4)CC3)CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)C2)cc1
4028,CHEMBL270567,XBWBWCMBNYVAKR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C7=CC(=NN7C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(-c7cc(C)nn7C)oc6cc5CC4)n3C)cccc2n1
4029,CHEMBL79249,XCCCRVPCDJNFIY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,26.3,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.580044251510242,C1COCCN1CC2CC3C4=CC=CC=C4CC5=CC=CC=C5N3O2,c1ccc2c(c1)Cc1ccccc1N1OC(CN3CCOCC3)CC21
4030,CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C
4031,CHEMBL3545252,XCDIRYDKECHIPE-QHEQPUDQSA-N,DOCETAXEL HYDRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O.O.O.O,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C
4032,CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
4033,CHEMBL442,XCGSFFUVFURLIX-VFGNJEKYSA-N,ERGOTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@H]5CN([C@@H]6CC7=CNC8=CC=CC(=C78)C6=C5)C,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21
4034,CHEMBL1774503,XCIDTTYEFDTNFF-UYOCIXKTSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,325.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.4881166390211265,CN1C(=CC(=O)N(C1=O)C)N2CCN(CC2)CC/C=C\3/C4=CC=CC=C4COC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCN(CC/C=C3/c4ccccc4COc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
4035,CHEMBL1403257,XCVMKCYUNNAQAM-UHFFFAOYSA-N,BAS 03602647,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,1905.46,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.720000163638921,C1CCN(C1)C2=NC(=NC(=N2)N3CCNCC3)N4CCCC4,C1CCN(c2nc(N3CCCC3)nc(N3CCNCC3)n2)C1
4036,CHEMBL95764,XDDAORKBJWWYJS-UHFFFAOYSA-N,GLYPHOSATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)NCP(=O)(O)O,O=C(O)CNCP(=O)(O)O
4037,CHEMBL95764,XDDAORKBJWWYJS-UHFFFAOYSA-N,GLYPHOSATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(C(=O)O)NCP(=O)(O)O,O=C(O)CNCP(=O)(O)O
4038,CHEMBL12620,XDKYTXBAVJELDQ-UHFFFAOYSA-N,2-METHYLHISTAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,EC50,=,794.33,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human recombinant histamine H1 receptor expressed in Sf9 cells coexpressing RGS4 by steady-state GTPase activity assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0999990348465305,CC1=NC=C(N1)CCN,Cc1ncc(CCN)[nH]1
4040,CHEMBL55,XDRYMKDFEDOLFX-UHFFFAOYSA-N,PENTAMIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1
4041,CHEMBL55,XDRYMKDFEDOLFX-UHFFFAOYSA-N,PENTAMIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N,N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1
4042,CHEMBL1117,XDXDZDZNSLXDNA-TZNDIEGXSA-N,IDARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
4043,CHEMBL1117,XDXDZDZNSLXDNA-TZNDIEGXSA-N,IDARUBICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O,CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O
4044,CHEMBL60509,XDXVWRAGPFLSNP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,4265.8,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.369999510099088,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CN=CO3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3cnco3)CC2)cc1
4045,CHEMBL577912,XEOSDWIUBUJPES-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,760.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1191864077192095,CC1=CN=C(N=C1N(C)C)NC2CCC(CC2)NC(=O)C3=CC=C(C=C3)Cl,Cc1cnc(NC2CCC(NC(=O)c3ccc(Cl)cc3)CC2)nc1N(C)C
4046,CHEMBL1754,XFDJYSQDBULQSI-UHFFFAOYSA-N,DOXAPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
4047,CHEMBL1754,XFDJYSQDBULQSI-UHFFFAOYSA-N,DOXAPRAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4,CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O
4051,CHEMBL3094213,XFMAJARUDAULHP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24161834.0,Ki,>,2511.89,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced effect by FLIPR assay,The discovery of the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CC(C)N1CCC(CC1)OC2=CC3=C(CCNCC3)C=C2,CC(C)N1CCC(Oc2ccc3c(c2)CCNCC3)CC1
4052,CHEMBL270177,XFMPGBXLGWZMQP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17998160.0,Ki,=,1100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.9586073148417755,CC1C2=C(C=CC=C2Cl)NC(=N1)N,CC1N=C(N)Nc2cccc(Cl)c21
4053,CHEMBL1935442,XFQZALCRWJDNNK-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,0.8,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.096910013008056,C1CO[C@H](CN1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,Fc1ccc(Cn2c([C@H]3CNCCO3)nc3ccccc32)cc1
4054,CHEMBL2103747,XFSBVAOIAHNAPC-FKHWODAVSA-N,ACONITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C[C@@]2([C@@H](C[C@H]([C@@]34[C@@H]2[C@H]([C@@H]([C@@H]31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC,CCN1C[C@@]2(COC)[C@H]3[C@@H](OC)[C@H]4[C@H]1[C@]3([C@H](OC)C[C@H]2O)[C@@H]1C[C@]2(O)[C@@H](OC)[C@H](O)[C@@]4(OC(C)=O)[C@H]1[C@H]2OC(=O)c1ccccc1
4055,CHEMBL2103747,XFSBVAOIAHNAPC-FKHWODAVSA-N,ACONITINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C[C@@]2([C@@H](C[C@H]([C@@]34[C@@H]2[C@H]([C@@H]([C@@H]31)[C@@]5([C@@H]6[C@H]4C[C@@]([C@@H]6OC(=O)C7=CC=CC=C7)([C@H]([C@@H]5O)OC)O)OC(=O)C)OC)OC)O)COC,CCN1C[C@@]2(COC)[C@H]3[C@@H](OC)[C@H]4[C@H]1[C@]3([C@H](OC)C[C@H]2O)[C@@H]1C[C@]2(O)[C@@H](OC)[C@H](O)[C@@]4(OC(C)=O)[C@H]1[C@H]2OC(=O)c1ccccc1
4057,CHEMBL1172775,XGWXPMUNGMSGIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20541426.0,Ki,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]rilamine from human histamine H1 receptor expressed in CHO cells after 1 hr by liquid scintillation counting,Synthesis and structure-activity relationships of N-aryl-piperidine derivatives as potent (partial) agonists for human histamine H3 receptor.,Bioorg. Med. Chem.,PUBLICATION,,6.0,COC1=CC=C(C=C1)N2CCC(CC2)CC3=CN=CN3,COc1ccc(N2CCC(Cc3cnc[nH]3)CC2)cc1
4058,CHEMBL271280,XHDPHPBWQCZQAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OC(=N5)C6CC6,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4nc(C5CC5)oc4cc3CC2)n1C
4059,CHEMBL330499,XHIAYAAKBSHSOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.3,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.200659450546418,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4)C6=CC=CC=C6,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5[nH]4)CC3)(c3ccccc3)C2)cc(OC)c1OC
4060,CHEMBL330499,XHIAYAAKBSHSOX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,500.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4)C6=CC=CC=C6,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5[nH]4)CC3)(c3ccccc3)C2)cc(OC)c1OC
4061,CHEMBL1940414,XHIUHIDIRNZTAW-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22245230.0,Ki,=,67.9,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor by liquid scintillation counting,Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.,Bioorg. Med. Chem.,PUBLICATION,,7.168130225719497,C1CN(CCN1CCCOC2=CC=CC=C2)C3=CC=CC=C3,c1ccc(OCCCN2CCN(c3ccccc3)CC2)cc1
4062,CHEMBL92860,XHLHZPFSBCZVEA-HOFKKMOUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,=,460.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.337242168318426,COC1=C(C=C2C(=C1)C3=NO[C@H]([C@@H]3CO2)CN4CCN(CC4)CC5=CC6=CC=CC=C6C=C5)OC,COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(Cc4ccc5ccccc5c4)CC3)[C@@H]1CO2
4064,CHEMBL474448,XHPXJEMBVQVQEF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,1698.24,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.770000934050707,C1=CC=C2C(=C1)C=C(N2)C(=O)NC(=NCCCC3=CN=CN3)N,NC(=NCCCc1cnc[nH]1)NC(=O)c1cc2ccccc2[nH]1
4066,CHEMBL62726,XIDMFZPTPXURCO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,74.13,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.130005999878257,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C3=CC=CS3,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)c3cccs3)CC2)cc1
4068,CHEMBL1231,XIQVNETUBQGFHX-UHFFFAOYSA-N,OXYBUTYNIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
4069,CHEMBL1231,XIQVNETUBQGFHX-UHFFFAOYSA-N,OXYBUTYNIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O,CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1
4070,CHEMBL3357024,XIUQXOBEGLVYPC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,1955.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,5.708853238268113,CCOC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC(=C4)OC)C=C(C=C3)Cl)CC1,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cc(OC)cnc32)CC1
4072,CHEMBL1909070,XJGBDJOMWKAZJS-UHFFFAOYSA-N,NAFENOPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,CC(C)(Oc1ccc(C2CCCc3ccccc32)cc1)C(=O)O
4073,CHEMBL1909070,XJGBDJOMWKAZJS-UHFFFAOYSA-N,NAFENOPIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C(=O)O)OC1=CC=C(C=C1)C2CCCC3=CC=CC=C23,CC(C)(Oc1ccc(C2CCCc3ccccc32)cc1)C(=O)O
4074,CHEMBL831,XJGVXQDUIWGIRW-UHFFFAOYSA-N,LOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,5.0,NM,,,,,,,,,,,,,,,,,,,,8.301029995663981,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1
4075,CHEMBL831,XJGVXQDUIWGIRW-UHFFFAOYSA-N,LOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,,,,,,8.309803919971486,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1
4076,CHEMBL831,XJGVXQDUIWGIRW-UHFFFAOYSA-N,LOXAPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,7.0,NM,,,,,,,,,,,,,,,,,,,,8.154901959985743,CN1CCN(CC1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl,CN1CCN(C2=Nc3ccccc3Oc3ccc(Cl)cc32)CC1
4079,CHEMBL439065,XJLKTBWZJKVXJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC=C(C=C5)C(F)(F)F,Cc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2ccc(C(F)(F)F)cc2)n1C)CC3
4080,CHEMBL3104093,XKGPHJMKJBEURD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24365159.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from histamine H1 receptor (unknown origin),"The synthesis and comparative receptor binding affinities of novel, isomeric pyridoindolobenzazepine scaffolds.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCC2=C(C1)C3=C4N2CCC5=CC=CC=C5C4=CC=C3,CN1CCc2c(c3cccc4c3n2CCc2ccccc2-4)C1
4082,CHEMBL313703,XKZZKFWMYWZWDI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN5CC6=CC=CC=C6C5,c1ccc2c(c1)CN(CC1CC3c4ccccc4Cc4ccccc4N3O1)C2
4083,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
4084,CHEMBL295698,XMAYWYJOQHXEEK-ZEQKJWHPSA-N,KETOCONAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl,CC(=O)N1CCN(c2ccc(OC[C@@H]3CO[C@@](Cn4ccnc4)(c4ccc(Cl)cc4Cl)O3)cc2)CC1
4085,CHEMBL64408,XMLVVFKBGQDKNU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1071.52,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.969999718407896,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OC,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)OC)CC2)cc1
4086,CHEMBL96441,XMRHEUULHFVWJE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,5.71,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.243363891754154,COC1=C(C=C(C=C1)C2(CCN(C2)C(=O)C3=CC(=C(C(=C3)OC)OC)OC)CCN4CCC(CC4)C(=O)C5=NC6=CC=CC=C6N5)OC,COc1ccc(C2(CCN3CCC(C(=O)c4nc5ccccc5[nH]4)CC3)CCN(C(=O)c3cc(OC)c(OC)c(OC)c3)C2)cc1OC
4087,CHEMBL1321154,XMVJITFPVVRMHC-UHFFFAOYSA-N,ROXARSONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,O=[N+]([O-])c1cc([As](=O)(O)O)ccc1O
4088,CHEMBL1321154,XMVJITFPVVRMHC-UHFFFAOYSA-N,ROXARSONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C=C1[As](=O)(O)O)[N+](=O)[O-])O,O=[N+]([O-])c1cc([As](=O)(O)O)ccc1O
4089,CHEMBL14376,XMXHEBAFVSFQEX-UHFFFAOYSA-N,ILOPERIDONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,12.3,NM,,,,,,,,,,,,,,,,,,,,7.910094888560603,CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC,COc1cc(C(C)=O)ccc1OCCCN1CCC(c2noc3cc(F)ccc23)CC1
4090,CHEMBL991,XNKLLVCARDGLGL-JGVFFNPUSA-N,STAVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
4091,CHEMBL991,XNKLLVCARDGLGL-JGVFFNPUSA-N,STAVUDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO,Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O
4092,CHEMBL1277585,XNPQDIOALLTRKK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.599980364934843,C1CC2(CC1N3CCC(CC3)CC(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)CC1CCN(C2CCC3(Cc4ccccc4Cc4ccccc43)C2)CC1
4095,CHEMBL1222764,XNVKJWRHFRDBHD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,125.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,CC(C)(CN1CCN(CC1)C2=CC3=CC=CC=C3CN4C2=NC=C4OC)C(=O)O,COc1cnc2n1Cc1ccccc1C=C2N1CCN(CC(C)(C)C(=O)O)CC1
4096,CHEMBL635,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,PREDNISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
4097,CHEMBL635,XOFYZVNMUHMLCC-ZPOLXVRWSA-N,PREDNISONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO
4098,CHEMBL975,XOGTZOOQQBDUSI-UHFFFAOYSA-M,MESNA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CS(=O)(=O)[O-])S.[Na+],O=S(=O)([O-])CCS
4099,CHEMBL975,XOGTZOOQQBDUSI-UHFFFAOYSA-M,MESNA,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CS(=O)(=O)[O-])S.[Na+],O=S(=O)([O-])CCS
4103,CHEMBL838,XPCFTKFZXHTYIP-PMACEKPBSA-N,BENAZEPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
4104,CHEMBL838,XPCFTKFZXHTYIP-PMACEKPBSA-N,BENAZEPRIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O,CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O
4106,CHEMBL918,XPFRXWCVYUEORT-UHFFFAOYSA-N,PHENACEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CC(=O)NC(=O)N,NC(=O)NC(=O)Cc1ccccc1
4107,CHEMBL918,XPFRXWCVYUEORT-UHFFFAOYSA-N,PHENACEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)CC(=O)NC(=O)N,NC(=O)NC(=O)Cc1ccccc1
4110,CHEMBL32813,XPQIPUZPSLAZDV-UHFFFAOYSA-N,2-(2-AMINOETHYL)PYRIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,1258.93,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.899998417198647,C1=CC=NC(=C1)CCN,NCCc1ccccn1
4111,CHEMBL32813,XPQIPUZPSLAZDV-UHFFFAOYSA-N,2-(2-AMINOETHYL)PYRIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,6309573444801.94,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-3.8000000000000007,C1=CC=NC(=C1)CCN,NCCc1ccccn1
4112,CHEMBL562638,XPYYQHFSTUXSTG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)OC3=C(C=C(C=C3)Cl)C(=O)O,Cn1c(NCCCN2CCC(Oc3ccc(Cl)cc3C(=O)O)CC2)cc(=O)n(C)c1=O
4113,CHEMBL605405,XQDRWCFJBHLWPR-RAXLEYEMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,70.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.154901959985742,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)/C=C\C4=CC=CC=C4,Cc1ccc2c(c1)c1c(n2/C=C\c2ccccc2)CCN(C)C1
4114,CHEMBL605405,XQDRWCFJBHLWPR-RAXLEYEMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,154.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.812479279163537,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)/C=C\C4=CC=CC=C4,Cc1ccc2c(c1)c1c(n2/C=C\c2ccccc2)CCN(C)C1
4115,CHEMBL788,XQFRJNBWHJMXHO-RRKCRQDMSA-N,IDOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I
4116,CHEMBL788,XQFRJNBWHJMXHO-RRKCRQDMSA-N,IDOXURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)I)CO)O,O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1I
4118,CHEMBL269959,XQYFTHHWGHOOSS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C)oc6cc5CC4)n3C)cccc2n1
4119,CHEMBL19224,XQYZDYMELSJDRZ-UHFFFAOYSA-N,PAPAVERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC
4120,CHEMBL19224,XQYZDYMELSJDRZ-UHFFFAOYSA-N,PAPAVERINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)CC2=NC=CC3=CC(=C(C=C32)OC)OC)OC,COc1ccc(Cc2nccc3cc(OC)c(OC)cc23)cc1OC
4121,CHEMBL712,XRCFXMGQEVUZFC-UHFFFAOYSA-N,ANISINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1
4122,CHEMBL712,XRCFXMGQEVUZFC-UHFFFAOYSA-N,ANISINDIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O,COc1ccc(C2C(=O)c3ccccc3C2=O)cc1
4123,CHEMBL2179222,XRDVQWJPAZZLKN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23006002.0,Ki,=,586.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,6.23210238398191,CC1=CN(C2=C1C=C(C=N2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)cnc32)cc1NC1CCN(C)CC1
4124,CHEMBL1463,XRECTZIEBJDKEO-UHFFFAOYSA-N,FLUCYTOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=O)NC(=C1F)N,Nc1[nH]c(=O)ncc1F
4125,CHEMBL1463,XRECTZIEBJDKEO-UHFFFAOYSA-N,FLUCYTOSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=NC(=O)NC(=C1F)N,Nc1[nH]c(=O)ncc1F
4126,CHEMBL61792,XRPRRDYTGFENHV-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,95499.26,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.019999993643078,C1CC1C(=O)C2=CC=C(C=C2)OCCCN3CCN(CC3)C(=O)[C@@H](CC4=CN=CN4)N,N[C@H](Cc1cnc[nH]1)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
4127,CHEMBL303313,XRYLGRGAWQSVQW-KRWDZBQOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,15.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.823908740944319,CN1CCN(CC1)[C@H]2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN([C@H]2Cc3ccccc3Sc3ccc(Cl)cc32)CC1
4128,CHEMBL64875,XRYLGRGAWQSVQW-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,12.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,7.920818753952375,CN1CCN(CC1)[C@@H]2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN([C@@H]2Cc3ccccc3Sc3ccc(Cl)cc32)CC1
4129,CHEMBL64249,XRYLGRGAWQSVQW-UHFFFAOYSA-N,CLOROTEPINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,0.19,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,9.721246399047173,CN1CCN(CC1)C2CC3=CC=CC=C3SC4=C2C=C(C=C4)Cl,CN1CCN(C2Cc3ccccc3Sc3ccc(Cl)cc32)CC1
4130,CHEMBL1935431,XRZMHKTZJWSXPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,5.7,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.244125144327509,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(C)C(=O)CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
4131,CHEMBL1935431,XRZMHKTZJWSXPQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,8.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.050609993355089,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)F,CN(C)C(=O)CN1CCCC(c2nc3ccccc3n2Cc2ccc(F)cc2)C1
4133,CHEMBL945,XSDQTOBWRPYKKA-UHFFFAOYSA-N,AMILORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,NC(N)=NC(=O)c1nc(Cl)c(N)nc1N
4134,CHEMBL945,XSDQTOBWRPYKKA-UHFFFAOYSA-N,AMILORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1(=C(N=C(C(=N1)Cl)N)N)C(=O)N=C(N)N,NC(N)=NC(=O)c1nc(Cl)c(N)nc1N
4135,CHEMBL1512,XSFJVAJPIHIPKU-XWCQMRHXSA-N,FLUNISOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
4136,CHEMBL1512,XSFJVAJPIHIPKU-XWCQMRHXSA-N,FLUNISOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)C[C@@H](C5=CC(=O)C=C[C@]35C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4C[C@H](F)C5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
4137,CHEMBL294087,XSLVAIIZNFBGBI-OAQYLSRUSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,34673.69,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.459999937940862,CC(C)[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)NC,CN[C@@H](C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1)C(C)C
4138,CHEMBL3357043,XSNLDSYJHLYUGZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,147.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.832682665251824,CCCCC(=O)N1CCC(=C2C3=C(CCC4=C2N=CC=C4)C=C(C=C3)Cl)CC1,CCCCC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
4139,CHEMBL240141,XSOFCOCSPTUCJQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CCN(C1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC=C(C=C4)C#N.C(=O)O,N#Cc1ccc(C(=O)N2CCN(c3ccc(OCCCN4CCCC4)cc3)C(=O)C2)cc1
4140,CHEMBL259765,XSZZVXRYXJUWCA-QZTJIDSGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,COC1=C(C=CC(=C1)F)O[C@@H]([C@H]2CNCCO2)C3=CC=CC=C3,COc1cc(F)ccc1O[C@H](c1ccccc1)[C@H]1CNCCO1
4142,CHEMBL1783957,XTVVBTLUOSFTHO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,120.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.920818753952375,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)Br,CN1CCc2c(c3cc(Br)ccc3n2CCc2ccccn2)C1
4143,CHEMBL1783957,XTVVBTLUOSFTHO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)Br,CN1CCc2c(c3cc(Br)ccc3n2CCc2ccccn2)C1
4144,CHEMBL31,XUBOMFCQGDBHNK-UHFFFAOYSA-N,GATIFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
4145,CHEMBL31,XUBOMFCQGDBHNK-UHFFFAOYSA-N,GATIFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F,COc1c(N2CCNC(C)C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12
4146,CHEMBL461727,XUCIJNAGGSZNQT-JHSLDZJXSA-N,AMYGDALIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,N#C[C@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)c1ccccc1
4147,CHEMBL461727,XUCIJNAGGSZNQT-JHSLDZJXSA-N,AMYGDALIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)[C@H](C#N)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O)O,N#C[C@H](O[C@@H]1O[C@H](CO[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O)c1ccccc1
4148,CHEMBL902,XUFQPHANEAPEMJ-UHFFFAOYSA-N,FAMOTIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1
4149,CHEMBL902,XUFQPHANEAPEMJ-UHFFFAOYSA-N,FAMOTIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(N=C(S1)N=C(N)N)CSCC/C(=N/S(=O)(=O)N)/N,NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1
4150,CHEMBL1566,XUFXOAAUWZOOIT-SXARVLRPSA-N,ACARBOSE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
4151,CHEMBL1566,XUFXOAAUWZOOIT-SXARVLRPSA-N,ACARBOSE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@H]([C@@H]([C@H]4O)O)O)CO,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
4152,CHEMBL54943,XUJNEKJLAYXESH-UHFFFAOYSA-N,CYSTEINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S,NC(CS)C(=O)O
4154,CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
4155,CHEMBL1487,XUKUURHRXDUEBC-KAYWLYCHSA-N,ATORVASTATIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4,CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O
4156,CHEMBL255618,XURXMJIMPKTNSF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCC(C)N4CCC5=CC6=C(C(=C5CC4)Br)OC(=N6)C(F)(F)F,Cc1ccc2c(-c3nnc(SCCC(C)N4CCc5cc6nc(C(F)(F)F)oc6c(Br)c5CC4)n3C)cccc2n1
4157,CHEMBL1774495,XURYOEGYBXTQTO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,150.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.823908740944319,CC(C)(C1=CC2=C(C=C1)OCC3=CC=CC=C3N2CCCN4CCCN(CC4)C5=CC(=O)N(C(=O)N5C)C)C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4COc4ccc(C(C)(C)C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
4158,CHEMBL1910381,XUSZWVLIKIUVKA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,7.08,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.14996674231023,CN(CCN1CCN(CC1)C(=O)C2=CC3=CC=CC=C3N2)CCN(CC4=CC=C(C=C4)OC)C5=CC=CC=N5,COc1ccc(CN(CCN(C)CCN2CCN(C(=O)c3cc4ccccc4[nH]3)CC2)c2ccccn2)cc1
4160,CHEMBL1171434,XVOYSCVBGLVSOL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12649361.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,C(C(C(=O)O)N)S(=O)(=O)O,NC(CS(=O)(=O)O)C(=O)O
4162,CHEMBL465170,XVZKDKXYAADAMU-UHFFFAOYSA-N,UR-PI295,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19317445.0,EC50,=,2187.76,NM,,,cell_based,,,,,,,,,,,,Agonist activity at human H1 receptor expressed in insect Sf9 cells co-expressing RGS4 assessed as gamma[32P]GTP binding by liquid scintillation counting,N(G)-acylated imidazolylpropylguanidines as potent histamine H4 receptor agonists: selectivity by variation of the N(G)-substituent.,J. Med. Chem.,PUBLICATION,,5.660000322371772,CCCC(=O)NC(=NCCCC1=CN=CN1)N,CCCC(=O)NC(N)=NCCCc1cnc[nH]1
4163,CHEMBL1235242,XWHHYOYVRVGJJY-QMMMGPOBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)F,N[C@@H](Cc1ccc(F)cc1)C(=O)O
4164,CHEMBL1235242,XWHHYOYVRVGJJY-QMMMGPOBSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1C[C@@H](C(=O)O)N)F,N[C@@H](Cc1ccc(F)cc1)C(=O)O
4165,CHEMBL64253,XWOZMTAARRXLLU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,2238.72,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.650000220873455,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CC3CC3,CCCCCC(=O)c1ccc(OCCCN2CCN(CC3CC3)CC2)cc1
4166,CHEMBL1760,XWTYSIMOBUGWOL-UHFFFAOYSA-N,TERBUTALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,CC(C)(C)NCC(O)c1cc(O)cc(O)c1
4167,CHEMBL1760,XWTYSIMOBUGWOL-UHFFFAOYSA-N,TERBUTALINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O,CC(C)(C)NCC(O)c1cc(O)cc(O)c1
4168,CHEMBL273575,XXPANQJNYNUNES-UHFFFAOYSA-N,NOMIFENSINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,2700.0,NM,,,,,,,,,,,,,,,,,,,,5.568636235841013,CN1CC(C2=C(C1)C(=CC=C2)N)C3=CC=CC=C3,CN1Cc2c(N)cccc2C(c2ccccc2)C1
4169,CHEMBL234926,XXROGKLTLUQVRX-UHFFFAOYSA-N,ALLYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCO,C=CCO
4170,CHEMBL234926,XXROGKLTLUQVRX-UHFFFAOYSA-N,ALLYL ALCOHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCO,C=CCO
4171,CHEMBL1535,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,HYDROXYCHLOROQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
4172,CHEMBL1535,XXSMGPRMXLTPCZ-UHFFFAOYSA-N,HYDROXYCHLOROQUINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN(CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl)CCO,CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12
4173,CHEMBL485549,XXUXXCZCUGIGPP-WLRTZDKTSA-N,NIFURSOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O,O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O
4174,CHEMBL485549,XXUXXCZCUGIGPP-WLRTZDKTSA-N,NIFURSOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=C(OC(=C1)[N+](=O)[O-])/C=N/NC(=O)C2=C(C(=CC(=C2)[N+](=O)[O-])[N+](=O)[O-])O,O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1cc([N+](=O)[O-])cc([N+](=O)[O-])c1O
4175,CHEMBL844,XYLJNLCSTIOKRM-UHFFFAOYSA-N,BRIMONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,Brc1c(NC2=NCCN2)ccc2nccnc12
4176,CHEMBL844,XYLJNLCSTIOKRM-UHFFFAOYSA-N,BRIMONIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br,Brc1c(NC2=NCCN2)ccc2nccnc12
4178,CHEMBL318801,XZKDSZJJFHAYFJ-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,5623.41,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.2500002511435815,C1CN(C[C@H]1O)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CC[C@H](O)C3)cc2)cc1
4179,CHEMBL104669,XZKDSZJJFHAYFJ-LJQANCHMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,4466.84,NM,,,,,,,,,,,,,,,Binding affinity at human cortical Histamine 1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.349999603463148,C1CN(C[C@@H]1O)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)C#N,N#Cc1ccc(-c2ccc(OCCCN3CC[C@@H](O)C3)cc2)cc1
4180,CHEMBL1431,XZWYZXLIPXDOLR-UHFFFAOYSA-N,METFORMIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=N)N=C(N)N,CN(C)C(=N)N=C(N)N
4181,CHEMBL1431,XZWYZXLIPXDOLR-UHFFFAOYSA-N,METFORMIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C(=N)N=C(N)N,CN(C)C(=N)N=C(N)N
4182,CHEMBL1774496,YAMCEGJVTDPCJX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,530.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,6.275724130399211,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4OCC5=C3C=C(C=C5)C(=O)O,Cn1c(N2CCCN(CCCN3c4cc(C(=O)O)ccc4COc4ccccc43)CC2)cc(=O)n(C)c1=O
4183,CHEMBL1767168,YANGEESWIGIKOP-UMSFTDKQSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,25.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,7.599980364934843,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
4184,CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,15.85,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,7.799970733446231,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
4187,CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.0,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
4189,CHEMBL1767164,YANGEESWIGIKOP-UUWRZZSWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,10.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,8.0,C1CCCN(CC1)CCCOC2=CC=C(C=C2)CCCCN3CCC[C@@H]3CN4C(=O)C5=CC=CC=C5C(=N4)CC6=CC=C(C=C6)Cl,O=c1c2ccccc2c(Cc2ccc(Cl)cc2)nn1C[C@H]1CCCN1CCCCc1ccc(OCCCN2CCCCCC2)cc1
4190,CHEMBL121,YASAKCUCGLMORW-UHFFFAOYSA-N,ROSIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
4191,CHEMBL121,YASAKCUCGLMORW-UHFFFAOYSA-N,ROSIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1
4192,CHEMBL1399,YBBLVLTVTVSKRW-UHFFFAOYSA-N,ANASTROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
4193,CHEMBL1399,YBBLVLTVTVSKRW-UHFFFAOYSA-N,ANASTROZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
4194,CHEMBL1259174,YBCFDDCJLZVHPZ-FQEVSTJZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,2.5,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.602059991327963,CC(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@@H]2N4CCN(CC4)C,CC(=O)NCc1ccc2c(c1)[C@@H](N1CCN(C)CC1)Cc1ccccc1S2
4195,CHEMBL1259173,YBCFDDCJLZVHPZ-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,=,3.6,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,8.443697499232712,CC(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3C[C@H]2N4CCN(CC4)C,CC(=O)NCc1ccc2c(c1)[C@H](N1CCN(C)CC1)Cc1ccccc1S2
4196,CHEMBL1259144,YBCFDDCJLZVHPZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20857909.0,Ki,,,,Non-toxic,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]prozosin from human cloned histamine H1 receptor expressed in CHO cells,Exploring the neuroleptic substituent in Octoclothepin: potential ligands for positron emission tomography with subnanomolar affinity for a(1)-adrenoceptors.,J. Med. Chem.,PUBLICATION,,,CC(=O)NCC1=CC2=C(C=C1)SC3=CC=CC=C3CC2N4CCN(CC4)C,CC(=O)NCc1ccc2c(c1)C(N1CCN(C)CC1)Cc1ccccc1S2
4197,CHEMBL1669422,YBDNLKCSUIZMPU-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,8.8,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.05551732784983,C[C@@H](C1=NC=CN=C1)C2=C(CC3=CC=CC=C32)CCN(C)CC4=NC=CN4,C[C@H](C1=C(CCN(C)Cc2ncc[nH]2)Cc2ccccc21)c1cnccn1
4198,CHEMBL85728,YBRVSVVVWCFQMG-UHFFFAOYSA-N,"4,4'-METHYLENEDIANILINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Nc1ccc(Cc2ccc(N)cc2)cc1
4199,CHEMBL85728,YBRVSVVVWCFQMG-UHFFFAOYSA-N,"4,4'-METHYLENEDIANILINE",,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=CC=C1CC2=CC=C(C=C2)N)N,Nc1ccc(Cc2ccc(N)cc2)cc1
4200,CHEMBL272775,YBTBFDQBPQHZEV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,<,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)N=C(O5)C(C)(F)F,Cc1ncoc1-c1nnc(SCCCN2CCc3ccc4nc(C(C)(F)F)oc4c3CC2)n1C
4202,CHEMBL599570,YCFWTCQCXNKWLE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20045641.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human cloned histamine H1 receptor,"9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,COC1=CC2=CC3=C(CC4=CC=CC=C4C3CN)C=C2C=C1,COc1ccc2cc3c(cc2c1)C(CN)c1ccccc1C3
4203,CHEMBL280998,YCIMNLLNPGFGHC-UHFFFAOYSA-N,CATECHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)O)O,Oc1ccccc1O
4204,CHEMBL280998,YCIMNLLNPGFGHC-UHFFFAOYSA-N,CATECHOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)O)O,Oc1ccccc1O
4205,CHEMBL495778,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,PENICILLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)C1(C(=CC(=O)O1)OC)O,C=C(C)C1(O)OC(=O)C=C1OC
4206,CHEMBL495778,YCOFRPYSZKIPBQ-UHFFFAOYSA-N,PENICILLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=C)C1(C(=CC(=O)O1)OC)O,C=C(C)C1(O)OC(=O)C=C1OC
4209,CHEMBL15928,YDBCEBYHYKAFRX-UHFFFAOYSA-N,GR-127935,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16143528.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Affinity towards cloned Histamine H1 receptor,Synthesis of potent and selective serotonin 5-HT1B receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=C(C=CC(=C1)C2=NOC(=N2)C)C3=CC=C(C=C3)C(=O)NC4=CC(=C(C=C4)OC)N5CCN(CC5)C,COc1ccc(NC(=O)c2ccc(-c3ccc(-c4noc(C)n4)cc3C)cc2)cc1N1CCN(C)CC1
4210,CHEMBL315424,YDCWINJIBUMKOY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C(=CC=C3)Cl,CN(C)CC1CC2c3cccc(Cl)c3Cc3ccccc3N2O1
4211,CHEMBL269646,YDDXVAXDYKBWDX-UHFFFAOYSA-N,TIOTIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,CN=C(NCCSCC1=CSC(=N1)N=C(N)N)NC#N,CN=C(NC#N)NCCSCc1csc(N=C(N)N)n1
4212,CHEMBL2158787,YDHQRFQQOKRWAD-MHZLTWQESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,C[C@](CC1=CC=C(C=C1)F)(C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,C[C@](Cc1ccc(F)cc1)(C(=O)O)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
4213,CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
4214,CHEMBL1403281,YDOTUXAWKBPQJW-NSLWYYNWSA-N,ERGOCRYPTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=CNC7=CC=CC(=C67)C5=C4)C)O,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
4215,CHEMBL2158836,YDRCHQQFHSPVMO-RUZDIDTESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@H](CC4=CC=CC=C4)C(=O)O,O=C(O)[C@@H](Cc1ccccc1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
4216,CHEMBL2158835,YDRCHQQFHSPVMO-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4)C(=O)O,O=C(O)[C@H](Cc1ccccc1)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
4218,CHEMBL346993,YDUBNWZTTFIXEZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,398107170553497.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.6,C1=CC=C(C=C1)C(CCC2=NC=C(N2)CCN)C3=CC=C(C=C3)Br,NCCc1cnc(CCC(c2ccccc2)c2ccc(Br)cc2)[nH]1
4220,CHEMBL294349,YDZORJBZHVTZSS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,21379.62,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6700000181810175,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)C(C)(C)O,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)C(C)(C)O)CC2)cc1
4221,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27876250.0,IC50,=,1.4,NM,,,cell_based,binding,,,,,,,,,,,,,,,,8.853871964321762,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4222,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,,,,,,8.397940008672037,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4223,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7925364.0,Ki,=,3.98,NM,,,,,,,,,,,,,,,,,,,,8.400116927926312,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4224,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8335064.0,Ki,=,4.7,NM,,,,,,,,,,,,,,,,,,,,8.327902142064282,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4225,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,3.7,NM,,,,,,,,,,,,,,,,,,,,8.431798275933005,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4226,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,2.5,NM,,,,,,,,,,,,,,,,,,,,8.602059991327963,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4227,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.01,NM,,,,,,,,,,,,,,,,,,,,8.995678626217357,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4228,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,1.18,NM,,,,,,,,,,,,,,,,,,,,8.928117992693872,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4231,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,12.59,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,7.899974269892138,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4232,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,5.0118723362727104e+17,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-8.7,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4234,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16408006.0,IC50,=,10.0,NM,,,,,,,,,,,,,,,Inverse agonist activity at human wild-type histamine H1 receptor assessed as NF-kappaB activation after 48 hrs by luciferase reporter gene assay,Linking agonist binding to histamine H1 receptor activation.,Nat. Chem. Biol.,PUBLICATION,,8.0,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4235,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16562853.0,EC50,=,2.6,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO-K1 cells,Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro.,J. Nat. Prod.,PUBLICATION,,8.585026652029184,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4236,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18588282.0,IC50,=,1.8,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,"Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.",J. Med. Chem.,PUBLICATION,,8.744727494896694,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4237,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,IC50,=,6.2,NM,,,,,,,,,,,,,,,Displacement of radiolabeled pyrilamine from human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,8.207608310501746,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4238,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18983139.0,Ki,=,2.2,NM,,,,,,,,,,,,,,,Displacement of radiolabeled pyrilamine from human histamine H1 receptor,"cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.",J. Med. Chem.,PUBLICATION,,8.657577319177793,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4239,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,4.47,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.349692476868062,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4241,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,2.09,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,8.679853713888948,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4242,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,46.77,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,7.330032630091495,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4243,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23403082.0,IC50,=,3.3,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells after 3 hrs,Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.481486060122112,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4245,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23403082.0,Ki,=,1.6,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells after 3 hrs,Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.795880017344075,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4246,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23466604.0,IC50,=,1.5,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.,Eur. J. Med. Chem.,PUBLICATION,,8.823908740944319,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4247,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23466604.0,Ki,=,0.95,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,Synthesis and structure-activity relationship studies in serotonin 5-HT1A receptor agonists based on fused pyrrolidone scaffolds.,Eur. J. Med. Chem.,PUBLICATION,,9.022276394711152,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4248,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23582449.0,IC50,=,0.82,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor by radioligand displacement assay,Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.,Bioorg. Med. Chem.,PUBLICATION,,9.086186147616283,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4249,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24805037.0,IC50,=,3.0,NM,,,cell_based,,,,,,,,,,,,Antagonist activity at human recombinant H1 receptor assessed as inhibition of histamine-induced intracellular Ca2+ release,Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia.,J. Med. Chem.,PUBLICATION,,8.522878745280337,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4250,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24805037.0,Ki,=,1.7,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant H1 receptor expressed in HEK293 cells,Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia.,J. Med. Chem.,PUBLICATION,,8.769551078621726,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4251,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25557493.0,Ki,=,1.7,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in HEK-293 cells,Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.,Eur. J. Med. Chem.,PUBLICATION,,8.769551078621726,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4252,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26988801.0,IC50,=,0.014,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in HEK293 cells,"Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.",Bioorg. Med. Chem.,PUBLICATION,,10.853871964321762,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4253,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.72,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.429457060118104,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4254,CHEMBL511,YECBIJXISLIIDS-UHFFFAOYSA-N,PYRILAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.4320000000000001,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.364516253185087,CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2,COc1ccc(CN(CCN(C)C)c2ccccn2)cc1
4256,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
4257,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
4258,CHEMBL603,YEEZWCHGZNKEEK-UHFFFAOYSA-N,ZAFIRLUKAST,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CC=CC=C1S(=O)(=O)NC(=O)C2=CC(=C(C=C2)CC3=CN(C4=C3C=C(C=C4)NC(=O)OC5CCCC5)C)OC,COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12
4259,CHEMBL1767146,YEFYNZHDZSJWCN-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.58,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.801342913045579,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=CC=C4)Cl,CN1CCC[C@@H]1Cn1nc(Cc2cccc(Cl)c2)c2ccccc2c1=O
4260,CHEMBL2207281,YEGSREZTMOWGTG-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=CC(=C4)S(=O)(=O)NCCO)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2cc(S(=O)(=O)NCCO)ccc12
4261,CHEMBL531,YEHCICAEULNIGD-MZMPZRCHSA-N,PERGOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
4262,CHEMBL531,YEHCICAEULNIGD-MZMPZRCHSA-N,PERGOLIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC,CCCN1C[C@H](CSC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
4263,CHEMBL148489,YFCWBKBNFCDPDF-UHFFFAOYSA-N,N-(3-PYRIDYLMETHYL)PYRROLIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22607684.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of H1 receptor,7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (s(2)) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,C1CCN(C1)CC2=CN=CC=C2,c1cncc(CN2CCCC2)c1
4264,CHEMBL1373,YFGHCGITMMYXAQ-UHFFFAOYSA-N,MODAFINIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1
4265,CHEMBL1373,YFGHCGITMMYXAQ-UHFFFAOYSA-N,MODAFINIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N,NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1
4266,CHEMBL104618,YFHPQEMWPYAXGG-IBGZPJMESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372500.0,Ki,=,9400.0,NM,,,,,,,,,,,,,,,Binding affinity to the human Histamine H1 receptor,Synthesis and evaluation of potent pyrrolidine H(3) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.026872146400302,C1CN(C[C@H]1NS(=O)(=O)C2=CC=CC=C2F)CCCOC3=CC=C(C=C3)C(=O)C4CC4,O=C(c1ccc(OCCCN2CC[C@H](NS(=O)(=O)c3ccccc3F)C2)cc1)C1CC1
4267,CHEMBL3092650,YFRBKEVUUCQYOW-UHFFFAOYSA-N,GSK239512,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24269482.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O,O=C1CCCN1c1ccc(Oc2ccc3c(c2)CCN(C2CCC2)CC3)nc1
4268,CHEMBL2158839,YFTFPJHCROIDGR-VWLOTQADSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,50.12,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.299988937677887,C1CN(CCC1CN2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)[C@@H](CC4=CC=CC=C4F)C(=O)O,O=C(O)[C@H](Cc1ccccc1F)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
4270,CHEMBL542908,YFWUUKSPYPKQPB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,9447.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.024706084643793,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCOC6=CC=CC=C6C(=O)O)C7=CC=CC=C7.Cl,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4CCCOc4ccccc4C(=O)O)CC3)(c3ccccc3)C2)cc(OC)c1OC
4272,CHEMBL272378,YGOJZWAMJUGUJD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,2511.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CCC1=NC2=C(O1)C(=C3CCN(CCC3=C2)CCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)Br,CCc1nc2cc3c(c(Br)c2o1)CCN(CCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
4273,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,6.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161150909262744,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
4274,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,6.9,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161150909262744,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
4275,CHEMBL556450,YGQQBKYVKLZEMA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,6.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.161150909262744,CC1=CN(N=C1)C2CCN(CC2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Cc1cnn(C2CCN(c3nc4ccccc4n3Cc3ccc(F)cc3)CC2)c1
4276,CHEMBL424,YGSDEFSMJLZEOE-UHFFFAOYSA-N,SALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)O)O,O=C(O)c1ccccc1O
4277,CHEMBL424,YGSDEFSMJLZEOE-UHFFFAOYSA-N,SALICYLIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C(=O)O)O,O=C(O)c1ccccc1O
4278,CHEMBL2207671,YGYJEYXHZXOPGM-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,CS(=O)(=O)C1=CC2=C(C=C1)C(=CNC2=O)C(=O)NC[C@H](CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl)O,CS(=O)(=O)c1ccc2c(C(=O)NC[C@@H](O)CN3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)c[nH]c(=O)c2c1
4279,CHEMBL272695,YHBNNSZPKVUPMG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,1584.89,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.800000874803202,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)C7CC7,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(C7CC7)oc6cc5CC4)n3C)cccc2n1
4280,CHEMBL610739,YHDCGYWZEFIUHE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,75.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,7.1249387366083,CN(C)CCC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCC(c1ccccc1)c1ccccc1
4283,CHEMBL1277400,YHPLTCSZJDWTFK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,79.43,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.100015437450608,C1CN(CC(=C1)C(=O)O)C2CCC3(C2)C4=CC=CC=C4CC5=CC=CC=C5C3=O,O=C(O)C1=CCCN(C2CCC3(C2)C(=O)c2ccccc2Cc2ccccc23)C1
4284,CHEMBL583014,YHSRTUXPXLVIAG-CALCHBBNSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773162.0,IC50,=,1210.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Pyrimidine-based antagonists of h-MCH-R1 derived from ATC0175: in vitro profiling and in vivo evaluation.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.917214629683549,CC1=CC(=NC(=N1)NC2CCC(CC2)NC(=O)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N(C)C,Cc1cc(N(C)C)nc(NC2CCC(NC(=O)c3cc(C(F)(F)F)cc(C(F)(F)F)c3)CC2)n1
4285,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
4286,CHEMBL86304,YHXISWVBGDMDLQ-UHFFFAOYSA-N,MOCLOBEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl,O=C(NCCN1CCOCC1)c1ccc(Cl)cc1
4287,CHEMBL491889,YHXSELHUXJAOLR-UHFFFAOYSA-N,KF-A6,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17846138.0,IC50,=,3600.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine receptor subtype 1 expressed in CHO cells,"Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum.",Antimicrob. Agents Chemother.,PUBLICATION,,5.443697499232713,CCN(CC)CCCCCCN1C2=CC=CC=C2C(=O)C3=CC=CC=C31,CCN(CC)CCCCCCn1c2ccccc2c(=O)c2ccccc21
4289,CHEMBL1783955,YIVBCXIAPLXDDK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,4670.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.330683119433887,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)OC,COc1ccc2c(c1)c1c(n2CCc2ccccn2)CCN(C)C1
4290,CHEMBL1783955,YIVBCXIAPLXDDK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)OC,COc1ccc2c(c1)c1c(n2CCc2ccccn2)CCN(C)C1
4291,CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
4292,CHEMBL61,YJGVMLPVUAXIQN-XVVDYKMHSA-N,PODOFILOX,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)[C@H]2[C@@H]3[C@H](COC3=O)[C@H](C4=CC5=C(C=C24)OCO5)O,COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OC
4293,CHEMBL559665,YJGZARVVQHKNAU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,23.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.638272163982407,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)CC(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(CC(=O)O)cc43)CC2)cc(=O)n(C)c1=O
4294,CHEMBL271034,YJTUMJAALUNJJT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)C6=C(C=C5)OC(=N6)C(C(F)(F)F)(F)F,Cc1ccc2c(-c3nnc(SCCCN4CCc5ccc6oc(C(F)(F)C(F)(F)F)nc6c5CC4)n3C)cccc2n1
4295,CHEMBL562792,YJYGESNCQHFTHG-BENRWUELSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,323.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.490797477668897,CN1C(=CC(=O)N(C1=O)C)N2CCCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)/C=C\C(=O)O,Cn1c(N2CCCN(CCCN3c4ccccc4Sc4ccc(/C=C\C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
4296,CHEMBL177756,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,FLUORESCEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O,O=C(O)c1ccccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12
4297,CHEMBL177756,YKGGGCXBWXHKIZ-UHFFFAOYSA-N,FLUORESCEIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C(C(=C1)C2=C3C=CC(=O)C=C3OC4=C2C=CC(=C4)O)C(=O)O,O=C(O)c1ccccc1-c1c2ccc(=O)cc-2oc2cc(O)ccc12
4298,CHEMBL423192,YKJYKKNCCRKFSL-RDBSUJKOSA-N,ANISOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1
4299,CHEMBL423192,YKJYKKNCCRKFSL-RDBSUJKOSA-N,ANISOMYCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)O[C@@H]1[C@H](CN[C@@H]1CC2=CC=C(C=C2)OC)O,COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1
4301,CHEMBL1935438,YKMYFJKVCCQVAY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,C1CC(CNC1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4,c1ccc(OCCn2c(C3CCCNC3)nc3ccccc32)cc1
4302,CHEMBL294199,YKPUWZUDDOIDPM-SOFGYWHQSA-N,CAPSAICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
4303,CHEMBL294199,YKPUWZUDDOIDPM-SOFGYWHQSA-N,CAPSAICIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC,COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O
4304,CHEMBL407135,YKQOSKADJPQZHB-YNWHQGOSSA-N,COLISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
4305,CHEMBL407135,YKQOSKADJPQZHB-YNWHQGOSSA-N,COLISTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCN)CC(C)C)CC(C)C)CCN)CCN)[C@H](C)O,CCC(C)CCCC(=O)N[C@@H](CCN)C(=O)N[C@H](C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O
4306,CHEMBL185905,YKSKLZDPBLSMIO-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,19.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.721246399047171,C1CC2=C(C=CC(=C2)Cl)C(=C3CCN(CC3)CCOC4=CC=C(C=C4)C#CCCN(C(=O)N)O)C5=C1C=CC=N5,NC(=O)N(O)CCC#Cc1ccc(OCCN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)cc1
4307,CHEMBL95,YLJREFDVOIBQDA-UHFFFAOYSA-N,TACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,Nc1c2c(nc3ccccc13)CCCC2
4308,CHEMBL95,YLJREFDVOIBQDA-UHFFFAOYSA-N,TACRINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCC2=NC3=CC=CC=C3C(=C2C1)N,Nc1c2c(nc3ccccc13)CCCC2
4309,CHEMBL2151155,YLMVVEDAZPUKCY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21062081.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Histamine H3 receptor as a drug discovery target.,J. Med. Chem.,PUBLICATION,,5.599999383023619,CS(=O)(=O)C1=CC=C(C=C1)C(=O)N2CCN(CC2)C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5,CS(=O)(=O)c1ccc(C(=O)N2CCN(c3ccc(OC4CCN(C5CCC5)CC4)cc3)CC2)cc1
4314,CHEMBL2146808,YLWRKTVVIPNRDE-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,1.0,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.0,COCCN1CCC[C@@H]1CN2C(=O)C3=C(C=CC=N3)C(=N2)CC4=CC=C(C=C4)Cl,COCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2cccnc2c1=O
4315,CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
4316,CHEMBL116,YMARZQAQMVYCKC-OEMFJLHTSA-N,AMPRENAVIR,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N,CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1
4317,CHEMBL19299,YMBXTVYHTMGZDW-UHFFFAOYSA-N,LOXOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
4318,CHEMBL19299,YMBXTVYHTMGZDW-UHFFFAOYSA-N,LOXOPROFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O,CC(C(=O)O)c1ccc(CC2CCCC2=O)cc1
4319,CHEMBL1767148,YMFHXRKTKHBRIX-GOSISDBHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,0.794,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,9.100179497572904,CC1=CC(=CC=C1)CC2=NN(C(=O)C3=CC=CC=C32)C[C@H]4CCCN4C,Cc1cccc(Cc2nn(C[C@H]3CCCN3C)c(=O)c3ccccc23)c1
4320,CHEMBL329055,YMHZUQFCCIVBOA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,6.67,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.175874166083451,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)F)C7=CC(=C(C=C7)Cl)Cl,COc1cc(C(=O)N2CCCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(F)cc4)CC3)(c3ccc(Cl)c(Cl)c3)C2)cc(OC)c1OC
4321,CHEMBL1910385,YMLNOWNONRZEDQ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,213.8,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.669992299127242,CC(CN(C)CCN(CC1=CC=C(C=C1)OC)C2=CC=CC=N2)NC3=CC4=C(C=C3)NC(=C4)C(=O)N5CCN(CC5)C,COc1ccc(CN(CCN(C)CC(C)Nc2ccc3[nH]c(C(=O)N4CCN(C)CC4)cc3c2)c2ccccn2)cc1
4324,CHEMBL672,YMTINGFKWWXKFG-UHFFFAOYSA-N,FENOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
4325,CHEMBL672,YMTINGFKWWXKFG-UHFFFAOYSA-N,FENOFIBRATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
4326,CHEMBL275035,YMVWDVNGNLXSKR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12626648.0,Ki,=,370.0,NM,,,,,,,,,,,,,,,,,,,,6.431798275933005,CNCCC1=CN=C(N1)CCC(C2=CC=CC=C2)C3=CC=CC=C3,CNCCc1cnc(CCC(c2ccccc2)c2ccccc2)[nH]1
4327,CHEMBL419316,YMYZKGIHGMHZDL-WDAWEKNVSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15771448.0,Ki,>,1000.0,NM,,,,,,,,,,,,,,,Inhibition of [3H]pyrilamine binding to Histamine H1 receptor,Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking activity.,J. Med. Chem.,PUBLICATION,,6.0,C/C(=C\CN1CCN(CC1)C[C@H]2[C@@H]3COC4=CC(=C(C=C4C3=NO2)OC)OC)/C5=CC=CC=C5,COc1cc2c(cc1OC)C1=NO[C@@H](CN3CCN(C/C=C(\C)c4ccccc4)CC3)[C@@H]1CO2
4328,CHEMBL2207283,YMYZSITWBGWUAF-MRXNPFEDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,63.1,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.199970640755867,CC1=C(C=CC(=C1Cl)OC2CCN(CC2)C[C@@H](CNC(=O)C3=CNC(=O)C4=C3C=C(C=C4)S(=O)(=O)C)O)Cl,Cc1c(Cl)ccc(OC2CCN(C[C@H](O)CNC(=O)c3c[nH]c(=O)c4ccc(S(C)(=O)=O)cc34)CC2)c1Cl
4329,CHEMBL1504,YNDXUCZADRHECN-JNQJZLCISA-N,TRIAMCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
4330,CHEMBL1504,YNDXUCZADRHECN-JNQJZLCISA-N,TRIAMCINOLONE ACETONIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@]12C[C@@H]([C@]3([C@H]([C@@H]1C[C@@H]4[C@]2(OC(O4)(C)C)C(=O)CO)CCC5=CC(=O)C=C[C@@]53C)F)O,CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
4332,CHEMBL14053,YNJBWRMUSHSURL-UHFFFAOYSA-N,TRICHLOROACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(C(Cl)(Cl)Cl)O,O=C(O)C(Cl)(Cl)Cl
4333,CHEMBL14053,YNJBWRMUSHSURL-UHFFFAOYSA-N,TRICHLOROACETIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(C(Cl)(Cl)Cl)O,O=C(O)C(Cl)(Cl)Cl
4334,CHEMBL432144,YNNQILILZIBLOF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,3388.44,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.470000200122707,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)CCC,CCCCCC(=O)c1ccc(OCCCN2CCN(CCC)CC2)cc1
4335,CHEMBL1626,YNNUSGIPVFPVBX-NHCUHLMSSA-N,CLEMASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,0.421,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.375717904164329,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
4336,CHEMBL1626,YNNUSGIPVFPVBX-NHCUHLMSSA-N,CLEMASTINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.049,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,10.309803919971486,C[C@@](C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCC[C@H]3CCCN3C,CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1
4337,CHEMBL1633,YNQQEYBLVYAWNX-WLHGVMLRSA-N,KETOTIFEN FUMARATE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,1.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,9.0,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1.C(=C/C(=O)O)\C(=O)O,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
4338,CHEMBL257716,YNRYXTYLZKMJRP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=C(CC4)N6C=C(C=CC6=N5)Cl,Cc1ccc2c(-c3nnc(SCCCN4CCc5nc6ccc(Cl)cn6c5CC4)n3C)cccc2n1
4339,CHEMBL983,YOEWQQVKRJEPAE-UHFFFAOYSA-L,SUCCINYLCHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
4340,CHEMBL983,YOEWQQVKRJEPAE-UHFFFAOYSA-L,SUCCINYLCHOLINE CHLORIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-],C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C
4341,CHEMBL1513,YOSHYTLCDANDAN-UHFFFAOYSA-N,IRBESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
4342,CHEMBL1513,YOSHYTLCDANDAN-UHFFFAOYSA-N,IRBESARTAN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5,CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1
4343,CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1
4344,CHEMBL60889,YPELFRMCRYSPKZ-UHFFFAOYSA-N,MOSAPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1
4345,CHEMBL123292,YPHMISFOHDHNIV-FSZOTQKASA-N,CYCLOHEXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C,C[C@H]1C[C@H](C)C(=O)[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C1
4346,CHEMBL123292,YPHMISFOHDHNIV-FSZOTQKASA-N,CYCLOHEXIMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@H]1C[C@@H](C(=O)[C@@H](C1)[C@@H](CC2CC(=O)NC(=O)C2)O)C,C[C@H]1C[C@H](C)C(=O)[C@H]([C@H](O)CC2CC(=O)NC(=O)C2)C1
4349,CHEMBL1372,YPZRWBKMTBYPTK-BJDJZHNGSA-N,OXIGLUTATIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
4350,CHEMBL1372,YPZRWBKMTBYPTK-BJDJZHNGSA-N,OXIGLUTATIONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(CC(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)C(=O)NCC(=O)O)[C@@H](C(=O)O)N,N[C@@H](CCC(=O)N[C@@H](CSSC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O)C(=O)NCC(=O)O)C(=O)O
4351,CHEMBL742,YQEZLKZALYSWHR-UHFFFAOYSA-N,KETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CNC1(c2ccccc2Cl)CCCCC1=O
4352,CHEMBL742,YQEZLKZALYSWHR-UHFFFAOYSA-N,KETAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CNC1(CCCCC1=O)C2=CC=CC=C2Cl,CNC1(c2ccccc2Cl)CCCCC1=O
4353,CHEMBL172233,YRDKYTTYDOWYLC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12593665.0,Ki,=,7.24,NM,,,cell_based,,,,,CHO-K1,,,,,,,Compound was evaluated for binding affinity towards cloned human histamine H1 receptors stably expressed in CHO-K1 cells using [3H]mepyramine,Structure-activity relationships of dimethindene derivatives as new M2-selective muscarinic receptor antagonists.,J. Med. Chem.,PUBLICATION,,8.140261433802854,CC(C1=CC=CC=N1)C2=C(CC3=CC=CC=C32)CCN(C)CCF,CC(C1=C(CCN(C)CCF)Cc2ccccc21)c1ccccn1
4354,CHEMBL1219,YREYEVIYCVEVJK-UHFFFAOYSA-N,RABEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C
4355,CHEMBL1219,YREYEVIYCVEVJK-UHFFFAOYSA-N,RABEPRAZOLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC,COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[nH]2)c1C
4356,CHEMBL1783971,YRIQXMPDJZLBBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1290.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.889410289700751,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C#N,CN1CCc2c(c3cc(C#N)ccc3n2CCc2ccccn2)C1
4357,CHEMBL1783971,YRIQXMPDJZLBBB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C#N,CN1CCc2c(c3cc(C#N)ccc3n2CCc2ccccn2)C1
4358,CHEMBL404404,YROMCCIDISNCOF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=NC=C(C=C1)C2=NN=C(N2C)SCCCN3CCC4=C(CC3)C5=C(C=C4)OC(=N5)C(F)(F)F,Cc1ccc(-c2nnc(SCCCN3CCc4ccc5oc(C(F)(F)F)nc5c4CC3)n2C)cn1
4359,CHEMBL399203,YRQLRCRBEYSAIN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,17524641.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,"3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1=CC=C(C=C1)OC2=CC=CC=C2NC3=NS(=O)(=O)C4=CC(=CC(=C4N3)O)[N+](=O)[O-],O=[N+]([O-])c1cc(O)c2c(c1)S(=O)(=O)N=C(Nc1ccccc1Oc1ccccc1)N2
4360,CHEMBL1923529,YRYLHJCFIVNEIH-UHFFFAOYSA-N,BAS 04061445,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,2630.27,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,5.579999668433626,C1CCN(CC1)CCN2C=NN3C2=NC4=CC=CC=C43,c1ccc2c(c1)nc1n(CCN3CCCCC3)cnn21
4361,CHEMBL83731,YRZFLXOYFQEHFH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,=,199.53,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.699991797446188,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN,NCC1CC2c3ccccc3Cc3ccccc3N2O1
4362,CHEMBL1632413,YSEFYTJOKARSSH-VKAVYKQESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,10000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CN1CCN(CC1)/C(=N\O)/C2=CC3=C(N2)C=CC(=C3)Cl,CN1CCN(/C(=N\O)c2cc3cc(Cl)ccc3[nH]2)CC1
4363,CHEMBL1189234,YSEXVIPNIGQQMN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1
4364,CHEMBL1189234,YSEXVIPNIGQQMN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1C2C3C4C1C5C2C6C3C4C5(N6CC7=CC=CC=C7)O,OC12C3C4CC5C6C4C1C6C(C53)N2Cc1ccccc1
4365,CHEMBL1935440,YSFFIZSLOXOSOV-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,24.6,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.609064892896622,C1CC(CN(C1)CC2=NC=CO2)C3=NC4=CC=CC=C4N3CCOC5=CC=CC=C5,c1ccc(OCCn2c(C3CCCN(Cc4ncco4)C3)nc3ccccc32)cc1
4366,CHEMBL1277770,YSGLQQUCJIOYSX-TUXUZCGSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,50.12,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,7.299988937677887,C1C[C@@]2(CC1N3CCC(CC3)C(=O)O)CC4=CC=CC=C4CC5=CC=CC=C25,O=C(O)C1CCN(C2CC[C@]3(Cc4ccccc4Cc4ccccc43)C2)CC1
4367,CHEMBL1566956,YSIITVVESCNIPR-UHFFFAOYSA-N,TROXIPIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCCNC2,COc1cc(C(=O)NC2CCCNC2)cc(OC)c1OC
4368,CHEMBL1566956,YSIITVVESCNIPR-UHFFFAOYSA-N,TROXIPIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC(=CC(=C1OC)OC)C(=O)NC2CCCNC2,COc1cc(C(=O)NC2CCCNC2)cc(OC)c1OC
4369,CHEMBL3357045,YSJZQHPNURRVLN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25318072.0,Ki,=,441.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in Sf9 cells by scintillation counting method,Loratadine and Analogues: Discovery and Preliminary Structure-Activity Relationship of Inhibitors of the Amino Acid Transporter B(0)AT2.,J. Med. Chem.,PUBLICATION,,6.355561410532162,C1CCC(CC1)CC(=O)N2CCC(=C3C4=C(CCC5=C3N=CC=C5)C=C(C=C4)Cl)CC2,O=C(CC1CCCCC1)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1
4370,CHEMBL2207666,YSQQOGOBORIIMG-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23116889.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human recombinant H1 histamine receptor expressed in CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part II: Optimising in vivo clearance.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2ccccc12
4372,CHEMBL2207666,YSQQOGOBORIIMG-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.98,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.400116927926312,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](CNC(=O)C3=CNC(=O)C4=CC=CC=C43)O,O=C(NC[C@@H](O)CN1CCC(Oc2ccc(Cl)c(Cl)c2)CC1)c1c[nH]c(=O)c2ccccc12
4375,CHEMBL14812,YTCGNPGLMAECND-UHFFFAOYSA-N,GT-2016,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15033391.0,Ki,=,2560.0,NM,,,,,,,,,,,,,,,,,,,,5.591760034688151,C1CCC(CC1)CCCCC(=O)N2CCC(CC2)C3=CN=CN3,O=C(CCCCC1CCCCC1)N1CCC(c2cnc[nH]2)CC1
4376,CHEMBL60598,YTEDUXKJYQFEKR-AREMUKBSSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,3311.31,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.480000159330324,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@@H](C(C)C)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@H](NC(=O)OC(C)(C)C)C(C)C)CC2)cc1
4377,CHEMBL312958,YTEDUXKJYQFEKR-SANMLTNESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,21379.62,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.6700000181810175,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)[C@H](C(C)C)NC(=O)OC(C)(C)C,CCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)C)CC2)cc1
4378,CHEMBL1078896,YTIWDXUZCLTCIF-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19786348.0,Ki,=,923.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0347982989740885,CCOC1=C(C=CC(=C1)CN2CCC(CC2)NC3=NC4=C(O3)C=CC(=C4)NC(=O)C5CCC5)OC,CCOc1cc(CN2CCC(Nc3nc4cc(NC(=O)C5CCC5)ccc4o3)CC2)ccc1OC
4380,CHEMBL38737,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,THIOACETAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=S)N,CC(N)=S
4381,CHEMBL38737,YUKQRDCYNOVPGJ-UHFFFAOYSA-N,THIOACETAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=S)N,CC(N)=S
4382,CHEMBL537219,YUWFKFBORNVPBT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,=,2511.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.599999383023619,C1CC(C1)N2CCC(CC2)OC3=CC=C(C=C3)N4CCN(CC4=O)C(=O)C5=CC=C(C=C5)F.Cl,O=C(c1ccc(F)cc1)N1CCN(c2ccc(OC3CCN(C4CCC4)CC3)cc2)C(=O)C1
4383,CHEMBL3217984,YVENIGOVHPMTDH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,3.16,NM,,,,,,,,,,,,,,,Binding affinity to H1 histamine receptor (unknown origin) by PDSP assay,,MedChemComm,PUBLICATION,,8.500312917381597,CN1CCC2C(C1)C3=C4N2C5=CC=CC=C5CSC4=CC=C3,CN1CCC2C(C1)c1cccc3c1N2c1ccccc1CS3
4384,CHEMBL1767150,YVEQOJSJKIAGFC-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1584.89,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,5.800000874803202,CN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC(=C(C=C4)OC)OC,COc1ccc(Cc2nn(C[C@H]3CCCN3C)c(=O)c3ccccc23)cc1OC
4385,CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,1.7,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3,CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1
4386,CHEMBL1092662,YVEWHDHDFNFTCD-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20800486.0,Ki,=,1.7,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Identification of a novel selective H1-antihistamine with optimized pharmacokinetic properties for clinical evaluation in the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.769551078621726,CN(C)CCC1=C(C2=C(C1)C=C(C=C2)F)CC3=NN=CC=C3,CN(C)CCC1=C(Cc2cccnn2)c2ccc(F)cc2C1
4387,CHEMBL1243366,YVGCLDBDDBQLIK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,5.0,CC(C)(C)C1=CC=C(C=C1)SCC(C2=CN=CC=C2)C3=CN=CN3,CC(C)(C)c1ccc(SCC(c2cccnc2)c2cnc[nH]2)cc1
4390,CHEMBL1201220,YVPYQUNUQOZFHG-UHFFFAOYSA-N,DIATRIZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
4391,CHEMBL1201220,YVPYQUNUQOZFHG-UHFFFAOYSA-N,DIATRIZOIC ACID,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I,CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)O)c1I
4392,CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11132243.0,Ki,=,25.0,NM,,,,,,,,,,,,,,,,,,,,7.602059991327962,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4393,CHEMBL1423,YVUQSNJEYSNKRX-UHFFFAOYSA-N,PIMOZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,692.0,NM,,,,,,,,,,,,,,,,,,,,6.1598939055432425,C1CN(CCC1N2C3=CC=CC=C3NC2=O)CCCC(C4=CC=C(C=C4)F)C5=CC=C(C=C5)F,O=c1[nH]c2ccccc2n1C1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1
4395,CHEMBL476109,YWOYXYWGFUHWBM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18595716.0,Ki,=,1014.0,NM,,,,,,,,,,,,,,,Binding affinity to human cloned histamine H1 receptor,"Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one.",Bioorg. Med. Chem.,PUBLICATION,,5.993962045002682,C1CC2CN(CCC1N2CCCC(=O)C3=CC=C(C=C3)F)C4=CC=C(C=C4)Cl,O=C(CCCN1C2CCC1CN(c1ccc(Cl)cc1)CC2)c1ccc(F)cc1
4397,CHEMBL1243367,YXEZVHWJNRFKSI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20690643.0,Ki,=,540.0,NM,,,,,,,,,,,,,,,Binding affinity to human histamine H1 receptor,Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain.,J. Med. Chem.,PUBLICATION,,6.267606240177032,C1=CC(=CC=C1C(F)(F)F)SCC(C2=CC=NC=C2)C3=CN=CN3,FC(F)(F)c1ccc(SCC(c2ccncc2)c2cnc[nH]2)cc1
4398,CHEMBL570296,YYCDRZDDLBLWPS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19632840.0,IC50,>,5000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.301029995663981,CCCNCC1=CC=C(C=C1)CCN2C=CC(=CC2=O)OCC3=CC=C(C=C3)F,CCCNCc1ccc(CCn2ccc(OCc3ccc(F)cc3)cc2=O)cc1
4399,CHEMBL62948,YYEJTQDGUKFSBP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,1412.54,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.849999245077862,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
4401,CHEMBL1093623,YYRVJJWBIQUZNR-CYBMUJFWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,2.5,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.602059991327963,C[C@H](C1=C(CC2=C1C=CC(=C2)OC)CCN(C)C)C3=NC=CS3,COc1ccc2c(c1)CC(CCN(C)C)=C2[C@@H](C)c1nccs1
4403,CHEMBL2146802,YZAHEHXQIMZHAJ-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22985961.0,Ki,=,0.912,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human H1 receptor expressed in CHO cells assessed as inhibition of calcium mobilization by FLIPR assay,Synthesis and pharmacological investigation of azaphthalazinone human histamine H(1) receptor antagonists.,Bioorg. Med. Chem.,PUBLICATION,,9.040005161671584,CCCCN1CCC[C@@H]1CN2C(=O)C3=CC=CC=C3C(=N2)CC4=CC=C(C=C4)Cl,CCCCN1CCC[C@@H]1Cn1nc(Cc2ccc(Cl)cc2)c2ccccc2c1=O
4404,CHEMBL7002,YZFWTZACSRHJQD-UHFFFAOYSA-N,CIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1
4405,CHEMBL7002,YZFWTZACSRHJQD-UHFFFAOYSA-N,CIGLITAZONE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1(CCCCC1)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3,CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1
4406,CHEMBL92337,YZIDTWIJPIHTCE-BPAKYRGESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,3.7,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.431798275933005,C1CN(CCN1CCO)CC2C[C@H]3[C@H](O2)C4=CC=CC=C4CC5=CC=CC=C35,OCCN1CCN(CC2C[C@@H]3c4ccccc4Cc4ccccc4[C@H]3O2)CC1
4407,CHEMBL255620,YZVLQPHHXCJUBM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3162.28,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.4999996786570655,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OC(=N6)N(C)C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6nc(N(C)C)oc6cc5CC4)n3C)cccc2n1
4408,CHEMBL1767153,ZAIFESHMEUUZQE-OAHLLOKOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21381763.0,Ki,=,1.58,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in intact CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization by FLIPR assay,The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis.,J. Med. Chem.,PUBLICATION,,8.801342913045579,CCCCCC1=NN(C(=O)C2=CC=CC=C21)C[C@H]3CCCN3C,CCCCCc1nn(C[C@H]2CCCN2C)c(=O)c2ccccc12
4409,CHEMBL1727,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,CEPHALEXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
4410,CHEMBL1727,ZAIPMKNFIOOWCQ-UEKVPHQBSA-N,CEPHALEXIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
4412,CHEMBL471,ZBMZVLHSJCTVON-UHFFFAOYSA-N,SOTALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
4413,CHEMBL471,ZBMZVLHSJCTVON-UHFFFAOYSA-N,SOTALOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O,CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1
4414,CHEMBL1077,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,BROMFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
4415,CHEMBL1077,ZBPLOVFIXSTCRZ-UHFFFAOYSA-N,BROMFENAC,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC(=C(C(=C1)C(=O)C2=CC=C(C=C2)Br)N)CC(=O)O,Nc1c(CC(=O)O)cccc1C(=O)c1ccc(Br)cc1
4416,CHEMBL74688,ZBUWQTCXTJMDCD-JIMJEQGWSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,180.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.7447274948966935,C1C[C@@H](O[C@H]1CN2CCN(CC2)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl)C#CCCN(C(=O)N)O,NC(=O)N(O)CCC#C[C@H]1CC[C@H](CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)O1
4417,CHEMBL305662,ZBUWQTCXTJMDCD-UODIDJSMSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,50.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.301029995663981,C1C[C@H](O[C@@H]1CN2CCN(CC2)[C@H](C3=CC=CC=C3)C4=CC=C(C=C4)Cl)C#CCCN(C(=O)N)O,NC(=O)N(O)CCC#C[C@@H]1CC[C@@H](CN2CCN([C@H](c3ccccc3)c3ccc(Cl)cc3)CC2)O1
4418,CHEMBL1087367,ZCRCTVHOBQJBNB-QGZVFWFLSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20347297.0,Ki,=,8.4,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,"The discovery and structure-activity relationships of 2-(piperidin-3-yl)-1H-benzimidazoles as selective, CNS penetrating H1-antihistamines for insomnia.",Bioorg. Med. Chem. Lett.,PUBLICATION,,8.075720713938116,CN(C)[C@@H]1CCN(C1)C2=NC3=CC=CC=C3N2CC4=CC=C(C=C4)OC,COc1ccc(Cn2c(N3CC[C@@H](N(C)C)C3)nc3ccccc32)cc1
4420,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,2300.0,NM,,,,binding,,,,,,,,,,,,,,,,5.638272163982407,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
4421,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20942472.0,Ki,=,0.158,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity against human histamine H1 receptor expressed in CHO cells by FLIPR assay,Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.,J. Med. Chem.,PUBLICATION,,9.801342913045575,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
4422,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21470866.0,IC50,=,1.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO-K1 cells after 60 mins by scintillation counting,Synthesis and structure-activity relationship of tricyclic carboxylic acids as novel anti-histamines.,Bioorg. Med. Chem.,PUBLICATION,,9.0,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
4423,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,1.19,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.924453038607469,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
4424,CHEMBL534,ZCVMWBYGMWKGHF-UHFFFAOYSA-N,KETOTIFEN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.138,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.860120913598763,CN1CCC(=C2C3=C(C(=O)CC4=CC=CC=C42)SC=C3)CC1,CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1
4425,CHEMBL811,ZDIGNSYAACHWNL-UHFFFAOYSA-N,BROMPHENIRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,7855217.0,Ki,=,6.06,NM,,,,,,,,,,,,,,,,,,,,8.217527375833713,CN(C)CCC(C1=CC=C(C=C1)Br)C2=CC=CC=N2,CN(C)CCC(c1ccc(Br)cc1)c1ccccn1
4426,CHEMBL105483,ZDLIRTGAWPEEKB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12372505.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity of human cortical histamine H1 receptor,Aminoalkoxybiphenylnitriles as histamine-3 receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4500041484693496,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C3=CC=C(C=C3)OC,CCOC(=O)N1CCN(CCCOc2ccc(-c3ccc(OC)cc3)cc2)CC1
4427,CHEMBL561,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,LOMEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
4428,CHEMBL561,ZEKZLJVOYLTDKK-UHFFFAOYSA-N,LOMEFLOXACIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O,CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c21
4429,CHEMBL1915534,ZELKFGCESYLZNT-NSHDSACASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21955944.0,Ki,>,40000.0,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3979400086720375,CC(C)(C)CCNC1=CC(=NC=N1)N[C@H]2CCNC2,CC(C)(C)CCNc1cc(N[C@H]2CCNC2)ncn1
4430,CHEMBL256652,ZENBFJWQHFZSBC-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,251.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.599997654072044,CC1=NC2=CC=CC(=C2C=C1)C3=NN=C(N3C)SCCCN4CCC5=CC6=C(C=C5CC4)OCC(=O)N6C,Cc1ccc2c(-c3nnc(SCCCN4CCc5cc6c(cc5CC4)N(C)C(=O)CO6)n3C)cccc2n1
4431,CHEMBL1175,ZEUITGRIYCTCEM-KRWDZBQOSA-N,DULOXETINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11750180.0,Ki,=,2300.0,NM,,,,,,,,,,,,,,,,,,,,5.638272163982407,CNCC[C@@H](C1=CC=CS1)OC2=CC=CC3=CC=CC=C32,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
4432,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,62.5,NM,,,,,,,,,,,,,,,,,,,,7.204119982655924,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
4433,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,62.0,NM,,,,,,,,,,,,,,,,,,,,7.207608310501746,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
4434,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,63.0,NM,,,,,,,,,,,,,,,,,,,,7.200659450546419,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
4435,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
4436,CHEMBL422,ZEWQUBUPAILYHI-UHFFFAOYSA-N,TRIFLUOPERAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F,CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
4438,CHEMBL802,ZFMITUMMTDLWHR-UHFFFAOYSA-N,MINOXIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,N=c1nc(N2CCCCC2)cc(N)n1O
4439,CHEMBL802,ZFMITUMMTDLWHR-UHFFFAOYSA-N,MINOXIDIL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O,N=c1nc(N2CCCCC2)cc(N)n1O
4440,CHEMBL316705,ZFPPUHTZTYNOKP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,994.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.002613615602686,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCCOC6=CC=CC=C6C(=O)OC)C7=CC=CC=C7,COC(=O)c1ccccc1OCCCn1c(C(=O)C2CCN(CCC3(c4ccccc4)CCN(C(=O)c4cc(OC)c(OC)c(OC)c4)C3)CC2)nc2ccccc21
4441,CHEMBL1935439,ZFUMGFQOKSXSLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,4.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.309803919971486,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4,CN(C)C(=O)CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1
4442,CHEMBL1935439,ZFUMGFQOKSXSLS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153347.0,Ki,=,11.9,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,Lead optimization of 2-(piperidin-3-yl)-1H-benzimidazoles: identification of 2-morpholin- and 2-thiomorpholin-2-yl-1H-benzimidazoles as selective and CNS penetrating H1-antihistamines for insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.924453038607469,CN(C)C(=O)CN1CCCC(C1)C2=NC3=CC=CC=C3N2CCOC4=CC=CC=C4,CN(C)C(=O)CN1CCCC(c2nc3ccccc3n2CCOc2ccccc2)C1
4443,CHEMBL482496,ZFUOLNAKPBFDIJ-VQBNBCTGSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18468904.0,Ki,=,189.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand.",Bioorg. Med. Chem.,PUBLICATION,,6.723538195826756,[3H]C([3H])([3H])OC1=CC=CC=C1CNCCC2=CC(=C(C=C2OC([3H])([3H])[3H])I)OC,[H]C([H])([H])Oc1cc(I)c(OC)cc1CCNCc1ccccc1OC([H])([H])[H]
4444,CHEMBL2171043,ZFVQRQOPWCBDOI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,7.94,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.100179497572904,C1CN(CCC1N2CCC(CC2)OC3=CC(=C(C=C3)Cl)Cl)C(=O)NS(=O)(=O)C4=CC(=CC=C4)Cl,O=C(NS(=O)(=O)c1cccc(Cl)c1)N1CCC(N2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
4446,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Cn1c(=O)c2[nH]cnc2n(C)c1=O
4447,CHEMBL190,ZFXYFBGIUFBOJW-UHFFFAOYSA-N,THEOPHYLLINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1C2=C(C(=O)N(C1=O)C)NC=N2,Cn1c(=O)c2[nH]cnc2n(C)c1=O
4450,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
4451,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
4452,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22793499.0,IC50,=,2454.71,NM,,,cell_based,,,,,HeLa,,,,,,,Antagonist activity at H1 receptor in human HeLa cells assessed as inhibition of histamine-induced Ca2+ release by using fura-2AM-based fluorescence assay,Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.,J. Med. Chem.,PUBLICATION,,5.6099998081597775,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
4453,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,3.44,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.46344155742847,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
4454,CHEMBL564,ZGUGWUXLJSTTMA-UHFFFAOYSA-N,PROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,0.399,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,9.399027104313252,CN(C)CCCN1C2=CC=CC=C2SC3=CC=CC=C31,CN(C)CCCN1c2ccccc2Sc2ccccc21
4455,CHEMBL1824777,ZHHLHBNBIKLLJG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)(N3CC4=CC=CC=C4)O.Cl,OC12CC3CC(CC(C3)N1Cc1ccccc1)C2
4457,CHEMBL260823,ZHYJMAJSBAQRIU-IAGOWNOFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18387300.0,Ki,=,10.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor,Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.0,C1CO[C@H](CN1)[C@@H](C2=CC=CC=C2)OC3=C(C=C(C=C3)F)Cl,Fc1ccc(O[C@H](c2ccccc2)[C@H]2CNCCO2)c(Cl)c1
4461,CHEMBL1824785,ZILQWXOKQUVSTI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21788137.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Inhibition of H1 receptor by NIMH PDSP,N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (s) receptor ligands.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C1C2CC3CC1CC(C2)N3CC4=CC(=CC=C4)F.Cl,Fc1cccc(CN2C3CC4CC(C3)CC2C4)c1
4463,CHEMBL666,ZJAOAACCNHFJAH-UHFFFAOYSA-N,FOSCARNET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(O)P(=O)(O)O,O=C(O)P(=O)(O)O
4464,CHEMBL666,ZJAOAACCNHFJAH-UHFFFAOYSA-N,FOSCARNET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C(=O)(O)P(=O)(O)O,O=C(O)P(=O)(O)O
4465,CHEMBL442456,ZJBDUXLBLPXVOM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.299997602857746,CCC1=NC2=C(O1)C=CC3=C2CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C,CCc1nc2c3c(ccc2o1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
4466,CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
4467,CHEMBL1073,ZJJXGWJIGJFDTL-UHFFFAOYSA-N,GLIPIZIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,Cc1cnc(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)NC3CCCCC3)cc2)cn1
4468,CHEMBL3233412,ZJYUQATUAGWNGI-FPOVZHCZSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,24559051.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin),Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders.,J. Med. Chem.,PUBLICATION,,,CN1CCN2[C@H]3CCN(C[C@H]3C4=C2C1=CC=C4)CCCC5=NOC6=C5C=CC(=C6)F,CN1CCN2c3c(cccc31)[C@@H]1CN(CCCc3noc4cc(F)ccc34)CC[C@@H]12
4469,CHEMBL571073,ZJZNOPQUDXUEDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,3200.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.494850021680094,CC1=CC=C(C=C1)CCCCN2CCCCC2,Cc1ccc(CCCCN2CCCCC2)cc1
4470,CHEMBL1783960,ZKAVOICTUKPVNY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,500.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.301029995663981,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=CC=C4,Cc1ccc2c(c1)c1c(n2CCc2cccnc2)CCN(C)C1
4471,CHEMBL1783960,ZKAVOICTUKPVNY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,3160.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.5003129173815966,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C)CCC4=CN=CC=C4,Cc1ccc2c(c1)c1c(n2CCc2cccnc2)CCN(C)C1
4474,CHEMBL1632414,ZKDRIYJOVIMHFC-AQTBWJFISA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21044842.0,Ki,>,1000.0,NM,,,cell_based,,,,,SK-N-MC,,,,,,,Binding affinity to human recombinant histamine H1 receptor expressed in human SK-N-MC cells by radioligand displacement assay,Histamine H4 receptor agonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,CN1CCC(CC1)/C(=N/O)/C2=NC3=C(N2)C=C(C=C3)Cl,CN1CCC(/C(=N/O)c2nc3ccc(Cl)cc3[nH]2)CC1
4475,CHEMBL2441619,ZKHOZLXKYFBVMY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,399.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin),,ACS Med. Chem. Lett.,PUBLICATION,,6.399027104313253,CC1=CC2=C(C=C1)N=C(C=C2N3CCNCC3)C(F)(F)F,Cc1ccc2nc(C(F)(F)F)cc(N3CCNCC3)c2c1
4476,CHEMBL28902,ZKHUZIGQNHJVGZ-WEVVVXLNSA-N,CP-96486,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibitory concentration against H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=NC2=C(N1C3=CC=C(C=C3)OCC4=CC(=CC=C4)/C=C/C5=NC6=C(C=CC(=C6)Cl)C=C5)C=CN=C2,Cc1nc2cnccc2n1-c1ccc(OCc2cccc(/C=C/c3ccc4ccc(Cl)cc4n3)c2)cc1
4477,CHEMBL329450,ZKIRNRZUIHQPCN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,446.0,NM,,,,,,,,,,,,,,,Antagonism of the human histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.350665141287857,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CCOC6=CC=CO6)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4CCOc4ccco4)CC3)(c3ccccc3)C2)cc(OC)c1OC
4478,CHEMBL1334217,ZKLPARSLTMPFCP-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,3.16,NM,,,,,,,,,,,,,,,,,,,,8.500312917381597,C1CN(CCN1CCOCC(=O)O)[C@@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1
4479,CHEMBL1334217,ZKLPARSLTMPFCP-NRFANRHFSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,,,,,,7.100015437450608,C1CN(CCN1CCOCC(=O)O)[C@@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN([C@@H](c2ccccc2)c2ccc(Cl)cc2)CC1
4480,CHEMBL1201191,ZKLPARSLTMPFCP-OAQYLSRUSA-N,LEVOCETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,8903934.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,,,,,,7.0,C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1
4481,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,3.16,NM,,,,,,,,,,,,,,,,,,,,8.500312917381597,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4482,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15081022.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,In vitro binding affinity towards histamine H1 receptor expressed in CHO-K1 cells,5-lipoxygenase inhibitors with histamine H(1) receptor antagonist activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321763,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4483,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,14.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.853871964321763,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4484,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,5.89,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human Histamine H1 receptor in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.229884705212896,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4485,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16220969.0,Ki,=,14.0,NM,,,,,,,,,,,,,,,Inhibition constant against histamine H1 receptor,Designed multiple ligands. An emerging drug discovery paradigm.,J. Med. Chem.,PUBLICATION,,7.853871964321763,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4486,CHEMBL1000,ZKLPARSLTMPFCP-UHFFFAOYSA-N,CETIRIZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,16408006.0,Ki,=,50.12,NM,,,cell_based,,,,,COS-7,,,,,,,Displacement of [3H]mepyramine from human wild-type histamine H1 receptor expressed in COS-7 cells by liquid scintillation counting,Linking agonist binding to histamine H1 receptor activation.,Nat. Chem. Biol.,PUBLICATION,,7.299988937677887,C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4487,CHEMBL2205811,ZKOQRCXMSDAJIR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,=,8858.0,NM,,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.05266432405126,COC1=CC=CC(=C1)CCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1cccc(CCN2C3C4C5CC6C7C5C3C7C2(O)C64)c1
4488,CHEMBL256442,ZLAONGKKHFSBFL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18178090.0,Ki,=,398.11,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part 2: [g]-fused and hetero-fused systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.399996913372259,CCC1=NC2=C(S1)C3=C(CCN(CC3)CCCSC4=NN=C(N4C)C5=C6C=CC(=NC6=CC=C5)C)C=C2,CCc1nc2ccc3c(c2s1)CCN(CCCSc1nnc(-c2cccc4nc(C)ccc24)n1C)CC3
4490,CHEMBL2171036,ZLPRNWIDJZJYMH-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23031591.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human H1 receptor expressed in CHOK1 cells,The discovery of CCR3/H1 dual antagonists with reduced hERG risk.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,COC1=CC=C(C=C1)S(=O)(=O)NC(=O)N2CCC(CC2)N3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,COc1ccc(S(=O)(=O)NC(=O)N2CCC(N3CCC(Oc4ccc(Cl)c(Cl)c4)CC3)CC2)cc1
4492,CHEMBL599913,ZLTIDZRETNUAHX-KAMYIIQDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,33.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as histamine-induced maximum intracellular calcium spike at phase 1 treated 10 to 15 seconds before histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.481486060122112,CN1CCC2=C(C1)C3=CC=CC=C3N2/C=C\C4=CC=CC=C4,CN1CCc2c(c3ccccc3n2/C=C\c2ccccc2)C1
4493,CHEMBL599913,ZLTIDZRETNUAHX-KAMYIIQDSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19945877.0,IC50,=,181.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at histamine H1 receptor in human SK-N-SH cells assessed as reduction of histamine-induced intracellular calcium spike at phase 2 treated 20 to 30 seconds after histamine challenge,"Synthesis and biological activity of 5-styryl and 5-phenethyl-substituted 2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indoles.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.742321425130816,CN1CCC2=C(C1)C3=CC=CC=C3N2/C=C\C4=CC=CC=C4,CN1CCc2c(c3ccccc3n2/C=C\c2ccccc2)C1
4494,CHEMBL343324,ZLTWNSXILLAQPT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22007643.0,Ki,=,794.33,NM,,,cell_based,,,,,HEK293,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in HEK293 cells after 1 to 1.5 hrs by scintillation counting,Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.,J. Med. Chem.,PUBLICATION,,6.0999990348465305,CNCCCOC1=CC=CC2=CC=CC=C21,CNCCCOc1cccc2ccccc12
4495,CHEMBL411691,ZLXCEBAWAKEHFS-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,4.47,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.349692476868062,COC1=CC(=CC(=C1OC)OC)C(=O)N2CCC(C2)(CCN3CCC(CC3)C(=O)C4=NC5=CC=CC=C5N4CC6=CC=C(C=C6)C(=O)O)C7=CC=CC=C7,COc1cc(C(=O)N2CCC(CCN3CCC(C(=O)c4nc5ccccc5n4Cc4ccc(C(=O)O)cc4)CC3)(c3ccccc3)C2)cc(OC)c1OC
4496,CHEMBL127508,ZMISODWVFHHWNR-UHFFFAOYSA-N,AZACYCLONOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19660947.0,Ki,=,659.0,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHO cell by Betaplate scintillation counting,"Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.1811145854059895,C1CNCCC1C(C2=CC=CC=C2)(C3=CC=CC=C3)O,OC(c1ccccc1)(c1ccccc1)C1CCNCC1
4499,CHEMBL1627,ZMOPTLXEYOVARP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18783208.0,Ki,=,4.2,NM,,,,,,,,,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor,Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function.,J. Med. Chem.,PUBLICATION,,8.3767507096021,CNC(=O)C(CCN1CCC(CC1)(C2=CC=C(C=C2)Cl)O)(C3=CC=CC=C3)C4=CC=CC=C4,CNC(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
4500,CHEMBL242273,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,SAFROLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCC1=CC2=C(C=C1)OCO2,C=CCc1ccc2c(c1)OCO2
4501,CHEMBL242273,ZMQAAUBTXCXRIC-UHFFFAOYSA-N,SAFROLE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C=CCC1=CC2=C(C=C1)OCO2,C=CCc1ccc2c(c1)OCO2
4502,CHEMBL98076,ZMTLNBBVFMZHTB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,7.33,NM,,,,,,,,,,,,,,,Antagonistic activity against histamine H1 receptor,,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.134896025358872,COC1=CC=C(C=C1)CCN2CCC(=NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F)CC2,COc1ccc(CCN2CCC(=Nc3nc4ccccc4n3Cc3ccc(F)cc3)CC2)cc1
4503,CHEMBL268291,ZMXDDKWLCZADIW-UHFFFAOYSA-N,DIMETHYLFORMAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C=O,CN(C)C=O
4504,CHEMBL268291,ZMXDDKWLCZADIW-UHFFFAOYSA-N,DIMETHYLFORMAMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C=O,CN(C)C=O
4505,CHEMBL1669417,ZMXXHEQIAQJFTR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,10.5,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.978810700930063,C1CN(CC1F)CCC2=C(C3=CC=CC=C3C2)CC4=NC=CN=C4,FC1CCN(CCC2=C(Cc3cnccn3)c3ccccc3C2)C1
4508,CHEMBL472,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,GLYBURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
4509,CHEMBL472,ZNNLBTZKUZBEKO-UHFFFAOYSA-N,GLYBURIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3,COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1
4510,CHEMBL2158786,ZNOFXQRZLXBDTB-MHZLTWQESA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23021991.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C[C@](CC1=CC=CC=C1)(C(=O)O)N2CCC(CC2)CN3CCC(CC3)OC4=CC(=C(C=C4)Cl)Cl,C[C@](Cc1ccccc1)(C(=O)O)N1CCC(CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)CC1
4511,CHEMBL1783966,ZNPXEYURFNQPAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,390.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4089353929735005,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)OC,COc1ccc2c(c1)c1c(n2CCc2ccncc2)CCN(C)C1
4512,CHEMBL1783966,ZNPXEYURFNQPAK-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CN1CCC2=C(C1)C3=C(N2CCC4=CC=NC=C4)C=CC(=C3)OC,COc1ccc2c(c1)c1c(n2CCc2ccncc2)CCN(C)C1
4513,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
4514,CHEMBL56564,ZNRGQMMCGHDTEI-ITGUQSILSA-N,TROPISETRON,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C3=CNC4=CC=CC=C43,CN1[C@H]2CC[C@@H]1CC(OC(=O)c1c[nH]c3ccccc13)C2
4515,CHEMBL84810,ZNWOCPPAOLYORT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,47.86,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.320027305722581,CN(C)CC1CC2C3=C(CC4=CC=CC=C4N2O1)C=CC=C3C(F)(F)F,CN(C)CC1CC2c3c(cccc3C(F)(F)F)Cc3ccccc3N2O1
4516,CHEMBL63632,ZOABVQXODSFSPN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,13489.63,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.869999962200743,CCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)S(=O)(=O)C3=CC=C(C=C3)C#N,CCCCCC(=O)c1ccc(OCCCN2CCN(S(=O)(=O)c3ccc(C#N)cc3)CC2)cc1
4517,CHEMBL1783958,ZOAGXBRERPVMMX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,560.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.251811972993798,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C(F)(F)F,CN1CCc2c(c3cc(C(F)(F)F)ccc3n2CCc2ccccn2)C1
4518,CHEMBL1783958,ZOAGXBRERPVMMX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,=,1590.0,NM,,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.798602875679547,CN1CCC2=C(C1)C3=C(N2CCC4=CC=CC=N4)C=CC(=C3)C(F)(F)F,CN1CCc2c(c3cc(C(F)(F)F)ccc3n2CCc2ccccn2)C1
4519,CHEMBL1779060,ZOAKYUHDXICZSY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21555222.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor,"Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=C1)OC)C(=O)NCCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccc(C)cc1C(=O)NCCN1C2C3C4CC5C6C4C2C6C1(O)C53
4520,CHEMBL1779060,ZOAKYUHDXICZSY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22959245.0,Ki,,,,Not Determined,,,,,,,,,,,,,,Binding affinity to Histamine H1 receptor,"A s(1) receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDs).",Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC(=C(C=C1)OC)C(=O)NCCN2C3C4C5CC6C4C2(C7C6C5C73)O,COc1ccc(C)cc1C(=O)NCCN1C2C3C4CC5C6C4C2C6C1(O)C53
4522,CHEMBL240394,ZOCDSDXGMIDSSE-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18052318.0,Ki,<,1995.26,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced cellular calcium mobilization,4-acyl-1-(4-aminoalkoxyphenyl)-2-ketopiperazines as a novel class of non-brain-penetrant histamine H3 receptor antagonists.,J. Med. Chem.,PUBLICATION,,5.700000503883016,C1CCN(CC1)CCCOC2=CC=C(C=C2)N3CCN(CC3=O)C(=O)C4=CC(=CC(=C4)F)F.C(=O)O,O=C(c1cc(F)cc(F)c1)N1CCN(c2ccc(OCCCN3CCCCC3)cc2)C(=O)C1
4524,CHEMBL2208419,ZOYPHDPQFYRSLG-INIZCTEOSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23142617.0,Ki,=,3.16,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]-pyrilamine from human histamine H1 receptor expressed in recombinant CHOK1 cells after 1 hr,Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H(1) antagonists. Part I.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.500312917381597,C1CN(CCC1OC2=CC(=C(C=C2)Cl)Cl)C[C@@H](COC3=CC=CC(=C3)C#N)O,N#Cc1cccc(OC[C@@H](O)CN2CCC(Oc3ccc(Cl)c(Cl)c3)CC2)c1
4525,CHEMBL593103,ZPAHWVAWJGJPSL-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19773175.0,Ki,>,1000.0,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in Sf9 cells co-expressing RGS4,"2,4-Diaminopyrimidines as histamine H4 receptor ligands--Scaffold optimization and pharmacological characterization.",Bioorg. Med. Chem.,PUBLICATION,,6.0,CN1CCN(CC1)C2=NC(=NC(=C2)NCC3=CC=C(C=C3)F)N,CN1CCN(c2cc(NCc3ccc(F)cc3)nc(N)n2)CC1
4526,CHEMBL563520,ZPASDZSMHRZWEN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19362477.0,IC50,=,46.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Displacement of [3H]pyrilamine from human recombinant histamine H1 receptor expressed in CHOK1 cells by scintillation counting,Synthesis and structure-activity relationships of phenothiazine carboxylic acids having pyrimidine-dione as novel histamine H(1) antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.337242168318426,CN1C(=CC(=O)N(C1=O)C)NCCCN2CCC(CC2)CN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(=O)O,Cn1c(NCCCN2CCC(CN3c4ccccc4Sc4ccc(C(=O)O)cc43)CC2)cc(=O)n(C)c1=O
4527,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,9.09,NM,,,,,,,,,,,,,,,,,,,,8.041436116778033,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4528,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,3.0,NM,,,,,,,,,,,,,,,,,,,,8.522878745280337,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4529,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,9.0,NM,,,,,,,,,,,,,,,,,,,,8.045757490560675,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4530,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12629531.0,Ki,=,6.0,NM,,,,,,,,,,,,,,,,,,,,8.221848749616356,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4531,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19091563.0,Ki,=,4.25,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO cells,Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.371611069949688,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4532,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23919353.0,IC50,=,12.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by radioligand binding assay,Polypharmacology - foe or friend?,J. Med. Chem.,PUBLICATION,,7.920818753952375,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4533,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,17.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.769551078621726,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4534,CHEMBL71,ZPEIMTDSQAKGNT-UHFFFAOYSA-N,CHLORPROMAZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1.96,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,8.707743928643524,CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21
4535,CHEMBL117287,ZPMNHBXQOOVQJL-UHFFFAOYSA-N,PRUCALOPRIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11438309.0,Ki,=,10000.0,NM,,,,,,,,,,,,,,,,,,,,5.0,COCCCN1CCC(CC1)NC(=O)C2=CC(=C(C3=C2OCC3)N)Cl,COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1
4536,CHEMBL2179217,ZPUAIXYROPYWKA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23006002.0,Ki,=,681.8,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,"Design, Synthesis, and Pharmacological Evaluation of Piperidin-4-yl amino aryl sulfonamides: Novel, Potent, Selective, Orally Active, and Brain Penetrant 5-HT(6) Receptor Antagonists.",J. Med. Chem.,PUBLICATION,,6.166343003107128,CC1=CN(C2=C1C=C(C=C2)Cl)S(=O)(=O)C3=CC(=C(C=C3)OC)NC4CCN(CC4)C,COc1ccc(S(=O)(=O)n2cc(C)c3cc(Cl)ccc32)cc1NC1CCN(C)CC1
4537,CHEMBL1092495,ZQADELCMZHYIPT-ZDUSSCGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20188547.0,Ki,=,13.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells after 90 mins by scintillation counting,Novel benzothiophene H1-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.886056647693162,C[C@@H](C1=NC=C(C=C1)F)C2=C(SC3=CC=CC=C32)CCN(C)C,C[C@@H](c1ccc(F)cn1)c1c(CCN(C)C)sc2ccccc12
4542,CHEMBL1651219,ZQBPXBADOJMCRU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23009245.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of radioligand binding to human histamine H1 receptor,Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence.,J. Med. Chem.,PUBLICATION,,5.0,C1CCC(C1)N2C(=O)C3=C(S2)C=C(C=C3)OCC4=CC(=CC=C4)C5=CC(=C(C=C5)Cl)C(=O)O,O=C(O)c1cc(-c2cccc(COc3ccc4c(=O)n(C5CCCC5)sc4c3)c2)ccc1Cl
4544,CHEMBL896,ZQDWXGKKHFNSQK-UHFFFAOYSA-N,HYDROXYZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,1.0,NM,,,,,,,,,,,,,,,,,,,,9.0,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4545,CHEMBL896,ZQDWXGKKHFNSQK-UHFFFAOYSA-N,HYDROXYZINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11809864.0,Ki,=,2.0,NM,,,,,,,,,,,,,,,,,,,,8.698970004336019,C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl,OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1
4546,CHEMBL305313,ZQJARSFDPKNFNT-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,354.81,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.4500041484693496,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C=C(C)C,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)C=C(C)C)cc2)CC1
4548,CHEMBL556449,ZQXPNWSXFWKXRZ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19553115.0,Ki,=,1.3,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation assay,Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.886056647693161,C1CN(CCC1N2C=CN=C2)C3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F,Fc1ccc(Cn2c(N3CCC(n4ccnc4)CC3)nc3ccccc32)cc1
4549,CHEMBL1255901,ZRJBHWIHUMBLCN-HZRLMBICSA-N,HUPERZINE A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C/1\[C@@H]2CC3=C([C@@]1(CC(=C2)C)N)C=CC(=O)N3,C/C=C1\[C@H]2C=C(C)C[C@@]1(N)c1ccc(=O)[nH]c1C2
4550,CHEMBL1255901,ZRJBHWIHUMBLCN-HZRLMBICSA-N,HUPERZINE A,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C/C=C/1\[C@@H]2CC3=C([C@@]1(CC(=C2)C)N)C=CC(=O)N3,C/C=C1\[C@H]2C=C(C)C[C@@]1(N)c1ccc(=O)[nH]c1C2
4551,CHEMBL291821,ZRMVWXJDKQRJLR-HXUWFJFHSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113836.0,Ki,=,46773.51,NM,,,,,,,,,,,,,,,Binding affinity towards Histamine H1 receptor of human membranes.,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 2: binding preference for D-amino acids motifs.,Bioorg. Med. Chem. Lett.,PUBLICATION,,4.3300000383353785,CCC[C@H](C(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C3CC3)N,CCC[C@@H](N)C(=O)N1CCN(CCCOc2ccc(C(=O)C3CC3)cc2)CC1
4552,CHEMBL599,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,MELOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
4553,CHEMBL599,ZRVUJXDFFKFLMG-UHFFFAOYSA-N,MELOXICAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O,Cc1cnc(NC(=O)C2=C(O)c3ccccc3S(=O)(=O)N2C)s1
4554,CHEMBL64799,ZRYOOEBGABRJDU-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,933.25,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.030002001401657,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)CC3=CC=CC=C3,CCOC(=O)N1CCN(CCCOc2ccc(C(=O)Cc3ccccc3)cc2)CC1
4555,CHEMBL644,ZSCDBOWYZJWBIY-UHFFFAOYSA-N,TRIMIPRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,1.4,NM,,,,,,,,,,,,,,,,,,,,8.853871964321762,CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C,CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
4557,CHEMBL1651906,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,STREPTOZOTOCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O)N=O,CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
4558,CHEMBL1651906,ZSJLQEPLLKMAKR-YDEIVXIUSA-N,STREPTOZOTOCIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](OC1O)CO)O)O)N=O,CN(N=O)C(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O
4560,CHEMBL1940402,ZTBBOIYRZHAFIN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,25070422.0,Ki,=,128.5,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human histamine H1 receptor by liquid scintillation counting,Further evaluation of the tropane analogs of haloperidol.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.891096872332687,C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCCC3=CC=C(C=C3)F,OC1(c2ccc(Cl)cc2)CCN(CCCCc2ccc(F)cc2)CC1
4563,CHEMBL269995,ZTSFFHIKWHSHGP-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,>,3981.07,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.40000018605658,CC1=NC2=C(O1)C=C3CCN(CCC3=C2)CCCSC4=NN=C(N4C)C5=CC(=C(C=C5)F)F,Cc1nc2cc3c(cc2o1)CCN(CCCSc1nnc(-c2ccc(F)c(F)c2)n1C)CC3
4564,CHEMBL314795,ZTXJDBYCWAXXCA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755365.0,IC50,=,11.75,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity at human cloned Histamine H1 receptor expressed in CHO cells by [3H]pyrilamine displacement.,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 2.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.929962133392243,CC1=C2C3CC(ON3C4=CC=CC=C4CC2=CC=C1)CN(C)C,Cc1cccc2c1C1CC(CN(C)C)ON1c1ccccc1C2
4566,CHEMBL1935571,ZULPGIJFVSVHRG-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,22153663.0,Ki,=,7373.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]histamine from human H1 receptor expressed in HEK cell membranes,Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.132355766096903,CN1CCN(CC1)C2=NC(=NC3=C2C=CC(=C3)C4=COC=C4)N,CN1CCN(c2nc(N)nc3cc(-c4ccoc4)ccc23)CC1
4567,CHEMBL444083,ZUSSMNOENOGGGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15482930.0,Ki,=,26.0,NM,,,cell_based,,,,,CHO-K1,,,,,,,Binding affinity towards human histamine H1 receptor expressed in CHO-K1 cells,Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.585026652029183,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,NC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
4568,CHEMBL444083,ZUSSMNOENOGGGY-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15686917.0,Ki,=,3.63,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for recombinant human Histamine H1 receptor expressed in CHO K1 cells,5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.440093374963888,C1CN(CCN1CCCCOC2=CC=C(C=C2)C#CCCN(C(=O)N)O)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F,NC(=O)N(O)CCC#Cc1ccc(OCCCCN2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)cc1
4569,CHEMBL1783973,ZVMAXLHJDKBSDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,>,10000.0,NM,,,cell_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium level increase during phase-1 compound incubated before histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=CC=N5,Cc1ccc2c(c1)c1c(n2CCc2ccccn2)CCN(C2CCN(C)CC2)C1
4570,CHEMBL1783973,ZVMAXLHJDKBSDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19443217.0,IC50,,,,Not Determined,,organism_based,,,,,SK-N-SH,,,,,,,Antagonist activity at human histamine H1 receptor in SK-N-SH cells assessed as inhibition of histamine-induced calcium flow during phase-II compound dosed after histamine addition by Fura-2 based fluorometric assay,Synthesis and biological evaluation of novel gamma-carboline analogues of Dimebon as potent 5-HT6 receptor antagonists.,Bioorg. Med. Chem. Lett.,PUBLICATION,,,CC1=CC2=C(C=C1)N(C3=C2CN(CC3)C4CCN(CC4)C)CCC5=CC=CC=N5,Cc1ccc2c(c1)c1c(n2CCc2ccccn2)CCN(C2CCN(C)CC2)C1
4572,CHEMBL1130,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,DOXIFLURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O,C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
4573,CHEMBL1130,ZWAOHEXOSAUJHY-ZIYNGMLESA-N,DOXIFLURIDINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=C(C(=O)NC2=O)F)O)O,C[C@H]1O[C@@H](n2cc(F)c(=O)[nH]c2=O)[C@H](O)[C@@H]1O
4575,CHEMBL157217,ZWBZUWWQDRQBAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,IC50,=,398.11,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,6.399996913372259,C1CCN(C1)CCCCCCCCCCC2=CN=CN2,c1ncc(CCCCCCCCCCN2CCCC2)[nH]1
4576,CHEMBL157217,ZWBZUWWQDRQBAX-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,14667234.0,Ki,=,251188643150958.0,NM,,,,,,,,,,,,,,,Inhibitory activity against human Histamine H1 receptor,Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.,J. Med. Chem.,PUBLICATION,,-5.4,C1CCN(C1)CCCCCCCCCCC2=CN=CN2,c1ncc(CCCCCCCCCCN2CCCC2)[nH]1
4577,CHEMBL2432045,ZWCQZHOWEDKJBN-CAUKCHDASA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,23981939.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of histamine H1 receptor (unknown origin) by PDSP assay,"N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as s receptor ligands with potential neuroprotective effects.",Bioorg. Med. Chem.,PUBLICATION,,5.0,C1C2C3CC4C2[C@@H](C5C1C3C45)NCC6=CC=CC=C6,c1ccc(CN[C@H]2C3C4CC5C6C4CC3C6C52)cc1
4578,CHEMBL257534,ZWHFNBRLUSRMFB-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18248991.0,Ki,=,1995.26,NM,,,,,,,,,,,,,,,Antagonist activity at histamine H1 receptor by FLIPR assay,New fused benzazepine as selective D3 receptor antagonists. Synthesis and biological evaluation. Part one: [h]-fused tricyclic systems.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.700000503883016,CC1=C(OC=N1)C2=NN=C(N2C)SCCCN3CCC4=CC5=C(C=C4CC3)OCC(=O)N5C,Cc1ncoc1-c1nnc(SCCCN2CCc3cc4c(cc3CC2)N(C)C(=O)CO4)n1C
4579,CHEMBL485543,ZWUFGBNOUKQGBR-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,18841880.0,IC50,>,10000.0,NM,,,,,,,,,,,,,,,Inhibition of human histamine H1 receptor,Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists.,J. Med. Chem.,PUBLICATION,,5.0,CC1=NC2=CC=CC(=C2C(=O)N1C3=CC=C(C=C3)OC4CCN(CC4)C5CCC5)C(F)(F)F,Cc1nc2cccc(C(F)(F)F)c2c(=O)n1-c1ccc(OC2CCN(C3CCC3)CC2)cc1
4581,CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19663387.0,Ki,=,4.0,NM,,,cell_based,,,,,CHO,,,,,,,Displacement of [3H]pyrilamine from human histamine H1 receptor expressed in CHO Flp-In cells by liquid scintillation counting,Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.,J. Med. Chem.,PUBLICATION,,8.397940008672037,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
4582,CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20227880.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Binding affinity at histamine H1 receptor,Selectivity profiling of novel indene H(1)-antihistamines for the treatment of insomnia.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
4583,CHEMBL559251,ZWZGWXZGAUJLHN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21232954.0,Ki,=,4.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor,Influence of pKa on the biotransformation of indene H1-antihistamines by CYP2D6.,Bioorg. Med. Chem. Lett.,PUBLICATION,,8.397940008672037,CN(C)CCC1=C(C2=CC=CC=C2C1)CC3=NC=CN=C3,CN(C)CCC1=C(Cc2cnccn2)c2ccccc2C1
4584,CHEMBL1222624,ZXFALDNPMLUADA-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,20674357.0,Ki,=,19.95,NM,,,cell_based,,,,,CHO,,,,,,,Antagonist activity at human recombinant histamine H1 receptor expressed in CHO cells by FLPR assay,Novel imidazobenzazepine derivatives as dual H1/5-HT2A antagonists for the treatment of sleep disorders.,Bioorg. Med. Chem. Lett.,PUBLICATION,,7.700057099977232,CC1CN(CC(N1CCC(=O)O)C)C2=CC3=CC=CC=C3CN4C2=NC=C4,CC1CN(C2=Cc3ccccc3Cn3ccnc32)CC(C)N1CCC(=O)O
4585,CHEMBL81435,ZXIPGUHBRFTYRJ-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,11755364.0,IC50,>,1000.0,NM,,,cell_based,,,,,CHO,,,,,,,Binding affinity for human cloned Histamine H1 receptor expressed in CHO cells using [3H]pyrilamine as radioligand,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-2,3,3a,8-tetrahydrodibenzo[c,f]isoxazolo[2,3-a]azepine derivatives: a novel series of 5-HT(2A/2C) receptor antagonists. Part 1.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.0,C1C(ON2C1C3=CC=CC=C3CC4=CC=CC=C42)CN5C(=O)C6=CC=CC=C6C5=O,O=C1c2ccccc2C(=O)N1CC1CC2c3ccccc3Cc3ccccc3N2O1
4586,CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
4587,CHEMBL64894,ZXJXZNDDNMQXFV-UHFFFAOYSA-M,GENTIAN VIOLET,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,CN(C)C1=CC=C(C=C1)C(=C2C=CC(=[N+](C)C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-],CN(C)c1ccc(C(=C2C=CC(=[N+](C)C)C=C2)c2ccc(N(C)C)cc2)cc1
4588,CHEMBL36994,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,ANIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,COc1ccc(C(=O)N2CCCC2=O)cc1
4589,CHEMBL36994,ZXNRTKGTQJPIJK-UHFFFAOYSA-N,ANIRACETAM,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=CC=C(C=C1)C(=O)N2CCCC2=O,COc1ccc(C(=O)N2CCCC2=O)cc1
4590,CHEMBL6466,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,COUMARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC(=O)O2,O=c1ccc2ccccc2o1
4591,CHEMBL6466,ZYGHJZDHTFUPRJ-UHFFFAOYSA-N,COUMARIN,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=CC=C2C(=C1)C=CC(=O)O2,O=c1ccc2ccccc2o1
4593,CHEMBL62840,ZYPSPPAGXNKFQM-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,2238.72,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,5.650000220873455,CCOC(=O)N1CCN(CC1)CCCOC2=CC=C(C=C2)C(=O)C,CCOC(=O)N1CCN(CCCOc2ccc(C(C)=O)cc2)CC1
4594,CHEMBL328209,ZYRROKHYEJZYKQ-RMNMTYGKSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,15125929.0,Ki,=,20.6,NM,,,cell_based,,,,,CHO,,,,,,,Ability to displace [3H]pyrilamine from human cloned histamine H1 receptor expressed in CHO cells,"Synthesis and structure-activity relationship of 2-(aminoalkyl)-3,3a,8,12b-tetrahydro-2H-dibenzocyclohepta[1,2-b]furan derivatives: a novel series of 5-HT(2A/2C) receptor antagonists.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.6861327796308485,CN(C)CC1C[C@H]2[C@H](O1)C3=CC=CC=C3OCC4=CC=CC=C24,CN(C)CC1C[C@@H]2c3ccccc3COc3ccccc3[C@H]2O1
4595,CHEMBL73307,ZZEQOXMRTJPRMI-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,19700330.0,Ki,=,189.0,NM,,,cell_based,,,,,,,,,,,,Displacement of [3H]chlorphniramine from human histamine H1 receptor expressed in cells,"Synthesis, structure-affinity relationships, and modeling of AMDA analogs at 5-HT2A and H1 receptors: structural factors contributing to selectivity.",Bioorg. Med. Chem.,PUBLICATION,,6.723538195826756,CNCC1C2=CC=CC=C2CC3=CC=CC=C13,CNCC1c2ccccc2Cc2ccccc21
4596,CHEMBL8514,ZZJYIKPMDIWRSN-HWBMXIPRSA-N,BUTACLAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,384.61,NM,,,,,,,,,,,,,,,,,,,,6.414979428136125,CC(C)(C)[C@@]1(CCN2C[C@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1
4597,CHEMBL8514,ZZJYIKPMDIWRSN-HWBMXIPRSA-N,BUTACLAMOL,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6149136.0,Ki,=,390.0,NM,,,,,,,,,,,,,,,,,,,,6.4089353929735005,CC(C)(C)[C@@]1(CCN2C[C@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@@H]2C1)O,CC(C)(C)[C@]1(O)CCN2C[C@H]3c4ccccc4CCc4cccc(c43)[C@@H]2C1
4598,CHEMBL62193,ZZORFUFYDOWNEF-UHFFFAOYSA-N,SULFADIMETHOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1
4599,CHEMBL62193,ZZORFUFYDOWNEF-UHFFFAOYSA-N,SULFADIMETHOXINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,COC1=NC(=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N)OC,COc1cc(NS(=O)(=O)c2ccc(N)cc2)nc(OC)n1
4600,CHEMBL35,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,FUROSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
4601,CHEMBL35,ZZUFCTLCJUWOSV-UHFFFAOYSA-N,FUROSEMIDE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,,,,Not Active (inhibition < 50% @ 10 uM and thus dose-reponse curve not measured),,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,,C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl,NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
4602,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,-1.0,IC50,=,84000.0,NM,,,,binding,,,,,,,,,,,,,,,,4.075720713938118,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4603,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,2904784.0,Ki,=,14.08,NM,,,,,,,,,,,,,,,,,,,,7.851397345193907,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4604,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,6146381.0,Ki,=,62.0,NM,,,,,,,,,,,,,,,,,,,,7.207608310501746,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4605,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,11.7,NM,,,,,,,,,,,,,,,,,,,,7.931814138253839,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4606,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12065734.0,Ki,=,13.5,NM,,,,,,,,,,,,,,,,,,,,7.8696662315049934,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4607,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,21944853.0,Ki,=,14.79,NM,,,cell_based,,,,,Sf9,,,,,,,Displacement of [3H]mepyramine from human H1R expressed in Sf9 cells co-expressing RGS4 after 90 mins by liquid scintillation counting,"Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH(1)R, but low affinity to hH(4)R.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.830031826003107,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4608,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,IC50,=,171.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,6.767003889607847,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4609,CHEMBL657,ZZVUWRFHKOJYTH-UHFFFAOYSA-N,DIPHENHYDRAMINE,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,20.0,NM,,,,,,,,CHO-K1,,,,,,,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",DrugMatrix in vitro pharmacology data,,DATASET,,7.698970004336019,CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2,CN(C)CCOC(c1ccccc1)c1ccccc1
4610,CHEMBL449040,ZZZDSDWPAFVIDN-UHFFFAOYSA-N,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,12113835.0,Ki,=,562.34,NM,,,,,,,,,,,,,,,Binding affinity for the human Histamine H1 Receptor,Structure-activity relationships of non-imidazole H(3) receptor ligands. Part 1.,Bioorg. Med. Chem. Lett.,PUBLICATION,,6.2500010234416505,CCCCCCCC(=O)C1=CC=C(C=C1)OCCCN2CCN(CC2)C(=O)OCC,CCCCCCCC(=O)c1ccc(OCCCN2CCN(C(=O)OCC)CC2)cc1
4669,CHEMBL3735756,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,=,1297.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 Histamine receptors stably expressed in HEK cell membrane after 90 mins by scintillation counting method,Identification of tris-(phenylalkyl)amines as new selective h5-HT2Breceptor antagonists,MedChemComm,PUBLICATION,,5.88706002391592,COC1=C(C=C(C=C1)CCN(CCCC2=CC=CC=C2)CCC3=CC4=C(C=C3)OCO4)OC,COc1ccc(CCN(CCCc2ccccc2)CCc2ccc3c(c2)OCO3)cc1OC
4670,CHEMBL3739949,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-mepyramine from human histamine H1 receptor expressed in HEK293T cells after 1 to 1.5 hrs by liquid scintillation counting analysis,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,MedChemComm,PUBLICATION,,5.0,CC1=CC2=C(C=C1C)N=C(N2)SCCN(C)C,Cc1cc2nc(SCCN(C)C)[nH]c2cc1C
4674,CHEMBL3740846,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]-mepyramine from human histamine H1 receptor expressed in HEK293T cells after 1 to 1.5 hrs by liquid scintillation counting analysis,Structure-based virtual screening for fragment-like ligands of the G protein-coupled histamine H4receptor,MedChemComm,PUBLICATION,,5.0,CC1=NN=C2N1C3=CC=CC=C3N=C2N4CCN(CC4)C,Cc1nnc2c(N3CCN(C)CC3)nc3ccccc3n12
4681,CHEMBL3752085,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1122.02,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.949999401714237,CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=CC=C3)NCC4=CC=CC=C4,CN1CCN(c2cc(-c3ccccc3)nc(NCc3ccccc3)n2)CC1
4682,CHEMBL3752195,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,5248.07,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.280000380871156,CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=CC=C3)NCC4=CC=C(C=C4)OC,COc1ccc(CNc2nc(-c3ccccc3)cc(N3CCN(C)CC3)n2)cc1
4683,CHEMBL3752225,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,5754.4,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.239999952707271,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCC5=CC=C(C=C5)OC,COc1ccc(CNc2nc3c(c(N4CCN(C)CC4)n2)CCc2ccccc2-3)cc1
4684,CHEMBL3752270,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,2089.3,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.679999195735272,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCC5=CC=CC=C5,CN1CCN(c2nc(NCc3ccccc3)nc3c2CCc2ccccc2-3)CC1
4685,CHEMBL3752383,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,3311.31,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.480000159330324,CN1CCN(CC1)C2=NC(=NC(=C2)C3=CC=CC=C3)NCCC4=CC=CC=C4,CN1CCN(c2cc(-c3ccccc3)nc(NCCc3ccccc3)n2)CC1
4686,CHEMBL3752576,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=CC=CC=C21)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccccc12
4687,CHEMBL3752576,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,125.89,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.900008766455317,C=CCN(CCC1=CNC2=CC=CC=C21)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccccc12
4688,CHEMBL3752885,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,891.25,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.050000457140078,CN1CCN(CC1)C2=NC3=C(CCC4=CC=CC=C43)C(=N2)NCC5=CC=CC=C5,CN1CCN(c2nc(NCc3ccccc3)c3c(n2)-c2ccccc2CC3)CC1
4689,CHEMBL3752900,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Cl)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12
4690,CHEMBL3752900,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Cl)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(Cl)cc12
4691,CHEMBL3752972,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1071.52,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.969999718407896,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)NCC5=CC=C(C=C5)OC,COc1ccc(CNc2nc3c(c(N4CCN(C)CC4)n2)-c2ccccc2CC3)cc1
4692,CHEMBL3752978,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1949.84,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7100010245185135,CN1CCN(CC1)C2=NC(=CC(=N2)NCCC3=CC=CC=C3)C4=CC=CC=C4,CN1CCN(c2nc(NCCc3ccccc3)cc(-c3ccccc3)n2)CC1
4693,CHEMBL3753318,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,CC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12
4694,CHEMBL3753318,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,676.08,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.170001911302621,CC1=CC2=C(C=C1)NC=C2CCN(CC=C)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(C)cc12
4695,CHEMBL3753334,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1949.84,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7100010245185135,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCC5=CC=C(C=C5)F,CN1CCN(c2nc(NCc3ccc(F)cc3)nc3c2CCc2ccccc2-3)CC1
4696,CHEMBL3753621,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,8128.31,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.089999741487069,CN1CCN(CC1)C2=NC3=C(CCC4=CC=CC=C43)C(=N2)NCCC5=CC=CC=C5,CN1CCN(c2nc(NCCc3ccccc3)c3c(n2)-c2ccccc2CC3)CC1
4697,CHEMBL3753705,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1174.9,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.929999096197656,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)N5CCN(CC5)C,CN1CCN(c2nc3c(c(N4CCN(C)CC4)n2)-c2ccccc2CC3)CC1
4698,CHEMBL3753784,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,6309.57,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.200000237109354,CN1CCN(CC1)C2=NC3=C(CCC4=CC=CC=C43)C(=N2)NCC5=CC(=C(C=C5)OC)C6=CC=C(C=C6)Cl,COc1ccc(CNc2nc(N3CCN(C)CC3)nc3c2CCc2ccccc2-3)cc1-c1ccc(Cl)cc1
4699,CHEMBL3753849,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,2511.89,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.599999383023619,CN1CCN(CC1)C2=NC(=CC(=N2)NCC3=CC=CC=C3)C4=CC=CC=C4,CN1CCN(c2nc(NCc3ccccc3)cc(-c3ccccc3)n2)CC1
4700,CHEMBL3753962,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,9332.54,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.030000139977383,CN1CCN(CC1)C2=NC(=NC3=C2CCC4=CC=CC=C43)NCCC5=CC=CC=C5,CN1CCN(c2nc(NCCc3ccccc3)nc3c2CCc2ccccc2-3)CC1
4701,CHEMBL3753967,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1905.46,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.720000163638921,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)NCC5=CC=CC=C5,CN1CCN(c2nc(NCc3ccccc3)nc3c2-c2ccccc2CC3)CC1
4702,CHEMBL3753985,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,1862.09,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.7299993321845495,CN1CCN(CC1)C2=NC(=NC3=C2C4=CC=CC=C4CC3)NCCC5=CC=CC=C5,CN1CCN(c2nc(NCCc3ccccc3)nc3c2-c2ccccc2CC3)CC1
4703,CHEMBL3754008,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,4168.69,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.380000399499542,CN1CCN(CC1)C2=NC(=CC(=N2)NCC3=CC=C(C=C3)OC)C4=CC=CC=C4,COc1ccc(CNc2cc(-c3ccccc3)nc(N3CCN(C)CC3)n2)cc1
4705,CHEMBL3754166,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Br)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12
4706,CHEMBL3754166,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,100.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)Br)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(Br)cc12
4707,CHEMBL3754176,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26718844.0,Ki,=,3388.44,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine 1 receptor expressed in Sf9 cell membranes by liquid scintillation counting,"2,4-Diaminopyrimidines as dual ligands at the histamine H1 and H4 receptor-H1/H4-receptor selectivity.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.470000200122707,CC1=CC=C(C=C1)CNC2=NC3=C(CCC4=CC=CC=C43)C(=N2)N5CCN(CC5)C,Cc1ccc(CNc2nc3c(c(N4CCN(C)CC4)n2)CCc2ccccc2-3)cc1
4708,CHEMBL3754496,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,<,10000.0,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.0,C=CCN(CCC1=CNC2=C1C=C(C=C2)F)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12
4709,CHEMBL3754496,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,26739781.0,Ki,=,79.43,NM,,,,,,,,,,,,,,,Binding affinity to histamine H1 receptor (unknown origin) by competition binding assay,"Receptor binding profiles and quantitative structure-affinity relationships of some 5-substituted-N,N-diallyltryptamines.",Bioorg. Med. Chem. Lett.,PUBLICATION,,7.100015437450608,C=CCN(CCC1=CNC2=C1C=C(C=C2)F)CC=C,C=CCN(CC=C)CCc1c[nH]c2ccc(F)cc12
4732,CHEMBL3804837,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NC#N)NC2CC2)C3=CN=CN3,N#CNC(=NC[C@H]1CC[C@H](c2cnc[nH]2)C1)NC1CC1
4734,CHEMBL3804862,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NCCOC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@H]1CC[C@H](c2cnc[nH]2)C1)NCCOc1ccccc1
4736,CHEMBL3804906,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@H]1CC[C@@H](C1)C2=CN=CN2)NC#N,CN=C(NC#N)NC[C@H]1CC[C@H](c2cnc[nH]2)C1
4738,CHEMBL3805003,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,8350.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.078313524516398,CC(C)CN=C(NC[C@@H]1CC[C@@H](C1)C2=CN=CN2)NC#N,CC(C)CN=C(NC#N)NC[C@@H]1CC[C@H](c2cnc[nH]2)C1
4740,CHEMBL3805178,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN=C(NCCNC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@@H]1CC[C@H](c2cnc[nH]2)C1)NCCNc1ccccc1
4742,CHEMBL3805220,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,7910.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.101823516502323,C1C[C@H](C[C@@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@@H]1CC[C@@H](c2cnc[nH]2)C1)NCCSc1ccccc1
4744,CHEMBL3805264,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NCCNC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@H]1CC[C@H](c2cnc[nH]2)C1)NCCNc1ccccc1
4747,CHEMBL3805361,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,6080.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.216096420727265,C1C[C@@H](C[C@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@H]1CC[C@H](c2cnc[nH]2)C1)NCCSc1ccccc1
4748,CHEMBL3805361,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,6520.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.1857524042680785,C1C[C@@H](C[C@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@H]1CC[C@H](c2cnc[nH]2)C1)NCCSc1ccccc1
4750,CHEMBL3805431,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,6780.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.168770306132936,C1C[C@H](C[C@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@H]1CC[C@@H](c2cnc[nH]2)C1)NCCSc1ccccc1
4752,CHEMBL3805437,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@@H]1CC[C@H](C1)C2=CN=CN2)NC#N,CN=C(NC#N)NC[C@@H]1CC[C@@H](c2cnc[nH]2)C1
4753,CHEMBL3805518,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,972.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,6.012333735073725,CNC(=O)C1=C(C=CC(=C1)OCCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)F,CNC(=O)c1cc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)ccc1F
4754,CHEMBL3805559,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27173799.0,IC50,=,2560.0,NM,,,,,,,,,,,,,,,Antagonistic activity at histamine1 receptor (unknown origin) after 10 mins by FLIPR assay,"Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics.",Bioorg. Med. Chem. Lett.,PUBLICATION,,5.591760034688151,CNC(=O)C1=CC(=CC=C1)OCCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F,CNC(=O)c1cccc(OCCCCN2CCC(c3noc4cc(F)ccc34)CC2)c1
4756,CHEMBL3805663,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,9350.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.029188389127482,C1C[C@@H](C[C@@H]1CN=C(NCCCC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@@H]1CC[C@H](c2cnc[nH]2)C1)NCCCc1ccccc1
4758,CHEMBL3805813,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN)C2=CN=CN2,NC[C@H]1CC[C@H](c2cnc[nH]2)C1
4760,CHEMBL3805995,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN)C2=CN=CN2,NC[C@@H]1CC[C@H](c2cnc[nH]2)C1
4762,CHEMBL3806015,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN=C(NCCOC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@@H]1CC[C@H](c2cnc[nH]2)C1)NCCOc1ccccc1
4765,CHEMBL3806079,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,3050.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.515700160653214,C1C[C@@H](C[C@@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@@H]1CC[C@H](c2cnc[nH]2)C1)NCCSc1ccccc1
4766,CHEMBL3806079,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,3800.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.420216403383191,C1C[C@@H](C[C@@H]1CN=C(NCCSC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@@H]1CC[C@H](c2cnc[nH]2)C1)NCCSc1ccccc1
4768,CHEMBL3806098,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@H]1CN=C(NCCCC2=CC=CC=C2)NC#N)C3=CN=CN3,N#CNC(=NC[C@H]1CC[C@H](c2cnc[nH]2)C1)NCCCc1ccccc1
4770,CHEMBL3806146,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,C1C[C@@H](C[C@@H]1CN=C(NC#N)NC2CC2)C3=CN=CN3,N#CNC(=NC[C@@H]1CC[C@H](c2cnc[nH]2)C1)NC1CC1
4772,CHEMBL3806162,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@H]1CC[C@H](C1)C2=CN=CN2)NC#N,CN=C(NC#N)NC[C@H]1CC[C@@H](c2cnc[nH]2)C1
4774,CHEMBL3806206,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,>,10000.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.0,CN=C(NC[C@@H]1CC[C@@H](C1)C2=CN=CN2)NC#N,CN=C(NC#N)NC[C@@H]1CC[C@H](c2cnc[nH]2)C1
4776,CHEMBL3806255,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27007611.0,Ki,=,8750.0,NM,,,,,,,,,,,,,,,Displacement of [3H]mepyramine from human histamine H1 receptor expressed in sf9 cell membrane co-expressing RGS4 incubated for 60 mins by liquid scintillation counting method,Conformational Restriction and Enantioseparation Increase Potency and Selectivity of Cyanoguanidine-Type Histamine H4 Receptor Agonists.,J. Med. Chem.,PUBLICATION,,5.057991946977686,CC(C)CN=C(NC[C@H]1CC[C@@H](C1)C2=CN=CN2)NC#N,CC(C)CN=C(NC#N)NC[C@H]1CC[C@H](c2cnc[nH]2)C1
4777,CHEMBL3817898,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,199.53,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.699991797446188,COC1=CC=C(C=C1)C(=O)CCCN2CCC3=CC=CC=C3C2,COc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1
4778,CHEMBL3817898,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,216.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.665546248849069,COC1=CC=C(C=C1)C(=O)CCCN2CCC3=CC=CC=C3C2,COc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1
4779,CHEMBL3817911,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,3630.78,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.44000006551306,C1CCC2CN(CCC2C1)CCCCN3C(=O)C4=CC=CC=C4C3=O,O=C1c2ccccc2C(=O)N1CCCCN1CCC2CCCCC2C1
4780,CHEMBL3817911,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,3632.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.4398541601509525,C1CCC2CN(CCC2C1)CCCCN3C(=O)C4=CC=CC=C4C3=O,O=C1c2ccccc2C(=O)N1CCCCN1CCC2CCCCC2C1
4781,CHEMBL3818047,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,597.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.22402566887063,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)Cl,O=C(CCCN1CCc2ccccc2C1)c1ccc(Cl)cc1
4782,CHEMBL3818047,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,602.56,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.219999701663428,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)Cl,O=C(CCCN1CCc2ccccc2C1)c1ccc(Cl)cc1
4784,CHEMBL3818124,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,263.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.580044251510242,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=C(S4)C=CC(=C5)Cl,O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3cc(Cl)ccc3s1)CC2
4785,CHEMBL3818124,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.5600045260461926,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=C(S4)C=CC(=C5)Cl,O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3cc(Cl)ccc3s1)CC2
4786,CHEMBL3818128,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,738.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.131943638176957,C1CN(CC2=CC=CC=C21)CCCCC3=CC=C(C=C3)F.Cl,Fc1ccc(CCCCN2CCc3ccccc3C2)cc1
4787,CHEMBL3818128,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,741.31,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.130000141365475,C1CN(CC2=CC=CC=C21)CCCCC3=CC=C(C=C3)F.Cl,Fc1ccc(CCCCN2CCc3ccccc3C2)cc1
4788,CHEMBL3818200,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,158.49,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.799998134593397,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C#N,N#Cc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1
4789,CHEMBL3818200,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,177.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.752026733638194,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C#N,N#Cc1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1
4790,CHEMBL3818478,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,273.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.563837352959244,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=CNC5=CC=CC=C54,O=C1NCN(c2ccccc2)C12CCN(CCCCc1c[nH]c3ccccc13)CC2
4791,CHEMBL3818478,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,275.42,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.5600045260461926,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=CNC5=CC=CC=C54,O=C1NCN(c2ccccc2)C12CCN(CCCCc1c[nH]c3ccccc13)CC2
4793,CHEMBL3818805,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,245.47,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.6100015773926675,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=CNC5=CC=CC=C54,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2c[nH]c3ccccc23)CC1
4794,CHEMBL3818805,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,255.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.5934598195660445,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=CNC5=CC=CC=C54,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2c[nH]c3ccccc23)CC1
4795,CHEMBL3818881,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,1023.29,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,5.9900012699519385,C1CC2CC(CC1N2CCCCC(=O)C3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl,O=C(CCCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1
4796,CHEMBL3818881,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,1028.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,5.9880068853407415,C1CC2CC(CC1N2CCCCC(=O)C3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl,O=C(CCCCN1C2CCC1CC(O)(c1ccc(Cl)cc1)C2)c1nc2ccccc2s1
4797,CHEMBL3818935,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,535.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.271646217978772,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5O4,O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3o1)CC2
4798,CHEMBL3818935,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,537.03,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.270001452716577,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5O4,O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3o1)CC2
4799,CHEMBL3818989,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,63.1,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.199970640755867,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=CC=C3,O=C(CCCN1CCc2ccccc2C1)c1ccccc1
4800,CHEMBL3818989,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,68.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.167491087293763,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=CC=C3,O=C(CCCN1CCc2ccccc2C1)c1ccccc1
4801,CHEMBL3818994,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,86.3,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,7.063989204284789,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)F,O=C(CCCN1CCc2ccccc2C1)c1ccc(F)cc1
4802,CHEMBL3819153,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,501.19,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.299997602857746,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=NC5=CC=CC=C5O4,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3o2)CC1
4803,CHEMBL3819153,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,510.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.292429823902062,C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCCC4=NC5=CC=CC=C5O4,O=c1[nH]c2cc(Cl)ccc2n1C1CCN(CCCCc2nc3ccccc3o2)CC1
4804,CHEMBL3819366,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,380.19,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.41999931041096,C1CN(CC2=CC=CC=C21)CCCOC3=CC=C(C=C3)F.Cl,Fc1ccc(OCCCN2CCc3ccccc3C2)cc1
4805,CHEMBL3819366,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,382.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.417936637088292,C1CN(CC2=CC=CC=C21)CCCOC3=CC=C(C=C3)F.Cl,Fc1ccc(OCCCN2CCc3ccccc3C2)cc1
4806,CHEMBL3819427,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,1427.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.845576026885352,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C(=O)N,NC(=O)c1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1
4807,CHEMBL3819427,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,1584.89,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,5.800000874803202,C1CN(CC2=CC=CC=C21)CCCC(=O)C3=CC=C(C=C3)C(=O)N,NC(=O)c1ccc(C(=O)CCCN2CCc3ccccc3C2)cc1
4808,CHEMBL3819434,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,186.21,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.729996999894941,C1CC2CC(CC1N2CCCCC3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1nc2ccccc2s1
4809,CHEMBL3819434,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,187.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.7281583934635005,C1CC2CC(CC1N2CCCCC3=NC4=CC=CC=C4S3)(C5=CC=C(C=C5)Cl)O.Cl,OC1(c2ccc(Cl)cc2)CC2CCC(C1)N2CCCCc1nc2ccccc2s1
4810,CHEMBL3819494,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,831.76,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.080001969035981,C1CN(CC2=CC=CC=C21)CCCCC3=CNC4=CC=CC=C43,c1ccc2c(c1)CCN(CCCCc1c[nH]c3ccccc13)C2
4811,CHEMBL3819494,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27312422.0,Ki,=,836.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human H1 receptor expressed in cell membranes after 1 hr by liquid scintillation counting,Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.,Bioorg. Med. Chem.,PUBLICATION,,6.077793722560982,C1CN(CC2=CC=CC=C21)CCCCC3=CNC4=CC=CC=C43,c1ccc2c(c1)CCN(CCCCc1c[nH]c3ccccc13)C2
4812,CHEMBL3819567,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,1.175,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,8.929962133392245,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5S4,O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3s1)CC2
4813,CHEMBL3819567,,,,P35367,HISTAMINE H1 RECEPTOR,HRH1,,,27364609.0,Ki,=,504.0,NM,,,,,,,,,,,,,,,Displacement of [3H]Pyrilamine from human recombinant histamine H1 receptor incubated for 1.5 hrs by microbeta scintillation counting method,Development of CNS multi-receptor ligands: Modification of known D2 pharmacophores.,Bioorg. Med. Chem.,PUBLICATION,,6.297569463554474,C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCCCC4=NC5=CC=CC=C5S4,O=C1NCN(c2ccccc2)C12CCN(CCCCc1nc3ccccc3s1)CC2
